Samson K. Orusa, M.D.; Decision and Order, 2986-3020 [2022-00952]
Download as PDF
2986
Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. 19–26]
Samson K. Orusa, M.D.; Decision and
Order
On May 31, 2019, a former Assistant
Administrator of the Drug Enforcement
Administration (hereinafter, DEA or
Government), issued an Order to Show
Cause (hereinafter, OSC) to Samson K.
Orusa (hereinafter, Respondent).
Administrative Law Judge Exhibit
(hereinafter, ALJ Ex.) 1, (OSC) at 1. The
OSC proposed revocation of
Respondent’s DEA Certificate of
Registration Number BO4959889
(hereinafter, registration or COR), the
denial of any pending applications for
renewal or modification of such
registration, and the denial of any
pending applications for additional DEA
registrations including the pending
application for COR Number
W18070589C pursuant to 21 U.S.C.
824(a)(4) and 823(f), because
Respondent’s continued ‘‘registrations
are inconsistent with the public
interest.’’ Id. (citing 21 U.S.C. 823(f)).
In response to the OSC, Respondent
timely requested a hearing before an
Administrative Law Judge. ALJ Ex. 2.
The hearing in this matter was
conducted on September 9, 2020,
October 15, 2020, and October 21, 2020,
via video teleconference technology. On
December 8, 2020, Administrative Law
Judge Mark M. Dowd, (hereinafter, ALJ)
issued his Recommended Rulings,
Findings of Fact, Conclusions of Law
and Decision (hereinafter,
Recommended Decision or RD) and
neither party filed exceptions. I issue
the final order in this case following the
RD. Having reviewed the entire record,
I adopt the ALJ’s Recommended
Decision with minor modifications, as
noted herein.*A
jspears on DSK121TN23PROD with NOTICES2
Recommended Rulings, Findings of
Fact, Conclusions of Law, and Decision
of the Administrative Law Judge *B
The Drug Enforcement
Administration (DEA) Assistant
Administrator, filed an Order to Show
*A I have made minor, nonsubstantive,
grammatical changes to the RD and nonsubstantive
conforming edits. Where I have made substantive
changes, omitted language for brevity or relevance,
or where I have added to or modified the Chief
ALJ’s opinion, I have noted the edits in brackets,
and I have included specific descriptions of the
modifications in brackets or in footnotes marked
with an asterisk and a letter. Within those brackets
and footnotes, the use of the personal pronoun ‘‘I’’
refers to myself—the Administrator.
*B I have omitted the RD’s discussion of the
procedural history to avoid repetition with my
introduction.
VerDate Sep<11>2014
18:06 Jan 18, 2022
Jkt 256001
Cause (OSC) 1 on May 31, 2019, the
Certificate of Registration (COR), No.
BO4959889, of Samson K. Orusa, M.D.
(Respondent), proposing to revoke the
Respondent’s COR pursuant to 21 U.S.C.
824(a)(4) on the ground that the
Respondent’s registration is inconsistent
with the public interest, as defined in 21
U.S.C. 823(f). [Omitted.] 2 3 In its
Supplemental Pre-hearing Statement
(GSPHS), the Government further
alleged that the Respondent made a
material falsification in his renewal
application of November 6, 2019, in
violation of 21 U.S.C. 824(a)(1). ALJ Ex.
53, 54.4 A hearing was conducted in this
matter on September 9, 2020, October
15, 2020, and October 21, 2020, via
video teleconference technology.5
The issue to be decided by the
Administrator is whether the record as
a whole establishes by a preponderance
of the evidence that the DEA Certificate
of Registration, No. BO4959889, issued
to Respondent should be revoked, and
any pending applications for
modification or renewal of the existing
registration should be denied, and any
pending applications for additional
registrations should be denied, because
his continued registration would be
inconsistent with the public interest
under 21 U.S.C. 823(f) and 824(a)(4) and
because he materially falsified his
application under 21 U.S.C. 824(a)(1).
After carefully considering the
testimony elicited at the hearing, the
admitted exhibits, the arguments of
counsel, and the record as a whole, I
have set forth my recommended
findings of fact and conclusions of law
below.
The Allegations
Overview
1. The Respondent is registered with
the DEA as a Practitioner authorized to
handle controlled substances in
1 ALJ
Ex. 1.
2 [Omitted.]
3 [Omitted.]
4 Allegations brought in the OSC and
Government’s Prehearing Statements provide
sufficient notice to the Respondent to defend
against. Jose G. Zavaleta, M.D., 78 FR 27431, 27439
(2013) (Where the Government did not allege
material falsification on the respondent’s
application in the Order to Show Cause, but did
raise the issue in its Supplemental Pre-hearing
Statement, the respondent was on notice that the
issue would be considered at the hearing).
5 Although in his Posthearing Brief, the
Respondent suggests the hearing was ‘‘truncated’’,
there was nothing abbreviated or shortened as to the
proceeding, which is now over 18 months and
counting, or as to the hearing. Neither party was
limited as to their time for presentation or number
of witnesses. The hearing ended on October 21,
2020, at 4:30 p.m., with 90 minutes remaining in
the day. I did inform the parties that we would be
finishing the hearing within the month of October,
and to make their arrangements accordingly.
PO 00000
Frm 00002
Fmt 4701
Sfmt 4703
Schedules II–V under DEA registration
number BO4959889 at 261
Stonecrossing Drive, Clarksville,
Tennessee 37042. His DEA COR
BO4959889 expired by its terms on
December 31, 2019.
2. On July 6, 2018, the Respondent
submitted an application (Application
Control No. Wl8070589C) to the DEA for
a new DEA COR (the ‘‘Application’’).
This application seeks a new DEA COR
under his Kentucky medical license at
316 Pappy Drive, Oak Grove, Kentucky
42262.6
3. Presently, the Respondent is
licensed in the State of Tennessee as a
medical doctor with license number
28275. The Respondent’s Tennessee
medical license expires by its own terms
on March 31, 2020. The Respondent is
also licensed in the State of Kentucky as
a physician with license number 33408.
The Respondent’s Kentucky medical
license expires by its own terms on
February 29, 2020.
4. As a licensed medical doctor in
Tennessee, the Respondent is subject to
TENN. CODE ANN. 63–6–6214(b)(12)
through (14), as those provisions pertain
to ‘‘dispensing, prescribing, or
otherwise distributing’’ controlled
substances. Specifically, section 63–6–
214(b)(12) prohibits a physician from
prescribing controlled substances ‘‘not
in the course of professional practice, or
not in good faith to relieve pain and
suffering, or not to cure an ailment,
physical infirmity or disease, or in
amounts and/or for durations not
medically necessary, advisable or
justified for a diagnosed condition.’’
Accordingly, section 63–6–214(b)(13)
prohibits a physician from prescribing
controlled substances to a person
‘‘addicted to the habit of using
controlled substances ‘‘without’’ making
a bona fide effort to cure the [patient’s]
habit.’’ To determine a violation of these
provisions, the Tennessee Board of
Medical Examiners uses a nonexhaustive list of guidelines (‘‘the
guidelines’’) found in TENN. COMP. R.
& REGS. 0880–02–.14(6)(e). The
guidelines require that a physician (1)
take a documented medical history; (2)
conduct a physical examination; and (3)
perform an adequate ‘‘assessment and
consideration of the [patient’s] pain,
physical and psychological function,
any history and potential for substance
abuse, coexisting diseases and
conditions, and the presence of a
recognized medical indication for the
use of a dangerous drug or controlled
substance.’’ TENN. COMP. R. & REGS.
6 See ALJ Ex. 65, Order Granting the
Government’s Motion for Partial Summary
Disposition (June 18, 2020).
E:\FR\FM\19JAN2.SGM
19JAN2
Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices
0880–02–.14(6)(e)(3)(i). Additionally,
Rule 0880–02–.14(6)(e) requires
physicians to create a ‘‘written
treatment plan tailored for the
individual needs of the patient’’ that
considers the patient’s ‘‘pertinent
medical history and physical
examination as well as the need for
further testing, consultation, referrals, or
use of other treatment modalities.’’ It
also requires the physician to ‘‘discuss
the risks and benefits of the use of
controlled substances,’’ do a
‘‘documented periodic review of the
care . . . at reasonable intervals,’’ and
‘‘keep [c]omplete and accurate records
of the care.’’ Id. at 0880–02–.14(e)(3)(ii)–
(v).
5. On October 3, 2017, the
Respondent issued a prescription for 42ten milligram tablets of oxycodone to
UC, a Tennessee state law enforcement
officer working in an undercover
capacity. The Respondent issued this
prescription following a brief meeting
with UC, during which he performed a
cursory and inadequate physical
examination and reviewed medical
records which did not justify the
prescribing of oxycodone in the amount
and dosage which he prescribed. He
also failed to: (1) Take an adequate
medical history; (2) assess the patient’s
pain, physical and psychological
function; (3) assess the patient’s history
and potential for substance abuse,
coexisting diseases and conditions, and
the presence of a recognized medical
indication for the use of oxycodone. The
Respondent further failed to create a
legitimate written treatment plan for the
patient’s individual needs or discuss the
risks and benefits of the use of
oxycodone with the patient.
6. Additionally, on October 18, 2017,
the Respondent’s office provided UC
with a prescription which the
Respondent signed and dated October
18, 2017, for 84-ten milligram tablets of
oxycodone. This occurred after UC paid
$377 for an office visit during which no
physical examination occurred and
virtually no medical information was
obtained or communicated.
Additionally, on November 20, 2017,
the Respondent’s office provided UC
with a prescription which he signed and
dated November 20, 2017, for 84-ten
milligram tablets of oxycodone. This
occurred after UC paid for another office
visit during which no physical
examination occurred and no medical
information was obtained or
communicated.
7. With respect to the prescriptions
the Respondent issued to UC, he issued
these prescriptions without: (1) Taking
a medical history or performing a
minimally sufficient physical
examination; (2) assessing the patient’s
pain, physical and psychological
Date written
jspears on DSK121TN23PROD with NOTICES2
1.3.17
1.4.17
1.4.17
2.3.17
2.6.17
2.6.17
2.6.17
3.3.17
3.6.17
3.6.17
3.6.17
3.6.17
4.3.17
4.4.17
4.4.17
4.4.17
.................................
.................................
.................................
.................................
.................................
.................................
.................................
.................................
.................................
.................................
.................................
.................................
.................................
.................................
.................................
.................................
VerDate Sep<11>2014
function; and (3) assessing the patient’s
history and potential for substance
abuse, coexisting diseases and
conditions, and the presence of a
recognized medical indication for the
use of oxycodone. The Respondent
further failed to create and follow a
legitimate written treatment plan for the
patient’s individual needs or discuss the
risks and benefits of the use of
oxycodone with the patient. Also, by
falsely indicating that UC was
physically examined on October 18 and
November 20 of 2017, he violated
TENN. COMP. R. & REGS. 0880–02–
.14(6)(e)(3)(v).
8. In addition to the medical records
for UC, medical records for more than
20 of the Respondent’s patients were
reviewed by a qualified medical expert
(‘‘reviewing expert’’) who concluded
that the Respondent’s continued
prescribing of controlled substances to
these patients was without a legitimate
medical purpose and/or outside the
usual course of professional practice.
Below are examples of some of the
patient records which were reviewed:
a. Patient M.H.: From August 2014
through February 2018, the Respondent
regularly issued prescriptions for large
quantities of alprazolam, carisoprodol,
oxycodone, and oxymorphone to M.H.
A representative sample of those
prescriptions follows below:
Drug
Dosage
Alprazolam ...............................................................................................................
Oxycodone ...............................................................................................................
Oxymorphone ...........................................................................................................
Alprazolam ...............................................................................................................
Carisoprodol .............................................................................................................
Oxycodone ...............................................................................................................
Oxymorphone ...........................................................................................................
Alprazolam ...............................................................................................................
Oxycodone ...............................................................................................................
Carisoprodol .............................................................................................................
Oxycodone ...............................................................................................................
Oxymorphone ...........................................................................................................
Alprazolam ...............................................................................................................
Carisoprodol .............................................................................................................
Oxycodone ...............................................................................................................
Oxymorphone ...........................................................................................................
.5 mg ............
30 mg ...........
15 mg ...........
.5 mg ............
350 mg .........
30 mg ...........
15 mg ...........
.5 mg ............
30 mg ...........
350 mg .........
30 mg ...........
15 mg ...........
.5 mg ............
350 mg .........
30 mg ...........
15 mg ...........
According to the reviewing expert, the
Respondent diagnosed M.H. with
‘‘chronic pain syndrome’’ even though
he made no attempt to diagnose a
specific pain etiology. The reviewing
expert found that the Respondent failed
to obtain diagnostic studies and current
medical records from M.H.’s other
medical providers and that the results of
the Respondent’s physical examination
and medical history did not justify the
18:06 Jan 18, 2022
Jkt 256001
continued prescribing of controlled
substances. The reviewing expert also
noted that he ignored a major surgical
intervention that occurred in September
2016 as well as an abnormal drug
screen. As such, the reviewing expert
concluded that much of the medical
record for M.H. was fabricated and
seemed to be copied from records of
other patients whose records contained
identically worded assessments. The
PO 00000
Frm 00003
Fmt 4701
Sfmt 4703
2987
Quantity
(number of
tablets)
120
84
56
112
56
84
56
112
84
56
84
56
112
56
84
56
Respondent also documented that the
patient provided ‘‘informed consent,’’
when no informed consent document
could be located. The expert also found
that, in some cases, the Respondent
failed to repeat certain physical exams
after his initial encounter with M.H.,
despite the fact he provided him with
prescriptions for controlled substances
for more than three years.
E:\FR\FM\19JAN2.SGM
19JAN2
2988
Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices
b. Patient C.F.: From August 2014
through August 2018, the Respondent
regularly issued prescriptions for
oxycodone and alprazolam to C.F. A
Date written
1.4.17 .................................
1.6.17 .................................
1.30.17 ...............................
2.3.17 .................................
2.3.17 .................................
3.1.17 .................................
3.1.17 .................................
3.4.17 .................................
3.13.17 ...............................
3.14.17 ...............................
3.14.17 ...............................
4.25.17 ...............................
4.28.17 ...............................
4.28.17 ...............................
5.8.17 .................................
5.8.17 .................................
Drug
Alprazolam
Oxycodone
Alprazolam
Oxycodone
Oxycodone
Alprazolam
Oxycodone
Oxycodone
Alprazolam
Oxycodone
Oxycodone
Alprazolam
Oxycodone
Oxycodone
Oxycodone
Oxycodone
Dosage
...............................................................................................................
...............................................................................................................
...............................................................................................................
...............................................................................................................
...............................................................................................................
...............................................................................................................
...............................................................................................................
...............................................................................................................
...............................................................................................................
...............................................................................................................
...............................................................................................................
...............................................................................................................
...............................................................................................................
...............................................................................................................
...............................................................................................................
...............................................................................................................
The reviewing expert found that no
credible physical examination had been
performed on C.F. and that the exam
results, as well as medical history, did
not justify the continued prescribing of
controlled substances. The expert
further found that no meaningful
follow-up physical exam was repeated,
that supported diagnostic studies were
not ordered, and that the Respondent
jspears on DSK121TN23PROD with NOTICES2
representative sample of those
prescriptions follows below:
failed to determine a chronic pain
etiology. The expert also found that he
ignored suspicious drug screen results
which indicated illegal drug use. The
reviewing expert concluded that much
of the medical record for C.F. was
fabricated and seemed to be copied from
records of other patients whose records
contained identically worded
assessments. The Respondent also
Drug
10.21.16 .............................
10.21.16 .............................
11.18.16 .............................
11.18.16 .............................
12.16.16 .............................
12.16.16 .............................
11.22.17 .............................
11.22.17 .............................
12.18.17 .............................
12.18.17 .............................
1.19.18 ...............................
1.19.18 ...............................
2.16.18 ...............................
2.16.18 ...............................
3.16.18 ...............................
3.16.18 ...............................
Oxycodone ...............................................................................................................
Oxymorphone ...........................................................................................................
Oxycodone ...............................................................................................................
Oxymorphone ...........................................................................................................
Oxycodone ...............................................................................................................
Oxymorphone ...........................................................................................................
Oxycodone ...............................................................................................................
Oxymorphone ...........................................................................................................
Oxycodone ...............................................................................................................
Oxymorphone ...........................................................................................................
Oxycodone ...............................................................................................................
Oxymorphone ...........................................................................................................
Oxycodone ...............................................................................................................
Oxymorphone ...........................................................................................................
Oxycodone ...............................................................................................................
Oxymorphone ...........................................................................................................
VerDate Sep<11>2014
18:06 Jan 18, 2022
Jkt 256001
Dosage
the fact that she suffered a heroin
overdose in his waiting room. As a
result, the expert found no objective
findings to justify the continued
prescribing of oxycodone and
oxymorphone. The reviewing expert
also concluded that much of the
medical record for M.P. was fabricated
and seemed to be copied from records
of other patients whose records
contained identically worded
PO 00000
Frm 00004
Fmt 4701
Sfmt 4703
28
84
28
84
28
28
28
84
28
28
28
28
21
7
84
28
documented that the patient provided
‘‘informed consent’’ when no informed
consent document could be located.
c. Patient M.P.: From September 2016
through April 2018, the Respondent
regularly issued prescriptions for large
quantities of oxycodone and
oxymorphone to M.P. A representative
sample of those prescriptions follows
below:
Date written
The reviewing expert found that he
failed to request and obtain past medical
records, he failed to order any
radiographic studies, and that his
physical examinations of M.P.,
including follow-up exams, were
substandard and not credible. The
expert found that he failed to document
any evidence to support a pain etiology
and that he failed to properly address
M.P.’s substance abuse disorder despite
.25 mg ..........
15 mg ...........
.25 mg ..........
15 mg ...........
7.5 mg ..........
.25 mg ..........
7.5 mg ..........
15 mg ...........
.25 mg ..........
15 mg ...........
7.5 mg ..........
.25 mg ..........
15 mg ...........
7.5mg ............
15 mg ...........
7.5 mg ..........
Quantity
(number of
tablets)
30 mg
7.5 mg
30 mg
7.5 mg
30 mg
7.5 mg
30 mg
7.5 mg
30 mg
7.5 mg
30 mg
7.5 mg
30 mg
7.5 mg
30 mg
7.5 mg
...........
..........
...........
..........
...........
..........
...........
..........
...........
..........
...........
..........
...........
..........
...........
..........
Quantity
(number of
tablets)
84
56
84
56
84
56
84
56
84
56
84
56
84
56
84
56
assessments. He also documented that
the patient provided ‘‘informed
consent’’ when no informed consent
document could be located.
d. Patient B.C.: From August 2014
through August 2018, the Respondent
regularly issued prescriptions for large
quantities of oxycodone, oxymorphone,
alprazolam, and carisoprodol to B.C. A
representative sample of those
prescriptions follows below:
E:\FR\FM\19JAN2.SGM
19JAN2
Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices
Date written
Drug
Dosage
4.10.18 ...............................
4.16.18 ...............................
4.21.18 ...............................
4.27.18 ...............................
5.14.18 ...............................
5.21.18 ...............................
5.22.18 ...............................
5.26.18 ...............................
6.12.18 ...............................
6.12.18 ...............................
6.19.18 ...............................
6.22.18 ...............................
6.22.18 ...............................
6.22.18 ...............................
7.9.18 .................................
7.25.18 ...............................
7.25.18 ...............................
7.25.18 ...............................
Alprazolam ...............................................................................................................
Oxycodone ...............................................................................................................
Oxymorphone ...........................................................................................................
Alprazolam ...............................................................................................................
Oxycodone ...............................................................................................................
Oxymorphone ...........................................................................................................
Oxycodone ...............................................................................................................
Oxymorphone ...........................................................................................................
Alprazolam ...............................................................................................................
Alprazolam ...............................................................................................................
Oxycodone ...............................................................................................................
Oxycodone ...............................................................................................................
Oxymorphone ...........................................................................................................
Carisoprodol .............................................................................................................
Alprazolam ...............................................................................................................
Carisoprodol .............................................................................................................
Oxycodone ...............................................................................................................
Oxymorphone ...........................................................................................................
1 mg .............
30 mg ...........
30 mg ...........
1 mg .............
30 mg ...........
30 mg ...........
30 mg ...........
30 mg ...........
1 mg .............
1 mg .............
30 mg ...........
30 mg ...........
30 gm ...........
350 mg .........
1 mg .............
350 mg .........
30 mg ...........
30 mg ...........
jspears on DSK121TN23PROD with NOTICES2
The reviewing expert found that the
physical examination and medical
history did not justify the continued
prescribing of controlled substances.
The expert found that he failed to: (1)
Obtain the patient’s past medical
records; (2) order radiologic and other
studies that would support the
treatment; (3) adequately address the
fact that B.C. lied about his scheduled
medications during his initial
encounter; and (4) pursue a specific
pain diagnosis. The expert also found
that he failed to document the patient’s
response to the medication which he
prescribed. The reviewing expert also
concluded that much of the medical
record for B.C. was fabricated and
seemed to be copied from records of
Drug
Dosage
4.3.17 .................................
4.4.17 .................................
4.4.17 .................................
4.4.17 .................................
4.28.17 ...............................
5.2.17 .................................
5.26.17 ...............................
7.7.17 .................................
7.31.17 ...............................
8.4.17 .................................
10.18.17 .............................
12.12.17 .............................
1.19.18 ...............................
2.12.18 ...............................
3.30.18 ...............................
4.6.18 .................................
4.27.18 ...............................
4.27.18 ...............................
5.15.18 ...............................
5.29.18 ...............................
5.29.18 ...............................
6.15.18 ...............................
7.2.18 .................................
7.2.18 .................................
8.29.18 ...............................
8.29.18 ...............................
Alprazolam ...............................................................................................................
Carisoprodol .............................................................................................................
Oxycodone ...............................................................................................................
Oxycodone ...............................................................................................................
Alprazolam ...............................................................................................................
Oxycodone ...............................................................................................................
Alprazolam ...............................................................................................................
Alprazolam ...............................................................................................................
Oxycodone ...............................................................................................................
Alprazolam ...............................................................................................................
Alprazolam ...............................................................................................................
Alprazolam ...............................................................................................................
Alprazolam ...............................................................................................................
Alprazolam ...............................................................................................................
Oxymorphone ...........................................................................................................
Alprazolam ...............................................................................................................
Oxycodone ...............................................................................................................
Oxymorphone ...........................................................................................................
Alprazolam ...............................................................................................................
Oxycodone ...............................................................................................................
Oxymorphone ...........................................................................................................
Alprazolam ...............................................................................................................
Oxycodone ...............................................................................................................
Oxymorphone ...........................................................................................................
Alprazolam ...............................................................................................................
Oxycodone ...............................................................................................................
2 mg .............
350 mg .........
30 mg ...........
15 mg ...........
2 mg .............
30 mg ...........
2 mg .............
2 mg .............
30 mg ...........
2 mg .............
2 mg .............
2 mg .............
2 mg .............
2 mg .............
15 mg ...........
2 mg .............
30 mg ...........
15 mg ...........
2 mg .............
30 mg ...........
15 mg ...........
2 mg .............
30 mg ...........
15 mg ...........
2 mg .............
30 mg ...........
VerDate Sep<11>2014
18:06 Jan 18, 2022
Jkt 256001
not meaningfully evidence any chronic
pain condition. The expert also found
that he failed to: (1) Order and obtain
diagnostic studies; and (2) adequately
address numerous instances in which
the patient had abnormal drug screens
PO 00000
Frm 00005
Fmt 4701
Sfmt 4703
Quantity
(number of
tablets)
84
84
56
84
21
14
84
56
5
84
21
84
56
56
84
56
84
56
other patients whose records contained
identically worded assessments.
e. Patient M.W.: From January 2014
through August 2018, the Respondent
regularly issued prescriptions for large
quantities and dosages of oxycodone,
oxymorphone, alprazolam, and
carispoprodol to M.W. A representative
sample of those prescriptions follows
below:
Date written
With respect to M.W., the reviewing
expert found that the initial physical
examination and medical history did
not justify the continued prescribing of
controlled substances and the
subsequent physical examinations did
2989
Quantity
(number of
tablets)
indicating possible diversion, abuse,
and/or use of illegal controlled
substances. The reviewing expert also
concluded that much of the medical
record for M.W. was fabricated and
seemed to be copied from records of
E:\FR\FM\19JAN2.SGM
19JAN2
56
28
56
56
56
56
56
56
56
56
56
56
56
56
56
56
28
56
56
28
56
56
56
56
56
56
jspears on DSK121TN23PROD with NOTICES2
2990
Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices
other patients whose records contained
identically worded assessments. The
Respondent also documented that the
patient provided ‘‘informed consent’’
when no informed consent document
could be located.
9. With respect to the Respondent’s
treatment of M.H., C.F., M.P., B.C., and
M.W. (‘‘the five patients’’), the
prescriptions for controlled substances
which he issued were not issued in the
course of professional practice
inasmuch as he failed to: (1) Take an
adequate medical history; (2) perform a
sufficient physical examination; and (3)
perform an adequate ‘‘assessment and
consideration of the [patients’] pain,
physical and psychological function,
any history and potential for substance
abuse, coexisting diseases and
conditions, and the presence of a
recognized medical indication for the
use of a dangerous drug or controlled
substance.’’ The Respondent also failed
to create a ‘‘written treatment plan
tailored for the individual needs’’ of
each of the five patients which
considered each of the patient’s
‘‘pertinent medical history and physical
examination as well as the need for
further testing, consultation, referrals, or
use of other treatment modalities.’’ He
also failed to: (1) ‘‘Discuss the risks and
benefits of the use of controlled
substances’’ with patients M.H., C.F.,
M.P., B.C., and M.W.; (2) do a
‘‘documented periodic review of the[ir]
care . . . at reasonable intervals in view
of the individual circumstances’’ of each
patient; and (3) keep ‘‘[c]omplete and
accurate records of the care provided.’’
As such, his conduct violated TENN.
CODE ANN. § 63–6–214(b)(12) and
TENN. COMP. R. & REGS. 0880–02
.14(6)(e)(3)(i)–(v).
10. With respect to C.F., M.P., and
M.W., the Respondent failed to address
substantial evidence that the patients
were engaged in abuse and/or diversion
of controlled substances, a violation of
TENN. CODE ANN. § 63–6–214(b)(l3).
11. The prescriptions the Respondent
issued to UC, M.H., C.F., M.P., B.C., and
M.W. failed to comply with Tennessee
state law in that they did not conform
to accept and prevailing medical
standards in Tennessee, and thus, were
issued outside the usual course of
professional practice. His conduct,
viewed as a whole, ‘‘completely
betrayed any semblance of legitimate
medical treatment.’’ Jack A. Danton,
D.O., 76 FR 60,900, 60,904 (2011). By
issuing these prescriptions for
controlled substances, he failed to take
reasonable steps to guard against
diversion of controlled substances. See
David A. Ruben, M.D., 78 FR 38,363,
38,382 (2013); Beinvenido Tan, M.D., 76
VerDate Sep<11>2014
18:06 Jan 18, 2022
Jkt 256001
FR 17,673, 17,689 (2011); Dewey C.
Mackay, M.D., 75 FR 49,956, 49,974
(2010); Physicians Pharmacy, L.L.C., 77
FR 47,096 (2012).
12. Even a single act of knowing
diversion is sufficient for the Agency to
revoke a registration. See Dewey C.
Mackay, 75 FR at 49,977. Detailed above
are numerous acts of alleged unlawful
prescribing, any one of which could
independently establish the sort of
intentional diversion on the part that
would justify the revocation of his DEA
registration and the denial of his
pending application as inconsistent
with the public interest. See 21 U.S.C.
824(a)(4), 823(f).
13. In addition to the legal authorities
cited above, the following cases and
Final Orders provide a summary of the
legal basis for this action: United States
v. Moore, 423 U.S. 122, 135, 143 (1975);
Randall L. Wolff, M.D., 77 FR 5,106
(February 1, 2012); Jack A. Danton,
D.O., 76 FR 60,900 (September 30,
2011); Robert F. Hunt, D.O., 75 FR
49,995 (August 16, 2010); Linda Sue
Cheek, M.D., 76 FR 66,972 (2011); Kathy
A. Moral, 69 FR 59,956 (2004); Rebecca
Sotelo, 70 FR 28,580 (2005); Patrick W.
Stodola, M.D., 85 FR 20,727 (2009);
Bob’s Pharmacy and Diabetic Supplies,
74 FR 19,599 (2009); Nirmal Saran,
M.D., 73 FR 78,827 (2008).
14. With regard to the Respondent’s
application for a new DEA COR in
Kentucky, there are additional grounds
for denying his application insofar as he
lacks state authority to handle
controlled substances in that state. On
January 15, 2019, the Commonwealth of
Kentucky, Board of Medical Licensure,
issued an Emergency Order of
Restriction prohibiting him from
‘‘prescribing, dispensing, or otherwise
professionally utilizing controlled
substances.’’ See 201 KY. ADMIN.
REGS. 9:240 1 and 3. Thus, he is
currently without authority to handle
controlled substances in the
Commonwealth of Kentucky, the state
in which he has applied for a new DEA
COR. Consequently, the DEA must deny
his application for a DEA COR based on
his lack of authority to handle
controlled substances in the
Commonwealth of Kentucky. 21 U.S.C.
824(a)(3); 21 CFR 1301.37(b). See e.g.,
Kenneth C. Beal, Jr., D.D.S. 83 FR 34,877
(2018); Mehdi Nikparvarfard, M.D., 83
FR 14,503 (2018); Leia A. Frickey, M.D.,
82 FR 37,113 (2017); Alaaeldin A.
Babiker, M.D., 81 FR 50,723 (2016);
James Dustin Chaney, D.O., 81 FR
47,416 (2016); Irwin August, D.O., 81 FR
3,158 (2016); Wayne D. Longmore, M.D.,
77 FR 67,669 (2012); Jovencio L.
Raneses, M.D., 75 FR 11,563 (2010);
John B. Freitas, D.O., 74 FR 17,524
PO 00000
Frm 00006
Fmt 4701
Sfmt 4703
(2009); Worth S. Wilkinson, M.D., 71 FR
30,173 (2006).
Material Falsification
In its Supplemental Prehearing
Statement, the Government alleged that,
on November 6, 2019, the Respondent
made a material falsification on his
renewal application for his Tennesseebased DEA COR, #59889. Specifically,
the Government alleged that in response
to liability question three, the
Respondent answered ‘‘no’’, which he
knew or should have known to be a
false response. GX 26. Liability question
three queries whether the applicant has
ever surrendered for cause, or had a
state professional license or controlled
substance registration revoked,
suspended, denied, restricted, or placed
on probation, or have any such action
pending. The Government alleged that
an affirmative answer to Question Three
would trigger an investigation by a
diversion investigator whether to issue
the registration or to deny it. The
Respondent answered ‘‘No’’ to question
3. A false ‘‘no’’ answer can result in an
improperly issued registration. GX 26.
In support, the Government cites to
the State of Tennessee Department of
Health, Notice of Charges and
Memorandum for Assessment of Civil
Penalties, see GX 29, an order from the
Chancery Court for the State of
Tennessee, 20th Judicial District,
Davidson County, Part 3, reversing
Denial of Stay, but Accompanying Stay
with Conditions. GX 27. The
Government contends that as of May
2019, the Conditions preclude the
Respondent from writing prescriptions
or providing direct patient care during
the pendency of the stay. The
Government also cites an Agreed Order
with the State of Tennessee, GX 27, in
which the Respondent was required to
surrender his Pain Management
Certificate, a professional license, in
2018, and prior to his application for
registration in November, 2019. GX 26;
GX 28. The Government alleges that,
although GX 28 related to the surrender
of the pain clinic license, and GX 26
was the Respondent’s personal
application, as the Respondent applied
for the pain clinic license himself, it
constitutes a surrender of his own
license, warranting an affirmative
response to Question Three of his DEA
application. GX 26.7
The Hearing
Government’s Opening Statement
The Government characterized the
Respondent as a willing enabler of drug
7 The surrender is signed by the Respondent
individually.
E:\FR\FM\19JAN2.SGM
19JAN2
Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices
jspears on DSK121TN23PROD with NOTICES2
abuse and diversion. Tr. 20. Rather than
maintaining medical records lacking in
detail, the Respondent’s records,
although detailed, were fabricated. The
Government’s expert reviewed twentyfour patient charts and discovered
identical language throughout. Some
phrases were repeated more than 100
times. Undercover 8 will testify that tests
described in his chart were not
performed. Test results were repeated
during three visits in which he was not
seen by the Respondent. The same
identical test results were repeated in
other patient charts. The Government’s
expert will testify that the Respondent
prescribed controlled substances
without a legitimate medical purpose
and outside the usual course of
professional practice, on the basis of the
subject medical charts. He will further
testify that the charts reveal multiple
red flags of abuse and diversion, which
were largely ignored by the Respondent.
Rather, he created records which were
deceptive, dishonest, and in some cases,
dangerous. Tr. 20.
Respondent’s Opening Statement
Samson Orusa contends that he is a
fine physician, who cares deeply about
his patients. Tr. 24. He spends a lot of
time getting to know his patients to
insure he understands their issues
relating to pain management. His system
is to use a number of documents, which
the patients fill out prior to the
Respondent seeing them, in order to get
a full picture of each patient. These
include the initial visit sheet, and a 41page pain management physical exam
sheet. He would go through these
documents with the patient
painstakingly. These forms take hours to
fill out and to review.
The undercover agent presented
himself to the Respondent under false
colors, under an assumed identity, and
with an MRI, which the Respondent
could not confirm. He claimed to be
from Missouri, a state without a PDMP.
He reported he had used over-thecounter medications to treat his pain,
and falsely claimed he had previously
been prescribed Schedule II controlled
substances, painting the picture that he
needed Schedule II pain medications
from the Respondent. The evidence will
fail to show that the Respondent has
done anything outside the bounds of
normal medical practice.
Furthermore, the Government’s case
relies solely on the opinion of its expert,
Dr. Kennedy, who we maintain is not an
expert in the field of pain management,
and whose qualifications are limited to
family practice. He holds himself out to
8 [Omitted
for privacy.]
VerDate Sep<11>2014
18:06 Jan 18, 2022
Jkt 256001
be a diplomat with the American
Academy of Pain Management, which is
a defunct organization. He has never
completed a fellowship in pain
management. He is not board-certified
in pain management, and would not be
qualified in the State of Tennessee to be
a medical director of a pain clinic. The
Respondent maintains Dr. Kennedy’s
opinion testimony should be afforded
no weight in these proceedings.9 Tr. 24
Government’s Case-in-Chief
The Government presented its casein-chief through the testimony of four
witnesses. First, the Government
presented UC. Secondly, the
Government presented the testimony of
Dr. Gene Kennedy. Thirdly, the
Government presented the testimony of
a DEA Special Agent assigned to this
matter. Finally, the Government
presented testimony of a DEA Diversion
Investigator assigned to this matter.
Undercover
[UC testified regarding his education,
credentials, and employment
background with the Tennessee Bureau
of Investigation].*C He has conducted
approximately twenty to thirty
investigations as the lead case agent in
cases involving allegations of fraud,
physicians prescribing narcotics
without medical necessity, and
physicians prescribing outside the scope
of processional practice. Tr. 31–32.
[Omitted.] 10 He provided lower back
pain as a false symptom in this case,
specifically because he has ‘‘absolutely
no back pain whatsoever.’’ Tr. 112–11.
Undercover was contacted by a
Special Agent (SA) with the United
States Department of Health, Office of
Inspector General (SA–DOH) who asked
him to make an appointment with the
Respondent in the late summer of 2017.
Tr. 34; 98.11 The initial goal in these
types of cases is to get an appointment
to see the doctor. Tr. 34. The ultimate
goal is to see if the physician will write
the undercover agent a prescription for
a controlled substance. Tr. 34, 101.
In this particular investigation, UC
contacted the Respondent’s office and
9 The Respondent’s written motion to exclude the
testimony of Dr. Kennedy was carried until the
Government offered Dr. Kennedy as an expert
witness at the hearing. Tr. 24–25, 26. The
Respondent’s Motion to Exclude was denied on its
merits in conjunction with his objection to having
Dr. Kennedy qualified as an expert witness. Tr. 201,
211–12. Contrary to the Respondent’s claims, the
motion was not denied as untimely.
*C In this section, I have omitted some
biographical and investigation-related information
to protect the identity and methodology of UC.
10 [Omitted original text in which footnote
appeared.]
11 He is familiar with the DEA Physician’s
Manual. Tr. 98.
PO 00000
Frm 00007
Fmt 4701
Sfmt 4703
2991
spoke with the receptionist over the
phone, who told him that he would be
scheduled for a new patient visit and
was required to bring certain items on
that day including; (1) an MRI report, (2)
the last three chart notes from a
previous physician, (3) the discharge
summary from his previous pain
management clinic, and (4) a printout of
the last three months from his
pharmacy. Tr. 35. UC already had some
of the items, such as the MRI report, but
there were other items he needed to put
together. Tr. 34–35. The MRI that UC
had was authentic, as it was his actual
MRI that was performed on September
2, 2016. Tr. 35–37, 106. The only thing
he altered was the ordering physician
and patient name of ‘‘Chris Rutledge.’’
Tr. 35–37.
The patient records that he presented
to the Respondent were fabricated. Tr.
37–38. DOH–SA and another SA
consulted with a nurse practitioner who
worked for TBI and instructed the
agents to generate medical records that
would be indicative of someone who
was seeing a nurse practitioner for pain.
Tr. 38, 108; GX 6. UC then provided his
personal information including his date
of birth and his medical complaints for
the agent to create a medical record. The
only medical record provided to the
Respondent’s office was signed by
‘‘S.C.,’’ who was not practicing
medicine at that time. Tr. 38, 133.
UC visited the Respondent’s office on
October 3, 2017, and recorded video and
audio of the visit. Tr. 40; 42–43.12 He set
up an appointment for 8:00 a.m. and
was told to bring the necessary
documents. Tr. 40. UC showed up for
the appointment at approximately 8:00
a.m.13 and gave the documents he had
to the receptionist, and explained why
he was missing two documents.14 Tr.
38–40, 108; GX 4.15 The receptionist
gave him about twenty pages of
paperwork and asked him to sit in the
waiting room to fill it out. At some point
he was called up by one of the
12 At this point, Government offered Government
Exhibit 3. The time stamp for the video of the
October 3, 2017 visit is 5:05:42. Tr. 74.
13 UC noted that he did not present in any
‘‘unusual way’’ to show that he had a disability,
limp, change or change his gait. Tr. 46.
14 As discussed supra, UC was asked to bring in
a discharge summary, which is a report that a pain
management clinic creates when the clinic releases
a patient. Tr. 38–39, 108. He ultimately did not
provide this document to the Respondent’s office,
stating that he was unable to obtain it. Tr. 39. He
also stated that did not provide the printout
showing the last three months of pharmaceutical
history, because he was unable to get it. Tr. 39–40.
15 No one asked for these records after his visit
and he never produced the pharmacy records. Tr.
55.
E:\FR\FM\19JAN2.SGM
19JAN2
2992
Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices
jspears on DSK121TN23PROD with NOTICES2
employees 16 who made a comment
about one of the pages in UC’s medical
record appeared to be ‘‘whited out’’ and
the employee then made a statement
that there are ‘‘people that are trying to
bring down [the Respondent]’’ and the
Respondent would therefore ‘‘be
reluctant to write any medications.’’ Tr.
41; GX 3. The receptionist then told UC
to have a seat and he would be called
back for triage to get his vitals. Tr. 41–
42, 44. UC paid for this visit with $311
of cash. Tr. 49, 110.17
UC filled out a pain disability index
and ranked his pain level as a nine out
of ten, which was not a truthful
response to how he felt at the time. Tr.
47, 101, 109–10, 123. As to his goals, his
second goal was to ‘‘sleep through the
night’’ but he did not check the box for
insomnia. Tr. 134–35, 139. Despite this
contradiction, no one in the office asked
about this. Tr. 139.18 He also filled out
a Zung Self-Rating Depression Scale,
selecting random answers. Tr. 102. He
also filled out a drug use questionnaire
regarding his drug history with the
intention of presenting a picture of a
person who is in pain. Tr.102–03. He
also filled out an agreement for opioid
maintenance therapy and for cancer and
non-cancer patients. Tr. 103. He also
filled out an American Chronic Pain
Association form including a chronic
problem list and reported that he was
only taking Advil, an over-the-counter,
anti-inflammatory and pain medication
of three pills, three times a day, with the
understanding that if he was performing
well with the over-the-counter
medicine, a doctor would likely not give
him a prescription. Tr. 103–105, 123. He
also filled out a multi-page pain
management physical form, which was
blank 19 in his seized medical record. Tr.
105, 128. He could not recall if the
Respondent went through every form
with him, but did remember the
Respondent asking him a couple
questions. Tr. 105. He also recalled
telling the Respondent that he had taken
prescription hydrocodone in the past
and it had helped him. Tr. 123.
At one point, a female wearing scrubs
took his blood pressure, asked about his
16 At this point in the testimony, Judge Dowd
stated that UC was not allowed to read from his
report directly. UC clarified that although he ‘‘did
have it open,’’ he had not ‘‘looked at it yet.’’ Tr. 41.
17 At this point in the testimony, the Government
played a video. Tr. 51; GX 4. Judge Dowd instructed
the court reporter not to transcribe the audio of the
video, as the recording itself is the best evidence.
UC confirmed that the transcript of the proceedings
was a fair and accurate representation of the
recording. Tr. 55; GX 4.
18 UC had noted that he may have stated that he
did not sleep well because he was awakened by his
pain.
19 UC noted that there were several forms that
were blank in the copies he had.
VerDate Sep<11>2014
18:06 Jan 18, 2022
Jkt 256001
weight, provided him a specimen cup,
and instructed him to go into the
bathroom located inside the waiting
room. Tr. 44–45. UC then produced a
urine sample. Tr. 45.
The time that passed from when UC
spoke with the employee about his
‘‘fabricated’’ records with the ‘‘whiteout’’ page until he met with the
Respondent, was about seven hours,
only leaving the office for
approximately forty-five minutes to get
lunch. Tr. 48–49, 100.
[Omitted to protect law enforcement
techniques]. UC told the Respondent
where his pain was located and if it hurt
he would respond that he had pain in
that area, but did not make any face or
wince. There was less than sixty
seconds of any kind of physical
touching between himself and the
Respondent, which he testified was
brief compared with other physicians.
The Respondent asked what his
previous diagnosis was and he
responded with arthritis and
degenerative disk disease. Tr. 105–06.20
During this visit, UC learned that the
office staff had tried to contact his
pharmacy and was unable to do so. Tr.
108–09. UC explained to the
Respondent that he would try to get a
hold of them and the Respondent’s
stated that his office would make
another attempt. Tr. 109. They also
discussed the alternative treatment of
injections for UC’s back pain, but UC
refused to get the injections. Tr. 117,
127. UC told the Respondent that he had
fallen off a truck sometime in 2013, was
seeing Dr. Chapman in Pierce City,
Missouri, and he moved to Tennessee
about one month prior to his first visit
on October 3, 2017. Tr. 117–18. None of
these statements were true. Tr. 117–18.
UC also shared a story about his aunt
breaking her hip and him going to the
clinic to obtain records, that he was
unable to do so because the clinic was
shut down, and that his aunt still lived
in Missouri. Tr. 118. None of these
statements were true. Tr. 118. UC
admitted that he stated all of these lies
in order to achieve his stated goal to get
a prescription from this visit and also
noted that ‘‘[u]ndercover operations
inherently rely upon some falsehoods in
all aspects of law enforcement.’’ Tr.
119–21.21
20 In fact, a physician had previously told UC that
he may have arthritis, UC was not given a diagnosis
of degenerative disk disease. Tr. 106–107.
21 At this point in the testimony, on crossexamination, the Respondent’s counsel made a
comparison to an undercover agent purchasing
heroin from a dealer and the Tribunal inquired of
the Respondent’s counsel as to the relevance of his
questioning. Tr. 121. The Respondent’s counsel
asserted that UC had lied to the Respondent to
PO 00000
Frm 00008
Fmt 4701
Sfmt 4703
He received a prescription for 42
oxycodone 10-milligram tablets, thirty
minutes after he left the exam room,
from one of the receptionists, despite
not asking for oxycodone. Tr. 56–57; GX
18. He also received prescriptions for
Meloxicam and flexeril. Tr. 57–58; GX
18.22 He filled the oxycodone
prescription, but not the other
prescriptions. Tr. 57, 58.23
UC went back to the office for a
second visit on October 15, 2017, which
was supposed to be his well-care visit
between receiving his two narcotic
prescriptions. Tr. 58–59. He did not
make an appointment. He showed up at
the office, and made a $25 payment to
the receptionist. Tr. 59. He was called
back to the triage room where the nurse
asked him his weight, to which he
replied, ‘‘210,’’ and if his blood pressure
was ok, to which he responded, ‘‘yes.’’
The nurse then directed him back to the
waiting room. He was later called to the
exam room.
This visit was recorded in the same
manner as the visit on October 3, 2017.
Tr. 59–60; GX 4 at 4.24 When he entered
achieve his goal of getting a prescription. Tr. 121.
The Tribunal asserted that ‘‘in principle this is an
undercover operation. [That is] the whole point of
it.’’ Tr. 122.
22 UC confirmed that this Government Exhibit 18
was a fair and accurate copy of the prescription he
received on October 3, 2017.
23 UC asserted that he did not expect to get
controlled substances on this first visit, as he
usually does not expect to get them, but from what
he had ‘‘been told regarding the clinic, it [did not]
shock him.’’ Tr. 125. If he had not received
prescriptions that first visit, it would not have
deterred him from making future appointments as
it usually takes several appointments to build up to
the point where the undercover agent receives
controlled substances. Tr. 125. There is no set
number for visits, but in cases where he has been
the case agent, he has looked for a progression from
other modalities of treatment first being offered and
then elevating to drugs like hydrocodone to
oxycodone, elevating the dosage or the quantities
over time. Tr. 126–27.
24 UC stated that Government Exhibit 4 is a
transcript of his interaction with the Respondent on
that date and is a fair and accurate representation
of their encounter. Tr. 60; GX 4 at 4. The transcript
reflects that the video was difficult to hear. The
Respondent’s counsel objected to the video being
put into evidence if the video could not be properly
played before the Tribunal. Tr. 64–66. The Tribunal
noted the objection and allowed the Government’s
counsel to proceed. The video was replayed and UC
asserted that he was able to hear the tape. The
Tribunal overruled the objection and noted that the
Respondent’s counsel could cross examine UC. The
Government later moved Government Exhibits 4
and 17 into the record. Tr. 69. The Tribunal
admitted pages 1, 2, and 3 of Exhibit 4 and part of
Government Exhibit 17, but noted that it was ‘‘not
convinced that [the] audio is intelligible, fully
audible, without interference, because [it] ha[s]
nothing but interference’’ on the Tribunal’s end. Tr.
70. On Day 3 of the hearing, the Tribunal
reconsidered its earlier ruling on the limited
admissibility of GX 4 and 17, and admitted the
exhibits in their entirety, noting that the video/
audio (GX 4) was played successfully at the hearing
to all participants, except the Tribunal and court
E:\FR\FM\19JAN2.SGM
19JAN2
jspears on DSK121TN23PROD with NOTICES2
Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices
the room, the Respondent asked if it was
UC’s first well visit or primary care visit
and UC affirmed it was. Tr. 71. The
Respondent asked if UC was taking
other medications and he stated that he
was not taking medications other than
pain medications. The Respondent
asked whether UC was sleeping well
and he responded ‘‘not really.’’ The
Respondent then stated that he would
write him a prescription for pain
medications to help him sleep. UC
asked what it was, and the Respondent
stated, ‘‘amitriptyline.’’ That marked the
end of the encounter. Tr. 71. There was
no further medical examination or
physical examination of his lower back,
of any of his extremities, or an
examination to determine if he had
muscle pain. Tr. 71–72.
UC had a third visit on October 18,
2017, when he was scheduled to get the
refills for his narcotic medications. Tr.
75. He went to the Respondent’s office
and first attempted to pay with cash, but
had to secure a debit card. Tr. 75–76. He
wrote his name on a clipboard, paid the
$377 fee for the office visit, and about
an hour later his name was called and
he got his prescription. Tr. 76. He was
at the clinic for approximately two and
half hours and was not examined by any
medical personnel nor did he provide
any medical records. Tr. 77. He received
a prescription for eighty-four tablets of
ten milligrams of oxycodone. Tr. 78, GX
18 at 3, 4. This dosage was less than the
Lortab of four times a day. He also
received the ‘‘euphoria drug’’ of Xanax
that he had falsely claimed he was
receiving in Missouri. Tr. 112.
Upon reviewing the medical records,
UC noted that despite his records stating
that ‘‘Mr. Rutledge . . . has had a
history of insomnia and anxiety for
several years,’’ he did not report anxiety
symptoms of shortness of breath, of
having palpitations, sweating, dizziness,
or shaking. Tr. 79–80; GX 5. The
medical record also reflects that he had
a headache that day, despite the fact
that UC did not report having a
headache, dizziness, nausea, or
vomiting. Tr. 80; GX 5. No one
questioned UC as to whether he had
abdominal pain, diarrhea, and
constipation. Tr. 80–81. UC reviewed
Government Exhibit 5 and noted that he
was not asked about any of these
symptoms. Tr. 81. He also assumes that
the office accessed and checked the
Tennessee controlled substance data
bank on his first visit as this was in his
medical records, but he was not
reporter, which the Tribunal attributed to a VTC
issue and not to a defect in the DVD itself. [I have
reviewed the contents of the DVD and find that the
videos play successfully.]
VerDate Sep<11>2014
18:06 Jan 18, 2022
Jkt 256001
specifically informed of it. Tr. 110. He
also believes that the UC’s assumed
identity has never had a controlled
substance filled in Tennessee. Tr. 111.
He also believes there was no Missouri
prescription database at that time,
where he asserted he was from, so the
office could not obtain information from
there. And the fact that Missouri did not
have a state-controlled prescription
monitoring program in Missouri was a
factor as to why the persona of UC’s
assumed identity was somebody from
Missouri. Tr. 110–11.
At the appointment on October 17,
2017, UC did not have his blood
pressure checked, was not weighed, did
not have his chest examined, and did
not have his breathing measured or
evaluated. Tr. 82. On October 18, 2017,
UC did not discuss muscle pain, back
pain, nor a Review of Systems (ROS).
Tr. 82–83. No one examined his chest,
or his breathing. Tr. 83.
UC had another visit on November 15,
2017, which was another well-visit. Tr.
84. He paid $25, waited for some time,
was called back and asked about his
weight and if his blood pressure was
okay. He specifically asked the nurse if
he was dismissed and after she said yes,
he left. He did not receive any
prescriptions that day. Tr. 85. Despite
what the medical records say regarding
this visit, there was no medical
examination conducted on that day,
including of his chest, or breathing. Tr.
86, 90; GX 5.
UC had another visit on November 20,
2017, for a medication visit. Tr. 87; GX
at 10. UC walked in, put his name on
a clip board, paid some money, waited
a certain amount of time for his name
to be called, and went to the window to
obtain his prescriptions. Tr. 88. On this
particular day, he was asked to provide
a urine sample. Tr. 88, 92. He received
a cup from the nurse, went into the
bathroom for his unsupervised urine
test, and provided a urine sample. He
had brought a vial of a substance that
would cause him to test positive for
Oxycodone, put that in the urine
sample, and returned the sample to the
nurse as instructed. Tr. 88, 92; GX 3. He
believes that, despite the added
substance, his urine drug screen came
back negative *D and the Respondent
never discussed this screen with UC nor
did anyone else at the practice. Tr. 91–
*D The Government did not fully explain this
portion of its case which I find to be immaterial.
Ultimately, inconsistent UDS results were not
relevant to Dr. Kennedy’s opinion that the
prescriptions issued to UC were issued outside of
the standard of care nor were they relevant to my
findings in this decision.
PO 00000
Frm 00009
Fmt 4701
Sfmt 4703
2993
92; GX 3.25 He received a prescription
for oxycodone for eighty-four tablets of
ten milligrams from one of the
receptionists, who provided the
prescription to him as well as several
others. Tr. 89. GX 18 at 4. UC did not
meet with the Respondent that day. The
medical records say ROS, but none of
the systems were examined during this
visit. Tr. 91.
Besides verbalizing and writing down
that his pain was nine out of ten, UC did
not do anything to indicate that his pain
was actually that level. Tr. 94–95; GX 3,
18. He did not present any falsified
records showing he had a history of
filling controlled substance
prescriptions in any state 26 and never
produced pharmacy records showing
his prescription history. Tr. 133. In UC’s
experience of working with people who
abuse drugs or obtain drugs to sell them,
he has found that these people are
pretty savvy about filling out their forms
when they go to the doctor. Tr. 133–34.
Dr. Gene Kennedy
Dr. Kennedy, who is licensed in
Georgia, is a family practitioner by
training and has treated patients for
pain since being licensed. Tr. 202. Dr.
Kennedy was offered, and qualified, as
an expert in the field of pain
management. Tr. 201, 211–12, 216.
Although not board certified in pain
management, he has been treating
people for pain full-time since 2004 or
2005, when he opened his own pain
management clinic. Tr. 178–80, 202–03,
427.27 He has treated all types of pain
patients: Patients suffering acute postsurgical pain; patients suffering from
back pain; cancer patients; and patients
referred by other pain management
physicians. Tr. 180–81, 355. He has
prescribed assorted controlled
substances, including opioids to treat
pain, including Schedule I. Tr. 181. He
treats patients over 120 MME. He noted
only UC and C.F. were being treated
below 120 MME. Tr. 427–28. He has
25 Although the Respondent objected to
Government Exhibit 3 being offered into evidence
based on hearsay, the Tribunal overruled the
objection finding that any hearsay statements in this
exhibit have been properly authenticated. Tr. 94.
The Tribunal also noted that UC could be crossexamined regarding his report.
26 UC noted in the Patient Pain History form that
he had previous medications including
hydrocodone between November 2016 and
September 2017, Xanax from approximately August
16, 2016 through September 2017, and oxycodone
from August 2017 to September 2017.
27 Although not dispositive in this setting, Dr.
Kennedy’s credentials would not permit him to be
a director of a pain clinic in Tennessee, without
annually consulting with a board certified pain
management specialist. Tr. 204–05, 428–30.
E:\FR\FM\19JAN2.SGM
19JAN2
jspears on DSK121TN23PROD with NOTICES2
2994
Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices
prescribed benzodiazepines. He
performs pain injections. Tr. 357.
He has previously been qualified as
an expert witness in administrative
hearings of the Alabama Medical Board,
the Georgia Medical Board, DEA, FBI
and DOJ. On thirteen occasions he has
testified regarding whether a physician
has properly prescribed controlled
substances. GX 24. He has served as an
adjunct lecturer regarding the proper
prescribing of controlled substances to
DEA, at the National Advocacy Center,
and on behalf of the DOJ. Tr. 185. He
estimated over half of his income comes
from the work and lectures given to
Government agencies. Tr. 359. In 2018,
he estimates he was paid over $100,000
by the Government. Tr. 432. For the
instant case, he is being paid $450 per
hour for an estimated forty hours of
preparation plus courtroom hours. Tr.
434–36. He has also lectured regarding
the PDMP to medical residents and
physicians and taught a course to
pharmacists in Tennessee regarding
legitimate prescribing. Tr. 185. He is
familiar with Tennessee law pertaining
to prescribing controlled substances,
and has relied on the following sources
in developing his opinions herein:
Tennessee Pain Clinic Guidelines, the
Federation of State Model Policy, AMA
Guidelines, the DEA Practitioner’s
Manual. Tr. 183, 360–62. He was hired
by the DEA to offer an expert opinion
on the Respondent’s prescribing and of
the medical practice, on the basis of
material the government provided him.
This material included approximately
twenty charts, surveillance videos, and
pharmacy reports. The surveillance
videos involved undercover encounters
between UC and the Respondent. Tr.
184; GX 8–23.
Dr. Kennedy is familiar with the
standard of care for a physician
prescribing controlled substances in
Tennessee. This standard requires an
adequate medical history, including all
the historical information helpful in
developing a diagnosis, course of
treatment and in understanding the
risks involved. Tr. 189, 195. The
standard requires diagnostic testing, if
indicated. Tr. 196. The standard
requires the physician to perform a
physical exam. Tr. 190, 200–01. The
standard requires a physician to
maintain medical records for patients to
whom controlled substances are
prescribed. Tr. 196. These medical
records should contain a pain history, a
history of drug abuse and termination
by other physicians, a physical exam
pertinent to the patient’s complaint,
efforts at obtaining state pharmacy
reports, the physician’s thoughtful
assessment of the patient’s condition,
VerDate Sep<11>2014
18:06 Jan 18, 2022
Jkt 256001
and an individualized treatment plan.
Tr. 196–98. Dr. Kennedy noted the
importance of maintaining complete
and accurate patient records. Tr. 353.
With patients sometimes on high doses
of potentially dangerous controlled
substances, the charts must be accurate
and honest, so any practitioner who
views the charts can make an accurate
assessment of the patient’s conditions.
Tr. 353–54.
In reviewing the subject medical
records, Dr. Kennedy recognized
indications of possible abuse and
diversion, including patients unable to
produce past medical records, a cloudy
history of drug abuse. Tr. 191–92. Dr.
Kennedy noted that the Tennessee
standard precludes a physician from
prescribing controlled substances to a
patient with a habit of improperly using
them, without first making a bona fide
effort to cure the patient’s addiction. Tr.
199. When a benzodiazepine and an
opioid are prescribed in combination,
the physician would have a heightened
sense of vigilance, which would need to
be documented within the chart. Tr.
190. Urine drug screening (UDS) is a
common practice in pain management
treatment. Tr. 192. It can reveal whether
a patient is taking a medication he is
prescribed and whether he is taking
medications or illegal drugs he is not
prescribed. Tr. 193–94. The standard of
care would require, at minimum, that
the physician document in the records
the inconsistent UDS, and describe his
plan of action. Tr. 194–95.
Dr. Kennedy reviewed the chart and
the undercover videos for Patient UC,
who was the undercover agent. Tr. 216–
17, 363; GX 6. Dr. Kennedy
acknowledged that in scheduling the
first visit, the Respondent’s staff
instructed UC to bring certain medical
records to his first visit: The previous
three physician notes, his discharge
summary, the record of the previous
three months prescriptions and an MRI,
an appropriate protocol in Dr.
Kennedy’s opinion. Tr. 364–65; GX 3 at
1. Dr. Kennedy did not believe the
medical chart justified the prescribing of
controlled substances. Tr. 230–31, 240;
GX 18 at 1, 3. Although an actual MRI
report of UC, Dr. Kennedy found the
MRI report internally inconsistent,
which did not justify controlled
substance medication. Tr. 387–94, 483–
86. UC was being treated for complaints
of back pain. However, Dr. Kennedy
opined that the physical exam detailed
in the chart was not sufficient under
Tennessee standards, and the exam
performed revealed a normal back.*E Tr.
*E Dr. Kennedy testified that an adequate back
exam would have required Respondent to look ‘‘for
PO 00000
Frm 00010
Fmt 4701
Sfmt 4703
217, 231, 237, 396–97, 440. On rebuttal,
Dr. Kennedy reiterated this assessment
after listening to the Respondent’s
explanation. Tr. 651–52. After filling out
extensive paperwork, the initial
examination by the Respondent
consisted of observing the UC, touching
his back and causing the patient to lift
his leg. Tr. 217–18, 359–60; GX 6 at 6.
Dr. Kennedy did not believe UC’s chart
reflected the Respondent maintained a
truthful and accurate record of the
treatment. Tr. 232; GX 3; 4. Dr. Kennedy
noted the taking of vital signs and a
general exam within the chart, however
he observed that from viewing the video
of this visit, such exam was not
performed as described, or not
performed at all. Tr. 218–19, 232–33,
379–81; GX 6 at 4. The prior medical
history reported by UC, was facially
suspicious and constituted a red flag.
Tr. 238. UC reportedly, came from a
clinic, which has since shut down, and
provided medical records from a Nurse
Practitioner, whose license has been
suspended. Tr. 238. Dr. Kennedy opined
that UC’s obfuscation, false and
misleading statements to the
Respondent and staff, did not relieve the
Respondent’s obligation to investigate
any suspicious circumstances. Tr. 375–
78, 382.
Dr. Kennedy noted that the physical
exam included in this first visit by UC
was repeated verbatim in most of the 20
or so charts he reviewed. Tr. 220; GX 7
at 65 (M.B.), GX 9 at 69 (M.W.). Dr.
Kennedy noted UC’s chart identified
him with a ‘‘long-standing history of
insomnia and anxiety,’’ however the
chart contained no examination, which
would support such findings. Tr. 233–
34; GX 5 at 4. Additionally, the reported
symptoms of the anxiety finding,
‘‘palpitations, sweating, dizziness,
shaking’’ was repeated almost
universally throughout the medical
records reviewed as to patients
diagnosed with insomnia and anxiety.
Tr. 233–34. Although UC reported his
pain level at 9 or 10, the exam results
do not support that, nor did the video
of this encounter. Tr. 234–35, 238.
Similarly, the visit of October 17, 2017,
by UC contains extensive medical
findings, although the video of that visit
does not support those findings. Tr.
235–37; GX 5 at 5. The video does
reveal the Respondent asking UC, ‘‘how
is your sleep,’’ to which UC responds,
‘‘not good.’’ Tr. 236. The Respondent
something that is out of place, muscle spasms, . . .
perform lumbar range of motion maneuvers where
the patient essentially bends at the waist in various
directions. Additionally, . . . a straight leg raised
test, . . . neurologic exam, which makes comment
on their motor deficits and their sensorium as
pertains to their complaint of low back pain.’’
E:\FR\FM\19JAN2.SGM
19JAN2
Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices
jspears on DSK121TN23PROD with NOTICES2
then prescribed Elavil, also called
amitriptyline. Tr. 236. Dr. Kennedy
made a similar observation as to
extensive medical findings on
subsequent visits, in which UC was not
seen by the Respondent. Tr. 235–37; GX
5 at 3–5. Although the medical records
reflect physical examination took place
at the level one visits, the Respondent
explained that it was permissible in
medical record-keeping to carry forward
results from prior examinations to later
visit records, with new findings added.
Tr. 623–28. Dr. Kennedy disagreed,
noting that it is never permissible for
charts to reflect examination results,
when no exam occurred. Tr. 652–53.
On the basis of the deficient physical
exam, Dr. Kennedy opined that
prescribing controlled substances to UC
was not justified.*F Although the
Respondent prescribed a much lower
MME than UC had purportedly been on
previously, it was not consistent with
the Tennessee standard, which would
include observation, looking for spasms,
lumbar range of motion maneuvers,
straight leg raise test, neurologic exam
and motor deficits. Tr. 221–25, 239,
382–83; GX 5 at 6. Other deficiencies in
the records that caused the controlled
substance prescriptions for UC to be
unjustified included the deficiency in
the prior medical records provided by
UC Tr. 228. UC’s chart revealed an
exploration of alternate treatment, by
prescribing Meloxicam. Tr. 228–29.
However, UC’s chart did not include an
adequate treatment plan. Tr. 229. The
records reveal a deficient discussion
regarding the risks and benefits of
controlled substance medication. Tr.
231. Dr. Kennedy deemed the diagnosis
of degenerative disc disease unjustified
on the basis of the chart and MRI. Tr.
240–42; GX 5 at 2, 6; GX 6 at 12.
Dr. Kennedy prepared reports or
charts containing his review of the
relevant medical evidence in this case.
His findings accurately reflect the
original medical records, which are in
evidence. His chart was admitted as a
*F Dr. Kennedy actually offered several bases for
his opinion that all of the controlled substances
Respondent prescribed to C.R. were issued outside
the usual course of professional practice. Tr. 239.
Specifically, Dr. Kennedy identified Respondent’s
failures to perform a sufficient physical
examination; to adequately assess the patient’s
pain, physical, and psychological function; to
sufficiently examine the patient’s history; to assess
a recognized medical indication for the use of
oxycodone; to create or follow a legitimate written
treatment plan; to discuss the risks and benefits of
using oxycodone with the patient; to maintain
truthful and accurate medical records; or to resolve
red flags arising from the medical records C.R.
provided, which stated that C.R. had been treated
at a clinic that had closed by a nurse practitioner,
whose license had been suspended. Tr. 237–39.
VerDate Sep<11>2014
18:06 Jan 18, 2022
Jkt 256001
chart of voluminous records under Fed.
R. Evid. 1006. Tr. 225–28; GX 6 at 2.
Patient M.W.
Dr. Kennedy identified his ‘‘chart
review’’ for M.W. Tr. 243–44; GX 9, 10.
M.W. was diagnosed with low back
pain, yet Dr. Kennedy opined that the
records did not support such diagnosis.
Tr. 245–46; GX 9 at 14; GX 10 at 3. The
notes did reference back to M.W.’s
initial encounter. Tr. 441. There were no
findings in the record which would
support a chronic pain condition and
justify prescribing controlled
substances. Tr. 246–47. Dr. Kennedy
found no credible physical exam to
justify the diagnosis. Tr. 247, 265. The
Respondent did not assess M.W.’s pain
level, physical and psychological
functioning, history, potential for drug
abuse, or coexisting diseases. Tr. 265.
The Respondent did not follow a
legitimate treatment plan. Tr. 265. The
physical exam findings were generally
normal findings, except for limited
range of motion at the lumbar spine. Tr.
247; GX 10 at 7. M.W. reported a pain
level, at worst, at 10 of 10, and at best,
6 of 10. Tr. 248–49; GX 9 at 19; GX 10
at 8. M.W.’s reported pain level was
inconsistent with the generally normal
results of the physical exam. Tr. 249–50.
The electronic medical record for this
visit does not contain the handwritten
information recorded in GX 10 at 8. Tr.
250–51; GX 10 at 9. Instead, the results
of the physical exam mirror those
findings made for UC, rendering M.W.’s
chart not credible. Tr. 251–52.
Additionally, the record contained
‘‘wildly abnormal’’ *G UDS results that
were ‘‘not meaningfully addressed.’’ Tr.
252–55; GX 9 at 2–4, 9–11, 84, 96, 102.
After a series of inconsistent UDS, the
Respondent noted in M.W.’s chart that
M.W. was dismissed from pain
management with one month notice. Tr.
258; GX 9 at 84. Yet, at the same visit
in which he had been notified he would
be dismissed, the history of present
illness (HPI) reports patient is compliant
and consistent. Tr. 258. Dr. Kennedy
deemed the chart not credible,
accordingly. Tr. 259. However, despite
being dismissed, M.W. continued to be
seen for months afterwards, without any
further explanation. Tr. 259–60. Dr.
Kennedy later conceded that M.W. was
reinstated consistent with the
*G For example, regarding the UDS at GX 9, 2–
4, M.W. was prescribed oxycodone, carisoprodol,
alprazolam, and ozymorphone. GX 9, 2–4. The drug
screen results were negative for the prescribed
drugs alprazolam and carisoprodol and, as Dr.
Kennedy testified, positive for non-prescribed
substances including ‘‘morphine, positive for
hydromorphone, positive for oxymorphone, . . .
positive for THC. . . .’’ Tr. 251–52.
PO 00000
Frm 00011
Fmt 4701
Sfmt 4703
2995
Respondent’s office protocol. Tr. 449–
50. The Respondent continued to
prescribe him Alprazalam,
amitriptyline, oxycodone, oxymorphone
and Soma. Regarding the Alprazalam
prescription, Dr. Kennedy found it
unjustified based on the information
supporting the anxiety diagnosis. Tr.
260–61, 442–44; Tr. 261; GX 9 at 85. Dr.
Kennedy noted the indications for
anxiety were not supported by the
findings within the chart, and mirrored
those in the charts for UC and the other
patients. Tr. 261–62. Although Dr.
Kennedy opined M.W. should have
been physically examined ‘‘on a regular
basis’’ during his treatment, the charts
suggest he was not examined again
following his first examination.*H Tr.
262. Dr. Kennedy further opined that as
M.W. was a 25 year-old diagnosed with
degenerative disc disease, the Tennessee
standards would require diagnostic
testing, such as an MRI to confirm the
diagnosis. Tr. 262, 447–48. Dr. Kennedy
found M.W.’s chart ‘‘not credible and
fabricated.’’ Tr. 263–64, 266; GX 10 at 5,
23. He noted that of 93 of 98 total visits
shared the identical findings for the
physical exams and ROS. Tr. 264.
Similarly, Dr. Kennedy found the
diagnosis of insomnia not credible. Tr.
264. A finding of drug abuse and
chemical dependency would have been
supportable, but such indications were
not sufficiently addressed by the
Respondent. Tr. 264–65. The credible
findings within M.W.’s chart did not
support the prescribing of controlled
substances,*I and the subject
prescriptions were issued without
medical justification and outside the
usual course of professional practice. Tr.
266–68.
Patient C.F.
Dr. Kennedy identified the summary
chart he prepared on Patent C.F. Tr. 268;
GX 12. C.F. was being treated for
chronic pain due to trauma, unspecified
inflammatory polyarthropathy. C.F. had
suffered stab wounds to the chest
requiring open heart surgery, which can
cause long-term neuropathic pain. Tr.
451–53. Dr. Kennedy opined the history,
*H Dr. Kennedy testified that the little
documentation there was suggesting a physical
exam could have been performed was ‘‘not
credible’’ because it was ‘‘repeated documentation
that we have described before.’’ Tr. 262.
*I Specifically, Dr. Kennedy testified that
Respondent failed: To perform a sufficient physical
examination; to adequately assess the patient’s
pain, physical, and psychological function; to
sufficiently examine the patient’s history and
potential for substance abuse; to identify a
recognized medical indication for the use of the
controlled substance prescriptions; to create or
follow a legitimate written treatment plan; and to
adequately address M.W.’s exhibited evidence of
drug abuse. Tr. 264–66.
E:\FR\FM\19JAN2.SGM
19JAN2
jspears on DSK121TN23PROD with NOTICES2
2996
Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices
physical exams, the pain and physical
and psychological functioning, the
potential for substance abuse, written
treatment plan, and alternate treatment
considerations were inadequate, and did
not justify the controlled substance
prescriptions. Tr. 269–70, 285, 455; GX
11 at 106; GX 12 at 7. The Respondent
did not discuss the risks and benefits of
controlled substance medications [and
did not keep accurate records of the care
he provided.] Tr. 285–86. The physical
exam notes revealed essentially normal
findings, however the electronic records
for this visit failed to include these
findings. Tr. 271; GX 11 at 69. Instead,
under physical exam, the same language
often duplicated in the records, is
included. Tr. 272. There were no
credible follow up physical exams,
supporting studies, and no reasonable
pain etiology. Tr. 272; GX 12 at 5, 6. The
ROS indications were identically
repeated in other charts. Tr. 272–73. Dr.
Kennedy noted that the language in the
general exam, ‘‘patient is alert and
oriented’’ is similarly repeated 102
times throughout the records. Dr.
Kennedy reported an inconsistent UDS
for C.F., collected on July 2, 2018, and
many thereafter. Tr. 273–80, 282; GX 11
at 9, 23, 24, 25, 28, 33, 44, 47, 54, 69,
78, 111, 117; GX 20. C.F.’s UDS result
was negative for all of the medications
he was prescribed. Tr. 275–77. C.F. also
tested positive for cocaine and
marijuana. Tr. 277, 280. An inconsistent
drug screen on July 26, 2017, is not
mentioned in the medical records. Tr.
288–89. Although the records
repeatedly noted that, ‘‘patient
counseled at length on unsatisfactory
UDS,’’ this was insufficient under
Tennessee standards in addressing
C.F.’s drug abuse and diversion [because
it did not document ‘‘anything
specific.’’] Tr. 280, 284. On May 3, 2017,
C.F. tested positive for buprenorphine, a
medication typically used for opioid use
disorder. Tr. 281–82. The Respondent
had not prescribed it [and failed to
investigate or address the issue.] Tr.
282. Dr. Kennedy opined that the
Respondent continued to improperly
prescribe controlled substance without
making a bona fide effort to cure C.F.’s
addiction. Tr. 284. The Respondent
prescribed alprazolam for anxiety and
insomnia. Tr. 286; GX 11 at 39.
However, the supporting indications are
identical to the other patients who were
diagnosed with anxiety and insomnia.
Tr. 286–87. The Respondent did not
maintain complete and accurate records
for C.F. Tr. 286. Dr. Kennedy concluded
that the controlled substance
prescriptions to C.F. were outside the
VerDate Sep<11>2014
18:06 Jan 18, 2022
Jkt 256001
usual course of professional practice. Tr.
287.
Patient B.C.
Dr. Kennedy identified his summary
chart for B.C. Tr. 289–90; GX 13; GX 14.
B.C. was being treated for chronic pain
syndrome. B.C. was referred from the
Clark County Jail, a potentially
challenging patient. Tr. 458–59. The
Respondent did not take an adequate
medical history. Tr. 304. Although
documentation of some physical exam
was evident, it was insufficient and
non-supportive to justify prescribing the
medications prescribed.*J Tr. 290–91,
304; GX 13 at 169; GX 14 at 7; GX 22.
He did not make an adequate
assessment of pain, physical and
psychological function, history of
substance abuse, coexisting diseases and
conditions, written treatment plan, or
alternate treatments. Tr. 304–06. He did
not conduct any periodic reviews, or
discuss the risks and benefits of the use
of controlled substances. Tr. 306. There
were no radiologic studies ordered. Tr.
303. There were no prior medical
records ordered or obtained, yet the
records did include hospital records. Tr.
303, 459–60. Dr. Kennedy noted
indications from the ROS were
duplicated throughout the records. Of
141 encounters, the ROS language was
duplicated 140 times, while the
physical exam language was duplicated
134 times. Tr. 291–92. He did not
maintain accurate and complete records.
Tr. 306. B.C. had serious health issues,
including Hodgkins lymphoma, a cancer
of the lymphatic system. Tr. 293. Dr.
Kennedy identified a document in the
chart indicating B.C. had been
dismissed from a prior physician, a
clear red flag [for which there was no
‘‘evidence in the medical record that
[the] red flag was investigated.’’] Tr.
293–94; GX 13 at 188.
Dr. Kennedy noted that B.C.’s pain
level was left blank in the medical
record for nine consecutive encounters,
suggesting [‘‘that [the] information is not
actually being obtained and that the
documentation is simply being inserted
in the chart.’’] Tr. 294–95; GX 13 at 159;
GX 14 at 8. One entry reveals, ‘‘patient
*J Dr. Kennedy testified that the documented
physical exam was insufficient, because ‘‘there are
no positive objective physical findings that rise to
the level of requiring medications prescribed.’’ Tr.
291. He further testified, that based on B.C.’s known
medical problems, ‘‘[it is] not impossible that this
patient had a chronic pain condition. But I would
note that over the course of 140 encounters the
chart does not mention, . . . on a single occasion
where [we are] consistently talking about what
specific pain the patient is experiencing.’’ Tr. 305.
Accordingly, Dr. Kennedy testified, the medical
record did not support a recognized medical
indication for the use of the prescribed controlled
substances. Id.
PO 00000
Frm 00012
Fmt 4701
Sfmt 4703
lied about his prescriptions,’’ an
alarming red flag left unaddressed by
the Respondent. Tr. 296; GX 13 at 169.
Despite noting that the ‘‘patient lied,’’
the Respondent issued controlled
medications and ‘‘held’’ up UDS for a
month. Tr. 297. Dr. Kennedy opined
that this prescribing was outside the
usual course of professional practice.
B.C. continued to have inconsistent
UDS results, which were insufficiently
addressed by the Respondent.*K Tr.
297–98; GX 13 at 33, 79, 150, 155, 156,
158, 164, 165. The information
contained in B.C.’s chart did not justify
the controlled medications prescribed
by the Respondent, nor support that
they were issued in the usual course of
professional practice. Tr. 307–08.
Patient M.H.
Dr. Kennedy identified his summary
chart for Patient M.H. Tr. 309; GX 15;
GX 16. M.H. was being treated for
chronic pain syndrome. GX 15 at 62, 63.
The physical exam indications are
identical to those repeated throughout
the medical records. Tr. 311. The
indications do not support any chronic
pain diagnosis. Tr. 311. The records
reveal M.H. suffered a gunshot wound
in 2008, and although serious, would
not in itself justify pain medication
eight years later. Tr. 323. Dr. Kennedy
assessed the Respondent’s treatment as
outside the scope of acceptable medical
practice.*L Tr. 312. He did not make an
adequate assessment of pain, and
physical and psychological function, of
medical history, of history of substance
abuse, coexisting diseases and
conditions, periodic review of care,
written treatment plan or alternate
treatments. Tr. 326–28. He did not
conduct any periodic reviews, or
discuss the risks and benefits of the use
of controlled substances. Tr. 328. M.H.
had inconsistent UDS. Tr. 314–20; GX
15 at 36, 39, 40, 47, 49, 53, 56, 63.
Although several inconsistent UDS were
noted in the chart, they were not
typically mentioned. The Respondent
failed to adequately address the UDS.
Tr. 314–20.
During his treatment with the
Respondent, M.H. underwent a serious
and complex spinal surgery, a major
surgery. Tr. 320–22, 462–63. GX 15 at
26; GX 16 at 9. M.H. was seen by the
Respondent the day after his release
*K According to Dr. Kennedy, the medical records
say ‘‘the patient is counseled at length, but again,
[there is] nothing specific about what the
counseling entailed or any decision made based on
it.’’ Tr. 301.
*L My findings in this matter are based solely on
Respondent’s prescribing of controlled substances,
not Respondent’s prescribing of non-controlled
substances or his overall treatment of patients.
E:\FR\FM\19JAN2.SGM
19JAN2
Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices
from the hospital. GX 15 at 48. Despite
his recent, major surgery, there is no
mention of the surgery in the encounter
notes.*M Tr. 322–23. The encounter
notes are identical to all the other
encounter notes reviewed. Tr. 323; GX
15 at 48. There is no updated physical
exam, as would be required by the
standard of care. Tr. 324. The PE and
HPI notes are the same as those the 4
months prior to the spinal surgery,
which is not credible. Tr. 324–25, 491–
92; GX 15 at 49, 51. The Respondent did
not maintain accurate and complete
records as to M.H. Tr. 328. Dr. Kennedy
reviewed the prescriptions issued. Tr.
325; GX 19 at 1–13. He opined that the
chart, including the number of
inconsistent UDS, reveals that there was
‘‘a significant probability’’ that M.H.
was addicted to the habit of using
controlled substances, yet the
Respondent continued prescribing them
without making a bona fide effort to
cure the addiction. Tr. 325. The subject
prescriptions were issued outside the
usual course of professional practice. Tr.
329–30, 493.
jspears on DSK121TN23PROD with NOTICES2
Patient M.P.
Dr. Kennedy identified his summary
chart for Patient M.P. Tr. 331; GX 8.
M.P. was being treated for low back,
neck, hip and shoulder pain. She was
later diagnosed with degenerative disc
disease and right shoulder pain.
Although a physical exam was
performed, it was inadequate to
substantiate the diagnoses. Tr. 331–34,
339–40, 343; GX 7 at 2. A mechanical
shoulder exam and range of motion back
and neck exam should have been
performed. Tr. 335. He did not make an
adequate assessment of pain, nor
physical and psychological function, of
medical history, of history of substance
abuse, coexisting diseases and
conditions, periodic review of care,
written treatment plan nor alternate
treatments. Tr. 349–51. He did not
conduct any periodic reviews, nor
discuss the risks and benefits of the use
of controlled substances. Tr. 349–50.
Her employment as a server, working
forty to sixty-five hours per week is
inconsistent with her ‘‘occupational
disability’’ score of 9 or 10, which Dr.
Kennedy described as a significant
conflict. Tr. 344–45; GX 7 at 3, 9, 10. Dr.
Kennedy noted the hand-written exam
notes did not appear in the electronic
*M Dr. Kennedy opined that the ‘‘spinal surgery
. . . definitely supported being on scheduled
medications. [But] [t]hat’s not even referenced in
the medical record.’’ Tr. 328. Accordingly, Dr.
Kennedy opined that Respondent failed to
document a ‘‘recognized medical indication for the
use of the controlled substances, which were
prescribed.’’ Id.
VerDate Sep<11>2014
18:06 Jan 18, 2022
Jkt 256001
medical records, Tr. 325–36; GX 7 at 68,
rather, the medical records reflected the
same PE notes duplicated throughout
the medical records for all of the
patients at issue. Tr. 336, 351. The pain
level is reported as 9, which is
inconsistent with the PE indications. Dr.
Kennedy indicated notes generated at
the initial visit appeared to be a
reminder to obtain certain prior medical
records from Dr. M. Tr. 337, 468; GX 7
at 1, 68. Those same notes appear in the
record repeatedly thereafter. Tr. 337; GX
7 at 59. Other than the requested
pharmacy report, the prior records were
never obtained. Tr. 338–39. The
Respondent did not maintain accurate
and complete records as to M.P., [and
the chart contained language that was
verbatim as other medical charts.] Tr.
350–51.
At M.P.’s initial visit, a UDS was
performed revealing inconsistent
results, which were never addressed in
the records. Tr. 338; GX 7 at 19, 68.
Notes reveal M.P. had been terminated
from a prior physician, which is a red
flag. Tr. 343. The records did reveal a
monitoring of the Tennessee PDMP, and
a successful pill count. Tr. 470. There
were emergency room notes, which
revealed she was admitted on April 17,
2018, and released on April 18 for
apparent heroin overdose, which
occurred in the Respondent’s waiting
room. Tr. 340–41; GX 7 at 25. [Dr.
Kennedy testified that, aside from the
ER records, ‘‘there is not a note in the
chart that specifically refers to this
patient overdosing or going
unresponsive in the waiting room.’’ Tr.
341.] At the next encounter, the
Respondent discontinued the previous
prescriptions for controlled substances,
discussed drug rehab with M.P., which
she declined to pursue, and prescribed
buprenorphine, an opioid abuse
treatment. Tr. 342. Dr. Kennedy viewed
this course of action as dangerous and
outside the standard. Tr. 342, 371–73,
465–66. As the patient was shown to be
on heroin, a UDS would be necessary to
determine if she had heroin in her
system before prescribing
buprenorphine, which in conjunction
with heroin could result in permanent
withdrawal. Tr. 343. There were
inconsistent UDS in the records for M.P.
Tr. 346; GX 7 at 48, 59.
Dr. Kennedy reviewed the
prescriptions issued. Tr. 348–49; GX 21.
He opined that the chart, including the
number of inconsistent UDS, reveals
that [Respondent should have been
concerned that M.P. had a habit of
being] addicted to controlled
substances, yet the Respondent
continued prescribing them without
making a bona fide effort to cure the
PO 00000
Frm 00013
Fmt 4701
Sfmt 4703
2997
addiction, until after she overdosed on
heroin. Tr. 348. The subject
prescriptions, as well as those
prescribed to the other charged patients,
were dangerous *N and were issued
without medical justification and
outside the usual course of professional
practice. Tr. 352, 488–89.
DEA Special Agent (SA1)
SA1 is a Special Agent with the Drug
Enforcement Administration, and has
been for ten years. Tr. 498. He attended
the Special Agent Academy in 2009. Tr.
498. He has been involved in three or
four investigations surrounding
prescriptions. Tr. 498. He served as case
agent for the current investigation. The
first search warrant was executed on
February 27, 2018, at the clinic and at
the Respondent’s residence in
Clarksville, Tennessee, where paper
records, patient files, financial records
and digital evidence from several
computers were seized. Tr. 500. The
second warrant was served on the
Respondent’s clinic in Millersville,
Tennessee in September, 2018. Tr. 500.
SA1 authenticated GX 5 as seized from
the Respondent’s clinic. Tr. 502–03.
SA1 noted that some medical
documents provided by UC to the clinic
were not found during the searches. Tr.
503–04. SA1 authenticated GX 7 as
medical records of M.P. seized from the
Respondent’s clinic. Tr. 505. SA1
authenticated GX 9, as the medical
records of M.W. seized from the
Respondent’s clinic. Tr. 506. SA1
authenticated GX 11 as medical records
of C.F. seized from the Respondent’s
clinic. Tr. 507. SA1 authenticated GX
13, as the medical records of B.C. seized
from Respondent’s clinic. Tr. 508. SA1
authenticated GX 15, as the medical
records of M.H. seized from the
Respondent’s clinic. Tr. 509–10. These
complete records were supplied to the
Government’s medical expert, Dr.
*N Dr. Kennedy went on to testify that all of the
controlled substances prescribed to the individuals
at issue (other than the undercover) were
‘‘dangerous.’’ Tr. 352. He stated, ‘‘[c]ontrolled
substances are dangerous. . . . [In the] context that
we’re talking about, because of the abnormal drug
screens that were essentially ignored, and the
documentation about the patient’s status was not
done. In the face of sometimes very alarming
patient red flags, I would say that it was clearly
dangerous.’’ Id. Dr. Kennedy further opines, ‘‘none
of the medical records are credible and . . .
maintaining a patient on scheduled medications
. . . sometimes at high dosages, without having
honest, accurate, complete medical records is
dangerous.’’ Tr. 352–53. This is because, according
to Dr. Kennedy, ‘‘those medical records will
instruct other people who look at them as to what
the motivation was for the treatment . . . [a]nd if
what is documented in the medical record simply
doesn’t made sense or is something that is in
conflict . . . [t]hat can . . . present a dangerous
situation.’’ Tr. 353.
E:\FR\FM\19JAN2.SGM
19JAN2
2998
Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices
jspears on DSK121TN23PROD with NOTICES2
Kennedy. Tr. 511–12. Additionally
supplied to the expert were PDMP
reports, the missing records supplied to
the clinic by UC and the video of the
undercover encounters. Tr. 512.
DEA Diversion Investigator (DI)
DI is a Diversion Investigator with the
Drug Enforcement Administration. Tr.
519–20. She has been with DEA for ten
years. She has been involved in 15–20
investigations involving physicians
prescribing controlled substances. As
part of the current investigation, she
collected relevant prescriptions, and
processed the documents in support of
the Order to Show Cause. Tr. 520. She
identified the Respondent’s DEA
Registration. GX 1. She authenticated
GX 18, which include the prescriptions
the Respondent issued to UC, which she
obtained from various pharmacies. Tr.
521–22. She authenticated GX 19,
which are the prescriptions the
Respondent issued to M.H., which DI
obtained from various pharmacies. Tr.
523–24. She authenticated GX 20,
which are the prescriptions the
Respondent issued to C.F., which DI
obtained from various pharmacies. Tr.
524–25. She authenticated GX 21,
which are the prescriptions the
Respondent issued to M.P., which DI
obtained from various pharmacies. Tr.
526. She authenticated GX 22, which
are the prescriptions the Respondent
issued to B.C., which DI obtained from
various pharmacies. Tr. 527. She
authenticated GX 23, which are the
prescriptions the Respondent issued to
M.W., which DI obtained from various
pharmacies. Tr. 528. She authenticated
the Respondent’s application for
renewal of his DEA Registration for the
State of Tennessee, # 59889, which was
submitted on November 6, 2019. Tr.
529–30; GX 26.
She explained the significance of
Question Three on the application, a
‘‘liability’’ question. It queries whether
the applicant has ever surrendered for
cause, or had a state professional license
or controlled substance registration
revoked, suspended, denied, restricted,
or placed on probation, or have any
such action pending. Tr. 530–31. An
affirmative answer to Question Three
would trigger an investigation by a
diversion investigator whether to issue
the registration or to deny it. The
Respondent answered ‘‘No’’ to Question
Three. Tr. 531; GX 26.
She also authenticated GX 29, the
State of Tennessee Department of
Health, Notice of Charges and
Memorandum for Assessment of Civil
Penalties. Tr. 531–32. She also
authenticated GX 27, an order from the
Chancery Court for the State of
VerDate Sep<11>2014
18:06 Jan 18, 2022
Jkt 256001
Tennessee, 20th Judicial District,
Davidson County, Part 3, reversing
Denial of Stay, but Accompanying Stay
with Conditions. Tr. 532–33. DI noted
that as of May 2019, the Conditions
preclude the Respondent from writing
prescriptions or providing direct patient
care during the pendency of the stay. Tr.
533–34. DI authenticated GX 28, An
Agreed Order with the State of
Tennessee, in which the Respondent
was required to surrender his Pain
Management Certificate, a professional
license, in 2018, and prior to his
application for registration in 2019. Tr.
534–35; GX 26; GX 28. DI authenticated
GX 25, an Emergency Order of
Restriction from the Commonwealth of
Kentucky board of License, issued on
January 15, 2019, which again predates
his subject DEA application, and is a
further restriction on a professional
license. Tr. 537–39.28 DI explained that
although GX 28 related to the surrender
of the pain clinic license and GX 26 was
the Respondent’s personal application,
as the Respondent applied for the pain
clinic license himself, it constitutes a
surrender of his license, warranting an
affirmative response to question 3 of his
DEA application. Tr. 542–43; GX 26.
Additionally, the surrender is signed by
the Respondent individually. Tr. 545.
Respondent’s Case-in-Chief
The Respondent presented his casein-chief through the testimony of one
witness, the Respondent, Samson K.
Orusa, M.D.
Samson K. Orusa, M.D.
Dr. Orusa was born in Bayelsa,
Nigeria. Tr. 547. Dr. Orusa finished his
medical education at a fully accredited
medical school in Benin City, Nigeria
and worked for a year in Nigeria. Tr.
548. He completed a one-year rotational
internship in internal medicine,
pediatrics, surgery and OBGYN at the
University of Port-Harcourt Teaching
Hospital. Tr. 549–50. He then spent a
year doing outpatient care at a rural
primary healthcare center. Thereafter,
he entered private practice in Lagos,
Nigeria in 1989. In 1992, Dr. Orusa
immigrated to the United States to
advance his medical training. He
28 Although relevant testimony herein, the
January 15, 2019 restriction as to the Respondent’s
Kentucky license does not constitute a ground for
the material falsification allegation. It was neither
charged in the OSC or the Government’s Prehearing Statements. Nor was it noticed by the
Government at the time of its offering as a proposed
additional charge under the principle of ‘‘litigation
by consent.’’ Where the Government has not
provided notice of a particular charge yet produces
evidence on that charge, and does not argue that the
issue was litigated by consent, the charge cannot
form the basis for revocation. Cove Inc., d/b/a
Allwell Pharmacy, 80 FR 29,037, 29,039 (2015).
PO 00000
Frm 00014
Fmt 4701
Sfmt 4703
completed a three-year residency
program in internal medicine at
Columbia University, College of
Physicians and Surgeons in 1996. Tr.
551. He obtained his Tennessee medical
license, and with his certification in
internal medicine, he was hired at a
clinic in Clarksville, Tennessee. Tr. 552,
555. He was admitted to practice at
Memorial Hospital. In 1997, he opened
his own clinic in Clarksville, where he
had a general medical practice. In 2004,
he began concentrating on pain
management. Tr. 553. In 2017, he was
board certified by the American Board
of Interventional Pain Physicians as a
specialist in interventional pain
medicine. Tr. 553, 555. His extensive
training involved the use of deep
injections, spinal nerve blocks, nerve
injections, foraminal blocks, and
epidural injections. Tr. 553–54. By
2018, he held sufficient certification to
operate his own pain clinic in
Tennessee. Tr. 555.
From 1998 to 2017, the clinic
transitioned from primary care to pain
management, but even by 2017, he still
had primary care patients. Tr. 557–58.
Initial visits required appointment,
which were scheduled for the first thing
in the morning. Returning pain patients
were permitted to walk in without
appointments. Tr. 558. He has had a
staff of ten, including a nurse
practitioner and physician’s assistant.
Tr. 559. By 2017, his pain management
practice included deep tissue injections,
cervical, lumbar and thoracic nerve
blocks, sacroiliac joint injections, and
bursitis injections. Tr. 60. In 2018, the
frequency of injections increased as the
Respondent began performing injections
under fluoroscopy. Tr. 560.
The Respondent had a protocol for
new pain patients. Tr. 561. Some of
these protocols were in writing, but not
produced at the hearing. Tr. 620. They
were required to bring a referral letter or
letter of dismissal from their previous
physician, any imaging reports, records
from their last three medical visits and
their pain medication. Tr. 561–62, 572.
If the patient did not produce the
materials, the clinic staff would attempt
to obtain them. Tr. 564–66. The initial
visit typically takes all day, as the
patient must fill out extensive
documentation (twenty pages with 252
questions), which is necessary for
diagnosis and selection of treatment. Tr.
566–67. Seventy-five questions relate
strictly to pain. It includes pain
disability index, depression assessment,
drug-use history and social history.
There is a pain management agreement.
Tr. 571–72. The staff explains the side
effects, the addiction process and the
E:\FR\FM\19JAN2.SGM
19JAN2
Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices
jspears on DSK121TN23PROD with NOTICES2
resources to help with addiction. Tr.
572.
The charts often contained the exact
same language for indications of anxiety
and insomnia. Tr. 633–34. The
Respondent explained that the language
was often identical as anxiety patients
typically share the same symptoms. Tr.
634–36.
Undercover
The Respondent took a medical
history, a condition-specific physical
exam for low back pain, reviewed the
MRI (GX 6) of UC. Tr. 575–80. The
Respondent noted that his physical
exam of UC was not captured by the
video of the encounter. The camera was
pointed at the wall. Tr. 581–82. The
Respondent spent no more than fifteen
minutes with UC in the examination
room. Tr. 621. The Respondent
performed the required assessments
related to pain, physical and
psychological function, and history and
potential for drug abuse. Tr. 582. This
involved the paperwork UC filled out,
authenticating that paperwork, the
triage of UC by staff, UDS, and a final
review of the paperwork by the
Respondent with the patient. Tr. 583,
584. Although UC’s chart contains an
entry that his pharmacy printout was
reviewed, the Respondent conceded that
no pharmacy printout was reviewed and
that such entry was in error. Tr. 631–32;
GX 5 at 6. UC was a challenge as the
clinic he reported had been closed, and
he could not obtain the pharmacy
information, so the Respondent could
not verify that source. Tr. 583–85.
The Respondent expected his patients
to be honest and truthful with him,
consistent with the DEA Physician’s
Manual, which requires patients to be
honest with their doctors. Tr. 586–87.
The Respondent explained that a
patient’s pain is very subjective. After
reviewing his paperwork, including the
MRI, examining UC, and speaking with
him, the Respondent had no reason not
to treat him as someone who had
genuine pain. Tr. 588. UC’s statement
that he had used controlled substances
for his pain and that ibuprofen was not
working supported the conclusion that
his pain was long-standing, and
warranted a Schedule II medication. As
UC’s prior medical records could not be
confirmed, the Respondent prescribed a
dosage appropriate to a patient just
starting opioid treatment. Tr. 589–90.
The Respondent testified that he
prepared a written treatment plan with
appropriate treatment goals and therapy.
Tr. 590–91.
The Respondent explained that his
electronic medical record often referred
to other records. For example under
VerDate Sep<11>2014
18:06 Jan 18, 2022
Jkt 256001
history of present illness (HPI), he
would often reference the initial
encounter paperwork as included in the
electronic record. Tr. 592. He also
explained that he performed a physical
exam at the initial visit of each of his
patients, as required by the Tennessee
pain management guidelines. Tr. 594.
Physical exams thereafter are at the
discretion of the physician. Tr. 594.
Although UC had five visits to the
clinic, only two involved encounters
with the Respondent. The other three
visits were ‘‘level one’’ visits, in which
UC met with the Respondent’s staff
only. Tr. 622–28, 645–50. Although the
medical records reflect a physical
examination took place at the level one
visits, the Respondent explained that it
was permissible in medical recordkeeping to carry forward results from
prior examinations to later visit records,
with new findings added. Tr. 623–28.
Patient M.W.
M.W. was first seen in January 2013.
Tr. 595. M.W. was a gunshot victim to
whom the Respondent prescribed
alprazolam. This was based on the
history and physical exam. Tr. 593. Tr.
635–36; GX 9 at 69. The Respondent
obtained a medical history, conducted a
physical exam, performed an adequate
pain, physical, and psychological
assessment, history and potential for
substance abuse. Tr. 596. The evaluation
of the patient’s potential for drug abuse
is an ongoing evaluation with UDS,
involving both office screens,
confirmatory lab screens, and pill
counts. Tr. 596–98, 600. Once an
inconsistent UDS is discovered, the
Respondent initiates a dismissal
process. Tr. 598–600. The Tennessee
pain management guidelines leave it to
the physician’s discretion on the
handling of confirmed inconsistent UDS
results. Tr. 598–99. The Respondent
gives the patient a month to come into
compliance. Tr. 600. If he has a
consistent UDS within the month, the
patient is permitted to remain in
treatment. Tr. 601. The Respondent was
able to bring M.W. back into compliance
through counseling; however, the chart
only documents that the patient was
counseled as to the inconsistent UDS.
Tr. 637–38. The Respondent prepared a
written treatment plan. Tr. 601.
Patient C.F.
Patient C.F. had a stab wound to the
chest, requiring heart surgery, resulting
in residual chronic pain. Tr. 601. The
Respondent took a medical history,
performed a physical exam, adequate
pain, physical and psychological
assessments, and evaluated her history
and potential for substance abuse. Tr.
PO 00000
Frm 00015
Fmt 4701
Sfmt 4703
2999
601–02. The Respondent noted that he
had the benefit of confirmatory records
from Vanderbilt University Medical
Center. Tr. 602. The Respondent
explained that the MED prescribed to
C.F. was a relatively low dose of 82.5,
noting the 120 MED threshold in which
primary care physicians in Tennessee
must consult with pain management
specialists. Tr. 603–05.
Patient B.C.
Patient B.C. was referred from jail on
December 19, 2012. The Respondent
noted the pain management guidelines
have changed since then. Tr. 605. The
Respondent explained why he kept
pharmacy printouts in his records
because they are easier and quicker to
obtain than medical records. Tr. 606.
The pharmacy printout informs how
long the patient has been prescribed
medications, changes in dosage, and the
prescriber. Tr. 607. Each of the
Respondent’s patient records contained
the instruction, ‘‘rule out doctor
shopping,’’ which was a prompt to
review the Tennessee PDMP to
determine if the patient was obtaining
controlled substances from multiple
physicians. Tr. 608.
The Respondent took a medical
history, performed a physical exam,
adequate pain, physical and
psychological assessments, and
evaluated his history and potential for
substance abuse, and prepared a written
treatment plan. Tr. 608. Although the
Respondent described the extensive
forms each patient is required to fill out
at the initial visit, some of the described
forms, which were referenced in B.C.’s
chart, were missing from the
Respondent’s records as relates to B.C.
Tr. 628–29; GX 13 at 5. The Respondent
explained that some records were lost in
2014. Tr. 630. The missing records were
not recreated as B.C. was a long-term
patient. Tr. 630.
Patient M.H.
Patient M.H. presented with a post
gunshot wound to the abdomen and
chronic low back pain secondary to
degenerative disc disease. Tr. 608. He
had already been treated for pain
management. He had a history of
extensive spinal surgery at Vanderbilt
University Medical Center, including a
laminectomy. Tr. 609–11. The
Respondent prescribed a lower MME
than the surgeon prescribed postoperative at Vanderbilt. Tr. 611. The
Respondent’s medical findings as to
Patient M.H. for the visit just prior to
M.H.’s major back surgery are the same
as the Respondent’s findings for the
visit the day after the surgery. Tr. 637–
38; GX 15 at 48–50. The Respondent
E:\FR\FM\19JAN2.SGM
19JAN2
3000
Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices
explained that the subject findings were
based on history. Tr. 638.
The chart reports M.H. has been
‘‘compliant,’’ however, on the next page
of the chart, it reports M.H. had an
inconsistent UDS. Tr. 638–40; GX 15 at
48–49. The Respondent explained that
the inconsistent UDS related to the
point of care test, not the confirmatory
lab test, so the chart was accurate. Tr.
640. M.H.’s chart contains apparently
inconsistent findings of long-term
insomnia, but with an entry of sleeping
well. Tr. 640–41; GX 15 at 47–48. The
Respondent conceded these were
inconsistent entries. Tr. 641.
jspears on DSK121TN23PROD with NOTICES2
Patient M.P.
Patient M.P. was being managed for
chronic pain. In her initial visit, she
reported conflicting information
regarding whether she had been in drug
rehab treatment. Tr. 641–42; GX 7. The
Respondent explained that he could
only rely on the information provided.
Tr. 642. Initially, in September of 2016,
the Respondent requested dismissal
records, an X-ray and an MRI from Dr.
M. Tr. 642–44; GX 7 at 48. Yet, eighteen
months later, the Respondent still had
not received the requested records. Tr.
644; GX 7 at 59.
Ultimately, she came to the clinic
overdosing on heroin. Tr. 611–12. She
had to be resuscitated until EMS was
able to reverse the effects of heroin with
Narcan. Tr. 612. In the post-overdose
notes the Respondent took an extensive
history again regarding her drug use. He
directed she cannot be on pain
management but must be on opioid
abuse treatment. So, the Respondent
started her on Suboxone. Tr. 613. The
Respondent explained his
understanding of Suboxone induction.
The first type of induction therapy is by
observation. You give the patient
Suboxone and observe them until they
reach the point of withdrawal. The other
form of induction is to give the patient
Suboxone and send her home without
observation by the physician. Tr. 612–
14. M.P. was initially receptive to drug
treatment, but later changed clinics. Tr.
615.
The Respondent took a medical
history, performed a physical exam,
adequate pain, physical and
psychological assessments, and
evaluated her history and potential for
substance abuse, and prepared a written
treatment plan. Tr. 615–17. Following
the heroin overdose, the determination
was made that she needed treatment of
Suboxone and no further opioid
prescriptions. Tr. 616.
VerDate Sep<11>2014
18:06 Jan 18, 2022
Jkt 256001
The Facts
Stipulations of Fact
The Government and the Respondent
have agreed to 1, 2 in part, 3, 4, 5, 6,
7 stipulations, which I recommend be
accepted as fact in these proceedings:
1. The Respondent is registered with
the DEA as a Practitioner authorized to
handle controlled substances in
Scheduled II–V under DEA COR No.
BO4959889 at 261 Stonecrossing Drive,
Clarksville, Tennessee 37042. DEA COR.
No. B04959889 expires by its terms in
December 31, 2019.*O
2. On July 6, 2018, the Respondent
submitted an application (No.
W18070589C) for a new DEA COR at
316 Pappy Drive, Oak Grove, Kentucky
42262. On January 15, 2019, the
Commonwealth of Kentucky, Board of
Medical Licensure, issued an
Emergency Order of Restriction
prohibiting Respondent from
‘‘prescribing, dispensing, or otherwise
professionally utilizing controlled
substances.’’ See 201 KY. ADMIN. REGS
9:240 Section 1 and 3. Thus the
Respondent is currently without
authority to handle controlled
substances in the Commonwealth of
Kentucky.
3. Soma is a brand name of
carisoprodol, a Schedule IV controlled
substance.
4. Percocet is a brand name for
oxycodone, a Schedule II controlled
substance.
5. Oxycodone is a Schedule II
controlled substance.
6. Oxymorphone is a Schedule II
controlled substance.
7. Alprazolam is a Schedule IV
controlled substance.
Findings of Fact
The factual findings below are based
on a preponderance of the evidence,
including the detailed, credible, and
competent testimony of the
aforementioned witnesses, the exhibits
entered into evidence, and the record
before me.
The Government’s case was largely
based on (1) several undercover visits to
Respondent’s medical office by UC; (2)
the medical charts and prescriptions
pertaining to UC as well as to five other
patients, M.H., M.W., C.F., B.C. and
M.P.; and (3) the testimony of Gene
Kennedy, M.D., the Government’s
expert.
The Undercover Operation
1. UC is currently an Assistant Special
Agent in Charge with the Tennessee
*O According to Agency records, this application
is pending renewal and has not expired.
PO 00000
Frm 00016
Fmt 4701
Sfmt 4703
Bureau of Investigation. Tr. 30. [Omitted
to preserve identity of UC.]
2. UC testified that he was contacted
by a Special Agent with the United
States Department of Health and Human
Services, Office of the Inspector
General, to conduct an undercover
operation at Respondent’s clinic. Tr. 33–
34. In preparation for this operation, UC
contacted Respondent’s clinic to set up
an appointment. Tr. 34. He was told to
bring several items to the appointment,
including an MRI report, prior ‘‘chart
notes’’ from his previous physician, a
discharge summary from his previous
physician, and documentation showing
his last three months of prescriptions.
Tr. 35.
October 3, 2017 Visit
3. UC testified he arrived at
Respondent’s office on October 3, 2017,
at approximately 8:00 a.m. Tr. 40. He
testified that he paid $311 for this
appointment. Tr. 49. He recorded
portions of the visit on a ‘‘covert video
camera device embedded’’ in a cell
phone case. Tr. 42–43. Upon arrival, he
provided an MRI report from September
2, 2016, that he testified was ‘‘authentic
in the sense that it was my physical
MRI.’’ However, the physician’s name
on the report had been altered. Tr. 35,
37; GX 6 at 8–9. UC also provided
‘‘fabricated’’ medical records which
appeared to be signed by a nurse
practitioner in Missouri. This nurse
practitioner, according to UC, was no
longer practicing in October 2017. Tr.
37–8; GX 6 at 10–11. UC did not provide
a discharge summary or any
prescription information. Tr. 39–40;
133. Nor did he provide any documents
to show he had undergone a prior
physical examination. Tr. 133.
4. After providing the materials, UC
was given what he estimated to be
approximately twenty pages of
paperwork to fill out, none of which
was included in his medical file seized
later by DEA. Tr. 40; GX 5. However, UC
took photographs of the forms before
turning them in. Tr. 100. When asked to
state his pain level, UC testified he told
the clinic staff that it was ‘‘9’’ out of
‘‘10’’ (‘‘9/10’’), but when he was
examined, he exhibited no overt
indications of pain. Tr. 47, 56. 95. In
fact, on one of the forms, he listed his
quality of life as nine out of ten. Tr.
131–32. On another form, he rated his
pain disability as only two out of ten.
Tr. 132. On one form, he also denied he
suffered from insomnia, Tr. 132–33, but
wrote on another form that he sought to
work without pain and sleep through
the night. Tr. 135. No one questioned
him about these contradictions. Tr. 139.
UC acknowledged that he filled out
E:\FR\FM\19JAN2.SGM
19JAN2
jspears on DSK121TN23PROD with NOTICES2
Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices
forms at his first appointment on
October 3, 2017, and took photographs
of the forms. Tr. 100. The completed
documents, however, were not part of
the Respondent’s medical file seized by
DEA and were not offered as exhibits by
either party. Tr. 100; GX 5.
5. UC testified that one of the
Respondent’s employees apparently
questioned the authenticity of the
records he provided, stating that people
are trying to ‘‘bring down Dr. Orusa.’’
Tr. 41–42. This employee was not
named, but was identified as the person
depicted in GX 30. UC testified that,
after providing the paperwork, his vital
signs were recorded, including his
blood pressure. He was also asked about
his weight and asked to give a urine
sample. Tr. 44–45.
6. UC described the October 3, 2017
visit as follows. He testified that he
made no attempt to demonstrate that he
had a disability. He did not limp or
change his gait. Tr. 45–46. Though UC
arrived at the clinic at approximately
8:00 a.m., he did not meet with
Respondent until approximately 4:00
p.m. Tr. 47–48. During UC’s encounter
with Respondent, UC informed
Respondent that the last ‘‘pain clinic’’
he visited was ‘‘Dr. Chapman in Pierce,
City, Missouri, and had recently ‘‘closed
down.’’ GX 4 at 1. He also told
Respondent that the person who
ordered his MRI was ‘‘Dr. Morgan,’’ a
fictitious person. Tr. 37; GX 4 at 2.
There was also a discussion about UC
providing ‘‘pharmacy information.’’ GX
4 at 3. UC told Respondent he would
‘‘get those records if I need to’’ but did
not know the pharmacy’s phone
number.
7. UC testified that he did not produce
any additional records. Tr. 55. UC
testified that, during his meeting with
Respondent, he saw Respondent ‘‘going
through some forms on the counter,’’
but could not determine what
Respondent was reviewing. Tr. 105. UC
testified that he told Respondent he fell
while unloading a truck in 2013. Tr.
117; GX at 1. He told Respondent that
he was managing his pain with over-thecounter medications. Tr. 104. Though
he told Respondent that he could
‘‘barely function,’’ he did not
‘‘elaborate’’ and there was no further
discussion about this statement. Tr. 124;
GX at 2; GX 17. UC testified that, in
response to Respondent’s question
about a previous diagnosis, he told
Respondent that a previous medical
provider told him he had degeneration
of some sort and ‘‘some arthritis.’’ Tr.
105–06; GX at 1.
8. UC testified that Respondent
performed a cursory physical exam
described as ‘‘less than 60 seconds of
VerDate Sep<11>2014
18:06 Jan 18, 2022
Jkt 256001
any kind of physical touching.’’ Tr. 56.
He testified that Respondent instructed
him to remain seated and UC ‘‘just told
[Respondent] where the pain was. If he
did something and asked me if it hurt
I would respond that I felt pain in that
area.’’ Tr. 56. He testified that he made
no ‘‘faces’’ and did not ‘‘wince’’ when
touched. Following the exam,
Respondent inquired about UC’s past
pharmacy records. UC told Respondent.
‘‘I’ll get those records if I need to.’’ Tr.
108–09; GX at 3. UC testified that
Respondent wanted to do ‘‘injections,’’
but UC refused. Tr. 117. According to
the transcript of the meeting, UC told
Respondent that he hated needles. GX at
3.
9. Approximately 30 minutes after he
left the exam room, UC received a
prescription for 42 tablets of 10 mg
oxycodone, even though he never asked
for oxycodone. GX 18 at 1; Tr. 57.
During the encounter with Respondent,
UC said that he had previously been
given hydrocodone, Xanax (alprazolam)
and ‘‘oxys.’’ GX 4 at 2. He also told
Respondent that he was currently
managing his pain with ‘‘Advil this past
month’’ and had been ‘‘miserable.’’ Id.
UC testified that he also received two
other prescriptions for non-controlled
substances, including Flexeril
(cyclobenzaprine) and meloxicam. Tr.
58.
10. When asked why, he told
Respondent he had lower back pain as
opposed to pain in some other area, UC
testified that, due to his exercise
schedule, which including running five
to seven miles each day, a practitioner
might find objective evidence to justify
complaints of knee, ankle, or shoulder
pain. Here, he testified, he had
‘‘absolutely no back pain whatsoever.’’
Tr. 114–15. He testified that, if
Respondent’s clinic had been ‘‘doing
their job,’’ he would ‘‘not expect to walk
out with a prescription.’’ Tr. 105. Also,
in his experience as an undercover
operative, he testified that ‘‘more often
than not’’ he has been refused
prescriptions for controlled substances
on the first visit. Tr. 123–24.
11. A video recording of UC’s meeting
with Respondent was played during the
hearing. GX 17. UC testified that the
video portion was a fair and accurate
recording of his ‘‘entire encounter with’’
Respondent on October 3, 2017. Tr. 55.
UC also testified that the transcript of
that encounter (GX 4) was an accurate
representation of the recording. Both the
recording and the transcript were
accepted into the official record. GX 4,
17; Tr. 70–71, 187–88.
PO 00000
Frm 00017
Fmt 4701
Sfmt 4703
3001
October 17, 2017 Visit
12. UC testified that, in order to
receive more ‘‘narcotic prescriptions,’’
he was required to come in for a ‘‘wellcare’’ visit before making an
appointment during which he would
receive narcotics. Tr. 57–58. On October
17, 2017, he returned to the clinic and
paid $25 for the visit. Tr. 57–59; GX 4,
GX 17. He was then called back to a
‘‘triage room’’ and asked about his
weight and blood pressure. Tr. 59.*P He
saw the Respondent for ‘‘about one
minute,’’ during which Respondent
asked him if he slept well. When he
responded, ‘‘not really,’’ Respondent
wrote him a prescription for
amitriptyline. Tr. 59; GX at 4. This
encounter was also recorded. GX 17. UC
testified that, during this visit, no
physical exam was performed. Tr. 71–
72. He testified that no one examined
his lower back, extremities, or checked
his muscles. Tr. 72.
October 18, 2017 Visit
13. UC testified that, on October 18,
2017, he returned to the clinic for refills
of narcotic medications. Tr. 74. Because
the clinic would no longer accept cash,
he secured a debit card to pay for the
appointment, which cost $377. Tr. 75–
76. During the October 18, 2017
appointment, UC waited approximately
two and a half hours. He was not
examined and he met with medical
personnel only for the purpose of
paying the fee and receiving his
prescription. There was no discussion
about his medical condition and he
provided no medical records. Tr. 76–77.
At the end of this visit, he received a
prescription for 84 tablets of 10 mg
oxycodone, twice as much as he
received 15 days earlier. Tr. 78; GX 18
at 3–4.
November 15, 2017 Visit
14. UC testified that, on November 15,
2017, he returned to the clinic for a
fourth time. On this visit, he testified
that he paid $25, ‘‘waited for some
amount of time,’’ was ‘‘asked’’ about his
weight and blood pressure, and was
dismissed. Tr. 83–84.
November 20, 2017
15. UC testified that, on November 20,
2017, he returned to the clinic for a fifth
time. He described this as a ‘‘medication
visit.’’ Tr. 87. UC testified that, during
this visit, he wrote down his name on
*P This section of the Recommended Decision
included several superscript numbers in the body
of the text without any corresponding text in
footnotes. As I believe that the superscript text was
likely the result of a scrivener’s error, I have deleted
them throughout this section without further
demarcation.
E:\FR\FM\19JAN2.SGM
19JAN2
3002
Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices
jspears on DSK121TN23PROD with NOTICES2
a clipboard, ‘‘paid a certain amount of
money,’’ and waited a ‘‘certain amount
of time’’ before he was given his
prescriptions. Tr. 87–8. UC testified that
he was asked to provide a urine sample
to which he added ‘‘a vial of a substance
that would cause me to test positive for
oxycodone.’’ Tr. 88. At this visit, he
received another prescription for 84
tablets of 10 mg oxycodone. GX 18 at 4;
Tr. 89.
Falsified Medical Records
16. UC identified numerous entries in
his medical record that indicated his
medical chart had been fabricated. For
instance, on October 17, 2017,
Respondent wrote that UC exhibited a
number of ‘‘[a]nxiety symptoms’’ such
as shortness of breath, ‘‘palpitations,
sweating, dizziness, [and] shaking.’’ GX
5 at 5. UC testified that he never
reported any of these symptoms. Tr. 79–
80. Respondent also wrote that UC
reported ‘‘no headache, no dizziness, no
nausea, no vomiting, no abdominal
pain, no diarrhea, no constipation, no
[shortness of breath], no chest pain,
[and] no palpitations.’’ GX 5 at 5. UC
testified that he was never asked about
any of these symptoms. Tr. 80–81. UC
was also asked about a notation for
October 17, 2017, where his weight and
blood pressure were recorded. GX 5 at
5. He testified that he was neither
weighed, nor did anyone measure his
blood pressure on that day. Also, on
October 17, 2017, Respondent wrote
‘‘Chest: no deformities, no asymmetry,
no rales, no wheezes, normal vesicular
breath sounds.’’ GX 5 at 5. UC testified
that no one ever examined his chest or
evaluated his breathing. Tr. 81–82.
17. Regarding the medical records for
October 18, 2017, Respondent’s entries
for this appointment were identical to
those made the day before. Again, he
wrote ‘‘ROS for MSS is positive for
muscle pain, back pain, joint pain, and
body aches and pain.’’ GX 5 at 4.
Respondent again repeated the same
notations about UC’s chest and
breathing. However, all of this was
created on a day when UC did not see
the Respondent. Nor was UC examined
by anyone else at the clinic that day. Tr.
82–83.
18. With respect to the November 15,
2017 visit, Respondent repeated the
same notations even though, as UC
testified, no exams were performed and
Respondent was not there to see him.
Nevertheless, Respondent wrote out a
list of symptoms in the section marked
‘‘HPI,’’ GX 5 at 4, which correspond to
the visit on November 15, 2017. Again,
UC testified that none of these
symptoms were ever discussed and no
examination was performed. Tr. 86.
VerDate Sep<11>2014
18:06 Jan 18, 2022
Jkt 256001
Likewise, with respect to Respondent’s
notes in the section marked ‘‘PE’’
(physical exam),’’ UC testified that no
one examined his chest or breathing. Tr.
86–87.
19. Finally, regarding the November
20, 2017 visit, Respondent wrote, as he
had four times previously, that UC was
‘‘positive for muscle pain, back pain,
joint pain and body aches.’’ GX 5 at 3.
UC testified that no physical exam was
performed on this day. Tr. 90–91.
Respondent also, for the fifth time,
described a physical examination
(section ‘‘PE’’) that was never
performed. GX 5 at 3; Tr. 91.
20. UC also testified about the results
of his urine drug screening. He noted
that, despite adding an oxycodone
solution to his urine on November 20,
2017, his records showed ‘‘UDS ALL
NEG.’’ Tr. 91–92; GX 5 at 3. UC also
testified that there was no discussion
about this result. Tr. 92.
Expert Review
21. Dr. Kennedy testified as the
Government’s expert. Dr. Kennedy owns
a pain management clinic on St. Simons
Island, Georgia; has treated more than
1000 patients, but his current practice
involves fewer than 100 patients. Tr.
143–46. He testified that he has treated
patients with post-surgical issues,
patients with cancer pain, and patients
with back pain. Tr. 178–80. Most of his
patients, he testified, need to have their
medications ‘‘managed.’’ Tr. 143–44. Dr.
Kennedy testified that he has been
practicing pain management for
approximately 15 years. Tr. 145, 179–
80. He is licensed to practice medicine
in Georgia and runs a ‘‘state licensed
pain management clinic.’’ Tr. 146; GX
24. Dr. Kennedy is not board certified.
Tr. 373.
22. Dr. Kennedy testified that, in his
practice, he prescribes controlled
substances, including opioids such as
oxycodone and hydrocodone. Tr. 181.
He has treated insomnia and/or anxiety
with benzodiazepines, such as
lorazepam, diazepam, and alprazolam.
Tr. 181–82. He has also prescribed
muscle relaxants such as carisoprodol.
Tr. 181–82.
23. Dr. Kennedy has also lectured on
controlled substances ‘‘numerous
times’’ at the DEA training facility in
Quantico. He has taught at the National
Advocacy Center, and at various DEA
and Department of Justice (‘‘DOJ’’)
‘‘venues’’ around the country. Tr. 184–
85. He also taught a course for
pharmacists in Tennessee. Tr. 185.
24. Dr. Kennedy testified he has
served as an expert witness in numerous
cases, including those involving
physicians alleged to have improperly
PO 00000
Frm 00018
Fmt 4701
Sfmt 4703
prescribed controlled substances. Tr.
182. He estimates he has testified 13–14
times. Id.
25. As the Government’s expert, Dr.
Kennedy reviewed the medical charts
for patients UC (GX 5), M.P. (GX 7),
M.W. (GX 9), C.F. (GX 11), B.C. (GX 13),
and M.W. (GX 15). He also reviewed the
prescriptions for these patients (GX 18–
23), the undercover video created by
UC, the transcripts (GX 17 and 4) of that
video, and UC’s reports of his
undercover visits (GX 3). Tr. 183–84,
186–89; 213–16.
26. Dr. Kennedy explained that,
according to the minimal standard of
care for prescribing controlled
substances in Tennessee, a physician
must: (1) Take an adequate medical
history; (2) perform a physical
examination; (3) obtain past medical
records; (4) order diagnostic testing if
indicated; [and (5) maintain complete
and accurate medical records.] Tr. 189–
90, 195–96, 353.
27. Dr. Kennedy testified that,
according to the minimal standard of
care, a physician’s medical records
should contain the following; (1) past
medical records or attempts to obtain
past medical records; (2) a ‘‘pain
history’’ or ‘‘collection of statements
pertaining directly’’ to the patient’s pain
history; (3) history of ‘‘drug abuse,
chemical dependency, [or] alcoholism;’’
(4) records of a physical examination
‘‘that is specific and pertinent to the
problem;’’ (5) patient assessment; (6)
treatment plan; and (7) efforts to obtain
state pharmacy reports. Tr. 197. He also
testified he was familiar with Tennessee
regulations requiring a physician to
keep accurate and complete medical
records. Tr. 201.
28. Dr. Kennedy testified that, in cases
where physicians prescribe opioids in
combination with benzodiazepines, a
physician must have a ‘‘heightened
sense of vigilance managing the patient’’
and this should be noted in the medical
record. Tr. 190–91.
29. Dr. Kennedy testified that there
are indications of possible drug abuse
and/or diversion in patients whose
medical histories are ‘‘difficult to
obtain’’ as well as patients with ‘‘cloudy
histories of drug abuse.’’ Tr. 191–92. He
discussed urine drug screening (‘‘UDS’’)
and how a physician must respond if a
patient’s UDS result shows an
‘‘abnormality, it’s not simply enough to
just to say a patient’s urine is positive
for cocaine or positive for
methamphetamine. The physician also
has an obligation to say that the patient
is positive for this substance, and I
discussed it with the patient, and I’m
going to do this if it happens again or
I’m going to adjust the medications or
E:\FR\FM\19JAN2.SGM
19JAN2
Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices
not adjust the medications. And it has
to be something that is utilized as a
diagnostic treatment.’’ Tr. 194. Dr.
Kennedy further testified that the above
information should be documented in
the medical record. Id.
30. Dr. Kennedy testified that, prior to
testifying in this matter, he reviewed
Tennessee regulations pertaining to the
prescribing of controlled substances. He
confirmed that these regulations
included requirements that a physician
must (1) take the patient’s documented
medical history; (2) perform a physical
examination; (3) perform an adequate
assessment and consideration of the
patient’s pain, physical, and
psychological function: And (4) take a
history for the potential of substance
abuse.*Q Tr. 200. Dr. Kennedy also
testified that he was familiar with rules
prohibiting a physician from prescribing
controlled substances to a person
addicted to the habit of using controlled
substances without making a bona fide
effort to the cure the patient’s habit. Tr.
199.
31. Based on his qualifications and
expertise, his knowledge of Tennessee
regulations and statutes, and his
experience as an operator of a pain
management clinic, Dr. Kennedy was
accepted as an expert in pain
management qualified to give an expert
opinion regarding Respondent’s
prescribing of controlled substances. Tr.
211–12; 216.
Undercover
jspears on DSK121TN23PROD with NOTICES2
32. With respect to the undercover
officer, Dr. Kennedy testified he
reviewed the video recording UC made
during his visits to Respondent’s clinic
on October 3 and October 17 of 2017
(GX 17); UC’s investigative reports for
all five of his visits to Respondent’s
clinic; the patient medical file
pertaining to patient UC; and the
prescriptions issued to UC by the
Respondent. GX 3, 5, 17–18; Tr. 184–86,
216, 239.
33. Dr. Kennedy testified that, based
on his review, UC was being treated for
back pain. He testified that the physical
exam was inadequate, describing it as
‘‘cursory in that it consisted of
essentially observing’’ UC, ‘‘touching
his back, and having him lift his leg
once.’’ Tr. 217. Dr. Kennedy testified
that a minimally adequate exam would
*Q I find that Dr. Kennedy credibly testified that
the applicable standard of care in Tennessee is as
described in Finding of Fact Nos. 26–27 supra. The
requirements of the Tennessee regulations are
clearly components of and incorporated into the
standard of care set forth by Dr. Kennedy at Finding
of Fact Nos. 26–27. TENN. COMP. R. & REGS.
0880–02–.14(6)(e)(3)(i). Further, Dr. Kennedy’s
expert testimony is unrebutted in this proceeding.
VerDate Sep<11>2014
18:06 Jan 18, 2022
Jkt 256001
include ‘‘observing the patient’s back,
looking for muscle spasms, performing
‘‘lumbar range of motion maneuvers
where the patient . . . bends at the
waist in various directions,’’ doing a
neurologic exam, and doing a ‘‘straight
leg raised test having the patient laying
supine on the table.’’ Tr. 224–25. Dr.
Kennedy concluded that, based on the
medical records, there were no ‘‘positive
findings on physical examination.’’ Tr.
226. In other words, he testified,
Respondent’s ‘‘physical exam findings’’
failed to support a ‘‘pain ideology’’ and
certainly could not justify a reported
pain level of 9/10. Tr. 226–27, 234. With
respect to the Respondent’s diagnosis
(GX 5 at 2) of ‘‘[d]egeneration of
[l]umbar [i]ntervertebral [d]isc . . .
[l[umbar [s]pondylosis . . ., and
[i]nsomnia,’’ Dr. Kennedy noted that
even the MRI failed to mention
degenerative disc disease and Dr.
Kennedy could identify no other
findings to justify that diagnosis. Tr.
240–42. And though spondylosis could
be severe enough to ‘‘be causing
symptoms,’’ Dr. Kennedy testified that
there was no evidence that these
symptoms existed. Tr. 242. Dr. Kennedy
also testified that neither UC’s MRI
report, nor the prior medical records,
justified the prescribing of controlled
substances. Tr. 228, 230.
34. Looking at Respondent’s medical
record for patient UC, Dr. Kennedy
further concluded that the record was
rife with fabrications as the following
testimony indicates: ‘‘. . . if you look it
says on the second line, chest, no
deformities, no asymmetry. The only
way to determine [this] is to look at
them with their shirt off. And this
patient was not required to disrobe . . .
there is also no indication . . . that the
heart and lungs were evaluated. But
there are heart and lung evaluations as
well as the chest appearance . . . . you
couldn’t see everything, but clearly
listening to the audio, I didn’t hear any
breathe in, breathe out, anything that
would indicate to me that there was a
physical exam that included these
things.’’ Tr. 218–19. Dr. Kennedy further
noted that the description of UC’s
general exam in the section marked
‘‘PE’’ (GX 5 at 6) was not only
inaccurate, but was identical to
language he found in more than 20
medical charts he reviewed for other
patients. Likewise, Dr. Kennedy
disputed the truth of the information
supposedly used to support a finding
that UC suffered from insomnia. Tr. 233.
This was further confirmed by UC’s
testimony, in which he testified that he
neither reported nor manifested any of
the listed ‘‘insomnia’’ symptoms. Tr.
PO 00000
Frm 00019
Fmt 4701
Sfmt 4703
3003
79–80, 134–35, 139. Dr. Kennedy also
testified that the physical exam depicted
in the video (GX 17) as well as UC’s
subsequent encounters could not
possibly support the repeated findings
corresponding to visits on October 17
and 18, as well as the visits on
November 15 and 20. GX 5 at 3–5; Tr.
235–37.
35. Dr. Kennedy testified that UC, as
an undercover patient, also manifested
various ‘‘red flags’’ for possible drug
abuse and/or diversion. Tr. 230. He
noted that UC’s prior medical records
showed only a ‘‘single office visit’’ (GX
6 at 10) from a provider in another state
and documentation from the encounter
showed a ‘‘completely normal physical
exam with no positive findings at all.’’
Tr. 220–31. Dr. Kennedy testified that a
patient who comes from a clinic that has
closed and provides medical records
from a practitioner whose license has
been suspended are red flags for
diversion. He further noted that none of
these red flags was ‘‘significantly’’
addressed by Respondent prior to
prescribing oxycodone. Tr. 238.
36. In summary, Dr. Kennedy testified
that, with respect to UC, Respondent: (1)
Failed to discuss the risks and benefits
of the use of oxycodone; (2) failed to
maintain truthful and accurate medical
records; (3) failed to assess the patient’s
pain, physical and psychological
function; (4) failed to assess the
patient’s history and potential for
substance abuse; (5) failed to assess any
co-existing diseases, conditions in the
presence of a recognized medical
indication for the use of oxycodone; and
(6) failed to create and follow a
legitimate written treatment plan for the
patient’s individual needs. Tr. 231–32,
237–38. Dr. Kennedy further concluded
that Respondent’s prescribing of
controlled substances to UC was outside
the usual course of professional
practice. Tr. 239. Additionally, Dr.
Kennedy concluded that the
prescriptions issued to UC lacked a
medical justification. Tr. 239; see also
GX 6 (Dr. Kennedy’s expert report on
patient UC), 18 (prescriptions issued to
UC).
Patient M.W.
37. Dr. Kennedy testified that
Respondent treated M.W. for lower back
and limb pain. Tr. 245. M.W. was
prescribed alprazolam, carisoprodol
(Soma), oxycodone, and oxymorphone.
GX 23. In his review, Dr. Kennedy
stated that there was nothing that
meaningfully supported a chronic pain
condition. Id. Dr. Kennedy discussed a
form in M.W.’s file titled ‘‘Pain
Management Physical Exam.’’ (GX 9 at
14/GE 10 at 7). He testified that the form
E:\FR\FM\19JAN2.SGM
19JAN2
jspears on DSK121TN23PROD with NOTICES2
3004
Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices
indicated only ‘‘normal findings’’ and
‘‘acute findings.’’ Tr. 247. Yet, the
patient reported a pain level of 10/10.
Tr. 248–49; GX 9 at 19; GX 10 at 8. As
Dr. Kennedy testified, in order to
support such a high pain level, there
would have to be ‘‘very, very significant
findings on lumbar exam.’’ For instance,
he testified, he would not expect to see
a patient whose ‘‘gait is normal.’’ Tr.
250. Dr. Kennedy also testified that it
would be unusual to see a 25 year old
patient with degenerative disc disease.
In that case, he testified, he would
expect Respondent to order radiologic
studies to confirm the diagnosis. Tr.
262–63; GX 10.
38. Dr. Kennedy also found nothing in
M.W.’s medical chart to justify the
continuing prescribing of alprazolam.
Tr. 260–62. Rather, he found ‘‘identical
language [to] that [which] was used to
diagnose insomnia’’ for UC. Tr. 261; see
also GX 9 at 84 (‘‘HPI’’ entry); compare
to GX 5 at 5 (same). There was no
evidence, Dr. Kennedy testified, that
M.W. suffered from insomnia. Tr. 264.
39. Dr. Kennedy also testified that
there were numerous red flags in M.W.’s
medical chart for abuse and/or
diversion. Specifically, M.W.’s chart
showed a ‘‘wildly abnormal’’ drug
screen in which M.W. tested positive for
morphine, hydromorphone, and THC in
March 2016. He was also negative for
carisoprodol and alprazolam, two drugs
he was being prescribed and was
supposed to be taking. Tr. 251–52; GX
9 at 2–4. Based on the medical record,
Dr. Kennedy testified that this abnormal
result was not ‘‘meaningfully
addressed.’’ Tr. 252. Elsewhere in the
chart, there were other examples of
abnormal drug screens. On March 28,
2016, Respondent wrote ‘‘UDS pos for
oxy-unsat.’’ GX 9 at 102. Then,
according to an UDS lab report dated
May 11, 2017, M.W. tested negative for
four controlled substances he had been
prescribed, including oxycodone,
oxymorphone, alprazolam, and
carisoprodol (Soma). GX 9 at 10.
Inexplicably, six days before M.W.
provided the specimen, Respondent
wrote that M.W. was negative for all
prescribed drugs. GX 9 at 85. On May
31, 2017, Respondent wrote that M.W.
is ‘‘dismissed’’ with ‘‘one month
notice,’’ but noted on the same day that
M.W. was ‘‘compliant and consistent.’’
GX 9 at 83–84. However, less than a
month later, the ‘‘dismissal [was]
reversed.’’ GX 9 at 83. Dr. Kennedy said,
‘‘[i]f the patient is negative for the
medication and its metabolites of
essentially everything that’s prescribed,
there’s a problem.’’ Tr. 260. Dr. Kennedy
testified that this was evidence of drug
VerDate Sep<11>2014
18:06 Jan 18, 2022
Jkt 256001
abuse, which Respondent failed to
adequately address. Tr. 265.
40. With respect to M.W.’s medical
records, Dr. Kennedy again cited
numerous inconsistences that
questioned Respondent’s credibility.
For, instance, he testified that the
findings on the handwritten physical
exam form (GX 9 at 14) did not match
those listed in Respondent’s electronic
medical record (GX 10 at 9). Instead, Dr.
Kennedy found the same language in
M.W.’s chart that was present in UC’s
medical chart and in the charts for other
patients he reviewed. Tr. 250–51. Dr.
Kennedy noted that, out of 98 different
encounters, Respondent repeated the
same notes 93 times. Tr. 264. This, he
testified, rendered the medical file ‘‘not
credible.’’ Tr. 251. Dr. Kennedy also
cited the fact that Respondent described
M.W. as ‘‘compliant and consistent’’ the
same day he tested negative for all the
controlled drugs he was supposed to be
taking. Tr. 258–59. Again, he described
the inconsistency as ‘‘simply not
credible.’’ Tr. 259.
41. In summary, Dr. Kennedy testified
that, with respect to M.W., Respondent:
(1) Failed to perform an adequate
physical examination; (2) failed to
assess the patient’s pain, physical,
psychological function; (3) failed to
assess the patient’s history and potential
for substance abuse, coexisting diseases
and conditions; and (4) failed to create
a legitimate written treatment plan for
the patient’s individual needs. Tr. 265.
He further testified that Respondent
failed to maintain a truthful and
accurate medical record for M.W. Tr.
265–66. Dr. Kennedy testified that the
controlled substances in GX 23 were
prescribed to M.W. outside the usual
course of professional practice. Tr. 266–
68. Lastly, Dr. Kennedy testified that his
opinions applied to all the prescriptions
in GX 23. Tr. 266.
Patient C.F.
42. Dr. Kennedy testified that patient
C.F. was treated for ‘‘chronic pain due
to trauma, unspecified inflammatory
polyarthropathy.’’ Tr. 269. However, he
testified that C.F.’s physical
examination did not support the
controlled substances prescribed. Id. Dr.
Kennedy noted that, while C.F. had
scars, her muscle strength was normal
as well as her tendon reflexes, and her
fine touch sensation. Also, he testified
that C.F.’s ‘‘[l]eg raise tests were normal
bilaterally’’ and her gait was normal. Tr.
270; GX 11 at 106. Dr. Kennedy also
testified that the findings in
Respondent’s ‘‘Pain Management
Physical Exam’’ (GX 11 at 106) were not
accurately reflected in Respondent’s
electronic medical record. Tr. 271.
PO 00000
Frm 00020
Fmt 4701
Sfmt 4703
Rather, he testified, that portion of
Respondent’s medical record contained
findings ‘‘present in the other charts
that we’ve already discussed.’’ Tr. 271–
72; GX 11 at 69. Dr. Kennedy also
testified that he could find no evidence
of any credible follow-up physical
exams being performed even though
C.F. remained a patient for nearly four
years. Tr. 272. Nor did he find any
evidence that Respondent ordered any
supporting studies. Id.
43. Dr. Kennedy testified regarding
the long term prescribing of alprazolam
to C.F. He testified that there was no
justification for this since the objective
findings to support a diagnosis of
insomnia and/or anxiety were identical
to those found in medical records for
other patients, including those
pertaining to UC. GX 11 at 39; Tr. 286–
87.
44. Dr. Kennedy testified he also
found evidence of possible abuse/
diversion that Respondent never
adequately addressed. In GX 11 at 117,
a laboratory report dated July 9, 2018,
shows that C.F. tested negative for
prescribed controlled medications, a
result that Respondent himself labeled
as ‘‘Unsat.’’ GX 11 at 117; Tr. 274.
According to Respondent’s own records,
this test was taken just three days after
C.F. was prescribed alprazolam,
oxycodone, and oxymorphone. GX 11 at
9; Tr. 274–75. Pursuant to a report dated
July 7, 2017, C.F. tested negative for
alprazolam and positive for
hydrocodone. GX 11 at 111; Tr. 275. On
June 30, 2017, Respondent’s records
showed C.F. was prescribed alprazolam,
but hydrocodone is not listed. GX 11 at
25; Tr. 275–76. Dr. Kennedy testified
that, according to notes from a
subsequent visit on July 26, 2017, the
abnormal drug screen result is never
mentioned. GX 11 at 23; Tr. 288–89.
45. Additionally, Dr. Kennedy
testified that, according to a lab report
dated July 13, 2014, C.F. tested positive
for a diazepam metabolite, negative for
alprazolam, and positive for cocaine,
oxycodone, oxymorphone, and THC. GX
11 at 79; Tr. 276–278. However, at the
next visit on August 11, 2014,
Respondent’s medical records made no
reference to these abnormal results. GX
11 at 69; Tr. 278–79.
46. Regarding C.F.’s multiple
unsatisfactory drug screens, Dr.
Kennedy testified that it is insufficient
for a physician to simply document that
the patient was counseled. Rather, he
testified, the doctor needs to document
how the abnormalities are ‘‘going to
affect treatment.’’ Tr. 283–84. Dr.
Kennedy testified that ‘‘repeating over
and over that the patient was
counseled. . . leads to the impression
E:\FR\FM\19JAN2.SGM
19JAN2
Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices
jspears on DSK121TN23PROD with NOTICES2
. . . that it’s not making any difference
to the prescriptions for schedule
medications that are being provided.’’
Id.
47. Regarding C.F.’s medical record,
Dr. Kennedy testified that Respondent’s
description of his review of systems
(‘‘ROS’’) was repeated throughout C.F.’s
chart and found in numerous other
charts. Tr. 272–73. Likewise, the section
labeled ‘‘Gen exam’’ was repeated 102
times and also found in other charts. Tr.
273. Also, as stated above, Respondent’s
description of the physical exam failed
to reflect the actual handwritten notes
but rather mirrored what had been
written about other patients, including
UC.
48. In summary, regarding patient
C.F., Dr. Kennedy testified that
Respondent: (1) Failed to take an
adequate medical history; (2) failed to
perform an adequate physical
examination; (3) failed to perform an
adequate assessment in consideration of
the patient’s pain, physical, and
psychological function; (4) failed to take
an adequate history and evaluate the
potential for substance abuse; (5) failed
to create a written treatment plan
tailored for the individual needs of the
patient; (6) failed to consider the
patient’s pertinent medical history and
physical examination as well as the
need for further testing, consultation,
referrals, or use of other treatment
modalities, (7) failed to discuss the
benefits and risks of the use of
controlled substances; (8) failed to
conduct a documented periodic review
of the care at reasonable intervals in
view of the individual circumstances of
each patient; (9) failed to keep complete
and accurate records of the care
provided; and (10) continued to issue
prescriptions for controlled substances
without making a bona fide effort to
cure the patient’s habit. Tr. 284–86.
49. Dr. Kennedy further testified that,
for the reasons in Finding of Fact no. 48
and given C.F.’s numerous abnormal
drug screen results, the issuing of
prescriptions for controlled substances
to C.F., including those in GX 20, were
issued ‘‘outside the scope of acceptable
medical practice.’’ Tr. 287.
Patient B.C.
50. Dr. Kennedy testified that B.C.
was treated for ‘‘chronic pain
syndrome.’’ Tr. 290. He testified that he
found no handwritten notes reflecting a
physical exam and that the electronic
records showed results that were ‘‘nonsupportive’’ of a chronic pain condition.
Tr. 290–91. Dr. Kennedy explained that
the electronic records, in the category of
‘‘systems review,’’ reflected 141
encounters with Respondent and the
VerDate Sep<11>2014
18:06 Jan 18, 2022
Jkt 256001
‘‘system review documentations was
repeated 140 times.’’ He also testified
that the ‘‘physical exam documentation
was repeated ‘‘approximately 134
times.’’ According to Dr. Kennedy, this
same documentation was found,
verbatim, in other charts. Tr. 292.
51. Though Dr. Kennedy
acknowledged that B.C. seemed to have
serious medical ‘‘problems,’’ such as
Hodgkin’s lymphoma, a cancer of the
lymphatic system, Respondent’s notes,
inexplicably, failed to reflect those
problems. Dr. Kennedy noted, for
instance, that the review of systems for
B.C. showed, among other things, that
B.C.’s ‘‘endocrine’’ was ‘‘negative.’’ Tr.
292–93; see, e.g., GX 13 at 169. Dr.
Kennedy also took issue with the fact
that Respondent, after repeatedly
reporting a nonsensical pain level of ‘‘/
10’’ over the course of nine sequential
encounters,’’ began to record a pain
level of 10/10 without medication and
8/10 with medication. Tr. 295–96. Dr.
Kennedy testified that, despite B.C.
being dismissed from another physician,
there was also no attempt to obtain prior
medical records. Tr. 304.
52. Dr. Kennedy testified that there
were numerous red flags in B.C.’s chart
for abuse and/or diversion. First, B.C.
had been dismissed from a previous
physician, GX 13 at 188, Tr. 293–94, an
issue that was not investigated. Tr. 294.
Respondent also noted that B.C. lied
about his prescriptions at the first
encounter—another issue that does not
appear to have been addressed. Tr. 296;
GX 13 at 169. In fact, Dr. Kennedy
testified that the record, despite
evidence of B.C.’s untruthfulness,
appears to show that Respondent
prescribed controlled substances to B.C.
without ordering a UDS screen,
something that ‘‘is outside the course of
usual medical practice.’’ Tr. 297; GX 13
at 169. Dr. Kennedy testified that there
were also abnormal drug screen results.
On February 20, 2013, B.C. was positive
only for oxycodone when he was also
prescribed alprazolam. Tr. 298; GX 13 at
166. A note dated March 26, 2013,
indicated ‘‘unsatisfactory benzo only
UDS.’’ Tr. 298–99; GX 13 at 165. On
August 19, 2013, B.C. was positive for
opioids only, another unsatisfactory
result. Tr. 299; GX 13 at 158. Dr.
Kennedy identified more abnormal
results, including one where B.C.
testified positive only for
benzodiazepines when he was also
being prescribed oxycodone. Tr. 299;
GX 13 at 156–57. In another note, B.C.
tested positive only for oxycodone when
he was also being prescribed
alprazolam. GX 13 at 155–65 (October 6,
2014 entry); Tr. 300. On December 22,
2014, Respondent noted that B.C. was
PO 00000
Frm 00021
Fmt 4701
Sfmt 4703
3005
negative for all drugs, another
unsatisfactory result. Tr. 300–01; GX 13
at 150. And though the record indicates
the patient was counseled, Dr. Kennedy
testified that there was ‘‘nothing specific
about what the counseling entailed or
any decisions’’ made as a result. Tr. 301.
53. Dr. Kennedy also testified that
B.C. had been in jail, another red flag.
Tr. 301–02. Dr. Kennedy testified that,
in this case, a ‘‘reasonable physician
would provide documentation that
supports that this was addressed and
taken into account in pursuing a
treatment plan.’’ Tr. 302–03.
54. Dr. Kennedy noted numerous
instances where the medical chart,
instead of recording an actual pain
level, listed a nonsensical pain level of
‘‘/10.’’ Tr. 294–95.
55. In summary, Dr. Kennedy testified
that Respondent’s examination of B.C.
did not support a chronic pain
condition. He testified that Respondent:
(1) Failed to take an adequate medical
history; (2) failed to perform a sufficient
physical examination; (3) failed to
perform an adequate assessment in
consideration of the patient’s pain,
physical and psychological function; (4)
failed to take an adequate history for the
potential for substance abuse, coexisting
diseases and condition; (5) failed to
show the presence of a recognized
medical indication for the use of a
dangerous drug or controlled substance;
(6) failed to create a written treatment
plan tailored to the individual needs of
the patient; (7) failed to adequately
address the need for further testing,
consultation, referrals or other treatment
modalities; (8) failed to discuss the risks
and benefits of the use of controlled
substances; (9) failed to do a
documented periodic review of his care
at reasonable intervals in view of the
individual circumstances; and (10)
failed to keep complete and accurate
records of the care provided. Tr. 304–06.
Dr. Kennedy testified that, in his view,
there was no medical justification for
issuing prescriptions for controlled
substances to B.C. and, as a result, the
prescriptions were issued outside the
usual course of professional practice. Tr.
307–08; GX 22.
Patient M.H.
56. Dr. Kennedy testified that M.H.
was being treated for ‘‘chronic pain
syndrome.’’ Tr. 309. He testified that
Respondent performed a physical exam;
however, the findings were identical to
those for other patients. See GX 15 at
62–63 (sections marked ‘‘PE’’ for
February 4, 2015, and April 1, 2015); Tr.
310–11. Moreover, Dr. Kennedy testified
that these findings did not support a
chronic pain condition and that the
E:\FR\FM\19JAN2.SGM
19JAN2
jspears on DSK121TN23PROD with NOTICES2
3006
Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices
treatment was ‘‘outside the scope of
acceptable medical practice.’’ Tr. 311–
12. Dr. Kennedy also testified about an
‘‘extremely’’ unusual situation in which
M.H. underwent extensive spinal
surgery and was discharged from the
hospital on October 4, 2016. However,
the medical chart entry dated October 5,
2016, shows no mention of the surgery
and no evidence that a physical exam
was performed. Tr. 320–22, 323–24; GX
15 at 26 (hospital notes), at 48
(encounter note for October 5, 2016). Dr.
Kennedy described the situation as
follows: ‘‘this whole thing is about
scheduled medications to begin with.
This is ostensibly a chronic pain
patient. He has been discharged from
the hospital the day before this
encounter after having had a major,
major spinal surgery. And not only it is
not mentioned in this encounter note,
but essentially this encounter note is
normal and identical to all the other
encounter notes.’’ Tr. 322–23. Dr.
Kennedy also found no justification for
the continued prescribing of alprazolam.
As with the other patients, the factual
findings related to insomnia/anxiety
were identical to the findings found in
charts of the other patients discussed
during the hearing. GX 15 at 49 (section
marked HPI).
57. Dr. Kennedy testified that he also
found evidence of abnormal drug
screens, even on M.H.’s initial visit. Tr.
313–14; GX 15 at 63. On some
occasions, M.H. tested positive for illicit
substances. See GX 15 at 56 (positive for
THC, cocaine, PCP); GX 15 at 53
(positive for amphetamines); Tr. 314–15.
In other cases, he tested negative for
drugs that had been prescribed. GX 15
at 51 (positive for opiates and
oxycodone when patient also prescribed
alprazolam and carisoprodol); GX 15 at
49 (same); GX 15 at 47 (same); GX 15 at
40 (UDS negative for all drugs while
patient was prescribed oxycodone
oxymorphone, alprazolam, and
carisoprodol); GX 15 at 39 (UDS
negative for all drugs); GX 15 at 36 (UDS
positive only for oxycodone). In these
cases, Dr. Kennedy testified, there was
no evidence that Respondent addressed
the abnormalities other than to order
repeat tests. Tr. 313–20.
58. Dr. Kennedy also reviewed the
prescriptions for M.H. identified as GX
19. These included alprazolam,
oxymorphone, carisoprodol, and
oxycodone. Tr. 325–27.
59. Dr. Kennedy testified that, in his
view, Respondent prescribed controlled
substances to M.H. despite evidence
that M.H. may have been addicted to the
habit of using controlled substances. Tr.
327. He testified that Respondent made
no effort to cure M.H.’s habit. Id. Dr.
VerDate Sep<11>2014
18:06 Jan 18, 2022
Jkt 256001
Kennedy further testified that
Respondent: (1) Failed to perform an
adequate assessment in consideration of
the patient’s pain, physical and
psychological function; (2) failed to
evaluate the patient’s history and
potential for substance abuse; (3) failed
to determine a recognized medication
indication for the use of controlled
substances; (4) failed to create a written
treatment plan tailored for the
individual needs of the patient; (5)
failed to consider the need for further
testing, consultation, referrals, or use of
other treatment modalities; (6) failed to
discuss the risks and benefits of the use
of controlled substances; (7) failed to do
a documented periodic review of the
patient’s care at reasonable intervals in
view of the individual circumstances of
each patient; and (8) failed to keep
complete and accurate records of the
care provided to M.H. Tr. 327–29.
60. Dr. Kennedy testified that the
controlled substances issued to M.H.
were not issued in the usual course of
professional practice. Tr. 329.
Patient M.P.
61. Dr. Kennedy testified that M.P.
was being treated for low back, neck,
hip, and shoulder pain. Tr. 331. Dr.
Kennedy testified that the physical
exam used to justify prescribing
controlled substances for M.P. was
inadequate. Tr. 334. As he explained,
M.P. was diagnosed with degenerative
disc disease and right shoulder pain. To
determine whether M.P. had shoulder
pain, Dr. Kennedy testified, a physician
would have to test the patient’s ‘‘range
of motion as far as extension, flexion,
abduction . . . tenderness to palpation
specific to the shoulder.’’ Tr. 335. With
respect to degenerative disc disease, Dr.
Kennedy testified that Respondent
should have found, for example, that the
‘‘dorsal lumber and C-spine range of
motion’’ was ‘‘decreased in all
directions.’’ Id. Dr. Kennedy testified he
saw no such findings in Respondent’s
medical record. Tr. 334–35. Dr.
Kennedy also testified that M.P.’s pain
level was inconsistent with other
information in the record.
62. Dr. Kennedy also testified that,
throughout M.P.’s medical records,
Respondent expressed a need to obtain
M.P.’s prior medical records, but
Respondent never followed through. GX
7 at 1, 59, 68; Tr. 337–38. This included
obtaining M.P.’s x-rays, MRI report, and
the dismissal form from her prior
physician. Id.
63. Dr. Kennedy testified that M.P.
manifested signs of abuse/diversion
which were not adequately addressed.
Initially, M.P. tested positive for
buprenorphine, benzodiazepines,
PO 00000
Frm 00022
Fmt 4701
Sfmt 4703
oxycodone, and THC. GX 7 at 68.
According to the pharmacy report,
which was part M.P.’s medical chart,
buprenorphine had never been
prescribed. Tr. 338–39; GX 7 at 19. Dr.
Kennedy also discussed that there was
mention of ‘‘termination paperwork
from a previous physician,’’ another red
flag for abuse and/or diversion. Tr. 342.
Dr. Kennedy pointed out ‘‘highly
conflicting’’ information in M.P.’s
medical chart. Tr. 345. For instance,
M.P. listed her occupational disability
as both ‘‘9’’ and ‘‘10,’’ but stated she
works ‘‘45–60 hours weekly’’ as a
waitress. GX 7 at 9–10. Dr. Kennedy also
questioned M.P.’s truthfulness when she
denied that she had ever been in a drug
treatment program (GX 7, 13). However,
following a heroin overdose, she told
Respondent that she refused to go into
such a program because she had tried
drug treatment before. GX 7 at 57
(section marked ‘‘HPI’’). Dr. Kennedy
also pointed out several abnormal drug
screen results. In GX 7, page 58, there
is a reference to a positive test for THC,
opioids, and benzodiazepines, none of
which had been prescribed. Tr. 347.
64. M.P. overdosed on heroin in
Respondent’s waiting room. GX 7 at 25;
Tr. 340–41. However, according to Dr.
Kennedy, Respondent incorrectly
treated M.P. with Suboxone
(buprenorphine).
65. Dr. Kennedy testified that
Respondent repeatedly issued
prescriptions for controlled substances
to M.P. despite the fact she was
addicted to the habit of using controlled
substances. Tr. 348. Also, up until the
point M.P. overdosed on heroin,
Respondent made no effort to cure
M.P.’s habit. Tr. 348–49. Dr. Kennedy
also testified that, with respect to M.P.,
Respondent: (1) Failed to perform a
sufficient physical examination; (2)
failed to perform an adequate
assessment in consideration of the
patient pain, physical and psychological
function; (3) failed to record an
adequate history of potential substance
abuse; (4) failed to determine a
recognized medical indication for the
use of controlled substances; (5) failed
to create a written treatment plan
tailored for the individual needs of the
patient; (6) failed to take a pertinent
medical history and perform a physical
examination as well as perform further
testing, consultation, referrals. And the
use of other treatment modalities; (7)
failed to discuss the risk and benefits of
the use of controlled substances; (8)
failed to do a documented periodic
review of M.P.’s care at reasonable
intervals in view of the individual
circumstances; and (9) failed to keep
E:\FR\FM\19JAN2.SGM
19JAN2
Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices
jspears on DSK121TN23PROD with NOTICES2
complete an accurate medical records of
the care provided to M.P. Tr. 348–50.
66. Dr. Kennedy also testified that the
prescriptions issued to M.P., including
those in GX 21, were issued outside the
usual course of professional practice,
and that Respondent lacked a medical
justification for issuing the
prescriptions. Tr. 352.
67. With respect to patients, B.C, C.F.,
M.H., M.W., and M.P., Dr. Kennedy
testified that the prescribing of
controlled substances to these patients
was dangerous. Tr. 352. As a basis for
that opinion, he cited: (1) Abnormal
drug screens that were ‘‘essentially
ignored,’’ (2) the lack of documentation
about the patients’ status; (3) medical
records that were not credible; (4) and
maintaining patients on scheduled
medications, sometimes at high dosages
‘‘without having honest, accurate,
complete medical records.’’ Tr. 352–53.
He testified that ‘‘[b]ecause medical
records will instruct other people who
look’’ at the patients later, a medical
record that ‘‘simply doesn’t make sense
or [has] something that is in conflict,’’
can ‘‘present a dangerous situation.’’ Tr.
353.
Respondent’s Falsification
68. DI testified that Respondent
submitted an application to renew his
DEA COR (No. BO4959889) on
November 6, 2019. Tr. 529; GX 26. She
testified that Respondent answered
‘‘no’’ to the third liability question on
the application. Specifically, the
question sought to determine whether
Respondent had ever ‘‘surrendered for
cause or had a state professional license
or controlled substance registration
revoked, suspended, denied, restricted,
or placed on probation.’’ Tr. 530.
69. DI introduced a document
outlining an administrative action
against Respondent, titled ‘‘Notice of
Charges and Memorandum for
Assessment of Civil Penalties,’’
submitted May 1, 2019, by the
Tennessee Department of Health. GX 29;
Tr. 531. As the document states,
Respondent was charged with, among
other things, prescribing ‘‘narcotics and
other medications and controlled
substances in amounts and/or duration
that were not medically necessary,
advisable, or justified for a diagnosed
condition.’’ GX 29 at 5.
70. DI introduced a document from
the Chancery Court for the State of
Tennessee, 20th Judicial District,
Davidson County, Part III (‘‘Chancery
Court’’), staying the proceedings brought
by the Tennessee Department of Health,
[omitted] and imposing restrictions on
Respondent’s license as conditions of
the stay. Those restrictions included
VerDate Sep<11>2014
18:06 Jan 18, 2022
Jkt 256001
prohibiting Respondent from: (1)
Writing prescriptions; (2) supervising or
collaborating with any mid-level
practitioners for the writing of
prescriptions; and (3) providing direct
patient care including but not limited to
diagnosing, treating, operating on or
prescribing for any person. GX 27 at 2–
3; Tr. 533–34. The order is dated May
17, 2019, approximately three months
before Respondent submitted his
renewal application. GX 27 at 4.
71. DI introduced a document, titled
Agreed Order, dated August 21, 2018.
GX 28. DI testified that the Order
provided that Respondent must
surrender his Tennessee Pain
Management Clinic Certificate (‘‘Pain
Clinic Certificate’’), No. 246, as a result
of violations related to the prescribing of
controlled substances. Id. at 5–7.
72. DI testified, as a result of having
surrendered his Pain Clinic Certificate
and the restrictions placed upon his
medical license by the Chancery Court,
that Respondent did not answer
truthfully on his renewal application.
Tr. 536.
Analysis
Findings as to Allegations
The Government alleges that the
Respondent’s COR should be revoked,
and any applications should be denied,
because the Respondent [has committed
such acts as would render his
registration inconsistent with the public
interest. 21 U.S.C. 824(a)(4); 21 U.S.C.
823(f) and in particular the Government
relies on Public Interest Factors Two
(the Respondent’s experience
conducting regulated activity) and Four
(the Respondent’s compliance with state
and federal laws related to controlled
substances)]. ALJ Ex. 1.29 In the
adjudication of a revocation of a DEA
COR, the DEA bears the burden of
proving that the requirements for such
revocation are satisfied. 21 CFR
1301.44(e). Where the Government has
sustained its burden and established
that a respondent has committed acts
that render his registration inconsistent
with the public interest, to rebut the
Government’s prima facie case, a
respondent must both accept
responsibility for his actions and
demonstrate that he will not engage in
future misconduct. Patrick W. Stodola,
M.D., 74 FR 20,727, 20,734 (2009).
Acceptance of responsibility and
remedial measures are assessed in the
context of the ‘‘egregiousness of the
violations and the [DEA’s] interest in
deterring similar misconduct by [the]
29 In its GPHB, the Government argues Factors
Two and Four should be combined for a joint
analysis.
PO 00000
Frm 00023
Fmt 4701
Sfmt 4703
3007
Respondent in the future as well as on
the part of others.’’ David A. Ruben,
M.D., 78 FR 38,363, 38,364 (2013).
Where the Government has sustained its
burden and established that a registrant
has committed acts inconsistent with
the public interest, that registrant must
present sufficient mitigating evidence to
assure the Administrator that he can be
entrusted with the responsibility
commensurate with such a registration.
Medicine Shoppe-Jonesborough, 73 FR
364, 387 (2008).
The Agency’s conclusion that ‘‘past
performance is the best predictor of
future performance’’ has been sustained
on review, Alra Labs., Inc. v. DEA, 54
F.3d 450, 452 (7th Cir. 1995), as has the
Agency’s consistent policy of strongly
weighing whether a registrant who has
committed acts inconsistent with the
public interest has accepted
responsibility and demonstrated that he
or she will not engage in future
misconduct. Hoxie v. DEA, 419 F.3d
477, 482–83 (6th Cir. 2005); see also
Ronald Lynch, M.D., 75 FR 78,745,
78,754 (2010) (holding that the
Respondent’s attempts to minimize
misconduct undermined acceptance of
responsibility); George C. Aycock, M.D.,
74 FR 17,529, 17,543 (2009) (finding
that much of the respondent’s testimony
undermined his initial acceptance that
he was ‘‘probably at fault’’ for some
misconduct); Jayam Krishna-Iyer, M.D.,
74 FR 459, 463 (2009) (noting, on
remand, that despite the respondent’s
having undertaken measures to reform
her practice, revocation had been
appropriate because the respondent had
refused to acknowledge her
responsibility under the law); Medicine
Shoppe–Jonesborough, 73 FR 364 at 387
(noting that the respondent did not
acknowledge recordkeeping problems,
let alone more serious violations of
federal law, and concluding that
revocation was warranted).*R
Tennessee Law
As a licensed medical doctor in
Tennessee, the Respondent was subject
to TENN. CODE ANN. § 63–6–214(b)(12)
through (14),30 as those provisions
*R Remaining text omitted for brevity and clarity.
30 T. C. A. § 63–6–214. License denial,
suspension, or revocation; grounds; examination;
investigations; abstract of record; report; standard of
care; disclosure of records; screening panels;
hearings; orders
(a) The board has the power to: (1) Deny an
application for a license to any applicant who
applies for the same through reciprocity or
otherwise; (2) Permanently or temporarily withhold
issuance of a license; (3) Suspend, or limit or
restrict a previously issued license for such time
and in such manner as the board may determine;
(4) Reprimand or take such action in relation to
E:\FR\FM\19JAN2.SGM
Continued
19JAN2
3008
Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices
jspears on DSK121TN23PROD with NOTICES2
pertain to ‘‘dispensing, prescribing, or
otherwise distributing’’ controlled
substances. Specifically, section 63–6–2
l 4(b)(12) prohibits a physician from
prescribing controlled substances ‘‘not
in the course of professional practice, or
not in good faith to relieve pain and
suffering, or not to cure an ailment,
physical infirmity or disease, or in
amounts and/or for durations not
medically necessary, advisable or
justified for a diagnosed condition.’’
Additionally, section 63–6–214(b)(13)
prohibits a physician from prescribing
controlled substances to a person
‘‘addicted to the habit of using
controlled substances’’ without ‘‘making
a bona fide effort to cure the [patient’s]
habit.’’ To determine a violation of these
provisions, the Tennessee Board of
Medical Examiners uses a
nonexhaustive list of guidelines (‘‘the
guidelines’’) found in TENN. COMP. R.
& REGS. 0880–02-.14(6)(e).31 The
guidelines require that a physician: (1)
Take a documented medical history; (2)
conduct a physical examination; and (3)
perform an adequate ‘‘assessment and
consideration of the [patient’s] pain,
physical and psychological function,
any history and potential for substance
abuse, coexisting diseases and
conditions, and the presence of a
recognized medical indication for the
use of a dangerous drug or controlled
substance.’’ TENN. COMP. R. & REGS.
0880–02–.14(6)(e)(3)(i). Additionally,
Rule 0880–02–.14 (6)(e) requires
physicians to create a ‘‘written
treatment plan tailored for the
individual needs of the patient’’ that
considers the patient’s ‘‘pertinent
medical history and physical
examination as well as the need for
further testing, consultation, referrals, or
disciplining an applicant or licensee, including, but
not limited to, informal settlements, private
censures and warnings, as the board in its
discretion may deem proper; or (5) Permanently
revoke a license.
(b) The grounds upon which the board shall
exercise such power include, but are not limited to:
. . . (12) Dispensing, prescribing or otherwise
distributing any controlled substance or any other
drug not in the course of professional practice, or
not in good faith to relieve pain and suffering, or
not to cure an ailment, physical infirmity or
disease, or in amounts and/or for durations not
medically necessary, advisable or justified for a
diagnosed condition; (13) Dispensing, prescribing
or otherwise distributing to any person a controlled
substance or other drug if such person is addicted
to the habit of using controlled substances without
making a bona fide effort to cure the habit of such
patient; (14) Dispensing, prescribing or otherwise
distributing any controlled substance, controlled
substance analogue or other drug to any person in
violation of any law of the state or of the United
States; . . . (emphasis added).
31 Tenn. Comp. R. & Regs. 0880–02–.14
SPECIALLY REGULATED AREAS AND ASPECTS
OF MEDICAL PRACTICE. [Omitted text of
guidelines for brevity.]
VerDate Sep<11>2014
18:06 Jan 18, 2022
Jkt 256001
use of other treatment modalities.’’ It
also requires the physician to ‘‘discuss
the risks and benefits of the use of
controlled substances,’’ complete a
‘‘documented periodic review of the
care . . . at reasonable intervals,’’ and
‘‘keep [c]omplete and accurate records
of the care.’’ Id. at 0880–02–
.14(6)(e)(3)(ii)–(v).
Exclusion of the Respondent’s
Testimony
The Government objected to the
Respondent’s testimony *S because prior
to the hearing Respondent identified
that he may testify regarding the
material falsification allegation, but said
he would not testify regarding the
prescribing allegations as he has another
matter pending. However, at the
hearing, the Respondent sought to
present testimony regarding the
allegations surrounding his prescribing.
He did not offer testimony regarding the
material falsification allegation. [The
ALJ permitted all portions of the
Respondent’s testimony that could have
been reasonably anticipated by the
Government and I have considered
Respondent’s testimony in reaching my
decision. I find it unnecessary to reach
any further conclusions and have
omitted the remainder of the ALJ’s
analysis for brevity, as the Government
did not take exception to the ALJ’s
ultimate decision.] 32 33
Accurate and Complete Medical
Records
The Government alleges that the
Respondent failed to maintain accurate
and complete medical records for each
of the subject patients, as mandated by
the relevant Tennessee regulations and
standard of care. The medical records
contain the results of physical
examinations and other tests, which did
not occur on the reported dates. The
records are rife, across all of the subject
patients, with identical findings,
suggesting the subject examinations
either did not take place, or the results
were not reported accurately.
In explaining the identical anxiety
and insomnia indications written in
each of his patients’ charts to justify
benzodiazepines, the Respondent
testified that his patients exhibited the
same symptoms which is common
among anxiety patients. However, the
fact that UC’s chart reflected that he had
the same anxiety indications and other
indications identical to the other five
patients, despite the fact that he testified
*S Text omitted for brevity.
32 [Omitted original text in which footnote
appeared.]
33 [Omitted original text in which footnote
appeared.]
PO 00000
Frm 00024
Fmt 4701
Sfmt 4703
credibly that he did not complain of any
anxiety symptoms, greatly reduces the
credibility of the Respondent’s subject
explanations. Tr. 79–80. Indeed, most of
the indications within UC’s chart were
unreported by him.34 UC reviewed
Government Exhibit 5 and noted that he
was not asked about any of the reported
symptoms. Tr. 81. As to why individual
patients had the same indications
within the chart for long periods of
time, the Respondent maintains that the
subject record findings were carried
forward from prior tests, as permitted by
the Tennessee standard of care.
[However, Dr. Kennedy testified, ‘‘there
is no regulation anywhere that allows a
physician [to] document physical exam
findings that he did not perform. That’s
not acceptable under any regulations.’’
Tr. 652.]
Similarly, the Respondent justified
reporting test results when no tests
occurred, as he claimed was permitted
by the Tennessee standard. Prior test
results were simply carried forward
within the electronic medical record. I
credit Dr. Kennedy’s opinion that
reporting test results purported to have
occurred on a particular date, which did
not then occur, is contrary to the
Tennessee standard of care. Even a
casual review of the relevant Tennessee
regulations reveals the prominence of
the Tennessee physician’s obligation to
accurately document. He is required to
establish a ‘‘written treatment plan
tailored for the individual needs of the
patient’’ that considers the patient’s
‘‘pertinent medical history and physical
examination as well as the need for
further testing, consultation, referrals, or
use of other treatment modalities.’’ It
also requires the physician to perform a
‘‘documented periodic review of the
care . . . at reasonable intervals,’’ and
‘‘keep [c]omplete and accurate records
of the care.’’ Id. at 0880–02–
.14(6)(e)(3)(ii)–(v).
Common sense itself would refute the
Respondent’s position. Indications and
exam results carried forward, perhaps
for months or even years, defeats the
whole purpose of medical records,
which is to inform the practitioner and
other potential treating practitioners of
the patient’s true and present condition,
progression of disease or efficacy of
treatment. [Dr. Kennedy testified that
34 UC noted that despite his records stating that
‘‘[UC] . . . has had a history of insomnia and
anxiety for several years,’’ he did not report anxiety
symptoms of shortness of breath, of having
palpitations, sweating, dizziness, or shaking. Tr.
79–80; GX 5. The medical record also reflects that
he had a headache that day, despite the fact that
UC did not report having a headache, dizziness,
nausea, or vomiting. Tr. 80; GX 5. No one
questioned UC as to whether he had abdominal
pain, diarrhea, and constipation. Tr. 80–81.
E:\FR\FM\19JAN2.SGM
19JAN2
jspears on DSK121TN23PROD with NOTICES2
Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices
here the documentation did not ‘‘make
sense’’ and was ‘‘in conflict,’’ which
‘‘present[s] a dangerous situation’’ for
‘‘other people who look at [the
records].’’ Tr. 353. Based on this
testimony, one could conclude that
wrong records are worse than no records
at all, as they would mislead other
treating practitioners. And as Dr.
Kennedy testified, here ‘‘you have a
medical record which shows
consistently documentation . . . that
did not occur, that is outside the scope
of acceptable medical practice, and it
does not support legitimate prescribing
of scheduled agents.’’ Tr. 652.]
The Respondent has conceded there
are factual errors in the subject records.
Although UC’s chart contains an entry
that his pharmacy printout was
reviewed, the Respondent conceded that
no pharmacy printout was reviewed and
that such entry was in ‘‘error.’’ Tr. 631–
32; GX 5 at 6. M.H.’s chart contains the
inconsistent finding of long-term
insomnia, but with an entry of sleeping
well. Tr. 640–41; GX 15 at 47–48. The
Respondent conceded they were
inconsistent entries. Tr. 641.
Additionally, while M.W.’s chart
reflects he had been dismissed, M.W.
continued to be seen for months
afterwards, without any further
explanation documented in the record.
Tr. 259–60. And, Respondent reported a
‘‘history of insomnia for several years’’
for M.H.; however, this note first
appears 19 months into treatment. GX
15; Tr. 49.
Additionally, there are conflicts
between the Respondent’s written notes
and the electronic medical records.
Documents UC filled out are missing
from his chart that was seized from the
Respondent. The electronic medical
record for a visit by M.W. does not
contain the handwritten information
recorded in GX 10 at 8. Tr. 250–51; GX
10 at 9. Instead, the results of the
physical exam mirror those findings
made for UC, rendering M.W.’s chart not
credible. Tr. 251–52. The physical exam
notes written for C.F. revealed
essentially normal findings, however
the electronic records for this visit failed
to include these findings. Tr. 271; GX 11
at 69. Instead, under physical exam, the
same language that is duplicated so
often in the records, appears. Tr. 272.
Dr. Kennedy noted the hand-written
exam notes for M.H. did not appear in
the electronic medical records. Tr. 325–
36; GX 7 at 68. Instead the same
physical exam notes duplicated
throughout the records appear. Tr. 336,
351. So, at times, verbatim records were
repeatedly and inaccurately inputted
into the electronic medical records
VerDate Sep<11>2014
18:06 Jan 18, 2022
Jkt 256001
when actual, accurate indications were
available.
Dr. Kennedy noted the actual pain
level was left blank at nine consecutive
encounters with B.C., suggesting it was
being added later and that the record
was being fabricated. Tr. 294–95; GX 13
at 159; GX 14 at 8.
For these reasons and those discussed
below, I find the Government has
sustained its burden in proving the
Respondent failed to maintain accurate
and complete medical records as to the
subject patients, in violation of TENN.
COMP. R. & REGS. Rule 0880–02–.14
(6)(e).*T [I further find that each of the
relevant prescriptions at issue in this
matter were issued outside the usual
course of professional practice and
beneath the standard of care due to
Respondent’s failure to maintain
complete and accurate records.]
Undercover
The Government alleges the
Respondent failed to perform an
adequate physical exam; take an
adequate medical history; assess UC’s
pain, physical and psychological
function; assess the patient’s history and
potential for substance abuse, coexisting
diseases and conditions, and the
presence of a recognized medical
indication for the use of oxycodone; and
failed to create a legitimate written
treatment plan for UC’s individual
needs or to discuss the risks and
benefits of the use of oxycodone with
UC. At three level one visits, the chart
falsely reflects the results of physical
exams, which did not occur. The
Government alleges the Respondent’s
continued prescribing of controlled
substances to UC was without a
legitimate medical purpose and/or
outside the usual course of professional
practice.
Dr. Kennedy reviewed the chart and
the undercover videos for UC, the
undercover agent. Tr. 216–17, 363; GX
6. Dr. Kennedy acknowledged that in
scheduling the first visit, the
Respondent’s staff instructed UC to
bring certain medical records to his first
visit, the previous three physician notes,
his discharge summary, the record of
the previous three months prescriptions
and an MRI, an appropriate protocol in
Dr. Kennedy’s opinion. Tr. 364–65; GX
3 at 1.
The Respondent testified that he took
a medical history, a condition-specific
physical exam for low back pain, and
reviewed the MRI (GX 6) of UC. Tr. 575–
80.35 The Respondent agreed that he
*T Omitted for brevity.
35 The Respondent noted that his physical exam
of C.R. was not captured by the video of the
PO 00000
Frm 00025
Fmt 4701
Sfmt 4703
3009
spent no more than fifteen minutes with
UC in the examination room. Tr. 621.
The Respondent maintains that he
performed the required assessments
related to pain, physical and
psychological function, and history and
potential for drug abuse. Tr. 582. This
involved reviewing the paperwork UC
filled out, authenticating that
paperwork, the triage of UC by staff,
UDS, and a final review of the
paperwork by the Respondent with the
patient. Tr. 583, 584. UC recalled the
Respondent going over his paperwork
with him, but could not remember the
extent of the review. According to UC,
the triage by other staff was minimal,
sporadic or non-existent. Tr. 59. UC
cited Dr. Morgan, who did not exist, in
his medical history paperwork, yet the
staff did not discover that fact. None of
UC’s paperwork could be authenticated,
as designed. UC’s history was similarly
designed to be a ‘‘dead end.’’ Tr. 238.
[Accordingly, I find Respondent’s
testimony that he authenticated UC’s
paperwork to lack credibility.] There
was no review of UC’s psychological
functioning, although he was diagnosed
with anxiety.36 The Respondent’s
instant claims are belied by the record.
The Respondent explained that a
patient’s pain is very subjective. After
reviewing his paperwork, including the
MRI, examining UC and speaking with
him, the Respondent claimed that he
had no reason not to treat him as
someone who has genuine pain. Tr. 588.
UC’s statement that he had used
controlled substances for his pain and
that ibuprofen was not working
supported the conclusion that his pain
was long standing, and warranted a
Schedule II medication. [Omitted for
relevance.]
Dr. Kennedy opined that UC’s
medical chart did not justify the
prescribing of controlled substances.37
Tr. 230–31, 240; GX 18 at 1, 3. Although
there was an actual MRI report of UC,
Dr. Kennedy found the MRI report
internally inconsistent [which Dr.
Kennedy testified should have caused
Respondent to question the MRI.] Tr.
387–94. Dr. Kennedy opined that it
encounter. The camera was pointed at the wall. Tr.
581–82.
36 Where practitioner asked his patient whether
there was ‘‘any other medication he took for
anxiety,’’ and where the practitioner made no effort
to determine the extent of the patient’s symptoms
before prescribing Xanax to him, the practitioner
was not engaged in the legitimate practice of
medicine but instead was dealing drugs. Henri
Wetselaar, M.D., 77 FR 57,126, 57,132 (2012).
37 The Respondent cautioned that in reviewing
his electronic medical record, it often referred to
other records. For example, under history of present
illness (HPI), he would often reference the initial
encounter paperwork, as included by reference, in
the electronic record. Tr. 592.
E:\FR\FM\19JAN2.SGM
19JAN2
3010
Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices
jspears on DSK121TN23PROD with NOTICES2
would be outside the usual course of
professional practice to prescribe
controlled substances based on this MRI
alone.*U Tr. 483–86.38 UC was being
treated for complaints of back pain.
However, Dr. Kennedy opined that the
physical exam detailed in the chart was
not sufficient under Tennessee
standards, and the exam that was
performed revealed, essentially, a
normal back. Tr. 217, 231, 237, 396–97,
440. On rebuttal, Dr. Kennedy reiterated
this assessment after listening to the
Respondent’s explanation. Tr. 651–52.
The Respondent explained his
treatment of UC. After the UC filled out
extensive paperwork, the initial
examination by the Respondent
consisted of observing UC, touching his
back and causing the patient to lift his
leg. Tr. 217–18, 359–60; GX 6 at 6. Dr.
Kennedy noted the taking of vital signs
and a general exam within the chart;
however, he observed that from viewing
and listening to the video of this visit,
such exam was not performed as
described, or not performed at all. Tr.
218–19, 379–81; GX 6, 4.39 The prior
medical history reported by UC was
facially suspicious and constituted a red
flag. Tr. 238. UC reportedly came from
a clinic, which had been shut down,
and provided medical records from a
Nurse Practitioner whose license had
been suspended. Tr. 238. The
Respondent conceded UC was a
challenge, as the clinic he reported had
been closed, and he could not obtain the
pharmacy information, so the
Respondent could not verify that source.
Tr. 583–85. As UC’s prior medical
records could not be confirmed, the
Respondent claimed that he prescribed
a dosage appropriate to a patient just
starting opioid treatment. Tr. 589–90.
The Respondent expected his patients
to be honest and truthful with him
consistent with the DEA Physician’s
Manual, which requires patients to be
honest with their doctors. Tr. 586–87.40
In his Post-hearing Brief, the
*U This sentence has been modified for clarity.
38 The Agency has previously found based on
credible expert testimony that relying exclusively
on MRI results for prescribing controlled substances
is unprofessional conduct in the applicable state.
Zvi H. Perper, M.D., 77 FR 64,131, 64,140 (2012).
39 The Agency has previously found that
falsifying a patient’s medical record to indicate that
respondent performed a physical exam but where
video/audio recordings show that a physical was
never conducted demonstrate that respondent
knowingly violated the CSA. Jeri Hassman, M.D., 75
FR 8194, 8236 (2010); Bernard Wilberforce Shelton,
M.D., 83 FR 14,028, 14,042 (2018).
40 ‘‘A practitioner who ignores the warning signs
that her patients are either personally abusing or
diverting controlled substances commits ‘acts
inconsistent with the public interest,’ 21 U.S.C.
824(a)(4), even if she is merely gullible or naı¨ve.’’
Krishna-Iyer, M.D., 74 FR 460 n.3.
VerDate Sep<11>2014
18:06 Jan 18, 2022
Jkt 256001
Respondent continues to complain of
the use of an undercover agent, who
operated under ‘‘false colors’’ to ensnare
the Respondent, and his disappointment
that the Tribunal does not share his
sentiment. The fact of the matter is,
there is nothing illegal or improper
regarding the Government’s use of
undercover agents.41 Even if I shared the
Respondent’s sentiment, and opined
that the use of undercover agents was
somehow unfair, this is not a court of
equity.42 We operate strictly by statute
and regulation [and here the evidence
clearly establishes that Respondent’s
prescribing to UC was outside the usual
course of professional practice and
beneath the standard of care in violation
of the CSA and its implementing
regulations.]
Dr. Kennedy opined that UC’s
obfuscation, false and misleading
statements to the Respondent and staff,
did not relieve the Respondent’s
obligation to investigate any suspicious
circumstances. Tr. 375–78, 382. The
Respondent misperceives his role.
[Omitted for relevance.] Physicians
must be wary of patients seeking
controlled substances for abuse and
diversion. Although the Respondent’s
staff was suspicious of UC’s prior
records, as they appeared to have been
altered, their concern appeared to be
that the UC was perhaps law
enforcement, ‘‘try[ing] to bring the
Respondent down,’’ rather than
someone attempting to divert or abuse
controlled substances. UC presented as
a patient with no verified history, his
paperwork contained indications of
alteration, he complained of pain
without overt indications; yet, the
Respondent opined that the record
supported his conclusion that UC was
legitimately in pain. Dr. Kennedy
disagreed and opined that it is the
practitioner’s responsibility to
investigate suspicious circumstances
and to resolve them prior to prescribing
controlled substances.
Dr. Kennedy noted that the physical
exam included in this first visit by UC
was repeated verbatim in most of the
approximately twenty charts he
reviewed. Tr. 220; GX 7 at 65 (M.B.), GX
9 at 69 (M.W.). The Respondent
explained that he performed a physical
exam at the initial visit of each of his
patients, as required by the Tennessee
pain management guidelines. Tr. 594.
Physical exams thereafter are at the
discretion of the physician. Tr. 594.
41 [Omitted
for relevance.]
Law Judges of the DEA ‘‘lack
the authority to exercise equitable powers’’ in
determining whether a registration is consistent
with the public interest. The Main Pharmacy, 80 FR
29,022, 29,024 (2015).
42 Administrative
PO 00000
Frm 00026
Fmt 4701
Sfmt 4703
Although UC had five visits to the
clinic, only two involved encounters
with the Respondent. The other three
visits were ‘‘level one’’ visits, in which
UC met with the Respondent’s staff
only. Tr. 622–28, 645–50. Although the
medical records reflect a physical
examination took place at the level one
visits, there was no physical exam.
Instead, the Respondent explained he
and his staff had carried forward results
from prior examinations to later visit
records with new findings added, which
Dr. Kennedy opined was not
permissible. Tr. 623–28; supra ‘‘The
Analysis, Accurate and Complete
Medical Records.’’
Dr. Kennedy noted UC’s chart
identified him with a ‘‘long-standing
history of insomnia and anxiety,’’
however the chart contained no
examination that would support such
findings. Tr. 233–34; GX 5 at 4.
Additionally, the reported symptoms of
the anxiety finding, ‘‘palpitations,
sweating, dizziness, shaking’’ was
repeated almost universally throughout
the medical records reviewed as to
patients diagnosed with insomnia and
anxiety. Tr. 233–34. Similarly, the visit
of October 17, 2017, by UC contains
extensive medical findings, but the
video of that visit does not support
those findings. Tr. 235–37; GX 5 at 5.
The video does reveal the Respondent
asking UC, ‘‘how is your sleep’’ to
which UC responds, ‘‘not good.’’ Tr.
236. The Respondent then prescribes
Elavil, or amitriptyline [which is not a
controlled substance and is not at issue
in this case.] Tr. 236. Dr. Kennedy made
a similar observation as to extensive
medical findings on subsequent visits in
which UC was not seen by the
Respondent. Tr. 235–37; GX 5 at 3–5.
Although the medical records state that
a physical examination took place at the
level one visits when no physical
examination occurred, the Respondent
explained that it was permissible in
medical record-keeping to carry forward
results from prior examinations to later
visit records, with new findings added.
Tr. 623–28. Dr. Kennedy disagreed,
noting that it is never permissible for
charts to reflect examination results,
when no exam occurred. Tr. 652–53. At
UC’s second visit, he was called back to
the triage room where the nurse asked
him his weight to which he replied,
‘‘210,’’ and if his blood pressure was ok
to which he responded, ‘‘yes.’’ Tr. 59.
He was not weighed, nor was his blood
pressure taken. Dr. Kennedy did not
believe UC’s chart reflected the
Respondent maintained a truthful and
accurate record of the treatment. Tr.
232; GX 3; 4. I credit Dr. Kennedy’s
E:\FR\FM\19JAN2.SGM
19JAN2
Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices
jspears on DSK121TN23PROD with NOTICES2
opinion regarding the results of nonexistent tests.
On the basis of the deficient physical
exam, Dr. Kennedy opined that
prescribing controlled substances to UC
was not justified. Although the
Respondent prescribed a much lower
MME than UC had purportedly been on
before, it was not consistent with the
Tennessee standard, which would
require observation, looking for spasms,
lumbar range of motion maneuvers,
straight leg raise test, neurologic exam
and motor deficits. Tr. 221–25, 239,
382–83; GX 5 at 6. Other deficiencies in
the records that caused the controlled
substance prescriptions for UC to be
unjustified included the deficiency in
the prior medical records provided by
UC. Tr. 228. On a positive note, UC’s
chart revealed an exploration of
alternate treatment by prescribing
Meloxicam, and offering injections. Tr.
228–29.
The Respondent testified he prepared
an adequate written treatment plan with
appropriate treatment goals and therapy.
Tr. 590–91. However, Dr. Kennedy
opined UC’s chart did not include an
adequate treatment plan. Tr. 229. The
records reveal a deficient discussion
regarding the risks and benefits of
controlled substance medication. Tr.
231. Dr. Kennedy deemed the diagnosis
of degenerative disc disease unjustified
on the basis of the chart and MRI. Tr.
240–42; GX 5 at 2, 6; GX 6 at 12. I find
Dr. Kennedy’s assessments credible.*V
[In accordance with Dr. Kennedy’s
credible and unrebutted expert
testimony, and for the reasons above, I
find that the three oxycodone
prescriptions Respondent issued to UC
were issued outside the usual course of
professional practice and beneath the
standard of care. The basis for Dr.
Kennedy’s opinion and my finding is
that Respondent failed to: Take an
adequate medical history including an
assessment of UC’s pain history and
potential for substance abuse; perform
and document an adequate physical
examination; and create a legitimate
written treatment plan for UC’s
individual needs or to discuss the risks
and benefits of the use of oxycodone
with UC. Additionally, and in
accordance with Dr. Kennedy’s
testimony, I find that the relevant
*V Omitted. The ALJ found that the diagnosis of
C.R. with insomnia was appropriate. The issue
relevant to this case is whether or not there was a
recognized medical indication for the use of
oxycodone. The medication prescribed as a result
of the insomnia diagnosis was not a controlled
substance and was not directly at issue in this case.
Accordingly, it is not necessary to determine
whether the records contained sufficient evidence
to support the insomnia diagnosis, because it is not
relevant to the case.
VerDate Sep<11>2014
18:06 Jan 18, 2022
Jkt 256001
prescriptions issued by Respondent
were outside the usual course of
professional practice and beneath the
standard of care due to Respondent’s
failure to maintain complete and
accurate records for UC.]
Allegations Common to the Five
Remaining Patients
With respect to the Respondent’s
treatment of M.H., C.F., M.P., B.C., and
M.W. (‘‘the five patients’’), the
Government alleges the prescriptions for
controlled substances were not issued in
the course of professional practice
inasmuch as the Respondent failed to:
(1) Take an adequate medical history;
(2) perform a sufficient physical
examination; and (3) perform an
adequate ‘‘assessment and consideration
of the (patients’] pain, physical and
psychological function, any history and
potential for substance abuse, coexisting
diseases and conditions, and the
presence of a recognized medical
indication for the use of a dangerous
drug or controlled substance.’’ The
Respondent also failed to create a
‘‘written treatment plan tailored for the
individual needs’’ of each of the five
patients that considered each of the
patient’s ‘‘pertinent medical history and
physical examination, as well as, the
need for further testing, consultation,
referrals, or use of other treatment
modalities.’’ The Respondent also failed
to: (1) ‘‘discuss the risks and benefits of
the use of controlled substances’’ with
patients M.H., C.F., M.P., B.C., and
M.W.; (2) conduct a ‘‘documented
periodic review of the[ir] care . . . at
reasonable intervals in view of the
individual circumstances’’ of each
patient; and (3) keep ‘‘(c]omplete and
accurate records of the care provided.’’
As such, the Respondent’s conduct
violated TENN. CODE ANN. § 63–6–
214(b)(12) and TENN. COMP. R. &
REGS. 0880–02 .14(6)(e)(3)(i)–(v).
The Government further alleges the
prescriptions the Respondent issued to
M.H., C.F., M.P., B.C., and M.W. failed
to comply with Tennessee state law in
that they did not conform to accepted
and prevailing medical standards in
Tennessee, and thus, were issued
outside the usual course of professional
practice. The Respondent’s conduct,
viewed as a whole, ‘‘completely
betrayed any semblance of legitimate
medical treatment.’’ Jack A. Danton,
D.O., 76 FR 60,900, 60,904 (2011).
By issuing these prescriptions for
controlled substances, the Respondent
failed to take reasonable steps to guard
against diversion of controlled
substances. See David A. Ruben, M.D.,
78 FR at 38,382; Beinvenido Tan, M.D.,
76 FR 17,673, 17,689 (2011); Dewey C.
PO 00000
Frm 00027
Fmt 4701
Sfmt 4703
3011
Mackay, M.D., 75 FR 49,956, 49,974
(2010); Physicians Pharmacy, L.L.C., 77
FR 47,096 (2012).
Allegations as to Specific Patients
As to the allegations regarding each of
the subject patients, in his Posthearing
Brief (PHB), the Respondent argues the
Government’s case suffers weakness by
the Government’s failure to present the
relevant patients’ testimony, testimony
of relevant pharmacists, any evaluation
regarding the volume of the
Respondent’s prescriptions in relation
to other physicians, the absence of any
complaints to law enforcement, and no
physician testimony that the subject
patients were seeking detox due to the
Respondent’s excessive prescribing.*W
In the context of the allegations and
evidence, none of the above constitutes
necessary evidence to prove the
allegations. Indeed, I struggle to see any
relevance to such evidence in the
context of the allegations made.
Patient M.W.
The Government alleged that the
Respondent regularly and improperly
issued prescriptions for large quantities
and dosages of oxycodone,
oxymorphone, alprazolam, and
carispoprodol to Patient M.W. The
Government further alleged that the
initial physical examination and
medical history did not justify the
continued prescribing of controlled
substances and the subsequent physical
examinations did not meaningfully
evidence any chronic pain condition.
The Government alleged that the
Respondent failed to: (1) Order and
obtain diagnostic studies; and (2)
adequately address numerous instances
in which the patient had inconsistent
drug screens indicating possible
diversion, abuse, and/or use of illegal
controlled substances. The Government
further alleged that much of the medical
record for M.W. was fabricated and
appeared to be copied from records of
other patients, whose records contained
identically worded assessments. Finally,
the Government alleged the Respondent
documented that the patient provided
‘‘informed consent’’ when no informed
consent document could be located.
Additionally, the Government alleged
the Respondent failed to address
substantial evidence that M.W. was
engaged in abuse and/or diversion of
controlled substances, a violation of
TENN. CODE ANN. 63–6–214(b)(13).
In support, the Government offered
the testimony of its expert, Dr. Kennedy.
*W It is also noted that Respondent did not offer
any of this testimony in an attempt to rebut the
Government’s case.
E:\FR\FM\19JAN2.SGM
19JAN2
jspears on DSK121TN23PROD with NOTICES2
3012
Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices
Dr. Kennedy identified his ‘‘chart
review’’ for M.W. Tr. 243–44; GX 9, 10.
M.W. was diagnosed with low back
pain, yet Dr. Kennedy credibly opined
that the records did not support such
diagnosis. Tr. 245–46; GX 9 at 14; GX
10 at 3. The notes did reference back to
M.W.’s initial encounter. Tr. 441. The
Respondent testified M.W. was first
seen in January 2013. Tr. 595. M.W. was
a gunshot victim to whom the
Respondent prescribed alprazolam.
This, according to Respondent, was
based on the history and physical exam.
Tr. 593, 635–36; GX 9 at 69. The
Respondent claimed he obtained a
medical history, conducted a physical
exam, performed an adequate pain,
physical, and psychological assessment,
history and potential for substance
abuse. Tr. 596. The Respondent claimed
that he prepared a written treatment
plan. Tr. 601.
Yet, Dr. Kennedy countered there
were no findings in the record that
would support a chronic pain condition
and justify prescribing controlled
substances. Tr. 246–47. Dr. Kennedy
found no credible physical exam to
justify the diagnosis. Tr. 247, 265. Dr.
Kennedy testified that the Respondent
did not assess M.W.’s pain level,
physical and psychological functioning,
history, potential for drug abuse, or
coexisting diseases. Tr. 265. The
Respondent did not follow a legitimate
written treatment plan. The physical
exam findings were generally normal
findings, except for limited range of
motion at the lumbar spine. Tr. 247; GX
10 at 7. M.W. reported a pain level, at
worst, at 10 of 10, and at best, 6 of 10.
Tr. 248–49; GX 9 at 19; GX 10 at 8.
M.W.’s reported pain level was
inconsistent with the generally normal
results of the physical exam. Tr. 249–50.
The electronic medical record for this
visit does not contain the handwritten
information recorded in GX 10. Tr. 250–
51; GX 10 at 9. Instead the results of the
physical exam mirror those findings
made for UC, rendering M.W.’s chart not
credible. Tr. 251–52. This finding was
bolstered by ‘‘wildly’’ inconsistent UDS
results. Tr. 252–55; GX 9 at 2–4, 9–11,
84, 96, 102. After a series of inconsistent
UDS, the Respondent noted in M.W.’s
chart that M.W. was dismissed from
pain management with one-month
notice. Tr. 258; GX 9 at 84. Yet, at the
same visit in which he had been
notified he will be dismissed, the
history of present illness reports the
patient is compliant and consistent. Tr.
258. Dr. Kennedy deemed the chart not
credible, accordingly. Tr. 259. However,
despite being dismissed, M.W.
continued to be seen for months
VerDate Sep<11>2014
18:06 Jan 18, 2022
Jkt 256001
afterwards without any further
explanation in the medical records. Tr.
259–60.
The Respondent explained that the
evaluation of the patient’s potential for
drug abuse is an ongoing evaluation
with UDS, involving office screens,
confirmatory lab screens, and pill
counts. Tr. 596–98, 600. Respondent
testified that once a lab-confirmed
inconsistent UDS is discovered, the
Respondent initiates a dismissal
process. Tr. 598–600. The Tennessee
pain management guidelines leave it to
the physician’s discretion on the
handling of confirmed inconsistent UDS
results. Tr. 598–99.43 The Respondent
gives the patient a month to come into
compliance. Tr. 600. If he has a
consistent UDS within the month, the
patient is permitted to remain in
treatment. Tr. 601. The Respondent
claimed was able to bring M.W. back
into compliance through counseling,
however, the chart only documents that
the patient was counseled as to the
inconsistent UDS without identifying
any specific information. Tr. 637–38. Dr.
Kennedy later conceded that M.W. was
reinstated consistent with the
Respondent’s described office protocol.
Tr. 459–60. The Respondent continued
to prescribe him alprazalam,
amitriptyline, oxycodone, oxymorphone
and Soma. As noted earlier,
Respondent’s documentation of these
events and his handling of M.W.’s
inconsistent UDS was clearly outside
the Tennessee standards.
Regarding the alprazolam
prescriptions, Dr. Kennedy found it
unjustified based on the information
supporting the anxiety diagnosis. Tr.
260–61, 442–44; GX 9 at 85. Dr.
Kennedy noted the indications for
anxiety were not supported by the
findings within the chart, and mirrored
those in the charts for UC and other
patients. Tr. 261–62. In his PHB, the
Respondent argued that Dr. Kennedy
conceded a gunshot victim would have
PTSD; however, I credit Dr. Kennedy’s
opinion that the chart did not justify the
alprazolam prescription.
Although Dr. Kennedy opined M.W.
should have been physically examined
periodically during his treatment, the
charts suggest he was not examined
again following his first examination.
Tr. 262. Dr. Kennedy further opined that
as M.W. was a 25-year-old diagnosed
with degenerative disc disease, the
43 The Respondent’s explanation of the Tennessee
standards was admitted, not as expert testimony, as
the Respondent had not been qualified as an expert
to opine on the Tennessee standards, but as
reflecting his understanding of the guidelines to
explain why he took or declined to take certain
action.
PO 00000
Frm 00028
Fmt 4701
Sfmt 4703
Tennessee standards would require
diagnostic testing, such as an MRI to
confirm the diagnosis. Tr. 262, 447–48.
Dr. Kennedy found M.W.’s chart ‘‘not
credible and fabricated.’’ Tr. 263–64,
266; GX 10 at 5, 23. He noted that of 93
of 98 total visits shared the identical
findings for the physical exams and
ROS. Tr. 264. Similarly, Dr. Kennedy
found the diagnosis of insomnia not
credible. Tr. 264. A finding of drug
abuse and chemical dependency would
have been supportable, but such
indications were not sufficiently
addressed by the Respondent. Tr. 264–
65. The credible findings within M.W.’s
chart did not support the prescribing of
controlled substances, and the subject
prescriptions were issued outside the
usual course of professional practice. Tr.
267–68. I credit Dr. Kennedy’s opinions
in finding the Respondent’s subject
actions fell below the Tennessee
standards, and the controlled substances
were prescribed outside the Tennessee
standards.
[In accordance with Dr. Kennedy’s
credible and unrebutted expert
testimony, and for the reasons above, I
find that the twenty-six identified
prescriptions for alprazolam,
carisoprodol, oxycodone, and
oxymorphone that Respondent issued to
M.W. were issued outside the usual
course of professional practice and
beneath the standard of care. The basis
for Dr. Kennedy’s opinion and my
finding is that Respondent failed to:
Take an adequate medical history
including an assessment of M.W.’s pain
history and potential for substance
abuse; perform and document an
adequate physical examination; and
create a legitimate written treatment
plan for M.W.’s individual needs. Tr.
265. In accordance with Dr. Kennedy’s
testimony, I further find that the
relevant prescriptions issued by
Respondent were outside the usual
course of professional practice and
beneath the standard of care due to
Respondent’s failure to maintain
complete and accurate records for M.W.
Tr. 265–66. Finally, in accordance with
Dr. Kennedy’s testimony, I find that
M.W. exhibited evidence of drug abuse
or chemical dependency that was not
adequately addressed by Respondent.
Tr. 264–64.]
Patient C.F.
The Government alleged that from
August 2014 through August 2018, the
Respondent regularly issued
prescriptions for oxycodone and
alprazolam to C.F. The Government
further alleged that no credible physical
examination had been performed on
C.F. and that the exam results, as well
E:\FR\FM\19JAN2.SGM
19JAN2
jspears on DSK121TN23PROD with NOTICES2
Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices
as medical history, did not justify the
continued prescribing of controlled
substances. The Government further
alleged that no meaningful follow-up
physical exam was repeated, that
supported diagnostic studies were not
ordered, and that the Respondent failed
to determine a chronic pain etiology.
The Government further alleged that the
Respondent ignored suspicious drug
screen results which indicated illegal
drug use. The Government alleged that
much of the medical record for C.F. was
fabricated and seemed to be copied from
records of other patients whose records
contained identically worded
assessments. Although the Respondent
documented that the patient provided
‘‘informed consent,’’ no informed
consent document could be located.
Additionally, the Government alleged
the Respondent failed to address
substantial evidence that C.F. was
engaged in abuse and/or diversion of
controlled substances, a violation of
TENN. CODE ANN. 63–6–214(b)(13).
The Respondent explained that
Patient C.F. had a stab wound to the
chest, requiring heart surgery, resulting
in residual chronic pain. Tr. 601. The
Respondent reported he took a medical
history, performed a physical exam, an
adequate pain, physical and
psychological assessments, and
evaluated her history and potential for
substance abuse. Tr. 601–02. The
Respondent noted that he had the
benefit of confirmatory records from
Vanderbilt University Medical Center.
Tr. 602.
Dr. Kennedy testified that the chart
revealed C.F. was being treated for
chronic pain due to trauma, and
unspecified inflammatory
polyarthropathy. Tr. 268; GX 12. Dr.
Kennedy conceded C.F. had suffered
stab wounds to the chest requiring open
heart surgery, which can cause longterm neuropathic pain. Tr. 451–53.
Although in his PHB, the Respondent
characterizes Dr. Kennedy’s criticism of
the Respondent’s subject treatment as
failing to order tests, Dr. Kennedy had
more extensive criticism than that. Dr.
Kennedy opined that the history,
physical exams, the pain and physical
and psychological functioning, the
potential for substance abuse, written
treatment plan, and alternate treatment
considerations were each inadequate,
and did not justify the controlled
substance prescriptions.44 Tr. 269–70,
44 The Agency has previously found based on the
expert testimony that where the respondent: (1)
‘‘gave inadequate examinations or none at all;’’ (2)
ignored the results of tests; and (3) ‘‘took no
precautions against misuse and diversion’’ of
controlled substances, the evidence established that
the respondent exceeded the bounds of professional
VerDate Sep<11>2014
18:06 Jan 18, 2022
Jkt 256001
285, 455; GX 11 at 106; GX 12, at 7. Dr.
Kennedy noted the Respondent did not
discuss the risks and benefits of
controlled substance medications. Tr.
285. The physical exam notes revealed
essentially normal findings, however
the electronic records for this visit failed
to include these findings. Tr. 271; GX 11
at 69. Instead, under physical exam, the
same language duplicated so often in
the records, is included. Tr. 272. There
were no credible follow up physical
exams, supporting studies, and no
reasonable pain etiology. Tr. 272; GX 12
at 5, 6. The ROS indications were
identically repeated in other charts. Tr.
272–73. Dr. Kennedy noted that the
language in the general exam, ‘‘patient
is alert and oriented’’ is similarly
repeated 102 times throughout the
records. Dr. Kennedy reported
inconsistent UDSs for C.F., collected on
July 2, 2018, and thereafter. Tr. 273–80,
282; GX 11 at 9, 23, 24, 25, 28, 33, 44,
47, 54, 69, 78, 111, 117; GX 20. Even
more concerning, C.F.’s UDS result was
negative for all of the medications she
was prescribed. Tr. 275–77. C.F. also
tested positive for cocaine and
marihuana. Tr. 277, 280. An
inconsistent drug screen on July 26,
2017, is not mentioned in the medical
records. Tr. 288–89. Although the
records repeatedly noted that, ‘‘patient
counseled at length on unsatisfactory
UDS,’’ Dr. Kennedy credibly testified
that this was insufficient under
Tennessee standards to address C.F.’s
drug abuse and diversion. Tr. 280, 284.
I credit Dr. Kennedy’s assessment
regarding the Respondent’s deficient
handling of C.F.’s ongoing drug abuse
and diversion.
On May 3, 2017, C.F. tested positive
for buprenorphine, a medication
typically used to treat opioid use
disorder. Tr. 281–82. The Respondent
had not prescribed it. Although the
Respondent explained that the MED
prescribed to C.F. was a relatively low
dose, Tr. 603–05; in light of C.F.’s
continued drug abuse and diversion, Dr.
Kennedy opined that the Respondent
continued to improperly prescribe
controlled substances without making a
bona fide effort to cure C.F.’s addiction.
Tr. 284. I agree.
The Respondent prescribed
alprazolam for anxiety and insomnia.
Tr. 286; GX 11 at 39. However, the
supporting indications are identical to
the other patients who were diagnosed
with anxiety and insomnia. Tr. 286–87.
The Respondent did not maintain
complete and accurate records for C.F.
practice. Carlos Gonzalez, M.D., 76 FR 63,118,
63,141 (2011) (citing United States v. Moore, 423
U.S. 122, 135, 142–43 (1975)).
PO 00000
Frm 00029
Fmt 4701
Sfmt 4703
3013
Tr. 286. Dr. Kennedy concluded that the
controlled substance prescriptions
issued to C.F. were outside the usual
course of professional practice. Tr. 287.
For the reasons detailed, I concur. I
credit Dr. Kennedy’s expert opinions
and find that the Respondent’s subject
prescribing to C.F. was in violation of
Tennessee regulations, and below the
Tennessee standards.
[In accordance with Dr. Kennedy’s
credible and unrebutted expert
testimony, and for the reasons above, I
find that the sixteen identified
prescriptions for alprazolam and
oxycodone that Respondent issued to
C.F. were issued outside the usual
course of professional practice and
beneath the standard of care. The basis
for Dr. Kennedy’s opinion and my
finding is that Respondent failed to:
Take an adequate medical history
including an assessment of C.F.’s pain
history and potential for substance
abuse; perform and document an
adequate physical examination; and
create a legitimate written treatment
plan for C.F.’s individual needs and
discuss the risks and benefits of using
controlled substances. In accordance
with Dr. Kennedy’s testimony, I further
find that the relevant prescriptions
issued by Respondent were outside the
usual course of professional practice
and beneath the standard of care due to
Respondent’s failure to maintain
complete and accurate records for C.F.
Finally, in accordance with Dr.
Kennedy’s testimony, I find that C.F.
exhibited evidence of drug abuse or
chemical dependency that was not
adequately addressed by Respondent.]
Patient B.C.
The Government alleges that from
August 2014 through August 2018, the
Respondent regularly issued
prescriptions for large quantities of
oxycodone, oxymorphone, alprazolam,
and carisoprodol to B.C. The
Government further alleged that no
credible physical examination had been
performed on B.C. and that the exam
results, as well as medical history, did
not justify the continued prescribing of
controlled substances. The Government
further alleged that no meaningful
follow-up physical exam was repeated,
that confirmatory diagnostic studies
were not ordered, and that the
Respondent failed to determine a
chronic pain etiology. The Government
further alleged that the Respondent
ignored suspicious drug screen results
which indicated illegal drug use. The
Government alleged that much of the
medical record for B.C. was fabricated
and seemed to be copied from records
of other patients whose records
E:\FR\FM\19JAN2.SGM
19JAN2
3014
Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices
jspears on DSK121TN23PROD with NOTICES2
contained identically worded
assessments. Although the Respondent
documented that the patient provided
‘‘informed consent,’’ no informed
consent document could be located.
Dr. Kennedy identified his summary
chart for B.C. Tr. 289–90; GX 13; GX 14.
B.C. was being treated for chronic pain
syndrome. B.C. was referred from the
Clark County Jail, on December 19,
2012,45 a potentially challenging
patient. Tr. 458–59. Although not
revealed in the chart, Respondent
testified that B.C. had previously been a
patient of the Respondent. The
Respondent maintained that he took a
medical history, performed a physical
exam, adequate pain, physical and
psychological assessments, and
evaluated his history and potential for
substance abuse, and prepared a written
treatment plan. Tr. 608.
Dr. Kennedy disagreed, claiming the
Respondent did not take an adequate
medical history. Tr. 304. Although a
physical exam was evident, Dr.
Kennedy testified that it was
insufficient and non-supportive to
justify prescribing the medications
prescribed. Tr. 290–91, 304; GX 13 at
169; GX 14 at 7; GX 22. Dr. Kennedy
asserted the Respondent did not make
an adequate assessment of pain, and
physical and psychological function, of
history of substance abuse, coexisting
diseases and conditions, written
treatment plan or alternate treatments.
Tr. 304–06. He did not conduct any
periodic reviews, or discuss the risks
and benefits of the use of controlled
substances. Tr. 306. There were no
radiologic studies ordered. Tr. 303.
There were no prior medical records
ordered or obtained, but the records did
include hospital records. Tr. 303, 459–
60. Although the Respondent described
the extensive forms each patient is
required to fill out at the initial visit,
some of the described forms, which
were referenced in B.C.’s chart, were
missing from the Respondent’s records.
Tr. 628–29; GX 13 at 5. The Respondent
explained that some records were lost in
2014.46 Tr. 630. However, the missing
records were not recreated despite B.C.
being a long-term patient. Tr. 630.
The Respondent explained why he
obtained and kept pharmacy printouts
45 The Respondent noted the pain management
guidelines have changed since then. Tr. 605. [It
appears that Tennessee has been regulating
authority for physicians to prescribe for treatment
of pain since 2014. As the changes seem to have
taken place well before the prescribing of the
controlled substances at issue in this case, this
information is not material to my decision.]
46 I ruled the evidence of lost files in 2014
inadmissible as unnoticed and not reasonably
anticipated by the Government, representing
surprise.
VerDate Sep<11>2014
18:06 Jan 18, 2022
Jkt 256001
in his records. They are easier and
quicker to obtain than medical records.
Tr. 606. The pharmacy printout informs
how long the patient has been
prescribed medications, changes in
dosage, and the prescriber. Tr. 607.
Dr. Kennedy noted indications from
the ROS were duplicated throughout the
records. Of 141 encounters, the ROS
language was duplicated 140 times,
while the physical exam language was
duplicated 134 times. Tr. 291–92. B.C.
had serious health issues, including
Hodgkins lymphoma, a cancer of the
lymphatic system. Tr. 293. Dr. Kennedy
identified a document in the chart
indicating B.C. had been dismissed from
a prior physician, a clear red flag which
was not resolved. Tr. 293–94; GX 13 at
188.
Dr. Kennedy noted the actual pain
level was left blank at nine consecutive
encounters, suggesting it is being added
later, a further indication of fabricated
records. Tr. 294–95; GX 13 at 159; GX
14 at 8. Dr. Kennedy opined the
Respondent did not maintain accurate
and complete records. Tr. 306. One
entry reveals, ‘‘patient lied about his
prescriptions,’’ an alarming red flag left
unaddressed by the Respondent. Tr.
296; GX 13 at 169. Despite noting that
the ‘‘patient lied,’’ the Respondent
issued controlled medications and
‘‘held’’ up UDS for a month. Tr. 297.
This is outside the usual course of
professional practice. B.C. continued to
have inconsistent UDS results, which
were insufficiently addressed by the
Respondent. Tr. 297–98; GX 13 at 33,
79, 150, 155, 156, 158, 164, 165. The
Respondent countered that each of the
Respondent’s patient records contained
the instruction, ‘‘rule out doctor
shopping’’, which was a prompt to
review the Tennessee PDMP to
determine if the patient was obtaining
controlled substances from multiple
physicians. Tr. 608. Although ruling out
doctor shopping is appropriate and
necessary action, it does not excuse the
failure to adequately address B.C.’s drug
abuse and other red flags. I credit Dr.
Kennedy’s findings, and I find that the
information contained in B.C.’s chart
did not justify the controlled
medications prescribed by the
Respondent, nor support that they were
issued in the usual course of
professional practice. Tr. 307–08.
[In accordance with Dr. Kennedy’s
credible and unrebutted expert
testimony, and for the reasons above, I
find that the eighteen identified
prescriptions for alprazolam,
oxymorphone, carisoprodol, and
oxycodone that Respondent issued to
B.C. were issued outside the usual
course of professional practice and
PO 00000
Frm 00030
Fmt 4701
Sfmt 4703
beneath the standard of care. The basis
for Dr. Kennedy’s opinion and my
finding is that Respondent failed to:
Take an adequate medical history
including an assessment of B.C.’s pain
history and potential for substance
abuse; perform and document an
adequate physical examination; and
create a legitimate written treatment
plan for B.C.’s individual needs and
discuss the risks and benefits of using
controlled substances. In accordance
with Dr. Kennedy’s testimony, I further
find that the relevant prescriptions
issued by Respondent were outside the
usual course of professional practice
and beneath the standard of care due to
Respondent’s failure to maintain
complete and accurate records for B.C.
Finally, in accordance with Dr.
Kennedy’s testimony, I find that B.C.’s
records included unresolved
inconsistent drug screens, a red flag that
was not adequately addressed by
Respondent.]
Patient M.H.
The Government alleges that from
August 2014 through February 2018, the
Respondent regularly issued
prescriptions for large quantities of
alprazolam, carisoprodol, oxycodone,
and oxymorphone to M.H. The
Government further alleges the
Respondent diagnosed M.H. with
‘‘chronic pain syndrome’’ even though
the Respondent made no attempt to
diagnose a specific pain etiology. The
Government further alleged that that the
Respondent failed to obtain diagnostic
studies and current medical records
from M.H.’s other medical providers
and that the results of the physical
examination and medical history did
not justify the continued prescribing of
controlled substances. The Government
alleged the Respondent ignored a major
surgical intervention that occurred in
September 2016 as well as an abnormal
drug screen. As such, the Government
concluded that much of the medical
record for M.H. was fabricated and
seemed to be copied from records of
other patients whose records contained
identically-worded assessments. The
Respondent also documented that the
patient provided ‘‘informed consent’’
when no informed consent document
could be located. The Government
alleged that, in some cases, the
Respondent failed to repeat certain
physical exams after the initial
encounter with M.H., despite the fact
the Respondent provided him with
prescriptions for controlled substances
for more than three years.
The Respondent explained Patient
M.H. presented with a post gunshot
wound to the abdomen and chronic low
E:\FR\FM\19JAN2.SGM
19JAN2
jspears on DSK121TN23PROD with NOTICES2
Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices
back pain secondary to degenerative
disc disease. Tr. 608. According to
Respondent, he had already been treated
for pain management. He had a history
of extensive spinal surgery at Vanderbilt
University Medical Center, including a
laminectomy. Tr. 609–11. The
Respondent testified that he prescribed
a lower MME than the surgeon
prescribed post-operative at Vanderbilt.
Tr. 611.
Dr. Kennedy identified his summary
chart for Patient M.H. Tr. 309; GX 15;
GX 16. The chart reveals M.H. was being
treated for chronic pain syndrome. GX
15 at 62, 63. The physical exam
indications are identical to those
repeated throughout the medical records
and, in Dr. Kennedy’s opinion, do not
support any chronic pain diagnosis. Tr.
311. The records reveal M.H. suffered a
gunshot wound in 2008, and although
serious, Dr. Kennedy opined that would
not in itself justify pain medication
eight years later. Tr. 323. Dr. Kennedy
assessed the Respondent’s treatment as
outside the scope of acceptable medical
practice because the Respondent did not
make an adequate assessment of pain,
and physical and psychological
function, of medical history, of history
of substance abuse, coexisting diseases
and conditions, periodic review of care,
written treatment plan or alternate
treatments. Tr. 312, 326–28. The
Respondent did not conduct any
periodic reviews, or discuss the risks
and benefits of the use of controlled
substances. Tr. 328. M.H. had
inconsistent UDSs. Tr. 314–20; GX 15 at
36, 39, 40, 47, 49, 53, 56, 63. Although
several inconsistent UDS were noted in
the chart, there were typically no notes
of discussions. The Respondent failed to
adequately address the UDS. Tr. 314–20.
During his treatment with the
Respondent, M.H. underwent a serious
and complex spinal surgery, a major
surgery. Tr. 320–22, 462–63; GX 15 at
26; GX 16, at 9. M.H. was seen by the
Respondent the day after his release
from the hospital. GX 15 at 48. Despite
his recent, major surgery, there is no
mention of the surgery in the encounter
notes. Tr. 322–23. The encounter notes
are identical to all the other encounter
notes for M.H. Tr. 323; GX 15 at 48. The
Respondent conceded his medical
findings as to Patient M.H. for the visit
just prior to M.H.’s major back surgery
are the same as the Respondent’s
findings for the visit the day after the
surgery. Tr. 637–38; GX 15 at 48–50.
The Respondent explained that the
subject findings were based on
‘‘history.’’ Tr. 638. Put another way,
Respondent carried forward the exam
indications from the pre-surgery visit to
the post-surgery visit.
VerDate Sep<11>2014
18:06 Jan 18, 2022
Jkt 256001
There is no updated physical exam, as
Dr. Kennedy opined would be required.
Tr. 324. The PE and HPI notes are the
same as those the four months prior to
the spinal surgery, which is not
credible. Tr. 324–25, 491–92; GX 15 at
49, 51. Dr. Kennedy opined that the
Respondent did not maintain accurate
and complete records as to M.H. Tr. 328.
Dr. Kennedy reviewed the prescriptions
issued. Tr. 325; GX 19 at 1–13. He
opined that the chart, including the
number of inconsistent UDS, reveals
that M.H. was addicted to controlled
substances, yet the Respondent
continued prescribing them without
making a bona fide effort to cure the
addiction. Tr. 325. The Respondent
conceded the chart reports that M.H. has
been ‘‘compliant,’’ however, on the next
page of the chart, it reports M.H. had an
inconsistent UDS. Tr. 638–40; GX 15 at
48–49. The Respondent explained that
the inconsistent UDS related to the
point of care test, not the confirmatory
lab test, so the chart was accurate in that
instance. Tr. 640. However, even if the
inconsistent UDS result were at the
point of care, as discussed supra, the
record discloses there were eight of
them, some of which went completely
unaddressed within the records. I credit
Dr. Kennedy’s opinion that the
Respondent’s failure to resolve the red
flag arising from inconsistent UDS
rendered the subsequent prescribing
outside the Tennessee standard of care.
Dr. Kennedy opined the subject
prescriptions were issued outside the
usual course of professional practice. Tr.
329–30, 493. I credit Dr. Kennedy’s
findings, and find that the Respondent’s
controlled substance prescribing were in
violation of Tennessee regulations and
the Tennessee standards.
[In accordance with Dr. Kennedy’s
credible and unrebutted expert
testimony, and for the reasons above, I
find that the approximately fifteen
identified prescriptions for alprazolam,
oxycodone, and oxymorphone that
Respondent issued to M.H. were issued
outside the usual course of professional
practice and beneath the standard of
care. The basis for Dr. Kennedy’s
opinion and my finding is that
Respondent failed to: Take an adequate
medical history including an assessment
of M.H.’s pain history and potential for
substance abuse; perform and document
an adequate physical examination; and
create a legitimate written treatment
plan for M.H.’s individual needs and
discuss the risks and benefits of using
controlled substances. In accordance
with Dr. Kennedy’s testimony, I further
find that the relevant prescriptions
issued by Respondent were outside the
usual course of professional practice
PO 00000
Frm 00031
Fmt 4701
Sfmt 4703
3015
and beneath the standard of care due to
Respondent’s failure to maintain
complete and accurate records for M.H.
Finally, in accordance with Dr.
Kennedy’s testimony, I find that M.H.
exhibited evidence of drug abuse or
chemical dependency that was not
adequately addressed by Respondent.]
Patient M.P.
The Government alleges that from
September 2016 through April 2018, the
Respondent regularly issued
prescriptions for large quantities of
oxycodone and oxymorphone to M.P.
The Government alleges that the
Respondent failed to request and obtain
past medical records, the Respondent
failed to order any radiographic studies,
and that the physical examinations of
M.P., including follow-up exams, were
substandard and not credible. The
Government alleged that the
Respondent failed to document any
evidence to support a pain etiology and
that the Respondent failed to properly
address M.P.’s substance abuse disorder
despite the fact that she suffered a
heroin overdose in the Respondent’s
waiting room. As a result, the
Government alleged there were no
objective findings to justify the
continued prescribing of oxycodone and
oxymorphone. The Government alleges
that much of the medical record for M.P.
was fabricated and seemed to be copied
from records of other patients whose
records contained identically worded
assessments. The Respondent also
documented that the patient provided
‘‘informed consent’’ when no informed
consent document could be located in
the medical record. Additionally, the
Government alleged the Respondent
failed to address substantial evidence
that M.P. was engaged in abuse and/or
diversion of controlled substances, a
violation of TENN. CODE ANN . § 63–
6–214(b)(13).
The Respondent explained Patient
M.P. was being managed for chronic
pain. In her initial visit, she reported
conflicting information regarding
whether she had been in drug rehab
treatment. Tr. 641–42; GX 7. The
Respondent explained that he could
only rely on the information provided
by the patient. Tr. 642. The Respondent
claimed that he took a medical history,
performed a physical exam, adequate
pain, physical and psychological
assessments, and evaluated her history
and potential for substance abuse, and
prepared a written treatment plan. Tr.
615–17.
Dr. Kennedy countered, noting he
reviewed the prescriptions issued. Tr.
348–49; GX 21. He opined that the
chart, including the number of
E:\FR\FM\19JAN2.SGM
19JAN2
jspears on DSK121TN23PROD with NOTICES2
3016
Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices
inconsistent UDS, reveals that M.P. was
addicted to controlled substances, yet
the Respondent continued prescribing
them without making a bona fide effort
to cure the addiction, until after she
overdosed on heroin. Tr. 348. The
subject prescriptions, as well as those
prescribed to the other charged patients,
were dangerous and issued outside the
usual course of professional practice. Tr.
352, 488–89.
Dr. Kennedy reported M.P. was being
treated for low back, neck, hip and
shoulder pain. Tr. 331; GX 8. She was
later diagnosed with degenerative disc
disease and right shoulder pain.
Although a physical exam was
performed, it was inadequate to
substantiate the diagnoses. Tr. 331–34,
339–40, 343; GX 7 at 2. A mechanical
shoulder exam and range of motion back
and neck exam should have been
performed. Dr. Kennedy opined that
Respondent did not make an adequate
assessment of pain, nor physical and
psychological function, of medical
history, of history of substance abuse,
coexisting diseases and conditions,
periodic review of care, written
treatment plan nor alternate treatments.
Tr. 349–51. He did not conduct any
periodic reviews, nor discuss the risks
and benefits of the use of controlled
substances. Tr. 349–50. Dr. Kennedy
stated that M.P.’s employment as a
server, working 45–60 hours per week is
inconsistent with her ‘‘occupational
disability’’ score of 9 or 10, a significant
conflict. Tr. 344–45; GX 7 at 3, 9, 10. Dr.
Kennedy noted the hand-written exam
notes did not appear in the electronic
medical records. Tr. 325–36; GX 7 at 68.
Instead the PE notes duplicated
throughout the records appears. Tr. 336,
351. The pain level is reported as 9,
which is inconsistent with the PE
indications. Dr. Kennedy indicated
notes generated at the initial visit
appeared to be a reminder to obtain
certain prior medical records from Dr.
M. Tr. 337, 468; GX 7 at 1, 68. Those
same notes appear in the record
repeatedly thereafter. Tr. 337; GX 7 at
59. Other than the requested pharmacy
report, the prior records were never
obtained. Tr. 338–39. The Respondent
explained that in September of 2016, the
Respondent requested dismissal
records, an X-ray, and an MRI from Dr.
M. Tr. 642–44; GX 7 at 48. Yet, eighteen
months later, the Respondent still had
not received the requested records. Tr.
644; GX 7 at 59. There is no
documentary proof records were ever
requested.
Dr. Kennedy concluded the
Respondent did not maintain accurate
and complete records as to M.P. Tr. 350.
At M.P.’s initial visit a UDS was
VerDate Sep<11>2014
18:06 Jan 18, 2022
Jkt 256001
performed revealing inconsistent
results, which were never addressed in
the records. Tr. 338; GX 7 at 19, 68.
Notes reveal M.B. had been terminated
from a prior physician, a red flag. Tr.
343. The records did reveal a
monitoring of the Tennessee PDMP, and
a successful pill count, both positive
steps by the Respondent. Tr. 470. There
were emergency room notes which
revealed she was admitted on April 17,
2018 and released on April 18 for
apparent heroin overdose, which
occurred in the Respondent’s waiting
room. Tr. 340–41; GX 7 at 25.
The Respondent explained those
events. He testified that M.P. came to
the clinic overdosing on heroin. Tr. 342,
611–12. She had to be resuscitated until
EMS was able to reverse the effects of
heroin with Narcan. Tr. 612. In the postoverdose notes the Respondent took an
extensive history again regarding her
drug use. Following the heroin
overdose, the determination was made
that she needed treatment of Suboxone
and no further opioid prescriptions. Tr.
616. He directed she cannot be on pain
management but must be on opioid
abuse treatment. So, the Respondent
started her on Suboxone. Tr. 613. The
Respondent explained his
understanding of Suboxone induction.
The first type of induction therapy is by
observation. He stated that you give the
patient Suboxone and observe them
until they reach the point of
withdrawal. The other form of induction
is to give the patient Suboxone and send
them home without observation by the
physician. Tr. 612–14. According to
Respondent, M.P. was initially receptive
to drug treatment, but later changed
clinics. Tr. 615.
Dr. Kennedy viewed Respondent’s
prescribing of Suboxone as dangerous
and outside the standard of care. Tr.
342, 371–73, 465–66. As the patient was
shown to be on heroin, a UDS would be
necessary to determine if she had heroin
in her system before prescribing
buprenorphine (Suboxone), which in
conjunction with heroin could result in
permanent withdrawal. Tr. 343. The
Respondent argues in his PHB that a
successful UDS was conducted.
However, I do not find a successful UDS
in the record prior to the Respondent
prescribing Suboxone. There were
inconsistent UDS in the records for M.P.
Tr. 346–; GX 7 at 48, 59. I credit Dr.
Kennedy’s findings. The Respondent’s
prescribing to M.B. was in violation of
Tennessee regulations and Tennessee
standards. The Suboxone prescription
without determining her heroin level
was dangerous and outside the course of
professional practice. The Respondent’s
failure to timely address M.P.’s
PO 00000
Frm 00032
Fmt 4701
Sfmt 4703
inconsistent UDS results was outside
the Tennessee standards.
[In accordance with Dr. Kennedy’s
credible and unrebutted testimony, and
for the reasons above, I find that the
sixteen identified prescriptions for
oxycodone and oxymorphone and the
prescription for buprenorphine that
Respondent issued to M.P. were issued
outside the usual course of professional
practice and beneath the standard of
care. The basis for Dr. Kennedy’s
opinion and my finding is that
Respondent failed to: Take an adequate
medical history including an assessment
of M.P.’s pain history and potential for
substance abuse; perform and document
an adequate physical examination; and
create a legitimate written treatment
plan for M.P.’s individual needs and
discuss the risks and benefits of using
controlled substances. In accordance
with Dr. Kennedy’s testimony, I further
find that the relevant prescriptions
issued by Respondent were outside the
usual course of professional practice
and beneath the standard of care due to
Respondent’s failure to maintain
complete and accurate records for M.P.
Finally, in accordance with Dr.
Kennedy’s testimony, I find that M.P.
exhibited evidence of drug abuse or
chemical dependency that was not
adequately addressed by Respondent
until after she overdosed in his office.]
Material Falsification
In its GSPHS, the Government alleged
that, on November 6, 2019, the
Respondent made a material
misrepresentation in his renewal
application for his Tennessee-based
DEA COR, W18070589C. Specifically, in
response to liability question three, the
Respondent answered ‘‘no,’’ which he
knew or should have known to be a
false response. GX 26. Liability question
three queries whether the applicant has
ever surrendered for cause, or had a
state professional license or controlled
substance registration revoked,
suspended, denied, restricted, or placed
on probation, or have any such action
pending. An affirmative answer to
question 3 would trigger an
investigation by a diversion investigator
whether to issue the registration or to
deny it. The Respondent answered ‘‘No’’
to question 3.
In support, the Government cites to
the State of Tennessee Department of
Health, Notice of Charges and
Memorandum for Assessment of Civil
Penalties, dated May 2018. GX 29. [In
this document, the state requested that
‘‘Respondent’s certificate to operate a
Pain Management Clinic . . . be
suspended, revoked, or otherwise
disciplined.’’ GX 29, at 25.] A year later
E:\FR\FM\19JAN2.SGM
19JAN2
Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices
jspears on DSK121TN23PROD with NOTICES2
in May 2019, the Chancery Court for the
State of Tennessee, 20th Judicial
District, Davidson County, Part 3, issued
an order Reversing Denial of Stay, but
Accompanying Stay with Conditions.
GX 27. The stay was conditioned upon
the Respondent ‘‘not writing any
prescriptions during the pendency of
the stay; . . . and/or not providing
direct patient care including but not
limited to diagnosing, treating,
operating on or prescribing for any
person.’’ GX 27, at 2. Therefore, as of
May 2019, the Conditions preclude the
Respondent from writing prescriptions
or providing direct patient care during
the pendency of the stay and were
reportable restrictions. When asked on
his November 6, 2019 application
whether Respondent had ever had a
state professional license or controlled
substance registration revoked,
suspended, or restricted or had any such
action pending, he was required to, but
did not, disclose these events.*X 47
Therefore, I find clear, unequivocal, and
convincing evidence that Respondent
submitted a registration application
containing a false answer to the third
Liability question.
[My finding about Respondent’s
submission of a false answer involves
restrictions on Respondent’s state
license to dispense controlled
substances. Id. In setting the
requirements for obtaining a
practitioner’s registration, Congress
directed that ‘‘[t]he Attorney General
shall register practitioners . . . if the
applicant is authorized to dispense . . .
controlled substances under the laws of
the State in which he practices.’’ 21
U.S.C. 823(f). Accordingly, it is clear
that having authorization to dispense
controlled substances is a prerequisite
to my ability to grant an applicant’s
application. Respondent’s false response
to the third Liability question directly
implicated my statutorily-mandated
analysis and my decision by depriving
me of legally relevant facts when I
evaluated Respondent’s registration
renewal application. See Frank Joseph
Stirlacci, M.D., 85 FR 45,229, 45,235
(2020). Accordingly, I find, based on the
CSA and the analysis underlying
multiple Supreme Court decisions
explaining ‘‘materiality,’’ that the falsity
*X Omitted text. The Government also alleged
that Respondent’s surrender of his pain clinic’s
license also warranted an affirmative response to
question 3 on Respondent’s personal application. I
find that I do not need to reach a decision on this
evidence as the Government has already presented
ample evidence that Respondent materially falsified
his application when he failed to report that his
authority to dispense controlled substances was
restricted.
47 [Omitted the original text containing this
footnote.]
VerDate Sep<11>2014
19:06 Jan 18, 2022
Jkt 256001
Respondent submitted was material.
Frank Joseph Stirlacci, M.D., 85 FR at
45,235.] *Y *Z
Government’s Burden of Proof and
Establishment of a Prima Facie Case
Based upon my review of each of the
allegations by the Government, it is
necessary to determine if it has met its
prima facie burden of proving the
requirements for a sanction pursuant to
21 U.S.C. 824(a)(4) and 21 U.S.C. 823(f).
At the outset, I find that the Government
has demonstrated and met its burden of
proof in support of its allegations
relating to the prescribing of controlled
substances to patients UC, M.P., M.W.,
C.F., B.C., and M.H. The Government
has also sustained their burden as to the
material misrepresentation allegation.
Public Interest Determination: The
Standard
[Under Section 304 of the CSA, ‘‘[a]
registration . . . to . . . dispense a
controlled substance . . . may be
suspended or revoked by the Attorney
General upon a finding that the
registrant . . . has committed such acts
as would render his registration under
section 823 of this title inconsistent
with the public interest as determined
by such section.’’ 21 U.S.C. 824(a)(4).] 48
Evaluation of the following factors have
been mandated by Congress in
determining whether maintaining such
registration would be inconsistent with
the ‘‘the public interest:’’
(1) The recommendation of the appropriate
State licensing board or professional
disciplinary authority.
(2) The [registrant’s] experience in
dispensing, or conducting research with
respect to controlled substances.
(3) The [registrant’s] conviction record
under Federal or State laws relating to the
manufacture, distribution, or dispensing of
controlled substances.
(4) Compliance with applicable State,
Federal, or local laws relating to controlled
substances.
(5) Such other conduct which may threaten
the public health and safety.
21 U.S.C. 823(f). ‘‘These factors are . . .
considered in the disjunctive.’’ Robert
A. Leslie, M.D., 68 FR 15227, 15230
(2003).
Any one or a combination of factors
may be relied upon, and when
exercising authority as an impartial
adjudicator, the Agency may properly
give each factor whatever weight it
*Y This language replaces the ALJ’s original
analysis for clarity.
*Z Omitted ALJ’s discussion of the pain clinic’s
license. See supra n. *X. I have also consolidated
the ALJ’s original section entitled ‘‘Conditions of
Stay’’ with the preceding paragraph for brevity.
48 [This text replaces the ALJ’s original text and
omits his original footnote for clarity.]
PO 00000
Frm 00033
Fmt 4701
Sfmt 4703
3017
deems appropriate in determining
whether a registrant’s registration
should be revoked. Id. (citation
omitted); David H. Gillis, M.D., 58 FR
37507, 37508 (1993); see also Morall v.
DEA at 173–74; Henry J. Schwarz, Jr.,
M.D., 54 FR 16422, 16424 (1989).
Moreover, the Agency is ‘‘not required
to make findings as to all of the factors.’’
Hoxie v. DEA, 419 F.3d at 482; see also
Morall, 412 F.3d at 173. [Omitted for
brevity.] The balancing of the public
interest factors ‘‘is not a contest in
which score is kept; the Agency is not
required to mechanically count up the
factors and determine how many favor
the Government and how many favor
the registrant. Rather, it is an inquiry
which focuses on protecting the public
interest . . . .’’ Krishna-Iyer, M.D., 74
FR at 462.
The Government’s case invoking the
public interest factors of 21 U.S.C. 823(f)
seeks the revocation of the Respondent’s
COR based primarily on conduct most
aptly considered under Public Interest
Factor’s [Two and] Four.49
[Factors Two and Four: The
Respondent’s Experience in Dispensing
Controlled Substances and Compliance
With Applicable Laws Related to
Controlled Substances] *AA
According to the Controlled
Substances Act’s (hereinafter, CSA)
implementing regulations, a lawful
controlled substance order or
prescription is one that is ‘‘issued for a
legitimate medical purpose by an
individual practitioner acting in the
usual course of his professional
practice.’’ 21 CFR 1306.04(a). The
Supreme Court has stated, in the context
of the CSA’s requirement that schedule
II controlled substances may be
dispensed only by written prescription,
49 [Where the record contains no evidence of a
recommendation by a state licensing board that
absence does not weigh for or against revocation.
See Roni Dreszer, M.D., 76 FR 19,434, 19,444 (2011)
(‘‘The fact that the record contains no evidence of
a recommendation by a state licensing board does
not weigh for or against a determination as to
whether continuation of the Respondent’s DEA
certification is consistent with the public
interest.’’). Here, to the extent that Tennessee’s
decision not to revoke or suspend Respondent’s
individual authority to handle controlled
substances could weigh in his favor, I find that any
such weight would be significantly reduced by the
circumstances of the loss of his practice’s license,
and the pending nature of the state action on his
individual license.] Likewise, the record contains
no evidence that the Respondent has been
convicted of a crime related to controlled
substances (Factor Three).
*AA The ALJ only evaluated the evidence under
Factor 4. However, Respondent’s dispensing
experience is clearly relevant to my determination
as to whether or not Respondent’s continued
registration is consistent with the public interest,
and I have made changes throughout this section
accordingly.
E:\FR\FM\19JAN2.SGM
19JAN2
jspears on DSK121TN23PROD with NOTICES2
3018
Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices
that ‘‘the prescription requirement . . .
ensures patients use controlled
substances under the supervision of a
doctor so as to prevent addiction and
recreational abuse . . . [and] also bars
doctors from peddling to patients who
crave the drugs for those prohibited
uses.’’ Gonzales v. Oregon, 546 U.S.
243, 274 (2006).
I found above that the Government’s
expert credibly testified as supported by
Tennessee law, that the standard of care
requires a practitioner, before
prescribing controlled substances, to
take an adequate medical history
including an assessment of the patient’s
pain history and potential for substance
abuse; perform and document an
adequate physical examination; and
create a legitimate written treatment
plan for the patient’s individual needs
and to discuss the risks and benefits of
the use of controlled substances with
the patient. Additionally, I found that
practitioners are required to maintain
complete and accurate records for their
patients. I also found above that
Respondent issued approximately
ninety-five controlled substance
prescriptions outside the usual course of
professional practice and beneath the
standard of care. This is because for
each of the relevant prescriptions, I
found that the Respondent failed to take
an adequate medical history including
an assessment of each patient’s pain
history and potential for substance
abuse; perform and document an
adequate physical examination; and/or
create a legitimate written treatment
plan for each patient’s individual needs
and/or discuss the risks and benefits of
using controlled substances with the
patient. I also found that each of the
relevant prescriptions were issued
outside the usual course of professional
practice and beneath the standard of
care due to Respondent’s failure to
maintain complete and accurate records.
Respondent repeatedly issued
prescriptions without complying with
the applicable standard of care and state
law thus demonstrating that his conduct
was not an isolated occurrence, but
occurred with multiple patients. See
Kaniz Khan Jaffery, 85 FR 45,667,
45,685 (2020). For example,
Respondent’s medical records for each
of the individuals at issue had verbatim
language repeated throughout the
relevant time frame stating, ‘‘Patient has
a long standing h/o insomnia and
anxiety for several years. Anxiety
symptoms include sob, palpitations,
sweating, dizziness, shaking, insomnia,
irritability, pacing, moodiness and
feeling faint. Right now no headache, no
dizziness, no nausea, no vomiting, no
abdominal pain, no diarrhoea [sic.], no
VerDate Sep<11>2014
18:06 Jan 18, 2022
Jkt 256001
constipation, no sob, no chest pain, no
palpitations.’’ GX 9, at 85; GX 11, at 39;
Tr. 286–87. This verbatim language was
included in each patient’s record and in
UC’s records to which UC testified
credibly that he did not report having
any of the anxiety symptoms identified
in the chart.
Agency decisions highlight the
Agency’s interpretation that
‘‘[c]onscientious documentation is
repeatedly emphasized as not just a
ministerial act, but a key treatment tool
and vital indicator to evaluate whether
the physician’s prescribing practices are
‘within the usual course of professional
practice.’ ’’ Cynthia M. Cadet, M.D., 76
FR 19,450, 19,464 (2011). DEA’s ability
to assess whether controlled substances
registrations are consistent with the
public interest is predicated upon the
ability to consider the evidence and
rationale of the practitioner at the time
that he prescribed a controlled
substance—adequate documentation is
critical to that assessment. See KanizKhan Jaffery, 85 FR at 45,686. Further,
as Dr. Kennedy testified, ‘‘maintaining a
patient on scheduled medications . . .
sometimes at high dosages, without
having honest, accurate, complete
medical records is dangerous.’’ Tr. 352–
53. This is because, according to Dr.
Kennedy, ‘‘those medical records will
instruct other people who look at them
as to what the motivation was for the
treatment . . . [a]nd if what is
documented in the medical record
simply doesn’t made sense or is
something that is in conflict . . . [t]hat
can . . . present a dangerous situation.’’
Tr. 353. Therefore, recordkeeping is not
only important for compliance, but also
for the safety of the patients.
DEA decisions have found that ‘‘just
because misconduct is unintentional,
innocent, or devoid of improper motive,
[it] does not preclude revocation or
denial. Careless or negligent handling of
controlled substances creates the
opportunity for diversion and [can]
justify the revocation of an existing
registration . . .’’ Bobby D. Reynolds,
N.P., Tina L. Killebrew, N.P., & David R.
Stout, N.P., 80 FR 28,643, 28662 (2015)
(quoting Paul J. Caragine, Jr. 63 FR
51,592, 51,601 (1998). ‘‘Diversion occurs
whenever controlled substances leave
‘the closed system of distribution
established by the CSA . . . .’ ’’ Id.
(citing Roy S. Schwartz, 79 FR 34,360,
34,363 (2014)). In this case, I have found
that Respondent issued controlled
substance prescriptions without
complying with his obligations under
the CSA and Tennessee law. See George
Mathew, M.D., 75 FR 66,138, 66,148
(2010)).
PO 00000
Frm 00034
Fmt 4701
Sfmt 4703
With regard to Tennessee law, I find
that in issuing controlled substances
prescriptions that were outside the
usual course of professional practice
and beneath the standard of care,
Respondent issued prescriptions that
were ‘‘not in the course of professional
practice’’ in violation of TENN. CODE
ANN. § 63–6–2l4(b)(12). The Tennessee
guidelines require that a physician: (1)
Take a documented medical history; (2)
conduct a physical examination; and (3)
perform an adequate ‘‘assessment and
consideration of the [patient’s] pain,
physical and psychological function,
any history and potential for substance
abuse, coexisting diseases and
conditions, and the presence of a
recognized medical indication for the
use of a dangerous drug or controlled
substance.’’ TENN. COMP. R. & REGS.
0880–02–.14(6)(e)(3)(i). I found above
that respondent failed to conduct an
adequate assessment and consideration
of the pain and potential for substance
abuse and failed to conduct a physical
examination for each of the individuals
at issue including UC. Additionally,
Rule 0880–02–.14 (6)(e) requires
physicians to create a ‘‘written
treatment plan tailored for the
individual needs of the patient’’ that
considers the patient’s ‘‘pertinent
medical history and physical
examination as well as the need for
further testing, consultation, referrals, or
use of other treatment modalities.’’ I
found above that respondent failed to
prepare a tailored written treatment
plan for each of the individuals at issue
including UC. Tennessee guidelines also
requires the physician to ‘‘discuss the
risks and benefits of the use of
controlled substances,’’ which I found
above that Respondent failed to do for
UC, C.F., B.C., M.H., and M.P., and
‘‘keep [c]omplete and accurate records
of the care,’’ which Respondent failed to
do for each of the individuals at issue
including UC. Id. at 0880–02.14(6)(e)(3)(ii)–(v).
Additionally, TENN. CODE ANN.
§ 63–6–214(b)(13) prohibits a physician
from prescribing controlled substances
to a person ‘‘addicted to the habit of
using controlled substances’’ without
‘‘making a bona fide effort to cure the
[patient’s] habit.’’ Crediting Dr.
Kennedy’s testimony, I found above that
Respondent acted outside the bounds of
this law with regard to patients M.W.,
C.F., M.H., and M.P.]
The evidence is clear the Respondent
violated the Tennessee regulations
alleged, and the Tennessee professional
standards. The Tennessee regulations
are related to controlled substances.
[Overall, I find that in issuing ninetyfive prescriptions beneath the
E:\FR\FM\19JAN2.SGM
19JAN2
Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices
applicable standard of care and outside
the usual course of professional practice
in Tennessee, Respondent violated 21
CFR 1306.04(a) in addition to Tennessee
law, and these violations of law weigh
against Respondent’s continued
registration under Public Interest
Factors 2 and 4.] 50
jspears on DSK121TN23PROD with NOTICES2
Sanctions *BB
[Where, as here, the Government has
met its prima facie burden of showing
that Respondent’s continued registration
is inconsistent with the public interest,
the burden shifts to the Respondent to
show why he can be entrusted with a
registration. Garrett Howard Smith,
M.D., 83 FR 18,882, 18,910 (2018)
(collecting cases). Respondent has made
minimal effort to establish that he can
be entrusted with a registration.
The CSA authorizes the Attorney
General to ‘‘promulgate and enforce any
rules, regulations, and procedures
which he may deem necessary and
appropriate for the efficient execution of
his functions under this subchapter.’’ 21
U.S.C. 871(b). This authority
specifically relates ‘‘to ‘registration’ and
‘control,’ and ‘for the efficient execution
of his functions’ under the statute.’’
Gonzales v. Oregon, 546 U.S. 243, 259
(2006). A clear purpose of this authority
is to ‘‘bar[ ] doctors from using their
prescription-writing powers as a means
to engage in illicit drug dealing and
trafficking.’’ Id. at 270.
In efficiently executing the revocation
and suspension authority delegated to
me under the CSA for the
aforementioned purposes, I review the
evidence and arguments Respondent
submitted to determine whether or not
he has presented ‘‘sufficient mitigating
evidence to assure the Administrator
that he can be trusted with the
responsibility carried by such a
registration.’’ Samuel S. Jackson, D.D.S.,
72 FR 23,848, 23,853 (2007) (quoting
Leo R. Miller, M.D., 53 FR 21,931,
21,932 (1988)). ‘‘ ‘Moreover, because
‘‘past performance is the best predictor
of future performance,’’ ALRA Labs, Inc.
v. DEA, 54 F.3d 450, 452 (7th Cir. 1995),
[the Agency] has repeatedly held that
where a registrant has committed acts
inconsistent with the public interest, the
registrant must accept responsibility for
[the registrant’s] actions and
demonstrate that [registrant] will not
engage in future misconduct.’ ’’ Jayam
50 An expert’s opinion that a doctor’s treatment of
patients fell below the standard of care is probative
of whether the doctor violated 21 CFR 1306.04(a).
Bienvenido Tan, M.D., 76 FR 17,673, 17,681 (2011).
*BB I am replacing portions of the Sanction
section in the RD with preferred language regarding
prior Agency decisions; however, the substance is
primarily the same.
VerDate Sep<11>2014
19:06 Jan 18, 2022
Jkt 256001
Krishna-Iyer, 74 FR 459, 463 (2009)
(quoting Medicine Shoppe, 73 FR 364,
387 (2008)); see also Jackson, 72 FR at
23,853; John H. Kennedy, M.D., 71 FR
35,705, 35,709 (2006); Prince George
Daniels, D.D.S., 60 FR 62,884, 62,887
(1995).
The issue of trust is necessarily a factdependent determination based on the
circumstances presented by the
individual respondent; therefore, the
Agency looks at factors, such as the
acceptance of responsibility and the
credibility of that acceptance as it
relates to the probability of repeat
violations or behavior and the nature of
the misconduct that forms the basis for
sanction, while also considering the
Agency’s interest in deterring similar
acts. See Arvinder Singh, M.D., 81 FR
8247, 8248 (2016).]
While the Respondent has conceded
that his medical charts contained
several errors he never accepted
responsibility for [the violations I have
found]. His testimony defending the
identical indications among his patients
in support of his anxiety and insomnia
diagnoses was not at all credible. The
lack of a credible explanation for the
inclusion of results in UC’s chart of tests
and examinations which did not take
place weighs heavily against a finding of
acceptance of responsibility.
Furthermore, although he testified, he
did not address the material falsification
allegation. I therefore find that any
acceptance of responsibility has neither
been unequivocal nor complete.
[In all, Respondent failed to explain
why, in spite of his misconduct, he can
be entrusted with a registration. ‘‘The
degree of acceptance of responsibility
that is required does not hinge on the
respondent uttering ‘‘magic words’’ of
repentance, but rather on whether the
respondent has credibly and candidly
demonstrated that he will not repeat the
same behavior and endanger the public
in a manner that instills confidence in
the Administrator.’’ Jeffrey Stein, M.D.,
84 FR 46,968, 49,973 (2019). Here,
having considered Respondent’s case
and statements, I am left with no
confidence in Respondent’s future
compliance with the CSA.]
Egregiousness and Deterrence
[The Agency also looks to the
egregiousness and extent of the
misconduct which are significant factors
in determining the appropriate sanction.
Garrett Howard Smith, M.D., 83 FR at
18,910 (collecting cases).] I find that the
proven misconduct is egregious and that
deterrence considerations weigh in
favor of revocation. [Respondent issued
approximately 95 prescriptions for
controlled substances outside the usual
PO 00000
Frm 00035
Fmt 4701
Sfmt 4703
3019
course of professional practice and
beneath the standard of care.] The
proven misconduct involved fabricated
medical charts, failure to meaningfully
address serious and ongoing indications
of drug abuse and diversion by several
of his patients, as well as other red flags.
The proven misconduct also involved
the material falsification of his
application for his CSA registration
renewal in Tennessee.*CC
[In sanction determinations, the
Agency has historically considered its
interest in deterring similar acts, both
with respect to the respondent in a
particular case and the community of
registrants. See Joseph Gaudio, M.D., 74
FR 10,083, 10,095 (2009); Singh, 81 FR
at 8248. I find that considerations of
both specific and general deterrence
weigh in favor of revocation in this
case.] Allowing the Respondent to retain
his COR despite the proven misconduct
would send the wrong message to the
regulated community. Imposing a
sanction less than revocation would
create the impression that registrants
can maintain DEA registration despite
ignoring obvious signs of abuse,
diversion and other serious red flags,
the wholesale failure to maintain
adequate, complete and accurate
medical charts, and after making a
material falsification on a renewal
application. Revoking the Respondent’s
COR communicates to registrants that
the DEA takes all of these failings under
the CSA seriously and that severe
violations will result in severe
sanctions.
[Omitted.] *DD
Loss of Trust
Where the Government has sustained
its burden and established that a
registrant has committed acts
inconsistent with the public interest,
that registrant must present sufficient
mitigating evidence to assure the
Administrator that he can be entrusted
with the responsibility commensurate
with such a registration. Medicine
Shoppe-Jonesborough, 73 FR at 387. The
Respondent’s material
misrepresentation compounds the
Respondent’s instant burden. Although
the Respondent offered some evidence
of mitigation, even if considered, it has
not overcome the loss of trust resulting
from the allegations found herein.
*CC Remaining analysis of egregiousness omitted
for relevance.
*DD I agree with the ALJ that Respondent’s
testimony lacked credibility and I have given it
little-to-no weight in reaching my decision.
However, in light of Respondent’s failure to
unequivocally accept responsibility, it is not
necessary for me to assess whether Respondent’s
testimony also lacked candor and I have therefore
omitted the ALJ’s discussion of this topic.
E:\FR\FM\19JAN2.SGM
19JAN2
3020
Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices
[There is simply no evidence that
Respondent’s behavior is not likely to
recur in the future such that I can
entrust him with a CSA registration; in
other words, the factors weigh in favor
of revocation as a sanction.]
jspears on DSK121TN23PROD with NOTICES2
Recommendation
Considering the entire record before
me, the conduct of the hearing, and
observation of the testimony of the
witnesses presented, I find that the
Government has met its burden of proof
and has established a prima facie case
for revocation. In evaluating Factors
[Two and] Four of 21 U.S.C. 823(f), I
find that the Respondent’s COR is
inconsistent with the public interest.
Furthermore, I find that the Respondent
has failed to overcome the
VerDate Sep<11>2014
18:06 Jan 18, 2022
Jkt 256001
Government’s prima facie case by
unequivocally accepting responsibility
and establishing that he can be trusted
with a registration.
Therefore, I recommend that the
Respondent’s DEA COR Control No.
BO4959889 should be revoked, and that
any pending applications for
modification or renewal of the existing
registration, including the pending
application for a new DEA COR Control
No. W18070589C, and any applications
for additional registrations, be denied.
Mark M. Dowd,
U.S. Administrative Law Judge.
revoke DEA Certificate of Registration
No. BO4959889 issued to Samson K.
Orusa, M.D. Pursuant to 28 CFR 0.100(b)
and the authority vested in me by 21
U.S.C. 824(a) and 21 U.S.C. 823(f), I
further hereby deny any other pending
applications for renewal or modification
of this registration, the pending
application for new DEA COR Control
No. W18070589C, as well as any other
pending application of Samson K.
Orusa, M.D., for registration in
Tennessee. This Order is effective
February 18, 2022.
Order
Pursuant to 28 CFR 0.100(b) and the
authority vested in me by 21 U.S.C.
824(a) and 21 U.S.C. 823(f), I hereby
Anne Milgram,
Administrator.
PO 00000
Frm 00036
Fmt 4701
Sfmt 9990
[FR Doc. 2022–00952 Filed 1–18–22; 8:45 am]
BILLING CODE 4410–09–P
E:\FR\FM\19JAN2.SGM
19JAN2
Agencies
[Federal Register Volume 87, Number 12 (Wednesday, January 19, 2022)]
[Notices]
[Pages 2986-3020]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-00952]
[[Page 2985]]
Vol. 87
Wednesday,
No. 12
January 19, 2022
Part II
Department of Justice
-----------------------------------------------------------------------
Drug Enforcement Administration
-----------------------------------------------------------------------
Samson K. Orusa, M.D.; Decision and Order; Notice
Federal Register / Vol. 87 , No. 12 / Wednesday, January 19, 2022 /
Notices
[[Page 2986]]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. 19-26]
Samson K. Orusa, M.D.; Decision and Order
On May 31, 2019, a former Assistant Administrator of the Drug
Enforcement Administration (hereinafter, DEA or Government), issued an
Order to Show Cause (hereinafter, OSC) to Samson K. Orusa (hereinafter,
Respondent). Administrative Law Judge Exhibit (hereinafter, ALJ Ex.) 1,
(OSC) at 1. The OSC proposed revocation of Respondent's DEA Certificate
of Registration Number BO4959889 (hereinafter, registration or COR),
the denial of any pending applications for renewal or modification of
such registration, and the denial of any pending applications for
additional DEA registrations including the pending application for COR
Number W18070589C pursuant to 21 U.S.C. 824(a)(4) and 823(f), because
Respondent's continued ``registrations are inconsistent with the public
interest.'' Id. (citing 21 U.S.C. 823(f)).
In response to the OSC, Respondent timely requested a hearing
before an Administrative Law Judge. ALJ Ex. 2. The hearing in this
matter was conducted on September 9, 2020, October 15, 2020, and
October 21, 2020, via video teleconference technology. On December 8,
2020, Administrative Law Judge Mark M. Dowd, (hereinafter, ALJ) issued
his Recommended Rulings, Findings of Fact, Conclusions of Law and
Decision (hereinafter, Recommended Decision or RD) and neither party
filed exceptions. I issue the final order in this case following the
RD. Having reviewed the entire record, I adopt the ALJ's Recommended
Decision with minor modifications, as noted herein.*\A\
---------------------------------------------------------------------------
*\A\ I have made minor, nonsubstantive, grammatical changes to
the RD and nonsubstantive conforming edits. Where I have made
substantive changes, omitted language for brevity or relevance, or
where I have added to or modified the Chief ALJ's opinion, I have
noted the edits in brackets, and I have included specific
descriptions of the modifications in brackets or in footnotes marked
with an asterisk and a letter. Within those brackets and footnotes,
the use of the personal pronoun ``I'' refers to myself--the
Administrator.
---------------------------------------------------------------------------
Recommended Rulings, Findings of Fact, Conclusions of Law, and Decision
of the Administrative Law Judge *B
---------------------------------------------------------------------------
*\B\ I have omitted the RD's discussion of the procedural
history to avoid repetition with my introduction.
---------------------------------------------------------------------------
The Drug Enforcement Administration (DEA) Assistant Administrator,
filed an Order to Show Cause (OSC) \1\ on May 31, 2019, the Certificate
of Registration (COR), No. BO4959889, of Samson K. Orusa, M.D.
(Respondent), proposing to revoke the Respondent's COR pursuant to 21
U.S.C. 824(a)(4) on the ground that the Respondent's registration is
inconsistent with the public interest, as defined in 21 U.S.C. 823(f).
[Omitted.] 2 3 In its Supplemental Pre-hearing Statement
(GSPHS), the Government further alleged that the Respondent made a
material falsification in his renewal application of November 6, 2019,
in violation of 21 U.S.C. 824(a)(1). ALJ Ex. 53, 54.\4\ A hearing was
conducted in this matter on September 9, 2020, October 15, 2020, and
October 21, 2020, via video teleconference technology.\5\
---------------------------------------------------------------------------
\1\ ALJ Ex. 1.
\2\ [Omitted.]
\3\ [Omitted.]
\4\ Allegations brought in the OSC and Government's Prehearing
Statements provide sufficient notice to the Respondent to defend
against. Jose G. Zavaleta, M.D., 78 FR 27431, 27439 (2013) (Where
the Government did not allege material falsification on the
respondent's application in the Order to Show Cause, but did raise
the issue in its Supplemental Pre-hearing Statement, the respondent
was on notice that the issue would be considered at the hearing).
\5\ Although in his Posthearing Brief, the Respondent suggests
the hearing was ``truncated'', there was nothing abbreviated or
shortened as to the proceeding, which is now over 18 months and
counting, or as to the hearing. Neither party was limited as to
their time for presentation or number of witnesses. The hearing
ended on October 21, 2020, at 4:30 p.m., with 90 minutes remaining
in the day. I did inform the parties that we would be finishing the
hearing within the month of October, and to make their arrangements
accordingly.
---------------------------------------------------------------------------
The issue to be decided by the Administrator is whether the record
as a whole establishes by a preponderance of the evidence that the DEA
Certificate of Registration, No. BO4959889, issued to Respondent should
be revoked, and any pending applications for modification or renewal of
the existing registration should be denied, and any pending
applications for additional registrations should be denied, because his
continued registration would be inconsistent with the public interest
under 21 U.S.C. 823(f) and 824(a)(4) and because he materially
falsified his application under 21 U.S.C. 824(a)(1).
After carefully considering the testimony elicited at the hearing,
the admitted exhibits, the arguments of counsel, and the record as a
whole, I have set forth my recommended findings of fact and conclusions
of law below.
The Allegations
Overview
1. The Respondent is registered with the DEA as a Practitioner
authorized to handle controlled substances in Schedules II-V under DEA
registration number BO4959889 at 261 Stonecrossing Drive, Clarksville,
Tennessee 37042. His DEA COR BO4959889 expired by its terms on December
31, 2019.
2. On July 6, 2018, the Respondent submitted an application
(Application Control No. Wl8070589C) to the DEA for a new DEA COR (the
``Application''). This application seeks a new DEA COR under his
Kentucky medical license at 316 Pappy Drive, Oak Grove, Kentucky
42262.\6\
---------------------------------------------------------------------------
\6\ See ALJ Ex. 65, Order Granting the Government's Motion for
Partial Summary Disposition (June 18, 2020).
---------------------------------------------------------------------------
3. Presently, the Respondent is licensed in the State of Tennessee
as a medical doctor with license number 28275. The Respondent's
Tennessee medical license expires by its own terms on March 31, 2020.
The Respondent is also licensed in the State of Kentucky as a physician
with license number 33408. The Respondent's Kentucky medical license
expires by its own terms on February 29, 2020.
4. As a licensed medical doctor in Tennessee, the Respondent is
subject to TENN. CODE ANN. 63-6-6214(b)(12) through (14), as those
provisions pertain to ``dispensing, prescribing, or otherwise
distributing'' controlled substances. Specifically, section 63-6-
214(b)(12) prohibits a physician from prescribing controlled substances
``not in the course of professional practice, or not in good faith to
relieve pain and suffering, or not to cure an ailment, physical
infirmity or disease, or in amounts and/or for durations not medically
necessary, advisable or justified for a diagnosed condition.''
Accordingly, section 63-6-214(b)(13) prohibits a physician from
prescribing controlled substances to a person ``addicted to the habit
of using controlled substances ``without'' making a bona fide effort to
cure the [patient's] habit.'' To determine a violation of these
provisions, the Tennessee Board of Medical Examiners uses a non-
exhaustive list of guidelines (``the guidelines'') found in TENN. COMP.
R. & REGS. 0880-02-.14(6)(e). The guidelines require that a physician
(1) take a documented medical history; (2) conduct a physical
examination; and (3) perform an adequate ``assessment and consideration
of the [patient's] pain, physical and psychological function, any
history and potential for substance abuse, coexisting diseases and
conditions, and the presence of a recognized medical indication for the
use of a dangerous drug or controlled substance.'' TENN. COMP. R. &
REGS.
[[Page 2987]]
0880-02-.14(6)(e)(3)(i). Additionally, Rule 0880-02-.14(6)(e) requires
physicians to create a ``written treatment plan tailored for the
individual needs of the patient'' that considers the patient's
``pertinent medical history and physical examination as well as the
need for further testing, consultation, referrals, or use of other
treatment modalities.'' It also requires the physician to ``discuss the
risks and benefits of the use of controlled substances,'' do a
``documented periodic review of the care . . . at reasonable
intervals,'' and ``keep [c]omplete and accurate records of the care.''
Id. at 0880-02-.14(e)(3)(ii)-(v).
5. On October 3, 2017, the Respondent issued a prescription for 42-
ten milligram tablets of oxycodone to UC, a Tennessee state law
enforcement officer working in an undercover capacity. The Respondent
issued this prescription following a brief meeting with UC, during
which he performed a cursory and inadequate physical examination and
reviewed medical records which did not justify the prescribing of
oxycodone in the amount and dosage which he prescribed. He also failed
to: (1) Take an adequate medical history; (2) assess the patient's
pain, physical and psychological function; (3) assess the patient's
history and potential for substance abuse, coexisting diseases and
conditions, and the presence of a recognized medical indication for the
use of oxycodone. The Respondent further failed to create a legitimate
written treatment plan for the patient's individual needs or discuss
the risks and benefits of the use of oxycodone with the patient.
6. Additionally, on October 18, 2017, the Respondent's office
provided UC with a prescription which the Respondent signed and dated
October 18, 2017, for 84-ten milligram tablets of oxycodone. This
occurred after UC paid $377 for an office visit during which no
physical examination occurred and virtually no medical information was
obtained or communicated. Additionally, on November 20, 2017, the
Respondent's office provided UC with a prescription which he signed and
dated November 20, 2017, for 84-ten milligram tablets of oxycodone.
This occurred after UC paid for another office visit during which no
physical examination occurred and no medical information was obtained
or communicated.
7. With respect to the prescriptions the Respondent issued to UC,
he issued these prescriptions without: (1) Taking a medical history or
performing a minimally sufficient physical examination; (2) assessing
the patient's pain, physical and psychological function; and (3)
assessing the patient's history and potential for substance abuse,
coexisting diseases and conditions, and the presence of a recognized
medical indication for the use of oxycodone. The Respondent further
failed to create and follow a legitimate written treatment plan for the
patient's individual needs or discuss the risks and benefits of the use
of oxycodone with the patient. Also, by falsely indicating that UC was
physically examined on October 18 and November 20 of 2017, he violated
TENN. COMP. R. & REGS. 0880-02-.14(6)(e)(3)(v).
8. In addition to the medical records for UC, medical records for
more than 20 of the Respondent's patients were reviewed by a qualified
medical expert (``reviewing expert'') who concluded that the
Respondent's continued prescribing of controlled substances to these
patients was without a legitimate medical purpose and/or outside the
usual course of professional practice. Below are examples of some of
the patient records which were reviewed:
a. Patient M.H.: From August 2014 through February 2018, the
Respondent regularly issued prescriptions for large quantities of
alprazolam, carisoprodol, oxycodone, and oxymorphone to M.H. A
representative sample of those prescriptions follows below:
----------------------------------------------------------------------------------------------------------------
Quantity
Date written Drug Dosage (number of
tablets)
----------------------------------------------------------------------------------------------------------------
1.3.17.................................. Alprazolam................ .5 mg..................... 120
1.4.17.................................. Oxycodone................. 30 mg..................... 84
1.4.17.................................. Oxymorphone............... 15 mg..................... 56
2.3.17.................................. Alprazolam................ .5 mg..................... 112
2.6.17.................................. Carisoprodol.............. 350 mg.................... 56
2.6.17.................................. Oxycodone................. 30 mg..................... 84
2.6.17.................................. Oxymorphone............... 15 mg..................... 56
3.3.17.................................. Alprazolam................ .5 mg..................... 112
3.6.17.................................. Oxycodone................. 30 mg..................... 84
3.6.17.................................. Carisoprodol.............. 350 mg.................... 56
3.6.17.................................. Oxycodone................. 30 mg..................... 84
3.6.17.................................. Oxymorphone............... 15 mg..................... 56
4.3.17.................................. Alprazolam................ .5 mg..................... 112
4.4.17.................................. Carisoprodol.............. 350 mg.................... 56
4.4.17.................................. Oxycodone................. 30 mg..................... 84
4.4.17.................................. Oxymorphone............... 15 mg..................... 56
----------------------------------------------------------------------------------------------------------------
According to the reviewing expert, the Respondent diagnosed M.H.
with ``chronic pain syndrome'' even though he made no attempt to
diagnose a specific pain etiology. The reviewing expert found that the
Respondent failed to obtain diagnostic studies and current medical
records from M.H.'s other medical providers and that the results of the
Respondent's physical examination and medical history did not justify
the continued prescribing of controlled substances. The reviewing
expert also noted that he ignored a major surgical intervention that
occurred in September 2016 as well as an abnormal drug screen. As such,
the reviewing expert concluded that much of the medical record for M.H.
was fabricated and seemed to be copied from records of other patients
whose records contained identically worded assessments. The Respondent
also documented that the patient provided ``informed consent,'' when no
informed consent document could be located. The expert also found that,
in some cases, the Respondent failed to repeat certain physical exams
after his initial encounter with M.H., despite the fact he provided him
with prescriptions for controlled substances for more than three years.
[[Page 2988]]
b. Patient C.F.: From August 2014 through August 2018, the
Respondent regularly issued prescriptions for oxycodone and alprazolam
to C.F. A representative sample of those prescriptions follows below:
----------------------------------------------------------------------------------------------------------------
Quantity
Date written Drug Dosage (number of
tablets)
----------------------------------------------------------------------------------------------------------------
1.4.17.................................. Alprazolam................ .25 mg.................... 28
1.6.17.................................. Oxycodone................. 15 mg..................... 84
1.30.17................................. Alprazolam................ .25 mg.................... 28
2.3.17.................................. Oxycodone................. 15 mg..................... 84
2.3.17.................................. Oxycodone................. 7.5 mg.................... 28
3.1.17.................................. Alprazolam................ .25 mg.................... 28
3.1.17.................................. Oxycodone................. 7.5 mg.................... 28
3.4.17.................................. Oxycodone................. 15 mg..................... 84
3.13.17................................. Alprazolam................ .25 mg.................... 28
3.14.17................................. Oxycodone................. 15 mg..................... 28
3.14.17................................. Oxycodone................. 7.5 mg.................... 28
4.25.17................................. Alprazolam................ .25 mg.................... 28
4.28.17................................. Oxycodone................. 15 mg..................... 21
4.28.17................................. Oxycodone................. 7.5mg..................... 7
5.8.17.................................. Oxycodone................. 15 mg..................... 84
5.8.17.................................. Oxycodone................. 7.5 mg.................... 28
----------------------------------------------------------------------------------------------------------------
The reviewing expert found that no credible physical examination
had been performed on C.F. and that the exam results, as well as
medical history, did not justify the continued prescribing of
controlled substances. The expert further found that no meaningful
follow-up physical exam was repeated, that supported diagnostic studies
were not ordered, and that the Respondent failed to determine a chronic
pain etiology. The expert also found that he ignored suspicious drug
screen results which indicated illegal drug use. The reviewing expert
concluded that much of the medical record for C.F. was fabricated and
seemed to be copied from records of other patients whose records
contained identically worded assessments. The Respondent also
documented that the patient provided ``informed consent'' when no
informed consent document could be located.
c. Patient M.P.: From September 2016 through April 2018, the
Respondent regularly issued prescriptions for large quantities of
oxycodone and oxymorphone to M.P. A representative sample of those
prescriptions follows below:
----------------------------------------------------------------------------------------------------------------
Quantity
Date written Drug Dosage (number of
tablets)
----------------------------------------------------------------------------------------------------------------
10.21.16................................ Oxycodone................. 30 mg..................... 84
10.21.16................................ Oxymorphone............... 7.5 mg.................... 56
11.18.16................................ Oxycodone................. 30 mg..................... 84
11.18.16................................ Oxymorphone............... 7.5 mg.................... 56
12.16.16................................ Oxycodone................. 30 mg..................... 84
12.16.16................................ Oxymorphone............... 7.5 mg.................... 56
11.22.17................................ Oxycodone................. 30 mg..................... 84
11.22.17................................ Oxymorphone............... 7.5 mg.................... 56
12.18.17................................ Oxycodone................. 30 mg..................... 84
12.18.17................................ Oxymorphone............... 7.5 mg.................... 56
1.19.18................................. Oxycodone................. 30 mg..................... 84
1.19.18................................. Oxymorphone............... 7.5 mg.................... 56
2.16.18................................. Oxycodone................. 30 mg..................... 84
2.16.18................................. Oxymorphone............... 7.5 mg.................... 56
3.16.18................................. Oxycodone................. 30 mg..................... 84
3.16.18................................. Oxymorphone............... 7.5 mg.................... 56
----------------------------------------------------------------------------------------------------------------
The reviewing expert found that he failed to request and obtain
past medical records, he failed to order any radiographic studies, and
that his physical examinations of M.P., including follow-up exams, were
substandard and not credible. The expert found that he failed to
document any evidence to support a pain etiology and that he failed to
properly address M.P.'s substance abuse disorder despite the fact that
she suffered a heroin overdose in his waiting room. As a result, the
expert found no objective findings to justify the continued prescribing
of oxycodone and oxymorphone. The reviewing expert also concluded that
much of the medical record for M.P. was fabricated and seemed to be
copied from records of other patients whose records contained
identically worded assessments. He also documented that the patient
provided ``informed consent'' when no informed consent document could
be located.
d. Patient B.C.: From August 2014 through August 2018, the
Respondent regularly issued prescriptions for large quantities of
oxycodone, oxymorphone, alprazolam, and carisoprodol to B.C. A
representative sample of those prescriptions follows below:
[[Page 2989]]
----------------------------------------------------------------------------------------------------------------
Quantity
Date written Drug Dosage (number of
tablets)
----------------------------------------------------------------------------------------------------------------
4.10.18................................. Alprazolam................ 1 mg...................... 84
4.16.18................................. Oxycodone................. 30 mg..................... 84
4.21.18................................. Oxymorphone............... 30 mg..................... 56
4.27.18................................. Alprazolam................ 1 mg...................... 84
5.14.18................................. Oxycodone................. 30 mg..................... 21
5.21.18................................. Oxymorphone............... 30 mg..................... 14
5.22.18................................. Oxycodone................. 30 mg..................... 84
5.26.18................................. Oxymorphone............... 30 mg..................... 56
6.12.18................................. Alprazolam................ 1 mg...................... 5
6.12.18................................. Alprazolam................ 1 mg...................... 84
6.19.18................................. Oxycodone................. 30 mg..................... 21
6.22.18................................. Oxycodone................. 30 mg..................... 84
6.22.18................................. Oxymorphone............... 30 gm..................... 56
6.22.18................................. Carisoprodol.............. 350 mg.................... 56
7.9.18.................................. Alprazolam................ 1 mg...................... 84
7.25.18................................. Carisoprodol.............. 350 mg.................... 56
7.25.18................................. Oxycodone................. 30 mg..................... 84
7.25.18................................. Oxymorphone............... 30 mg..................... 56
----------------------------------------------------------------------------------------------------------------
The reviewing expert found that the physical examination and
medical history did not justify the continued prescribing of controlled
substances. The expert found that he failed to: (1) Obtain the
patient's past medical records; (2) order radiologic and other studies
that would support the treatment; (3) adequately address the fact that
B.C. lied about his scheduled medications during his initial encounter;
and (4) pursue a specific pain diagnosis. The expert also found that he
failed to document the patient's response to the medication which he
prescribed. The reviewing expert also concluded that much of the
medical record for B.C. was fabricated and seemed to be copied from
records of other patients whose records contained identically worded
assessments.
e. Patient M.W.: From January 2014 through August 2018, the
Respondent regularly issued prescriptions for large quantities and
dosages of oxycodone, oxymorphone, alprazolam, and carispoprodol to
M.W. A representative sample of those prescriptions follows below:
----------------------------------------------------------------------------------------------------------------
Quantity
Date written Drug Dosage (number of
tablets)
----------------------------------------------------------------------------------------------------------------
4.3.17.................................. Alprazolam................ 2 mg...................... 56
4.4.17.................................. Carisoprodol.............. 350 mg.................... 28
4.4.17.................................. Oxycodone................. 30 mg..................... 56
4.4.17.................................. Oxycodone................. 15 mg..................... 56
4.28.17................................. Alprazolam................ 2 mg...................... 56
5.2.17.................................. Oxycodone................. 30 mg..................... 56
5.26.17................................. Alprazolam................ 2 mg...................... 56
7.7.17.................................. Alprazolam................ 2 mg...................... 56
7.31.17................................. Oxycodone................. 30 mg..................... 56
8.4.17.................................. Alprazolam................ 2 mg...................... 56
10.18.17................................ Alprazolam................ 2 mg...................... 56
12.12.17................................ Alprazolam................ 2 mg...................... 56
1.19.18................................. Alprazolam................ 2 mg...................... 56
2.12.18................................. Alprazolam................ 2 mg...................... 56
3.30.18................................. Oxymorphone............... 15 mg..................... 56
4.6.18.................................. Alprazolam................ 2 mg...................... 56
4.27.18................................. Oxycodone................. 30 mg..................... 28
4.27.18................................. Oxymorphone............... 15 mg..................... 56
5.15.18................................. Alprazolam................ 2 mg...................... 56
5.29.18................................. Oxycodone................. 30 mg..................... 28
5.29.18................................. Oxymorphone............... 15 mg..................... 56
6.15.18................................. Alprazolam................ 2 mg...................... 56
7.2.18.................................. Oxycodone................. 30 mg..................... 56
7.2.18.................................. Oxymorphone............... 15 mg..................... 56
8.29.18................................. Alprazolam................ 2 mg...................... 56
8.29.18................................. Oxycodone................. 30 mg..................... 56
----------------------------------------------------------------------------------------------------------------
With respect to M.W., the reviewing expert found that the initial
physical examination and medical history did not justify the continued
prescribing of controlled substances and the subsequent physical
examinations did not meaningfully evidence any chronic pain condition.
The expert also found that he failed to: (1) Order and obtain
diagnostic studies; and (2) adequately address numerous instances in
which the patient had abnormal drug screens indicating possible
diversion, abuse, and/or use of illegal controlled substances. The
reviewing expert also concluded that much of the medical record for
M.W. was fabricated and seemed to be copied from records of
[[Page 2990]]
other patients whose records contained identically worded assessments.
The Respondent also documented that the patient provided ``informed
consent'' when no informed consent document could be located.
9. With respect to the Respondent's treatment of M.H., C.F., M.P.,
B.C., and M.W. (``the five patients''), the prescriptions for
controlled substances which he issued were not issued in the course of
professional practice inasmuch as he failed to: (1) Take an adequate
medical history; (2) perform a sufficient physical examination; and (3)
perform an adequate ``assessment and consideration of the [patients']
pain, physical and psychological function, any history and potential
for substance abuse, coexisting diseases and conditions, and the
presence of a recognized medical indication for the use of a dangerous
drug or controlled substance.'' The Respondent also failed to create a
``written treatment plan tailored for the individual needs'' of each of
the five patients which considered each of the patient's ``pertinent
medical history and physical examination as well as the need for
further testing, consultation, referrals, or use of other treatment
modalities.'' He also failed to: (1) ``Discuss the risks and benefits
of the use of controlled substances'' with patients M.H., C.F., M.P.,
B.C., and M.W.; (2) do a ``documented periodic review of the[ir] care .
. . at reasonable intervals in view of the individual circumstances''
of each patient; and (3) keep ``[c]omplete and accurate records of the
care provided.'' As such, his conduct violated TENN. CODE ANN. Sec.
63-6-214(b)(12) and TENN. COMP. R. & REGS. 0880-02 .14(6)(e)(3)(i)-(v).
10. With respect to C.F., M.P., and M.W., the Respondent failed to
address substantial evidence that the patients were engaged in abuse
and/or diversion of controlled substances, a violation of TENN. CODE
ANN. Sec. 63-6-214(b)(l3).
11. The prescriptions the Respondent issued to UC, M.H., C.F.,
M.P., B.C., and M.W. failed to comply with Tennessee state law in that
they did not conform to accept and prevailing medical standards in
Tennessee, and thus, were issued outside the usual course of
professional practice. His conduct, viewed as a whole, ``completely
betrayed any semblance of legitimate medical treatment.'' Jack A.
Danton, D.O., 76 FR 60,900, 60,904 (2011). By issuing these
prescriptions for controlled substances, he failed to take reasonable
steps to guard against diversion of controlled substances. See David A.
Ruben, M.D., 78 FR 38,363, 38,382 (2013); Beinvenido Tan, M.D., 76 FR
17,673, 17,689 (2011); Dewey C. Mackay, M.D., 75 FR 49,956, 49,974
(2010); Physicians Pharmacy, L.L.C., 77 FR 47,096 (2012).
12. Even a single act of knowing diversion is sufficient for the
Agency to revoke a registration. See Dewey C. Mackay, 75 FR at 49,977.
Detailed above are numerous acts of alleged unlawful prescribing, any
one of which could independently establish the sort of intentional
diversion on the part that would justify the revocation of his DEA
registration and the denial of his pending application as inconsistent
with the public interest. See 21 U.S.C. 824(a)(4), 823(f).
13. In addition to the legal authorities cited above, the following
cases and Final Orders provide a summary of the legal basis for this
action: United States v. Moore, 423 U.S. 122, 135, 143 (1975); Randall
L. Wolff, M.D., 77 FR 5,106 (February 1, 2012); Jack A. Danton, D.O.,
76 FR 60,900 (September 30, 2011); Robert F. Hunt, D.O., 75 FR 49,995
(August 16, 2010); Linda Sue Cheek, M.D., 76 FR 66,972 (2011); Kathy A.
Moral, 69 FR 59,956 (2004); Rebecca Sotelo, 70 FR 28,580 (2005);
Patrick W. Stodola, M.D., 85 FR 20,727 (2009); Bob's Pharmacy and
Diabetic Supplies, 74 FR 19,599 (2009); Nirmal Saran, M.D., 73 FR
78,827 (2008).
14. With regard to the Respondent's application for a new DEA COR
in Kentucky, there are additional grounds for denying his application
insofar as he lacks state authority to handle controlled substances in
that state. On January 15, 2019, the Commonwealth of Kentucky, Board of
Medical Licensure, issued an Emergency Order of Restriction prohibiting
him from ``prescribing, dispensing, or otherwise professionally
utilizing controlled substances.'' See 201 KY. ADMIN. REGS. 9:240 1 and
3. Thus, he is currently without authority to handle controlled
substances in the Commonwealth of Kentucky, the state in which he has
applied for a new DEA COR. Consequently, the DEA must deny his
application for a DEA COR based on his lack of authority to handle
controlled substances in the Commonwealth of Kentucky. 21 U.S.C.
824(a)(3); 21 CFR 1301.37(b). See e.g., Kenneth C. Beal, Jr., D.D.S. 83
FR 34,877 (2018); Mehdi Nikparvarfard, M.D., 83 FR 14,503 (2018); Leia
A. Frickey, M.D., 82 FR 37,113 (2017); Alaaeldin A. Babiker, M.D., 81
FR 50,723 (2016); James Dustin Chaney, D.O., 81 FR 47,416 (2016); Irwin
August, D.O., 81 FR 3,158 (2016); Wayne D. Longmore, M.D., 77 FR 67,669
(2012); Jovencio L. Raneses, M.D., 75 FR 11,563 (2010); John B.
Freitas, D.O., 74 FR 17,524 (2009); Worth S. Wilkinson, M.D., 71 FR
30,173 (2006).
Material Falsification
In its Supplemental Prehearing Statement, the Government alleged
that, on November 6, 2019, the Respondent made a material falsification
on his renewal application for his Tennessee-based DEA COR, #59889.
Specifically, the Government alleged that in response to liability
question three, the Respondent answered ``no'', which he knew or should
have known to be a false response. GX 26. Liability question three
queries whether the applicant has ever surrendered for cause, or had a
state professional license or controlled substance registration
revoked, suspended, denied, restricted, or placed on probation, or have
any such action pending. The Government alleged that an affirmative
answer to Question Three would trigger an investigation by a diversion
investigator whether to issue the registration or to deny it. The
Respondent answered ``No'' to question 3. A false ``no'' answer can
result in an improperly issued registration. GX 26.
In support, the Government cites to the State of Tennessee
Department of Health, Notice of Charges and Memorandum for Assessment
of Civil Penalties, see GX 29, an order from the Chancery Court for the
State of Tennessee, 20th Judicial District, Davidson County, Part 3,
reversing Denial of Stay, but Accompanying Stay with Conditions. GX 27.
The Government contends that as of May 2019, the Conditions preclude
the Respondent from writing prescriptions or providing direct patient
care during the pendency of the stay. The Government also cites an
Agreed Order with the State of Tennessee, GX 27, in which the
Respondent was required to surrender his Pain Management Certificate, a
professional license, in 2018, and prior to his application for
registration in November, 2019. GX 26; GX 28. The Government alleges
that, although GX 28 related to the surrender of the pain clinic
license, and GX 26 was the Respondent's personal application, as the
Respondent applied for the pain clinic license himself, it constitutes
a surrender of his own license, warranting an affirmative response to
Question Three of his DEA application. GX 26.\7\
---------------------------------------------------------------------------
\7\ The surrender is signed by the Respondent individually.
---------------------------------------------------------------------------
The Hearing
Government's Opening Statement
The Government characterized the Respondent as a willing enabler of
drug
[[Page 2991]]
abuse and diversion. Tr. 20. Rather than maintaining medical records
lacking in detail, the Respondent's records, although detailed, were
fabricated. The Government's expert reviewed twenty-four patient charts
and discovered identical language throughout. Some phrases were
repeated more than 100 times. Undercover \8\ will testify that tests
described in his chart were not performed. Test results were repeated
during three visits in which he was not seen by the Respondent. The
same identical test results were repeated in other patient charts. The
Government's expert will testify that the Respondent prescribed
controlled substances without a legitimate medical purpose and outside
the usual course of professional practice, on the basis of the subject
medical charts. He will further testify that the charts reveal multiple
red flags of abuse and diversion, which were largely ignored by the
Respondent. Rather, he created records which were deceptive, dishonest,
and in some cases, dangerous. Tr. 20.
---------------------------------------------------------------------------
\8\ [Omitted for privacy.]
---------------------------------------------------------------------------
Respondent's Opening Statement
Samson Orusa contends that he is a fine physician, who cares deeply
about his patients. Tr. 24. He spends a lot of time getting to know his
patients to insure he understands their issues relating to pain
management. His system is to use a number of documents, which the
patients fill out prior to the Respondent seeing them, in order to get
a full picture of each patient. These include the initial visit sheet,
and a 41-page pain management physical exam sheet. He would go through
these documents with the patient painstakingly. These forms take hours
to fill out and to review.
The undercover agent presented himself to the Respondent under
false colors, under an assumed identity, and with an MRI, which the
Respondent could not confirm. He claimed to be from Missouri, a state
without a PDMP. He reported he had used over-the-counter medications to
treat his pain, and falsely claimed he had previously been prescribed
Schedule II controlled substances, painting the picture that he needed
Schedule II pain medications from the Respondent. The evidence will
fail to show that the Respondent has done anything outside the bounds
of normal medical practice.
Furthermore, the Government's case relies solely on the opinion of
its expert, Dr. Kennedy, who we maintain is not an expert in the field
of pain management, and whose qualifications are limited to family
practice. He holds himself out to be a diplomat with the American
Academy of Pain Management, which is a defunct organization. He has
never completed a fellowship in pain management. He is not board-
certified in pain management, and would not be qualified in the State
of Tennessee to be a medical director of a pain clinic. The Respondent
maintains Dr. Kennedy's opinion testimony should be afforded no weight
in these proceedings.\9\ Tr. 24
---------------------------------------------------------------------------
\9\ The Respondent's written motion to exclude the testimony of
Dr. Kennedy was carried until the Government offered Dr. Kennedy as
an expert witness at the hearing. Tr. 24-25, 26. The Respondent's
Motion to Exclude was denied on its merits in conjunction with his
objection to having Dr. Kennedy qualified as an expert witness. Tr.
201, 211-12. Contrary to the Respondent's claims, the motion was not
denied as untimely.
---------------------------------------------------------------------------
Government's Case-in-Chief
The Government presented its case-in-chief through the testimony of
four witnesses. First, the Government presented UC. Secondly, the
Government presented the testimony of Dr. Gene Kennedy. Thirdly, the
Government presented the testimony of a DEA Special Agent assigned to
this matter. Finally, the Government presented testimony of a DEA
Diversion Investigator assigned to this matter.
Undercover
[UC testified regarding his education, credentials, and employment
background with the Tennessee Bureau of Investigation].*\C\ He has
conducted approximately twenty to thirty investigations as the lead
case agent in cases involving allegations of fraud, physicians
prescribing narcotics without medical necessity, and physicians
prescribing outside the scope of processional practice. Tr. 31-32.
[Omitted.] \10\ He provided lower back pain as a false symptom in this
case, specifically because he has ``absolutely no back pain
whatsoever.'' Tr. 112-11.
---------------------------------------------------------------------------
*\C\ In this section, I have omitted some biographical and
investigation-related information to protect the identity and
methodology of UC.
\10\ [Omitted original text in which footnote appeared.]
---------------------------------------------------------------------------
Undercover was contacted by a Special Agent (SA) with the United
States Department of Health, Office of Inspector General (SA-DOH) who
asked him to make an appointment with the Respondent in the late summer
of 2017. Tr. 34; 98.\11\ The initial goal in these types of cases is to
get an appointment to see the doctor. Tr. 34. The ultimate goal is to
see if the physician will write the undercover agent a prescription for
a controlled substance. Tr. 34, 101.
---------------------------------------------------------------------------
\11\ He is familiar with the DEA Physician's Manual. Tr. 98.
---------------------------------------------------------------------------
In this particular investigation, UC contacted the Respondent's
office and spoke with the receptionist over the phone, who told him
that he would be scheduled for a new patient visit and was required to
bring certain items on that day including; (1) an MRI report, (2) the
last three chart notes from a previous physician, (3) the discharge
summary from his previous pain management clinic, and (4) a printout of
the last three months from his pharmacy. Tr. 35. UC already had some of
the items, such as the MRI report, but there were other items he needed
to put together. Tr. 34-35. The MRI that UC had was authentic, as it
was his actual MRI that was performed on September 2, 2016. Tr. 35-37,
106. The only thing he altered was the ordering physician and patient
name of ``Chris Rutledge.'' Tr. 35-37.
The patient records that he presented to the Respondent were
fabricated. Tr. 37-38. DOH-SA and another SA consulted with a nurse
practitioner who worked for TBI and instructed the agents to generate
medical records that would be indicative of someone who was seeing a
nurse practitioner for pain. Tr. 38, 108; GX 6. UC then provided his
personal information including his date of birth and his medical
complaints for the agent to create a medical record. The only medical
record provided to the Respondent's office was signed by ``S.C.,'' who
was not practicing medicine at that time. Tr. 38, 133.
UC visited the Respondent's office on October 3, 2017, and recorded
video and audio of the visit. Tr. 40; 42-43.\12\ He set up an
appointment for 8:00 a.m. and was told to bring the necessary
documents. Tr. 40. UC showed up for the appointment at approximately
8:00 a.m.\13\ and gave the documents he had to the receptionist, and
explained why he was missing two documents.\14\ Tr. 38-40, 108; GX
4.\15\ The receptionist gave him about twenty pages of paperwork and
asked him to sit in the waiting room to fill it out. At some point he
was called up by one of the
[[Page 2992]]
employees \16\ who made a comment about one of the pages in UC's
medical record appeared to be ``whited out'' and the employee then made
a statement that there are ``people that are trying to bring down [the
Respondent]'' and the Respondent would therefore ``be reluctant to
write any medications.'' Tr. 41; GX 3. The receptionist then told UC to
have a seat and he would be called back for triage to get his vitals.
Tr. 41-42, 44. UC paid for this visit with $311 of cash. Tr. 49,
110.\17\
---------------------------------------------------------------------------
\12\ At this point, Government offered Government Exhibit 3. The
time stamp for the video of the October 3, 2017 visit is 5:05:42.
Tr. 74.
\13\ UC noted that he did not present in any ``unusual way'' to
show that he had a disability, limp, change or change his gait. Tr.
46.
\14\ As discussed supra, UC was asked to bring in a discharge
summary, which is a report that a pain management clinic creates
when the clinic releases a patient. Tr. 38-39, 108. He ultimately
did not provide this document to the Respondent's office, stating
that he was unable to obtain it. Tr. 39. He also stated that did not
provide the printout showing the last three months of pharmaceutical
history, because he was unable to get it. Tr. 39-40.
\15\ No one asked for these records after his visit and he never
produced the pharmacy records. Tr. 55.
\16\ At this point in the testimony, Judge Dowd stated that UC
was not allowed to read from his report directly. UC clarified that
although he ``did have it open,'' he had not ``looked at it yet.''
Tr. 41.
\17\ At this point in the testimony, the Government played a
video. Tr. 51; GX 4. Judge Dowd instructed the court reporter not to
transcribe the audio of the video, as the recording itself is the
best evidence. UC confirmed that the transcript of the proceedings
was a fair and accurate representation of the recording. Tr. 55; GX
4.
---------------------------------------------------------------------------
UC filled out a pain disability index and ranked his pain level as
a nine out of ten, which was not a truthful response to how he felt at
the time. Tr. 47, 101, 109-10, 123. As to his goals, his second goal
was to ``sleep through the night'' but he did not check the box for
insomnia. Tr. 134-35, 139. Despite this contradiction, no one in the
office asked about this. Tr. 139.\18\ He also filled out a Zung Self-
Rating Depression Scale, selecting random answers. Tr. 102. He also
filled out a drug use questionnaire regarding his drug history with the
intention of presenting a picture of a person who is in pain. Tr.102-
03. He also filled out an agreement for opioid maintenance therapy and
for cancer and non-cancer patients. Tr. 103. He also filled out an
American Chronic Pain Association form including a chronic problem list
and reported that he was only taking Advil, an over-the-counter, anti-
inflammatory and pain medication of three pills, three times a day,
with the understanding that if he was performing well with the over-
the-counter medicine, a doctor would likely not give him a
prescription. Tr. 103-105, 123. He also filled out a multi-page pain
management physical form, which was blank \19\ in his seized medical
record. Tr. 105, 128. He could not recall if the Respondent went
through every form with him, but did remember the Respondent asking him
a couple questions. Tr. 105. He also recalled telling the Respondent
that he had taken prescription hydrocodone in the past and it had
helped him. Tr. 123.
---------------------------------------------------------------------------
\18\ UC had noted that he may have stated that he did not sleep
well because he was awakened by his pain.
\19\ UC noted that there were several forms that were blank in
the copies he had.
---------------------------------------------------------------------------
At one point, a female wearing scrubs took his blood pressure,
asked about his weight, provided him a specimen cup, and instructed him
to go into the bathroom located inside the waiting room. Tr. 44-45. UC
then produced a urine sample. Tr. 45.
The time that passed from when UC spoke with the employee about his
``fabricated'' records with the ``white-out'' page until he met with
the Respondent, was about seven hours, only leaving the office for
approximately forty-five minutes to get lunch. Tr. 48-49, 100.
[Omitted to protect law enforcement techniques]. UC told the
Respondent where his pain was located and if it hurt he would respond
that he had pain in that area, but did not make any face or wince.
There was less than sixty seconds of any kind of physical touching
between himself and the Respondent, which he testified was brief
compared with other physicians.
The Respondent asked what his previous diagnosis was and he
responded with arthritis and degenerative disk disease. Tr. 105-06.\20\
During this visit, UC learned that the office staff had tried to
contact his pharmacy and was unable to do so. Tr. 108-09. UC explained
to the Respondent that he would try to get a hold of them and the
Respondent's stated that his office would make another attempt. Tr.
109. They also discussed the alternative treatment of injections for
UC's back pain, but UC refused to get the injections. Tr. 117, 127. UC
told the Respondent that he had fallen off a truck sometime in 2013,
was seeing Dr. Chapman in Pierce City, Missouri, and he moved to
Tennessee about one month prior to his first visit on October 3, 2017.
Tr. 117-18. None of these statements were true. Tr. 117-18. UC also
shared a story about his aunt breaking her hip and him going to the
clinic to obtain records, that he was unable to do so because the
clinic was shut down, and that his aunt still lived in Missouri. Tr.
118. None of these statements were true. Tr. 118. UC admitted that he
stated all of these lies in order to achieve his stated goal to get a
prescription from this visit and also noted that ``[u]ndercover
operations inherently rely upon some falsehoods in all aspects of law
enforcement.'' Tr. 119-21.\21\
---------------------------------------------------------------------------
\20\ In fact, a physician had previously told UC that he may
have arthritis, UC was not given a diagnosis of degenerative disk
disease. Tr. 106-107.
\21\ At this point in the testimony, on cross-examination, the
Respondent's counsel made a comparison to an undercover agent
purchasing heroin from a dealer and the Tribunal inquired of the
Respondent's counsel as to the relevance of his questioning. Tr.
121. The Respondent's counsel asserted that UC had lied to the
Respondent to achieve his goal of getting a prescription. Tr. 121.
The Tribunal asserted that ``in principle this is an undercover
operation. [That is] the whole point of it.'' Tr. 122.
---------------------------------------------------------------------------
He received a prescription for 42 oxycodone 10-milligram tablets,
thirty minutes after he left the exam room, from one of the
receptionists, despite not asking for oxycodone. Tr. 56-57; GX 18. He
also received prescriptions for Meloxicam and flexeril. Tr. 57-58; GX
18.\22\ He filled the oxycodone prescription, but not the other
prescriptions. Tr. 57, 58.\23\
---------------------------------------------------------------------------
\22\ UC confirmed that this Government Exhibit 18 was a fair and
accurate copy of the prescription he received on October 3, 2017.
\23\ UC asserted that he did not expect to get controlled
substances on this first visit, as he usually does not expect to get
them, but from what he had ``been told regarding the clinic, it [did
not] shock him.'' Tr. 125. If he had not received prescriptions that
first visit, it would not have deterred him from making future
appointments as it usually takes several appointments to build up to
the point where the undercover agent receives controlled substances.
Tr. 125. There is no set number for visits, but in cases where he
has been the case agent, he has looked for a progression from other
modalities of treatment first being offered and then elevating to
drugs like hydrocodone to oxycodone, elevating the dosage or the
quantities over time. Tr. 126-27.
---------------------------------------------------------------------------
UC went back to the office for a second visit on October 15, 2017,
which was supposed to be his well-care visit between receiving his two
narcotic prescriptions. Tr. 58-59. He did not make an appointment. He
showed up at the office, and made a $25 payment to the receptionist.
Tr. 59. He was called back to the triage room where the nurse asked him
his weight, to which he replied, ``210,'' and if his blood pressure was
ok, to which he responded, ``yes.'' The nurse then directed him back to
the waiting room. He was later called to the exam room.
This visit was recorded in the same manner as the visit on October
3, 2017. Tr. 59-60; GX 4 at 4.\24\ When he entered
[[Page 2993]]
the room, the Respondent asked if it was UC's first well visit or
primary care visit and UC affirmed it was. Tr. 71. The Respondent asked
if UC was taking other medications and he stated that he was not taking
medications other than pain medications. The Respondent asked whether
UC was sleeping well and he responded ``not really.'' The Respondent
then stated that he would write him a prescription for pain medications
to help him sleep. UC asked what it was, and the Respondent stated,
``amitriptyline.'' That marked the end of the encounter. Tr. 71. There
was no further medical examination or physical examination of his lower
back, of any of his extremities, or an examination to determine if he
had muscle pain. Tr. 71-72.
---------------------------------------------------------------------------
\24\ UC stated that Government Exhibit 4 is a transcript of his
interaction with the Respondent on that date and is a fair and
accurate representation of their encounter. Tr. 60; GX 4 at 4. The
transcript reflects that the video was difficult to hear. The
Respondent's counsel objected to the video being put into evidence
if the video could not be properly played before the Tribunal. Tr.
64-66. The Tribunal noted the objection and allowed the Government's
counsel to proceed. The video was replayed and UC asserted that he
was able to hear the tape. The Tribunal overruled the objection and
noted that the Respondent's counsel could cross examine UC. The
Government later moved Government Exhibits 4 and 17 into the record.
Tr. 69. The Tribunal admitted pages 1, 2, and 3 of Exhibit 4 and
part of Government Exhibit 17, but noted that it was ``not convinced
that [the] audio is intelligible, fully audible, without
interference, because [it] ha[s] nothing but interference'' on the
Tribunal's end. Tr. 70. On Day 3 of the hearing, the Tribunal
reconsidered its earlier ruling on the limited admissibility of GX 4
and 17, and admitted the exhibits in their entirety, noting that the
video/audio (GX 4) was played successfully at the hearing to all
participants, except the Tribunal and court reporter, which the
Tribunal attributed to a VTC issue and not to a defect in the DVD
itself. [I have reviewed the contents of the DVD and find that the
videos play successfully.]
---------------------------------------------------------------------------
UC had a third visit on October 18, 2017, when he was scheduled to
get the refills for his narcotic medications. Tr. 75. He went to the
Respondent's office and first attempted to pay with cash, but had to
secure a debit card. Tr. 75-76. He wrote his name on a clipboard, paid
the $377 fee for the office visit, and about an hour later his name was
called and he got his prescription. Tr. 76. He was at the clinic for
approximately two and half hours and was not examined by any medical
personnel nor did he provide any medical records. Tr. 77. He received a
prescription for eighty-four tablets of ten milligrams of oxycodone.
Tr. 78, GX 18 at 3, 4. This dosage was less than the Lortab of four
times a day. He also received the ``euphoria drug'' of Xanax that he
had falsely claimed he was receiving in Missouri. Tr. 112.
Upon reviewing the medical records, UC noted that despite his
records stating that ``Mr. Rutledge . . . has had a history of insomnia
and anxiety for several years,'' he did not report anxiety symptoms of
shortness of breath, of having palpitations, sweating, dizziness, or
shaking. Tr. 79-80; GX 5. The medical record also reflects that he had
a headache that day, despite the fact that UC did not report having a
headache, dizziness, nausea, or vomiting. Tr. 80; GX 5. No one
questioned UC as to whether he had abdominal pain, diarrhea, and
constipation. Tr. 80-81. UC reviewed Government Exhibit 5 and noted
that he was not asked about any of these symptoms. Tr. 81. He also
assumes that the office accessed and checked the Tennessee controlled
substance data bank on his first visit as this was in his medical
records, but he was not specifically informed of it. Tr. 110. He also
believes that the UC's assumed identity has never had a controlled
substance filled in Tennessee. Tr. 111. He also believes there was no
Missouri prescription database at that time, where he asserted he was
from, so the office could not obtain information from there. And the
fact that Missouri did not have a state-controlled prescription
monitoring program in Missouri was a factor as to why the persona of
UC's assumed identity was somebody from Missouri. Tr. 110-11.
At the appointment on October 17, 2017, UC did not have his blood
pressure checked, was not weighed, did not have his chest examined, and
did not have his breathing measured or evaluated. Tr. 82. On October
18, 2017, UC did not discuss muscle pain, back pain, nor a Review of
Systems (ROS). Tr. 82-83. No one examined his chest, or his breathing.
Tr. 83.
UC had another visit on November 15, 2017, which was another well-
visit. Tr. 84. He paid $25, waited for some time, was called back and
asked about his weight and if his blood pressure was okay. He
specifically asked the nurse if he was dismissed and after she said
yes, he left. He did not receive any prescriptions that day. Tr. 85.
Despite what the medical records say regarding this visit, there was no
medical examination conducted on that day, including of his chest, or
breathing. Tr. 86, 90; GX 5.
UC had another visit on November 20, 2017, for a medication visit.
Tr. 87; GX at 10. UC walked in, put his name on a clip board, paid some
money, waited a certain amount of time for his name to be called, and
went to the window to obtain his prescriptions. Tr. 88. On this
particular day, he was asked to provide a urine sample. Tr. 88, 92. He
received a cup from the nurse, went into the bathroom for his
unsupervised urine test, and provided a urine sample. He had brought a
vial of a substance that would cause him to test positive for
Oxycodone, put that in the urine sample, and returned the sample to the
nurse as instructed. Tr. 88, 92; GX 3. He believes that, despite the
added substance, his urine drug screen came back negative *\D\ and the
Respondent never discussed this screen with UC nor did anyone else at
the practice. Tr. 91-92; GX 3.\25\ He received a prescription for
oxycodone for eighty-four tablets of ten milligrams from one of the
receptionists, who provided the prescription to him as well as several
others. Tr. 89. GX 18 at 4. UC did not meet with the Respondent that
day. The medical records say ROS, but none of the systems were examined
during this visit. Tr. 91.
---------------------------------------------------------------------------
*\D\ The Government did not fully explain this portion of its
case which I find to be immaterial. Ultimately, inconsistent UDS
results were not relevant to Dr. Kennedy's opinion that the
prescriptions issued to UC were issued outside of the standard of
care nor were they relevant to my findings in this decision.
\25\ Although the Respondent objected to Government Exhibit 3
being offered into evidence based on hearsay, the Tribunal overruled
the objection finding that any hearsay statements in this exhibit
have been properly authenticated. Tr. 94. The Tribunal also noted
that UC could be cross-examined regarding his report.
---------------------------------------------------------------------------
Besides verbalizing and writing down that his pain was nine out of
ten, UC did not do anything to indicate that his pain was actually that
level. Tr. 94-95; GX 3, 18. He did not present any falsified records
showing he had a history of filling controlled substance prescriptions
in any state \26\ and never produced pharmacy records showing his
prescription history. Tr. 133. In UC's experience of working with
people who abuse drugs or obtain drugs to sell them, he has found that
these people are pretty savvy about filling out their forms when they
go to the doctor. Tr. 133-34.
---------------------------------------------------------------------------
\26\ UC noted in the Patient Pain History form that he had
previous medications including hydrocodone between November 2016 and
September 2017, Xanax from approximately August 16, 2016 through
September 2017, and oxycodone from August 2017 to September 2017.
---------------------------------------------------------------------------
Dr. Gene Kennedy
Dr. Kennedy, who is licensed in Georgia, is a family practitioner
by training and has treated patients for pain since being licensed. Tr.
202. Dr. Kennedy was offered, and qualified, as an expert in the field
of pain management. Tr. 201, 211-12, 216. Although not board certified
in pain management, he has been treating people for pain full-time
since 2004 or 2005, when he opened his own pain management clinic. Tr.
178-80, 202-03, 427.\27\ He has treated all types of pain patients:
Patients suffering acute post-surgical pain; patients suffering from
back pain; cancer patients; and patients referred by other pain
management physicians. Tr. 180-81, 355. He has prescribed assorted
controlled substances, including opioids to treat pain, including
Schedule I. Tr. 181. He treats patients over 120 MME. He noted only UC
and C.F. were being treated below 120 MME. Tr. 427-28. He has
[[Page 2994]]
prescribed benzodiazepines. He performs pain injections. Tr. 357.
---------------------------------------------------------------------------
\27\ Although not dispositive in this setting, Dr. Kennedy's
credentials would not permit him to be a director of a pain clinic
in Tennessee, without annually consulting with a board certified
pain management specialist. Tr. 204-05, 428-30.
---------------------------------------------------------------------------
He has previously been qualified as an expert witness in
administrative hearings of the Alabama Medical Board, the Georgia
Medical Board, DEA, FBI and DOJ. On thirteen occasions he has testified
regarding whether a physician has properly prescribed controlled
substances. GX 24. He has served as an adjunct lecturer regarding the
proper prescribing of controlled substances to DEA, at the National
Advocacy Center, and on behalf of the DOJ. Tr. 185. He estimated over
half of his income comes from the work and lectures given to Government
agencies. Tr. 359. In 2018, he estimates he was paid over $100,000 by
the Government. Tr. 432. For the instant case, he is being paid $450
per hour for an estimated forty hours of preparation plus courtroom
hours. Tr. 434-36. He has also lectured regarding the PDMP to medical
residents and physicians and taught a course to pharmacists in
Tennessee regarding legitimate prescribing. Tr. 185. He is familiar
with Tennessee law pertaining to prescribing controlled substances, and
has relied on the following sources in developing his opinions herein:
Tennessee Pain Clinic Guidelines, the Federation of State Model Policy,
AMA Guidelines, the DEA Practitioner's Manual. Tr. 183, 360-62. He was
hired by the DEA to offer an expert opinion on the Respondent's
prescribing and of the medical practice, on the basis of material the
government provided him. This material included approximately twenty
charts, surveillance videos, and pharmacy reports. The surveillance
videos involved undercover encounters between UC and the Respondent.
Tr. 184; GX 8-23.
Dr. Kennedy is familiar with the standard of care for a physician
prescribing controlled substances in Tennessee. This standard requires
an adequate medical history, including all the historical information
helpful in developing a diagnosis, course of treatment and in
understanding the risks involved. Tr. 189, 195. The standard requires
diagnostic testing, if indicated. Tr. 196. The standard requires the
physician to perform a physical exam. Tr. 190, 200-01. The standard
requires a physician to maintain medical records for patients to whom
controlled substances are prescribed. Tr. 196. These medical records
should contain a pain history, a history of drug abuse and termination
by other physicians, a physical exam pertinent to the patient's
complaint, efforts at obtaining state pharmacy reports, the physician's
thoughtful assessment of the patient's condition, and an individualized
treatment plan. Tr. 196-98. Dr. Kennedy noted the importance of
maintaining complete and accurate patient records. Tr. 353. With
patients sometimes on high doses of potentially dangerous controlled
substances, the charts must be accurate and honest, so any practitioner
who views the charts can make an accurate assessment of the patient's
conditions. Tr. 353-54.
In reviewing the subject medical records, Dr. Kennedy recognized
indications of possible abuse and diversion, including patients unable
to produce past medical records, a cloudy history of drug abuse. Tr.
191-92. Dr. Kennedy noted that the Tennessee standard precludes a
physician from prescribing controlled substances to a patient with a
habit of improperly using them, without first making a bona fide effort
to cure the patient's addiction. Tr. 199. When a benzodiazepine and an
opioid are prescribed in combination, the physician would have a
heightened sense of vigilance, which would need to be documented within
the chart. Tr. 190. Urine drug screening (UDS) is a common practice in
pain management treatment. Tr. 192. It can reveal whether a patient is
taking a medication he is prescribed and whether he is taking
medications or illegal drugs he is not prescribed. Tr. 193-94. The
standard of care would require, at minimum, that the physician document
in the records the inconsistent UDS, and describe his plan of action.
Tr. 194-95.
Dr. Kennedy reviewed the chart and the undercover videos for
Patient UC, who was the undercover agent. Tr. 216-17, 363; GX 6. Dr.
Kennedy acknowledged that in scheduling the first visit, the
Respondent's staff instructed UC to bring certain medical records to
his first visit: The previous three physician notes, his discharge
summary, the record of the previous three months prescriptions and an
MRI, an appropriate protocol in Dr. Kennedy's opinion. Tr. 364-65; GX 3
at 1. Dr. Kennedy did not believe the medical chart justified the
prescribing of controlled substances. Tr. 230-31, 240; GX 18 at 1, 3.
Although an actual MRI report of UC, Dr. Kennedy found the MRI report
internally inconsistent, which did not justify controlled substance
medication. Tr. 387-94, 483-86. UC was being treated for complaints of
back pain. However, Dr. Kennedy opined that the physical exam detailed
in the chart was not sufficient under Tennessee standards, and the exam
performed revealed a normal back.*\E\ Tr. 217, 231, 237, 396-97, 440.
On rebuttal, Dr. Kennedy reiterated this assessment after listening to
the Respondent's explanation. Tr. 651-52. After filling out extensive
paperwork, the initial examination by the Respondent consisted of
observing the UC, touching his back and causing the patient to lift his
leg. Tr. 217-18, 359-60; GX 6 at 6. Dr. Kennedy did not believe UC's
chart reflected the Respondent maintained a truthful and accurate
record of the treatment. Tr. 232; GX 3; 4. Dr. Kennedy noted the taking
of vital signs and a general exam within the chart, however he observed
that from viewing the video of this visit, such exam was not performed
as described, or not performed at all. Tr. 218-19, 232-33, 379-81; GX 6
at 4. The prior medical history reported by UC, was facially suspicious
and constituted a red flag. Tr. 238. UC reportedly, came from a clinic,
which has since shut down, and provided medical records from a Nurse
Practitioner, whose license has been suspended. Tr. 238. Dr. Kennedy
opined that UC's obfuscation, false and misleading statements to the
Respondent and staff, did not relieve the Respondent's obligation to
investigate any suspicious circumstances. Tr. 375-78, 382.
---------------------------------------------------------------------------
*\E\ Dr. Kennedy testified that an adequate back exam would have
required Respondent to look ``for something that is out of place,
muscle spasms, . . . perform lumbar range of motion maneuvers where
the patient essentially bends at the waist in various directions.
Additionally, . . . a straight leg raised test, . . . neurologic
exam, which makes comment on their motor deficits and their
sensorium as pertains to their complaint of low back pain.''
---------------------------------------------------------------------------
Dr. Kennedy noted that the physical exam included in this first
visit by UC was repeated verbatim in most of the 20 or so charts he
reviewed. Tr. 220; GX 7 at 65 (M.B.), GX 9 at 69 (M.W.). Dr. Kennedy
noted UC's chart identified him with a ``long-standing history of
insomnia and anxiety,'' however the chart contained no examination,
which would support such findings. Tr. 233-34; GX 5 at 4. Additionally,
the reported symptoms of the anxiety finding, ``palpitations, sweating,
dizziness, shaking'' was repeated almost universally throughout the
medical records reviewed as to patients diagnosed with insomnia and
anxiety. Tr. 233-34. Although UC reported his pain level at 9 or 10,
the exam results do not support that, nor did the video of this
encounter. Tr. 234-35, 238. Similarly, the visit of October 17, 2017,
by UC contains extensive medical findings, although the video of that
visit does not support those findings. Tr. 235-37; GX 5 at 5. The video
does reveal the Respondent asking UC, ``how is your sleep,'' to which
UC responds, ``not good.'' Tr. 236. The Respondent
[[Page 2995]]
then prescribed Elavil, also called amitriptyline. Tr. 236. Dr. Kennedy
made a similar observation as to extensive medical findings on
subsequent visits, in which UC was not seen by the Respondent. Tr. 235-
37; GX 5 at 3-5. Although the medical records reflect physical
examination took place at the level one visits, the Respondent
explained that it was permissible in medical record-keeping to carry
forward results from prior examinations to later visit records, with
new findings added. Tr. 623-28. Dr. Kennedy disagreed, noting that it
is never permissible for charts to reflect examination results, when no
exam occurred. Tr. 652-53.
On the basis of the deficient physical exam, Dr. Kennedy opined
that prescribing controlled substances to UC was not justified.*\F\
Although the Respondent prescribed a much lower MME than UC had
purportedly been on previously, it was not consistent with the
Tennessee standard, which would include observation, looking for
spasms, lumbar range of motion maneuvers, straight leg raise test,
neurologic exam and motor deficits. Tr. 221-25, 239, 382-83; GX 5 at 6.
Other deficiencies in the records that caused the controlled substance
prescriptions for UC to be unjustified included the deficiency in the
prior medical records provided by UC Tr. 228. UC's chart revealed an
exploration of alternate treatment, by prescribing Meloxicam. Tr. 228-
29. However, UC's chart did not include an adequate treatment plan. Tr.
229. The records reveal a deficient discussion regarding the risks and
benefits of controlled substance medication. Tr. 231. Dr. Kennedy
deemed the diagnosis of degenerative disc disease unjustified on the
basis of the chart and MRI. Tr. 240-42; GX 5 at 2, 6; GX 6 at 12.
---------------------------------------------------------------------------
*\F\ Dr. Kennedy actually offered several bases for his opinion
that all of the controlled substances Respondent prescribed to C.R.
were issued outside the usual course of professional practice. Tr.
239. Specifically, Dr. Kennedy identified Respondent's failures to
perform a sufficient physical examination; to adequately assess the
patient's pain, physical, and psychological function; to
sufficiently examine the patient's history; to assess a recognized
medical indication for the use of oxycodone; to create or follow a
legitimate written treatment plan; to discuss the risks and benefits
of using oxycodone with the patient; to maintain truthful and
accurate medical records; or to resolve red flags arising from the
medical records C.R. provided, which stated that C.R. had been
treated at a clinic that had closed by a nurse practitioner, whose
license had been suspended. Tr. 237-39.
---------------------------------------------------------------------------
Dr. Kennedy prepared reports or charts containing his review of the
relevant medical evidence in this case. His findings accurately reflect
the original medical records, which are in evidence. His chart was
admitted as a chart of voluminous records under Fed. R. Evid. 1006. Tr.
225-28; GX 6 at 2.
Patient M.W.
Dr. Kennedy identified his ``chart review'' for M.W. Tr. 243-44; GX
9, 10. M.W. was diagnosed with low back pain, yet Dr. Kennedy opined
that the records did not support such diagnosis. Tr. 245-46; GX 9 at
14; GX 10 at 3. The notes did reference back to M.W.'s initial
encounter. Tr. 441. There were no findings in the record which would
support a chronic pain condition and justify prescribing controlled
substances. Tr. 246-47. Dr. Kennedy found no credible physical exam to
justify the diagnosis. Tr. 247, 265. The Respondent did not assess
M.W.'s pain level, physical and psychological functioning, history,
potential for drug abuse, or coexisting diseases. Tr. 265. The
Respondent did not follow a legitimate treatment plan. Tr. 265. The
physical exam findings were generally normal findings, except for
limited range of motion at the lumbar spine. Tr. 247; GX 10 at 7. M.W.
reported a pain level, at worst, at 10 of 10, and at best, 6 of 10. Tr.
248-49; GX 9 at 19; GX 10 at 8. M.W.'s reported pain level was
inconsistent with the generally normal results of the physical exam.
Tr. 249-50.
The electronic medical record for this visit does not contain the
handwritten information recorded in GX 10 at 8. Tr. 250-51; GX 10 at 9.
Instead, the results of the physical exam mirror those findings made
for UC, rendering M.W.'s chart not credible. Tr. 251-52. Additionally,
the record contained ``wildly abnormal'' *\G\ UDS results that were
``not meaningfully addressed.'' Tr. 252-55; GX 9 at 2-4, 9-11, 84, 96,
102. After a series of inconsistent UDS, the Respondent noted in M.W.'s
chart that M.W. was dismissed from pain management with one month
notice. Tr. 258; GX 9 at 84. Yet, at the same visit in which he had
been notified he would be dismissed, the history of present illness
(HPI) reports patient is compliant and consistent. Tr. 258. Dr. Kennedy
deemed the chart not credible, accordingly. Tr. 259. However, despite
being dismissed, M.W. continued to be seen for months afterwards,
without any further explanation. Tr. 259-60. Dr. Kennedy later conceded
that M.W. was reinstated consistent with the Respondent's office
protocol. Tr. 449-50. The Respondent continued to prescribe him
Alprazalam, amitriptyline, oxycodone, oxymorphone and Soma. Regarding
the Alprazalam prescription, Dr. Kennedy found it unjustified based on
the information supporting the anxiety diagnosis. Tr. 260-61, 442-44;
Tr. 261; GX 9 at 85. Dr. Kennedy noted the indications for anxiety were
not supported by the findings within the chart, and mirrored those in
the charts for UC and the other patients. Tr. 261-62. Although Dr.
Kennedy opined M.W. should have been physically examined ``on a regular
basis'' during his treatment, the charts suggest he was not examined
again following his first examination.*\H\ Tr. 262. Dr. Kennedy further
opined that as M.W. was a 25 year-old diagnosed with degenerative disc
disease, the Tennessee standards would require diagnostic testing, such
as an MRI to confirm the diagnosis. Tr. 262, 447-48. Dr. Kennedy found
M.W.'s chart ``not credible and fabricated.'' Tr. 263-64, 266; GX 10 at
5, 23. He noted that of 93 of 98 total visits shared the identical
findings for the physical exams and ROS. Tr. 264. Similarly, Dr.
Kennedy found the diagnosis of insomnia not credible. Tr. 264. A
finding of drug abuse and chemical dependency would have been
supportable, but such indications were not sufficiently addressed by
the Respondent. Tr. 264-65. The credible findings within M.W.'s chart
did not support the prescribing of controlled substances,*\I\ and the
subject prescriptions were issued without medical justification and
outside the usual course of professional practice. Tr. 266-68.
---------------------------------------------------------------------------
*\G\ For example, regarding the UDS at GX 9, 2-4, M.W. was
prescribed oxycodone, carisoprodol, alprazolam, and ozymorphone. GX
9, 2-4. The drug screen results were negative for the prescribed
drugs alprazolam and carisoprodol and, as Dr. Kennedy testified,
positive for non-prescribed substances including ``morphine,
positive for hydromorphone, positive for oxymorphone, . . . positive
for THC. . . .'' Tr. 251-52.
*\H\ Dr. Kennedy testified that the little documentation there
was suggesting a physical exam could have been performed was ``not
credible'' because it was ``repeated documentation that we have
described before.'' Tr. 262.
*\I\ Specifically, Dr. Kennedy testified that Respondent failed:
To perform a sufficient physical examination; to adequately assess
the patient's pain, physical, and psychological function; to
sufficiently examine the patient's history and potential for
substance abuse; to identify a recognized medical indication for the
use of the controlled substance prescriptions; to create or follow a
legitimate written treatment plan; and to adequately address M.W.'s
exhibited evidence of drug abuse. Tr. 264-66.
---------------------------------------------------------------------------
Patient C.F.
Dr. Kennedy identified the summary chart he prepared on Patent C.F.
Tr. 268; GX 12. C.F. was being treated for chronic pain due to trauma,
unspecified inflammatory polyarthropathy. C.F. had suffered stab wounds
to the chest requiring open heart surgery, which can cause long-term
neuropathic pain. Tr. 451-53. Dr. Kennedy opined the history,
[[Page 2996]]
physical exams, the pain and physical and psychological functioning,
the potential for substance abuse, written treatment plan, and
alternate treatment considerations were inadequate, and did not justify
the controlled substance prescriptions. Tr. 269-70, 285, 455; GX 11 at
106; GX 12 at 7. The Respondent did not discuss the risks and benefits
of controlled substance medications [and did not keep accurate records
of the care he provided.] Tr. 285-86. The physical exam notes revealed
essentially normal findings, however the electronic records for this
visit failed to include these findings. Tr. 271; GX 11 at 69. Instead,
under physical exam, the same language often duplicated in the records,
is included. Tr. 272. There were no credible follow up physical exams,
supporting studies, and no reasonable pain etiology. Tr. 272; GX 12 at
5, 6. The ROS indications were identically repeated in other charts.
Tr. 272-73. Dr. Kennedy noted that the language in the general exam,
``patient is alert and oriented'' is similarly repeated 102 times
throughout the records. Dr. Kennedy reported an inconsistent UDS for
C.F., collected on July 2, 2018, and many thereafter. Tr. 273-80, 282;
GX 11 at 9, 23, 24, 25, 28, 33, 44, 47, 54, 69, 78, 111, 117; GX 20.
C.F.'s UDS result was negative for all of the medications he was
prescribed. Tr. 275-77. C.F. also tested positive for cocaine and
marijuana. Tr. 277, 280. An inconsistent drug screen on July 26, 2017,
is not mentioned in the medical records. Tr. 288-89. Although the
records repeatedly noted that, ``patient counseled at length on
unsatisfactory UDS,'' this was insufficient under Tennessee standards
in addressing C.F.'s drug abuse and diversion [because it did not
document ``anything specific.''] Tr. 280, 284. On May 3, 2017, C.F.
tested positive for buprenorphine, a medication typically used for
opioid use disorder. Tr. 281-82. The Respondent had not prescribed it
[and failed to investigate or address the issue.] Tr. 282. Dr. Kennedy
opined that the Respondent continued to improperly prescribe controlled
substance without making a bona fide effort to cure C.F.'s addiction.
Tr. 284. The Respondent prescribed alprazolam for anxiety and insomnia.
Tr. 286; GX 11 at 39. However, the supporting indications are identical
to the other patients who were diagnosed with anxiety and insomnia. Tr.
286-87. The Respondent did not maintain complete and accurate records
for C.F. Tr. 286. Dr. Kennedy concluded that the controlled substance
prescriptions to C.F. were outside the usual course of professional
practice. Tr. 287.
Patient B.C.
Dr. Kennedy identified his summary chart for B.C. Tr. 289-90; GX
13; GX 14. B.C. was being treated for chronic pain syndrome. B.C. was
referred from the Clark County Jail, a potentially challenging patient.
Tr. 458-59. The Respondent did not take an adequate medical history.
Tr. 304. Although documentation of some physical exam was evident, it
was insufficient and non-supportive to justify prescribing the
medications prescribed.*\J\ Tr. 290-91, 304; GX 13 at 169; GX 14 at 7;
GX 22. He did not make an adequate assessment of pain, physical and
psychological function, history of substance abuse, coexisting diseases
and conditions, written treatment plan, or alternate treatments. Tr.
304-06. He did not conduct any periodic reviews, or discuss the risks
and benefits of the use of controlled substances. Tr. 306. There were
no radiologic studies ordered. Tr. 303. There were no prior medical
records ordered or obtained, yet the records did include hospital
records. Tr. 303, 459-60. Dr. Kennedy noted indications from the ROS
were duplicated throughout the records. Of 141 encounters, the ROS
language was duplicated 140 times, while the physical exam language was
duplicated 134 times. Tr. 291-92. He did not maintain accurate and
complete records. Tr. 306. B.C. had serious health issues, including
Hodgkins lymphoma, a cancer of the lymphatic system. Tr. 293. Dr.
Kennedy identified a document in the chart indicating B.C. had been
dismissed from a prior physician, a clear red flag [for which there was
no ``evidence in the medical record that [the] red flag was
investigated.''] Tr. 293-94; GX 13 at 188.
---------------------------------------------------------------------------
*\J\ Dr. Kennedy testified that the documented physical exam was
insufficient, because ``there are no positive objective physical
findings that rise to the level of requiring medications
prescribed.'' Tr. 291. He further testified, that based on B.C.'s
known medical problems, ``[it is] not impossible that this patient
had a chronic pain condition. But I would note that over the course
of 140 encounters the chart does not mention, . . . on a single
occasion where [we are] consistently talking about what specific
pain the patient is experiencing.'' Tr. 305. Accordingly, Dr.
Kennedy testified, the medical record did not support a recognized
medical indication for the use of the prescribed controlled
substances. Id.
---------------------------------------------------------------------------
Dr. Kennedy noted that B.C.'s pain level was left blank in the
medical record for nine consecutive encounters, suggesting [``that
[the] information is not actually being obtained and that the
documentation is simply being inserted in the chart.''] Tr. 294-95; GX
13 at 159; GX 14 at 8. One entry reveals, ``patient lied about his
prescriptions,'' an alarming red flag left unaddressed by the
Respondent. Tr. 296; GX 13 at 169. Despite noting that the ``patient
lied,'' the Respondent issued controlled medications and ``held'' up
UDS for a month. Tr. 297. Dr. Kennedy opined that this prescribing was
outside the usual course of professional practice. B.C. continued to
have inconsistent UDS results, which were insufficiently addressed by
the Respondent.*\K\ Tr. 297-98; GX 13 at 33, 79, 150, 155, 156, 158,
164, 165. The information contained in B.C.'s chart did not justify the
controlled medications prescribed by the Respondent, nor support that
they were issued in the usual course of professional practice. Tr. 307-
08.
---------------------------------------------------------------------------
*\K\ According to Dr. Kennedy, the medical records say ``the
patient is counseled at length, but again, [there is] nothing
specific about what the counseling entailed or any decision made
based on it.'' Tr. 301.
---------------------------------------------------------------------------
Patient M.H.
Dr. Kennedy identified his summary chart for Patient M.H. Tr. 309;
GX 15; GX 16. M.H. was being treated for chronic pain syndrome. GX 15
at 62, 63. The physical exam indications are identical to those
repeated throughout the medical records. Tr. 311. The indications do
not support any chronic pain diagnosis. Tr. 311. The records reveal
M.H. suffered a gunshot wound in 2008, and although serious, would not
in itself justify pain medication eight years later. Tr. 323. Dr.
Kennedy assessed the Respondent's treatment as outside the scope of
acceptable medical practice.*\L\ Tr. 312. He did not make an adequate
assessment of pain, and physical and psychological function, of medical
history, of history of substance abuse, coexisting diseases and
conditions, periodic review of care, written treatment plan or
alternate treatments. Tr. 326-28. He did not conduct any periodic
reviews, or discuss the risks and benefits of the use of controlled
substances. Tr. 328. M.H. had inconsistent UDS. Tr. 314-20; GX 15 at
36, 39, 40, 47, 49, 53, 56, 63. Although several inconsistent UDS were
noted in the chart, they were not typically mentioned. The Respondent
failed to adequately address the UDS. Tr. 314-20.
---------------------------------------------------------------------------
*\L\ My findings in this matter are based solely on Respondent's
prescribing of controlled substances, not Respondent's prescribing
of non-controlled substances or his overall treatment of patients.
---------------------------------------------------------------------------
During his treatment with the Respondent, M.H. underwent a serious
and complex spinal surgery, a major surgery. Tr. 320-22, 462-63. GX 15
at 26; GX 16 at 9. M.H. was seen by the Respondent the day after his
release
[[Page 2997]]
from the hospital. GX 15 at 48. Despite his recent, major surgery,
there is no mention of the surgery in the encounter notes.*\M\ Tr. 322-
23. The encounter notes are identical to all the other encounter notes
reviewed. Tr. 323; GX 15 at 48. There is no updated physical exam, as
would be required by the standard of care. Tr. 324. The PE and HPI
notes are the same as those the 4 months prior to the spinal surgery,
which is not credible. Tr. 324-25, 491-92; GX 15 at 49, 51. The
Respondent did not maintain accurate and complete records as to M.H.
Tr. 328. Dr. Kennedy reviewed the prescriptions issued. Tr. 325; GX 19
at 1-13. He opined that the chart, including the number of inconsistent
UDS, reveals that there was ``a significant probability'' that M.H. was
addicted to the habit of using controlled substances, yet the
Respondent continued prescribing them without making a bona fide effort
to cure the addiction. Tr. 325. The subject prescriptions were issued
outside the usual course of professional practice. Tr. 329-30, 493.
---------------------------------------------------------------------------
*\M\ Dr. Kennedy opined that the ``spinal surgery . . .
definitely supported being on scheduled medications. [But] [t]hat's
not even referenced in the medical record.'' Tr. 328. Accordingly,
Dr. Kennedy opined that Respondent failed to document a ``recognized
medical indication for the use of the controlled substances, which
were prescribed.'' Id.
---------------------------------------------------------------------------
Patient M.P.
Dr. Kennedy identified his summary chart for Patient M.P. Tr. 331;
GX 8. M.P. was being treated for low back, neck, hip and shoulder pain.
She was later diagnosed with degenerative disc disease and right
shoulder pain. Although a physical exam was performed, it was
inadequate to substantiate the diagnoses. Tr. 331-34, 339-40, 343; GX 7
at 2. A mechanical shoulder exam and range of motion back and neck exam
should have been performed. Tr. 335. He did not make an adequate
assessment of pain, nor physical and psychological function, of medical
history, of history of substance abuse, coexisting diseases and
conditions, periodic review of care, written treatment plan nor
alternate treatments. Tr. 349-51. He did not conduct any periodic
reviews, nor discuss the risks and benefits of the use of controlled
substances. Tr. 349-50. Her employment as a server, working forty to
sixty-five hours per week is inconsistent with her ``occupational
disability'' score of 9 or 10, which Dr. Kennedy described as a
significant conflict. Tr. 344-45; GX 7 at 3, 9, 10. Dr. Kennedy noted
the hand-written exam notes did not appear in the electronic medical
records, Tr. 325-36; GX 7 at 68, rather, the medical records reflected
the same PE notes duplicated throughout the medical records for all of
the patients at issue. Tr. 336, 351. The pain level is reported as 9,
which is inconsistent with the PE indications. Dr. Kennedy indicated
notes generated at the initial visit appeared to be a reminder to
obtain certain prior medical records from Dr. M. Tr. 337, 468; GX 7 at
1, 68. Those same notes appear in the record repeatedly thereafter. Tr.
337; GX 7 at 59. Other than the requested pharmacy report, the prior
records were never obtained. Tr. 338-39. The Respondent did not
maintain accurate and complete records as to M.P., [and the chart
contained language that was verbatim as other medical charts.] Tr. 350-
51.
At M.P.'s initial visit, a UDS was performed revealing inconsistent
results, which were never addressed in the records. Tr. 338; GX 7 at
19, 68. Notes reveal M.P. had been terminated from a prior physician,
which is a red flag. Tr. 343. The records did reveal a monitoring of
the Tennessee PDMP, and a successful pill count. Tr. 470. There were
emergency room notes, which revealed she was admitted on April 17,
2018, and released on April 18 for apparent heroin overdose, which
occurred in the Respondent's waiting room. Tr. 340-41; GX 7 at 25. [Dr.
Kennedy testified that, aside from the ER records, ``there is not a
note in the chart that specifically refers to this patient overdosing
or going unresponsive in the waiting room.'' Tr. 341.] At the next
encounter, the Respondent discontinued the previous prescriptions for
controlled substances, discussed drug rehab with M.P., which she
declined to pursue, and prescribed buprenorphine, an opioid abuse
treatment. Tr. 342. Dr. Kennedy viewed this course of action as
dangerous and outside the standard. Tr. 342, 371-73, 465-66. As the
patient was shown to be on heroin, a UDS would be necessary to
determine if she had heroin in her system before prescribing
buprenorphine, which in conjunction with heroin could result in
permanent withdrawal. Tr. 343. There were inconsistent UDS in the
records for M.P. Tr. 346; GX 7 at 48, 59.
Dr. Kennedy reviewed the prescriptions issued. Tr. 348-49; GX 21.
He opined that the chart, including the number of inconsistent UDS,
reveals that [Respondent should have been concerned that M.P. had a
habit of being] addicted to controlled substances, yet the Respondent
continued prescribing them without making a bona fide effort to cure
the addiction, until after she overdosed on heroin. Tr. 348. The
subject prescriptions, as well as those prescribed to the other charged
patients, were dangerous *\N\ and were issued without medical
justification and outside the usual course of professional practice.
Tr. 352, 488-89.
---------------------------------------------------------------------------
*\N\ Dr. Kennedy went on to testify that all of the controlled
substances prescribed to the individuals at issue (other than the
undercover) were ``dangerous.'' Tr. 352. He stated, ``[c]ontrolled
substances are dangerous. . . . [In the] context that we're talking
about, because of the abnormal drug screens that were essentially
ignored, and the documentation about the patient's status was not
done. In the face of sometimes very alarming patient red flags, I
would say that it was clearly dangerous.'' Id. Dr. Kennedy further
opines, ``none of the medical records are credible and . . .
maintaining a patient on scheduled medications . . . sometimes at
high dosages, without having honest, accurate, complete medical
records is dangerous.'' Tr. 352-53. This is because, according to
Dr. Kennedy, ``those medical records will instruct other people who
look at them as to what the motivation was for the treatment . . .
[a]nd if what is documented in the medical record simply doesn't
made sense or is something that is in conflict . . . [t]hat can . .
. present a dangerous situation.'' Tr. 353.
---------------------------------------------------------------------------
DEA Special Agent (SA1)
SA1 is a Special Agent with the Drug Enforcement Administration,
and has been for ten years. Tr. 498. He attended the Special Agent
Academy in 2009. Tr. 498. He has been involved in three or four
investigations surrounding prescriptions. Tr. 498. He served as case
agent for the current investigation. The first search warrant was
executed on February 27, 2018, at the clinic and at the Respondent's
residence in Clarksville, Tennessee, where paper records, patient
files, financial records and digital evidence from several computers
were seized. Tr. 500. The second warrant was served on the Respondent's
clinic in Millersville, Tennessee in September, 2018. Tr. 500. SA1
authenticated GX 5 as seized from the Respondent's clinic. Tr. 502-03.
SA1 noted that some medical documents provided by UC to the clinic were
not found during the searches. Tr. 503-04. SA1 authenticated GX 7 as
medical records of M.P. seized from the Respondent's clinic. Tr. 505.
SA1 authenticated GX 9, as the medical records of M.W. seized from the
Respondent's clinic. Tr. 506. SA1 authenticated GX 11 as medical
records of C.F. seized from the Respondent's clinic. Tr. 507. SA1
authenticated GX 13, as the medical records of B.C. seized from
Respondent's clinic. Tr. 508. SA1 authenticated GX 15, as the medical
records of M.H. seized from the Respondent's clinic. Tr. 509-10. These
complete records were supplied to the Government's medical expert, Dr.
[[Page 2998]]
Kennedy. Tr. 511-12. Additionally supplied to the expert were PDMP
reports, the missing records supplied to the clinic by UC and the video
of the undercover encounters. Tr. 512.
DEA Diversion Investigator (DI)
DI is a Diversion Investigator with the Drug Enforcement
Administration. Tr. 519-20. She has been with DEA for ten years. She
has been involved in 15-20 investigations involving physicians
prescribing controlled substances. As part of the current
investigation, she collected relevant prescriptions, and processed the
documents in support of the Order to Show Cause. Tr. 520. She
identified the Respondent's DEA Registration. GX 1. She authenticated
GX 18, which include the prescriptions the Respondent issued to UC,
which she obtained from various pharmacies. Tr. 521-22. She
authenticated GX 19, which are the prescriptions the Respondent issued
to M.H., which DI obtained from various pharmacies. Tr. 523-24. She
authenticated GX 20, which are the prescriptions the Respondent issued
to C.F., which DI obtained from various pharmacies. Tr. 524-25. She
authenticated GX 21, which are the prescriptions the Respondent issued
to M.P., which DI obtained from various pharmacies. Tr. 526. She
authenticated GX 22, which are the prescriptions the Respondent issued
to B.C., which DI obtained from various pharmacies. Tr. 527. She
authenticated GX 23, which are the prescriptions the Respondent issued
to M.W., which DI obtained from various pharmacies. Tr. 528. She
authenticated the Respondent's application for renewal of his DEA
Registration for the State of Tennessee, # 59889, which was submitted
on November 6, 2019. Tr. 529-30; GX 26.
She explained the significance of Question Three on the
application, a ``liability'' question. It queries whether the applicant
has ever surrendered for cause, or had a state professional license or
controlled substance registration revoked, suspended, denied,
restricted, or placed on probation, or have any such action pending.
Tr. 530-31. An affirmative answer to Question Three would trigger an
investigation by a diversion investigator whether to issue the
registration or to deny it. The Respondent answered ``No'' to Question
Three. Tr. 531; GX 26.
She also authenticated GX 29, the State of Tennessee Department of
Health, Notice of Charges and Memorandum for Assessment of Civil
Penalties. Tr. 531-32. She also authenticated GX 27, an order from the
Chancery Court for the State of Tennessee, 20th Judicial District,
Davidson County, Part 3, reversing Denial of Stay, but Accompanying
Stay with Conditions. Tr. 532-33. DI noted that as of May 2019, the
Conditions preclude the Respondent from writing prescriptions or
providing direct patient care during the pendency of the stay. Tr. 533-
34. DI authenticated GX 28, An Agreed Order with the State of
Tennessee, in which the Respondent was required to surrender his Pain
Management Certificate, a professional license, in 2018, and prior to
his application for registration in 2019. Tr. 534-35; GX 26; GX 28. DI
authenticated GX 25, an Emergency Order of Restriction from the
Commonwealth of Kentucky board of License, issued on January 15, 2019,
which again predates his subject DEA application, and is a further
restriction on a professional license. Tr. 537-39.\28\ DI explained
that although GX 28 related to the surrender of the pain clinic license
and GX 26 was the Respondent's personal application, as the Respondent
applied for the pain clinic license himself, it constitutes a surrender
of his license, warranting an affirmative response to question 3 of his
DEA application. Tr. 542-43; GX 26. Additionally, the surrender is
signed by the Respondent individually. Tr. 545.
---------------------------------------------------------------------------
\28\ Although relevant testimony herein, the January 15, 2019
restriction as to the Respondent's Kentucky license does not
constitute a ground for the material falsification allegation. It
was neither charged in the OSC or the Government's Pre-hearing
Statements. Nor was it noticed by the Government at the time of its
offering as a proposed additional charge under the principle of
``litigation by consent.'' Where the Government has not provided
notice of a particular charge yet produces evidence on that charge,
and does not argue that the issue was litigated by consent, the
charge cannot form the basis for revocation. Cove Inc., d/b/a
Allwell Pharmacy, 80 FR 29,037, 29,039 (2015).
---------------------------------------------------------------------------
Respondent's Case-in-Chief
The Respondent presented his case-in-chief through the testimony of
one witness, the Respondent, Samson K. Orusa, M.D.
Samson K. Orusa, M.D.
Dr. Orusa was born in Bayelsa, Nigeria. Tr. 547. Dr. Orusa finished
his medical education at a fully accredited medical school in Benin
City, Nigeria and worked for a year in Nigeria. Tr. 548. He completed a
one-year rotational internship in internal medicine, pediatrics,
surgery and OBGYN at the University of Port-Harcourt Teaching Hospital.
Tr. 549-50. He then spent a year doing outpatient care at a rural
primary healthcare center. Thereafter, he entered private practice in
Lagos, Nigeria in 1989. In 1992, Dr. Orusa immigrated to the United
States to advance his medical training. He completed a three-year
residency program in internal medicine at Columbia University, College
of Physicians and Surgeons in 1996. Tr. 551. He obtained his Tennessee
medical license, and with his certification in internal medicine, he
was hired at a clinic in Clarksville, Tennessee. Tr. 552, 555. He was
admitted to practice at Memorial Hospital. In 1997, he opened his own
clinic in Clarksville, where he had a general medical practice. In
2004, he began concentrating on pain management. Tr. 553. In 2017, he
was board certified by the American Board of Interventional Pain
Physicians as a specialist in interventional pain medicine. Tr. 553,
555. His extensive training involved the use of deep injections, spinal
nerve blocks, nerve injections, foraminal blocks, and epidural
injections. Tr. 553-54. By 2018, he held sufficient certification to
operate his own pain clinic in Tennessee. Tr. 555.
From 1998 to 2017, the clinic transitioned from primary care to
pain management, but even by 2017, he still had primary care patients.
Tr. 557-58. Initial visits required appointment, which were scheduled
for the first thing in the morning. Returning pain patients were
permitted to walk in without appointments. Tr. 558. He has had a staff
of ten, including a nurse practitioner and physician's assistant. Tr.
559. By 2017, his pain management practice included deep tissue
injections, cervical, lumbar and thoracic nerve blocks, sacroiliac
joint injections, and bursitis injections. Tr. 60. In 2018, the
frequency of injections increased as the Respondent began performing
injections under fluoroscopy. Tr. 560.
The Respondent had a protocol for new pain patients. Tr. 561. Some
of these protocols were in writing, but not produced at the hearing.
Tr. 620. They were required to bring a referral letter or letter of
dismissal from their previous physician, any imaging reports, records
from their last three medical visits and their pain medication. Tr.
561-62, 572. If the patient did not produce the materials, the clinic
staff would attempt to obtain them. Tr. 564-66. The initial visit
typically takes all day, as the patient must fill out extensive
documentation (twenty pages with 252 questions), which is necessary for
diagnosis and selection of treatment. Tr. 566-67. Seventy-five
questions relate strictly to pain. It includes pain disability index,
depression assessment, drug-use history and social history. There is a
pain management agreement. Tr. 571-72. The staff explains the side
effects, the addiction process and the
[[Page 2999]]
resources to help with addiction. Tr. 572.
The charts often contained the exact same language for indications
of anxiety and insomnia. Tr. 633-34. The Respondent explained that the
language was often identical as anxiety patients typically share the
same symptoms. Tr. 634-36.
Undercover
The Respondent took a medical history, a condition-specific
physical exam for low back pain, reviewed the MRI (GX 6) of UC. Tr.
575-80. The Respondent noted that his physical exam of UC was not
captured by the video of the encounter. The camera was pointed at the
wall. Tr. 581-82. The Respondent spent no more than fifteen minutes
with UC in the examination room. Tr. 621. The Respondent performed the
required assessments related to pain, physical and psychological
function, and history and potential for drug abuse. Tr. 582. This
involved the paperwork UC filled out, authenticating that paperwork,
the triage of UC by staff, UDS, and a final review of the paperwork by
the Respondent with the patient. Tr. 583, 584. Although UC's chart
contains an entry that his pharmacy printout was reviewed, the
Respondent conceded that no pharmacy printout was reviewed and that
such entry was in error. Tr. 631-32; GX 5 at 6. UC was a challenge as
the clinic he reported had been closed, and he could not obtain the
pharmacy information, so the Respondent could not verify that source.
Tr. 583-85.
The Respondent expected his patients to be honest and truthful with
him, consistent with the DEA Physician's Manual, which requires
patients to be honest with their doctors. Tr. 586-87. The Respondent
explained that a patient's pain is very subjective. After reviewing his
paperwork, including the MRI, examining UC, and speaking with him, the
Respondent had no reason not to treat him as someone who had genuine
pain. Tr. 588. UC's statement that he had used controlled substances
for his pain and that ibuprofen was not working supported the
conclusion that his pain was long-standing, and warranted a Schedule II
medication. As UC's prior medical records could not be confirmed, the
Respondent prescribed a dosage appropriate to a patient just starting
opioid treatment. Tr. 589-90. The Respondent testified that he prepared
a written treatment plan with appropriate treatment goals and therapy.
Tr. 590-91.
The Respondent explained that his electronic medical record often
referred to other records. For example under history of present illness
(HPI), he would often reference the initial encounter paperwork as
included in the electronic record. Tr. 592. He also explained that he
performed a physical exam at the initial visit of each of his patients,
as required by the Tennessee pain management guidelines. Tr. 594.
Physical exams thereafter are at the discretion of the physician. Tr.
594. Although UC had five visits to the clinic, only two involved
encounters with the Respondent. The other three visits were ``level
one'' visits, in which UC met with the Respondent's staff only. Tr.
622-28, 645-50. Although the medical records reflect a physical
examination took place at the level one visits, the Respondent
explained that it was permissible in medical record-keeping to carry
forward results from prior examinations to later visit records, with
new findings added. Tr. 623-28.
Patient M.W.
M.W. was first seen in January 2013. Tr. 595. M.W. was a gunshot
victim to whom the Respondent prescribed alprazolam. This was based on
the history and physical exam. Tr. 593. Tr. 635-36; GX 9 at 69. The
Respondent obtained a medical history, conducted a physical exam,
performed an adequate pain, physical, and psychological assessment,
history and potential for substance abuse. Tr. 596. The evaluation of
the patient's potential for drug abuse is an ongoing evaluation with
UDS, involving both office screens, confirmatory lab screens, and pill
counts. Tr. 596-98, 600. Once an inconsistent UDS is discovered, the
Respondent initiates a dismissal process. Tr. 598-600. The Tennessee
pain management guidelines leave it to the physician's discretion on
the handling of confirmed inconsistent UDS results. Tr. 598-99. The
Respondent gives the patient a month to come into compliance. Tr. 600.
If he has a consistent UDS within the month, the patient is permitted
to remain in treatment. Tr. 601. The Respondent was able to bring M.W.
back into compliance through counseling; however, the chart only
documents that the patient was counseled as to the inconsistent UDS.
Tr. 637-38. The Respondent prepared a written treatment plan. Tr. 601.
Patient C.F.
Patient C.F. had a stab wound to the chest, requiring heart
surgery, resulting in residual chronic pain. Tr. 601. The Respondent
took a medical history, performed a physical exam, adequate pain,
physical and psychological assessments, and evaluated her history and
potential for substance abuse. Tr. 601-02. The Respondent noted that he
had the benefit of confirmatory records from Vanderbilt University
Medical Center. Tr. 602. The Respondent explained that the MED
prescribed to C.F. was a relatively low dose of 82.5, noting the 120
MED threshold in which primary care physicians in Tennessee must
consult with pain management specialists. Tr. 603-05.
Patient B.C.
Patient B.C. was referred from jail on December 19, 2012. The
Respondent noted the pain management guidelines have changed since
then. Tr. 605. The Respondent explained why he kept pharmacy printouts
in his records because they are easier and quicker to obtain than
medical records. Tr. 606. The pharmacy printout informs how long the
patient has been prescribed medications, changes in dosage, and the
prescriber. Tr. 607. Each of the Respondent's patient records contained
the instruction, ``rule out doctor shopping,'' which was a prompt to
review the Tennessee PDMP to determine if the patient was obtaining
controlled substances from multiple physicians. Tr. 608.
The Respondent took a medical history, performed a physical exam,
adequate pain, physical and psychological assessments, and evaluated
his history and potential for substance abuse, and prepared a written
treatment plan. Tr. 608. Although the Respondent described the
extensive forms each patient is required to fill out at the initial
visit, some of the described forms, which were referenced in B.C.'s
chart, were missing from the Respondent's records as relates to B.C.
Tr. 628-29; GX 13 at 5. The Respondent explained that some records were
lost in 2014. Tr. 630. The missing records were not recreated as B.C.
was a long-term patient. Tr. 630.
Patient M.H.
Patient M.H. presented with a post gunshot wound to the abdomen and
chronic low back pain secondary to degenerative disc disease. Tr. 608.
He had already been treated for pain management. He had a history of
extensive spinal surgery at Vanderbilt University Medical Center,
including a laminectomy. Tr. 609-11. The Respondent prescribed a lower
MME than the surgeon prescribed post-operative at Vanderbilt. Tr. 611.
The Respondent's medical findings as to Patient M.H. for the visit just
prior to M.H.'s major back surgery are the same as the Respondent's
findings for the visit the day after the surgery. Tr. 637-38; GX 15 at
48-50. The Respondent
[[Page 3000]]
explained that the subject findings were based on history. Tr. 638.
The chart reports M.H. has been ``compliant,'' however, on the next
page of the chart, it reports M.H. had an inconsistent UDS. Tr. 638-40;
GX 15 at 48-49. The Respondent explained that the inconsistent UDS
related to the point of care test, not the confirmatory lab test, so
the chart was accurate. Tr. 640. M.H.'s chart contains apparently
inconsistent findings of long-term insomnia, but with an entry of
sleeping well. Tr. 640-41; GX 15 at 47-48. The Respondent conceded
these were inconsistent entries. Tr. 641.
Patient M.P.
Patient M.P. was being managed for chronic pain. In her initial
visit, she reported conflicting information regarding whether she had
been in drug rehab treatment. Tr. 641-42; GX 7. The Respondent
explained that he could only rely on the information provided. Tr. 642.
Initially, in September of 2016, the Respondent requested dismissal
records, an X-ray and an MRI from Dr. M. Tr. 642-44; GX 7 at 48. Yet,
eighteen months later, the Respondent still had not received the
requested records. Tr. 644; GX 7 at 59.
Ultimately, she came to the clinic overdosing on heroin. Tr. 611-
12. She had to be resuscitated until EMS was able to reverse the
effects of heroin with Narcan. Tr. 612. In the post-overdose notes the
Respondent took an extensive history again regarding her drug use. He
directed she cannot be on pain management but must be on opioid abuse
treatment. So, the Respondent started her on Suboxone. Tr. 613. The
Respondent explained his understanding of Suboxone induction. The first
type of induction therapy is by observation. You give the patient
Suboxone and observe them until they reach the point of withdrawal. The
other form of induction is to give the patient Suboxone and send her
home without observation by the physician. Tr. 612-14. M.P. was
initially receptive to drug treatment, but later changed clinics. Tr.
615.
The Respondent took a medical history, performed a physical exam,
adequate pain, physical and psychological assessments, and evaluated
her history and potential for substance abuse, and prepared a written
treatment plan. Tr. 615-17. Following the heroin overdose, the
determination was made that she needed treatment of Suboxone and no
further opioid prescriptions. Tr. 616.
The Facts
Stipulations of Fact
The Government and the Respondent have agreed to 1, 2 in part, 3,
4, 5, 6, 7 stipulations, which I recommend be accepted as fact in these
proceedings:
1. The Respondent is registered with the DEA as a Practitioner
authorized to handle controlled substances in Scheduled II-V under DEA
COR No. BO4959889 at 261 Stonecrossing Drive, Clarksville, Tennessee
37042. DEA COR. No. B04959889 expires by its terms in December 31,
2019.*\O\
---------------------------------------------------------------------------
*\O\ According to Agency records, this application is pending
renewal and has not expired.
---------------------------------------------------------------------------
2. On July 6, 2018, the Respondent submitted an application (No.
W18070589C) for a new DEA COR at 316 Pappy Drive, Oak Grove, Kentucky
42262. On January 15, 2019, the Commonwealth of Kentucky, Board of
Medical Licensure, issued an Emergency Order of Restriction prohibiting
Respondent from ``prescribing, dispensing, or otherwise professionally
utilizing controlled substances.'' See 201 KY. ADMIN. REGS 9:240
Section 1 and 3. Thus the Respondent is currently without authority to
handle controlled substances in the Commonwealth of Kentucky.
3. Soma is a brand name of carisoprodol, a Schedule IV controlled
substance.
4. Percocet is a brand name for oxycodone, a Schedule II controlled
substance.
5. Oxycodone is a Schedule II controlled substance.
6. Oxymorphone is a Schedule II controlled substance.
7. Alprazolam is a Schedule IV controlled substance.
Findings of Fact
The factual findings below are based on a preponderance of the
evidence, including the detailed, credible, and competent testimony of
the aforementioned witnesses, the exhibits entered into evidence, and
the record before me.
The Government's case was largely based on (1) several undercover
visits to Respondent's medical office by UC; (2) the medical charts and
prescriptions pertaining to UC as well as to five other patients, M.H.,
M.W., C.F., B.C. and M.P.; and (3) the testimony of Gene Kennedy, M.D.,
the Government's expert.
The Undercover Operation
1. UC is currently an Assistant Special Agent in Charge with the
Tennessee Bureau of Investigation. Tr. 30. [Omitted to preserve
identity of UC.]
2. UC testified that he was contacted by a Special Agent with the
United States Department of Health and Human Services, Office of the
Inspector General, to conduct an undercover operation at Respondent's
clinic. Tr. 33-34. In preparation for this operation, UC contacted
Respondent's clinic to set up an appointment. Tr. 34. He was told to
bring several items to the appointment, including an MRI report, prior
``chart notes'' from his previous physician, a discharge summary from
his previous physician, and documentation showing his last three months
of prescriptions. Tr. 35.
October 3, 2017 Visit
3. UC testified he arrived at Respondent's office on October 3,
2017, at approximately 8:00 a.m. Tr. 40. He testified that he paid $311
for this appointment. Tr. 49. He recorded portions of the visit on a
``covert video camera device embedded'' in a cell phone case. Tr. 42-
43. Upon arrival, he provided an MRI report from September 2, 2016,
that he testified was ``authentic in the sense that it was my physical
MRI.'' However, the physician's name on the report had been altered.
Tr. 35, 37; GX 6 at 8-9. UC also provided ``fabricated'' medical
records which appeared to be signed by a nurse practitioner in
Missouri. This nurse practitioner, according to UC, was no longer
practicing in October 2017. Tr. 37-8; GX 6 at 10-11. UC did not provide
a discharge summary or any prescription information. Tr. 39-40; 133.
Nor did he provide any documents to show he had undergone a prior
physical examination. Tr. 133.
4. After providing the materials, UC was given what he estimated to
be approximately twenty pages of paperwork to fill out, none of which
was included in his medical file seized later by DEA. Tr. 40; GX 5.
However, UC took photographs of the forms before turning them in. Tr.
100. When asked to state his pain level, UC testified he told the
clinic staff that it was ``9'' out of ``10'' (``9/10''), but when he
was examined, he exhibited no overt indications of pain. Tr. 47, 56.
95. In fact, on one of the forms, he listed his quality of life as nine
out of ten. Tr. 131-32. On another form, he rated his pain disability
as only two out of ten. Tr. 132. On one form, he also denied he
suffered from insomnia, Tr. 132-33, but wrote on another form that he
sought to work without pain and sleep through the night. Tr. 135. No
one questioned him about these contradictions. Tr. 139. UC acknowledged
that he filled out
[[Page 3001]]
forms at his first appointment on October 3, 2017, and took photographs
of the forms. Tr. 100. The completed documents, however, were not part
of the Respondent's medical file seized by DEA and were not offered as
exhibits by either party. Tr. 100; GX 5.
5. UC testified that one of the Respondent's employees apparently
questioned the authenticity of the records he provided, stating that
people are trying to ``bring down Dr. Orusa.'' Tr. 41-42. This employee
was not named, but was identified as the person depicted in GX 30. UC
testified that, after providing the paperwork, his vital signs were
recorded, including his blood pressure. He was also asked about his
weight and asked to give a urine sample. Tr. 44-45.
6. UC described the October 3, 2017 visit as follows. He testified
that he made no attempt to demonstrate that he had a disability. He did
not limp or change his gait. Tr. 45-46. Though UC arrived at the clinic
at approximately 8:00 a.m., he did not meet with Respondent until
approximately 4:00 p.m. Tr. 47-48. During UC's encounter with
Respondent, UC informed Respondent that the last ``pain clinic'' he
visited was ``Dr. Chapman in Pierce, City, Missouri, and had recently
``closed down.'' GX 4 at 1. He also told Respondent that the person who
ordered his MRI was ``Dr. Morgan,'' a fictitious person. Tr. 37; GX 4
at 2. There was also a discussion about UC providing ``pharmacy
information.'' GX 4 at 3. UC told Respondent he would ``get those
records if I need to'' but did not know the pharmacy's phone number.
7. UC testified that he did not produce any additional records. Tr.
55. UC testified that, during his meeting with Respondent, he saw
Respondent ``going through some forms on the counter,'' but could not
determine what Respondent was reviewing. Tr. 105. UC testified that he
told Respondent he fell while unloading a truck in 2013. Tr. 117; GX at
1. He told Respondent that he was managing his pain with over-the-
counter medications. Tr. 104. Though he told Respondent that he could
``barely function,'' he did not ``elaborate'' and there was no further
discussion about this statement. Tr. 124; GX at 2; GX 17. UC testified
that, in response to Respondent's question about a previous diagnosis,
he told Respondent that a previous medical provider told him he had
degeneration of some sort and ``some arthritis.'' Tr. 105-06; GX at 1.
8. UC testified that Respondent performed a cursory physical exam
described as ``less than 60 seconds of any kind of physical touching.''
Tr. 56. He testified that Respondent instructed him to remain seated
and UC ``just told [Respondent] where the pain was. If he did something
and asked me if it hurt I would respond that I felt pain in that
area.'' Tr. 56. He testified that he made no ``faces'' and did not
``wince'' when touched. Following the exam, Respondent inquired about
UC's past pharmacy records. UC told Respondent. ``I'll get those
records if I need to.'' Tr. 108-09; GX at 3. UC testified that
Respondent wanted to do ``injections,'' but UC refused. Tr. 117.
According to the transcript of the meeting, UC told Respondent that he
hated needles. GX at 3.
9. Approximately 30 minutes after he left the exam room, UC
received a prescription for 42 tablets of 10 mg oxycodone, even though
he never asked for oxycodone. GX 18 at 1; Tr. 57. During the encounter
with Respondent, UC said that he had previously been given hydrocodone,
Xanax (alprazolam) and ``oxys.'' GX 4 at 2. He also told Respondent
that he was currently managing his pain with ``Advil this past month''
and had been ``miserable.'' Id. UC testified that he also received two
other prescriptions for non-controlled substances, including Flexeril
(cyclobenzaprine) and meloxicam. Tr. 58.
10. When asked why, he told Respondent he had lower back pain as
opposed to pain in some other area, UC testified that, due to his
exercise schedule, which including running five to seven miles each
day, a practitioner might find objective evidence to justify complaints
of knee, ankle, or shoulder pain. Here, he testified, he had
``absolutely no back pain whatsoever.'' Tr. 114-15. He testified that,
if Respondent's clinic had been ``doing their job,'' he would ``not
expect to walk out with a prescription.'' Tr. 105. Also, in his
experience as an undercover operative, he testified that ``more often
than not'' he has been refused prescriptions for controlled substances
on the first visit. Tr. 123-24.
11. A video recording of UC's meeting with Respondent was played
during the hearing. GX 17. UC testified that the video portion was a
fair and accurate recording of his ``entire encounter with'' Respondent
on October 3, 2017. Tr. 55. UC also testified that the transcript of
that encounter (GX 4) was an accurate representation of the recording.
Both the recording and the transcript were accepted into the official
record. GX 4, 17; Tr. 70-71, 187-88.
October 17, 2017 Visit
12. UC testified that, in order to receive more ``narcotic
prescriptions,'' he was required to come in for a ``well-care'' visit
before making an appointment during which he would receive narcotics.
Tr. 57-58. On October 17, 2017, he returned to the clinic and paid $25
for the visit. Tr. 57-59; GX 4, GX 17. He was then called back to a
``triage room'' and asked about his weight and blood pressure. Tr.
59.*\P\ He saw the Respondent for ``about one minute,'' during which
Respondent asked him if he slept well. When he responded, ``not
really,'' Respondent wrote him a prescription for amitriptyline. Tr.
59; GX at 4. This encounter was also recorded. GX 17. UC testified
that, during this visit, no physical exam was performed. Tr. 71-72. He
testified that no one examined his lower back, extremities, or checked
his muscles. Tr. 72.
---------------------------------------------------------------------------
*\P\ This section of the Recommended Decision included several
superscript numbers in the body of the text without any
corresponding text in footnotes. As I believe that the superscript
text was likely the result of a scrivener's error, I have deleted
them throughout this section without further demarcation.
---------------------------------------------------------------------------
October 18, 2017 Visit
13. UC testified that, on October 18, 2017, he returned to the
clinic for refills of narcotic medications. Tr. 74. Because the clinic
would no longer accept cash, he secured a debit card to pay for the
appointment, which cost $377. Tr. 75-76. During the October 18, 2017
appointment, UC waited approximately two and a half hours. He was not
examined and he met with medical personnel only for the purpose of
paying the fee and receiving his prescription. There was no discussion
about his medical condition and he provided no medical records. Tr. 76-
77. At the end of this visit, he received a prescription for 84 tablets
of 10 mg oxycodone, twice as much as he received 15 days earlier. Tr.
78; GX 18 at 3-4.
November 15, 2017 Visit
14. UC testified that, on November 15, 2017, he returned to the
clinic for a fourth time. On this visit, he testified that he paid $25,
``waited for some amount of time,'' was ``asked'' about his weight and
blood pressure, and was dismissed. Tr. 83-84.
November 20, 2017
15. UC testified that, on November 20, 2017, he returned to the
clinic for a fifth time. He described this as a ``medication visit.''
Tr. 87. UC testified that, during this visit, he wrote down his name on
[[Page 3002]]
a clipboard, ``paid a certain amount of money,'' and waited a ``certain
amount of time'' before he was given his prescriptions. Tr. 87-8. UC
testified that he was asked to provide a urine sample to which he added
``a vial of a substance that would cause me to test positive for
oxycodone.'' Tr. 88. At this visit, he received another prescription
for 84 tablets of 10 mg oxycodone. GX 18 at 4; Tr. 89.
Falsified Medical Records
16. UC identified numerous entries in his medical record that
indicated his medical chart had been fabricated. For instance, on
October 17, 2017, Respondent wrote that UC exhibited a number of
``[a]nxiety symptoms'' such as shortness of breath, ``palpitations,
sweating, dizziness, [and] shaking.'' GX 5 at 5. UC testified that he
never reported any of these symptoms. Tr. 79-80. Respondent also wrote
that UC reported ``no headache, no dizziness, no nausea, no vomiting,
no abdominal pain, no diarrhea, no constipation, no [shortness of
breath], no chest pain, [and] no palpitations.'' GX 5 at 5. UC
testified that he was never asked about any of these symptoms. Tr. 80-
81. UC was also asked about a notation for October 17, 2017, where his
weight and blood pressure were recorded. GX 5 at 5. He testified that
he was neither weighed, nor did anyone measure his blood pressure on
that day. Also, on October 17, 2017, Respondent wrote ``Chest: no
deformities, no asymmetry, no rales, no wheezes, normal vesicular
breath sounds.'' GX 5 at 5. UC testified that no one ever examined his
chest or evaluated his breathing. Tr. 81-82.
17. Regarding the medical records for October 18, 2017,
Respondent's entries for this appointment were identical to those made
the day before. Again, he wrote ``ROS for MSS is positive for muscle
pain, back pain, joint pain, and body aches and pain.'' GX 5 at 4.
Respondent again repeated the same notations about UC's chest and
breathing. However, all of this was created on a day when UC did not
see the Respondent. Nor was UC examined by anyone else at the clinic
that day. Tr. 82-83.
18. With respect to the November 15, 2017 visit, Respondent
repeated the same notations even though, as UC testified, no exams were
performed and Respondent was not there to see him. Nevertheless,
Respondent wrote out a list of symptoms in the section marked ``HPI,''
GX 5 at 4, which correspond to the visit on November 15, 2017. Again,
UC testified that none of these symptoms were ever discussed and no
examination was performed. Tr. 86. Likewise, with respect to
Respondent's notes in the section marked ``PE'' (physical exam),'' UC
testified that no one examined his chest or breathing. Tr. 86-87.
19. Finally, regarding the November 20, 2017 visit, Respondent
wrote, as he had four times previously, that UC was ``positive for
muscle pain, back pain, joint pain and body aches.'' GX 5 at 3. UC
testified that no physical exam was performed on this day. Tr. 90-91.
Respondent also, for the fifth time, described a physical examination
(section ``PE'') that was never performed. GX 5 at 3; Tr. 91.
20. UC also testified about the results of his urine drug
screening. He noted that, despite adding an oxycodone solution to his
urine on November 20, 2017, his records showed ``UDS ALL NEG.'' Tr. 91-
92; GX 5 at 3. UC also testified that there was no discussion about
this result. Tr. 92.
Expert Review
21. Dr. Kennedy testified as the Government's expert. Dr. Kennedy
owns a pain management clinic on St. Simons Island, Georgia; has
treated more than 1000 patients, but his current practice involves
fewer than 100 patients. Tr. 143-46. He testified that he has treated
patients with post-surgical issues, patients with cancer pain, and
patients with back pain. Tr. 178-80. Most of his patients, he
testified, need to have their medications ``managed.'' Tr. 143-44. Dr.
Kennedy testified that he has been practicing pain management for
approximately 15 years. Tr. 145, 179-80. He is licensed to practice
medicine in Georgia and runs a ``state licensed pain management
clinic.'' Tr. 146; GX 24. Dr. Kennedy is not board certified. Tr. 373.
22. Dr. Kennedy testified that, in his practice, he prescribes
controlled substances, including opioids such as oxycodone and
hydrocodone. Tr. 181. He has treated insomnia and/or anxiety with
benzodiazepines, such as lorazepam, diazepam, and alprazolam. Tr. 181-
82. He has also prescribed muscle relaxants such as carisoprodol. Tr.
181-82.
23. Dr. Kennedy has also lectured on controlled substances
``numerous times'' at the DEA training facility in Quantico. He has
taught at the National Advocacy Center, and at various DEA and
Department of Justice (``DOJ'') ``venues'' around the country. Tr. 184-
85. He also taught a course for pharmacists in Tennessee. Tr. 185.
24. Dr. Kennedy testified he has served as an expert witness in
numerous cases, including those involving physicians alleged to have
improperly prescribed controlled substances. Tr. 182. He estimates he
has testified 13-14 times. Id.
25. As the Government's expert, Dr. Kennedy reviewed the medical
charts for patients UC (GX 5), M.P. (GX 7), M.W. (GX 9), C.F. (GX 11),
B.C. (GX 13), and M.W. (GX 15). He also reviewed the prescriptions for
these patients (GX 18-23), the undercover video created by UC, the
transcripts (GX 17 and 4) of that video, and UC's reports of his
undercover visits (GX 3). Tr. 183-84, 186-89; 213-16.
26. Dr. Kennedy explained that, according to the minimal standard
of care for prescribing controlled substances in Tennessee, a physician
must: (1) Take an adequate medical history; (2) perform a physical
examination; (3) obtain past medical records; (4) order diagnostic
testing if indicated; [and (5) maintain complete and accurate medical
records.] Tr. 189-90, 195-96, 353.
27. Dr. Kennedy testified that, according to the minimal standard
of care, a physician's medical records should contain the following;
(1) past medical records or attempts to obtain past medical records;
(2) a ``pain history'' or ``collection of statements pertaining
directly'' to the patient's pain history; (3) history of ``drug abuse,
chemical dependency, [or] alcoholism;'' (4) records of a physical
examination ``that is specific and pertinent to the problem;'' (5)
patient assessment; (6) treatment plan; and (7) efforts to obtain state
pharmacy reports. Tr. 197. He also testified he was familiar with
Tennessee regulations requiring a physician to keep accurate and
complete medical records. Tr. 201.
28. Dr. Kennedy testified that, in cases where physicians prescribe
opioids in combination with benzodiazepines, a physician must have a
``heightened sense of vigilance managing the patient'' and this should
be noted in the medical record. Tr. 190-91.
29. Dr. Kennedy testified that there are indications of possible
drug abuse and/or diversion in patients whose medical histories are
``difficult to obtain'' as well as patients with ``cloudy histories of
drug abuse.'' Tr. 191-92. He discussed urine drug screening (``UDS'')
and how a physician must respond if a patient's UDS result shows an
``abnormality, it's not simply enough to just to say a patient's urine
is positive for cocaine or positive for methamphetamine. The physician
also has an obligation to say that the patient is positive for this
substance, and I discussed it with the patient, and I'm going to do
this if it happens again or I'm going to adjust the medications or
[[Page 3003]]
not adjust the medications. And it has to be something that is utilized
as a diagnostic treatment.'' Tr. 194. Dr. Kennedy further testified
that the above information should be documented in the medical record.
Id.
30. Dr. Kennedy testified that, prior to testifying in this matter,
he reviewed Tennessee regulations pertaining to the prescribing of
controlled substances. He confirmed that these regulations included
requirements that a physician must (1) take the patient's documented
medical history; (2) perform a physical examination; (3) perform an
adequate assessment and consideration of the patient's pain, physical,
and psychological function: And (4) take a history for the potential of
substance abuse.*\Q\ Tr. 200. Dr. Kennedy also testified that he was
familiar with rules prohibiting a physician from prescribing controlled
substances to a person addicted to the habit of using controlled
substances without making a bona fide effort to the cure the patient's
habit. Tr. 199.
---------------------------------------------------------------------------
*\Q\ I find that Dr. Kennedy credibly testified that the
applicable standard of care in Tennessee is as described in Finding
of Fact Nos. 26-27 supra. The requirements of the Tennessee
regulations are clearly components of and incorporated into the
standard of care set forth by Dr. Kennedy at Finding of Fact Nos.
26-27. TENN. COMP. R. & REGS. 0880-02-.14(6)(e)(3)(i). Further, Dr.
Kennedy's expert testimony is unrebutted in this proceeding.
---------------------------------------------------------------------------
31. Based on his qualifications and expertise, his knowledge of
Tennessee regulations and statutes, and his experience as an operator
of a pain management clinic, Dr. Kennedy was accepted as an expert in
pain management qualified to give an expert opinion regarding
Respondent's prescribing of controlled substances. Tr. 211-12; 216.
Undercover
32. With respect to the undercover officer, Dr. Kennedy testified
he reviewed the video recording UC made during his visits to
Respondent's clinic on October 3 and October 17 of 2017 (GX 17); UC's
investigative reports for all five of his visits to Respondent's
clinic; the patient medical file pertaining to patient UC; and the
prescriptions issued to UC by the Respondent. GX 3, 5, 17-18; Tr. 184-
86, 216, 239.
33. Dr. Kennedy testified that, based on his review, UC was being
treated for back pain. He testified that the physical exam was
inadequate, describing it as ``cursory in that it consisted of
essentially observing'' UC, ``touching his back, and having him lift
his leg once.'' Tr. 217. Dr. Kennedy testified that a minimally
adequate exam would include ``observing the patient's back, looking for
muscle spasms, performing ``lumbar range of motion maneuvers where the
patient . . . bends at the waist in various directions,'' doing a
neurologic exam, and doing a ``straight leg raised test having the
patient laying supine on the table.'' Tr. 224-25. Dr. Kennedy concluded
that, based on the medical records, there were no ``positive findings
on physical examination.'' Tr. 226. In other words, he testified,
Respondent's ``physical exam findings'' failed to support a ``pain
ideology'' and certainly could not justify a reported pain level of 9/
10. Tr. 226-27, 234. With respect to the Respondent's diagnosis (GX 5
at 2) of ``[d]egeneration of [l]umbar [i]ntervertebral [d]isc . . .
[l[umbar [s]pondylosis . . ., and [i]nsomnia,'' Dr. Kennedy noted that
even the MRI failed to mention degenerative disc disease and Dr.
Kennedy could identify no other findings to justify that diagnosis. Tr.
240-42. And though spondylosis could be severe enough to ``be causing
symptoms,'' Dr. Kennedy testified that there was no evidence that these
symptoms existed. Tr. 242. Dr. Kennedy also testified that neither UC's
MRI report, nor the prior medical records, justified the prescribing of
controlled substances. Tr. 228, 230.
34. Looking at Respondent's medical record for patient UC, Dr.
Kennedy further concluded that the record was rife with fabrications as
the following testimony indicates: ``. . . if you look it says on the
second line, chest, no deformities, no asymmetry. The only way to
determine [this] is to look at them with their shirt off. And this
patient was not required to disrobe . . . there is also no indication .
. . that the heart and lungs were evaluated. But there are heart and
lung evaluations as well as the chest appearance . . . . you couldn't
see everything, but clearly listening to the audio, I didn't hear any
breathe in, breathe out, anything that would indicate to me that there
was a physical exam that included these things.'' Tr. 218-19. Dr.
Kennedy further noted that the description of UC's general exam in the
section marked ``PE'' (GX 5 at 6) was not only inaccurate, but was
identical to language he found in more than 20 medical charts he
reviewed for other patients. Likewise, Dr. Kennedy disputed the truth
of the information supposedly used to support a finding that UC
suffered from insomnia. Tr. 233. This was further confirmed by UC's
testimony, in which he testified that he neither reported nor
manifested any of the listed ``insomnia'' symptoms. Tr. 79-80, 134-35,
139. Dr. Kennedy also testified that the physical exam depicted in the
video (GX 17) as well as UC's subsequent encounters could not possibly
support the repeated findings corresponding to visits on October 17 and
18, as well as the visits on November 15 and 20. GX 5 at 3-5; Tr. 235-
37.
35. Dr. Kennedy testified that UC, as an undercover patient, also
manifested various ``red flags'' for possible drug abuse and/or
diversion. Tr. 230. He noted that UC's prior medical records showed
only a ``single office visit'' (GX 6 at 10) from a provider in another
state and documentation from the encounter showed a ``completely normal
physical exam with no positive findings at all.'' Tr. 220-31. Dr.
Kennedy testified that a patient who comes from a clinic that has
closed and provides medical records from a practitioner whose license
has been suspended are red flags for diversion. He further noted that
none of these red flags was ``significantly'' addressed by Respondent
prior to prescribing oxycodone. Tr. 238.
36. In summary, Dr. Kennedy testified that, with respect to UC,
Respondent: (1) Failed to discuss the risks and benefits of the use of
oxycodone; (2) failed to maintain truthful and accurate medical
records; (3) failed to assess the patient's pain, physical and
psychological function; (4) failed to assess the patient's history and
potential for substance abuse; (5) failed to assess any co-existing
diseases, conditions in the presence of a recognized medical indication
for the use of oxycodone; and (6) failed to create and follow a
legitimate written treatment plan for the patient's individual needs.
Tr. 231-32, 237-38. Dr. Kennedy further concluded that Respondent's
prescribing of controlled substances to UC was outside the usual course
of professional practice. Tr. 239. Additionally, Dr. Kennedy concluded
that the prescriptions issued to UC lacked a medical justification. Tr.
239; see also GX 6 (Dr. Kennedy's expert report on patient UC), 18
(prescriptions issued to UC).
Patient M.W.
37. Dr. Kennedy testified that Respondent treated M.W. for lower
back and limb pain. Tr. 245. M.W. was prescribed alprazolam,
carisoprodol (Soma), oxycodone, and oxymorphone. GX 23. In his review,
Dr. Kennedy stated that there was nothing that meaningfully supported a
chronic pain condition. Id. Dr. Kennedy discussed a form in M.W.'s file
titled ``Pain Management Physical Exam.'' (GX 9 at 14/GE 10 at 7). He
testified that the form
[[Page 3004]]
indicated only ``normal findings'' and ``acute findings.'' Tr. 247.
Yet, the patient reported a pain level of 10/10. Tr. 248-49; GX 9 at
19; GX 10 at 8. As Dr. Kennedy testified, in order to support such a
high pain level, there would have to be ``very, very significant
findings on lumbar exam.'' For instance, he testified, he would not
expect to see a patient whose ``gait is normal.'' Tr. 250. Dr. Kennedy
also testified that it would be unusual to see a 25 year old patient
with degenerative disc disease. In that case, he testified, he would
expect Respondent to order radiologic studies to confirm the diagnosis.
Tr. 262-63; GX 10.
38. Dr. Kennedy also found nothing in M.W.'s medical chart to
justify the continuing prescribing of alprazolam. Tr. 260-62. Rather,
he found ``identical language [to] that [which] was used to diagnose
insomnia'' for UC. Tr. 261; see also GX 9 at 84 (``HPI'' entry);
compare to GX 5 at 5 (same). There was no evidence, Dr. Kennedy
testified, that M.W. suffered from insomnia. Tr. 264.
39. Dr. Kennedy also testified that there were numerous red flags
in M.W.'s medical chart for abuse and/or diversion. Specifically,
M.W.'s chart showed a ``wildly abnormal'' drug screen in which M.W.
tested positive for morphine, hydromorphone, and THC in March 2016. He
was also negative for carisoprodol and alprazolam, two drugs he was
being prescribed and was supposed to be taking. Tr. 251-52; GX 9 at 2-
4. Based on the medical record, Dr. Kennedy testified that this
abnormal result was not ``meaningfully addressed.'' Tr. 252. Elsewhere
in the chart, there were other examples of abnormal drug screens. On
March 28, 2016, Respondent wrote ``UDS pos for oxy-unsat.'' GX 9 at
102. Then, according to an UDS lab report dated May 11, 2017, M.W.
tested negative for four controlled substances he had been prescribed,
including oxycodone, oxymorphone, alprazolam, and carisoprodol (Soma).
GX 9 at 10. Inexplicably, six days before M.W. provided the specimen,
Respondent wrote that M.W. was negative for all prescribed drugs. GX 9
at 85. On May 31, 2017, Respondent wrote that M.W. is ``dismissed''
with ``one month notice,'' but noted on the same day that M.W. was
``compliant and consistent.'' GX 9 at 83-84. However, less than a month
later, the ``dismissal [was] reversed.'' GX 9 at 83. Dr. Kennedy said,
``[i]f the patient is negative for the medication and its metabolites
of essentially everything that's prescribed, there's a problem.'' Tr.
260. Dr. Kennedy testified that this was evidence of drug abuse, which
Respondent failed to adequately address. Tr. 265.
40. With respect to M.W.'s medical records, Dr. Kennedy again cited
numerous inconsistences that questioned Respondent's credibility. For,
instance, he testified that the findings on the handwritten physical
exam form (GX 9 at 14) did not match those listed in Respondent's
electronic medical record (GX 10 at 9). Instead, Dr. Kennedy found the
same language in M.W.'s chart that was present in UC's medical chart
and in the charts for other patients he reviewed. Tr. 250-51. Dr.
Kennedy noted that, out of 98 different encounters, Respondent repeated
the same notes 93 times. Tr. 264. This, he testified, rendered the
medical file ``not credible.'' Tr. 251. Dr. Kennedy also cited the fact
that Respondent described M.W. as ``compliant and consistent'' the same
day he tested negative for all the controlled drugs he was supposed to
be taking. Tr. 258-59. Again, he described the inconsistency as
``simply not credible.'' Tr. 259.
41. In summary, Dr. Kennedy testified that, with respect to M.W.,
Respondent: (1) Failed to perform an adequate physical examination; (2)
failed to assess the patient's pain, physical, psychological function;
(3) failed to assess the patient's history and potential for substance
abuse, coexisting diseases and conditions; and (4) failed to create a
legitimate written treatment plan for the patient's individual needs.
Tr. 265. He further testified that Respondent failed to maintain a
truthful and accurate medical record for M.W. Tr. 265-66. Dr. Kennedy
testified that the controlled substances in GX 23 were prescribed to
M.W. outside the usual course of professional practice. Tr. 266-68.
Lastly, Dr. Kennedy testified that his opinions applied to all the
prescriptions in GX 23. Tr. 266.
Patient C.F.
42. Dr. Kennedy testified that patient C.F. was treated for
``chronic pain due to trauma, unspecified inflammatory
polyarthropathy.'' Tr. 269. However, he testified that C.F.'s physical
examination did not support the controlled substances prescribed. Id.
Dr. Kennedy noted that, while C.F. had scars, her muscle strength was
normal as well as her tendon reflexes, and her fine touch sensation.
Also, he testified that C.F.'s ``[l]eg raise tests were normal
bilaterally'' and her gait was normal. Tr. 270; GX 11 at 106. Dr.
Kennedy also testified that the findings in Respondent's ``Pain
Management Physical Exam'' (GX 11 at 106) were not accurately reflected
in Respondent's electronic medical record. Tr. 271. Rather, he
testified, that portion of Respondent's medical record contained
findings ``present in the other charts that we've already discussed.''
Tr. 271-72; GX 11 at 69. Dr. Kennedy also testified that he could find
no evidence of any credible follow-up physical exams being performed
even though C.F. remained a patient for nearly four years. Tr. 272. Nor
did he find any evidence that Respondent ordered any supporting
studies. Id.
43. Dr. Kennedy testified regarding the long term prescribing of
alprazolam to C.F. He testified that there was no justification for
this since the objective findings to support a diagnosis of insomnia
and/or anxiety were identical to those found in medical records for
other patients, including those pertaining to UC. GX 11 at 39; Tr. 286-
87.
44. Dr. Kennedy testified he also found evidence of possible abuse/
diversion that Respondent never adequately addressed. In GX 11 at 117,
a laboratory report dated July 9, 2018, shows that C.F. tested negative
for prescribed controlled medications, a result that Respondent himself
labeled as ``Unsat.'' GX 11 at 117; Tr. 274. According to Respondent's
own records, this test was taken just three days after C.F. was
prescribed alprazolam, oxycodone, and oxymorphone. GX 11 at 9; Tr. 274-
75. Pursuant to a report dated July 7, 2017, C.F. tested negative for
alprazolam and positive for hydrocodone. GX 11 at 111; Tr. 275. On June
30, 2017, Respondent's records showed C.F. was prescribed alprazolam,
but hydrocodone is not listed. GX 11 at 25; Tr. 275-76. Dr. Kennedy
testified that, according to notes from a subsequent visit on July 26,
2017, the abnormal drug screen result is never mentioned. GX 11 at 23;
Tr. 288-89.
45. Additionally, Dr. Kennedy testified that, according to a lab
report dated July 13, 2014, C.F. tested positive for a diazepam
metabolite, negative for alprazolam, and positive for cocaine,
oxycodone, oxymorphone, and THC. GX 11 at 79; Tr. 276-278. However, at
the next visit on August 11, 2014, Respondent's medical records made no
reference to these abnormal results. GX 11 at 69; Tr. 278-79.
46. Regarding C.F.'s multiple unsatisfactory drug screens, Dr.
Kennedy testified that it is insufficient for a physician to simply
document that the patient was counseled. Rather, he testified, the
doctor needs to document how the abnormalities are ``going to affect
treatment.'' Tr. 283-84. Dr. Kennedy testified that ``repeating over
and over that the patient was counseled. . . leads to the impression
[[Page 3005]]
. . . that it's not making any difference to the prescriptions for
schedule medications that are being provided.'' Id.
47. Regarding C.F.'s medical record, Dr. Kennedy testified that
Respondent's description of his review of systems (``ROS'') was
repeated throughout C.F.'s chart and found in numerous other charts.
Tr. 272-73. Likewise, the section labeled ``Gen exam'' was repeated 102
times and also found in other charts. Tr. 273. Also, as stated above,
Respondent's description of the physical exam failed to reflect the
actual handwritten notes but rather mirrored what had been written
about other patients, including UC.
48. In summary, regarding patient C.F., Dr. Kennedy testified that
Respondent: (1) Failed to take an adequate medical history; (2) failed
to perform an adequate physical examination; (3) failed to perform an
adequate assessment in consideration of the patient's pain, physical,
and psychological function; (4) failed to take an adequate history and
evaluate the potential for substance abuse; (5) failed to create a
written treatment plan tailored for the individual needs of the
patient; (6) failed to consider the patient's pertinent medical history
and physical examination as well as the need for further testing,
consultation, referrals, or use of other treatment modalities, (7)
failed to discuss the benefits and risks of the use of controlled
substances; (8) failed to conduct a documented periodic review of the
care at reasonable intervals in view of the individual circumstances of
each patient; (9) failed to keep complete and accurate records of the
care provided; and (10) continued to issue prescriptions for controlled
substances without making a bona fide effort to cure the patient's
habit. Tr. 284-86.
49. Dr. Kennedy further testified that, for the reasons in Finding
of Fact no. 48 and given C.F.'s numerous abnormal drug screen results,
the issuing of prescriptions for controlled substances to C.F.,
including those in GX 20, were issued ``outside the scope of acceptable
medical practice.'' Tr. 287.
Patient B.C.
50. Dr. Kennedy testified that B.C. was treated for ``chronic pain
syndrome.'' Tr. 290. He testified that he found no handwritten notes
reflecting a physical exam and that the electronic records showed
results that were ``non-supportive'' of a chronic pain condition. Tr.
290-91. Dr. Kennedy explained that the electronic records, in the
category of ``systems review,'' reflected 141 encounters with
Respondent and the ``system review documentations was repeated 140
times.'' He also testified that the ``physical exam documentation was
repeated ``approximately 134 times.'' According to Dr. Kennedy, this
same documentation was found, verbatim, in other charts. Tr. 292.
51. Though Dr. Kennedy acknowledged that B.C. seemed to have
serious medical ``problems,'' such as Hodgkin's lymphoma, a cancer of
the lymphatic system, Respondent's notes, inexplicably, failed to
reflect those problems. Dr. Kennedy noted, for instance, that the
review of systems for B.C. showed, among other things, that B.C.'s
``endocrine'' was ``negative.'' Tr. 292-93; see, e.g., GX 13 at 169.
Dr. Kennedy also took issue with the fact that Respondent, after
repeatedly reporting a nonsensical pain level of ``/10'' over the
course of nine sequential encounters,'' began to record a pain level of
10/10 without medication and 8/10 with medication. Tr. 295-96. Dr.
Kennedy testified that, despite B.C. being dismissed from another
physician, there was also no attempt to obtain prior medical records.
Tr. 304.
52. Dr. Kennedy testified that there were numerous red flags in
B.C.'s chart for abuse and/or diversion. First, B.C. had been dismissed
from a previous physician, GX 13 at 188, Tr. 293-94, an issue that was
not investigated. Tr. 294. Respondent also noted that B.C. lied about
his prescriptions at the first encounter--another issue that does not
appear to have been addressed. Tr. 296; GX 13 at 169. In fact, Dr.
Kennedy testified that the record, despite evidence of B.C.'s
untruthfulness, appears to show that Respondent prescribed controlled
substances to B.C. without ordering a UDS screen, something that ``is
outside the course of usual medical practice.'' Tr. 297; GX 13 at 169.
Dr. Kennedy testified that there were also abnormal drug screen
results. On February 20, 2013, B.C. was positive only for oxycodone
when he was also prescribed alprazolam. Tr. 298; GX 13 at 166. A note
dated March 26, 2013, indicated ``unsatisfactory benzo only UDS.'' Tr.
298-99; GX 13 at 165. On August 19, 2013, B.C. was positive for opioids
only, another unsatisfactory result. Tr. 299; GX 13 at 158. Dr. Kennedy
identified more abnormal results, including one where B.C. testified
positive only for benzodiazepines when he was also being prescribed
oxycodone. Tr. 299; GX 13 at 156-57. In another note, B.C. tested
positive only for oxycodone when he was also being prescribed
alprazolam. GX 13 at 155-65 (October 6, 2014 entry); Tr. 300. On
December 22, 2014, Respondent noted that B.C. was negative for all
drugs, another unsatisfactory result. Tr. 300-01; GX 13 at 150. And
though the record indicates the patient was counseled, Dr. Kennedy
testified that there was ``nothing specific about what the counseling
entailed or any decisions'' made as a result. Tr. 301.
53. Dr. Kennedy also testified that B.C. had been in jail, another
red flag. Tr. 301-02. Dr. Kennedy testified that, in this case, a
``reasonable physician would provide documentation that supports that
this was addressed and taken into account in pursuing a treatment
plan.'' Tr. 302-03.
54. Dr. Kennedy noted numerous instances where the medical chart,
instead of recording an actual pain level, listed a nonsensical pain
level of ``/10.'' Tr. 294-95.
55. In summary, Dr. Kennedy testified that Respondent's examination
of B.C. did not support a chronic pain condition. He testified that
Respondent: (1) Failed to take an adequate medical history; (2) failed
to perform a sufficient physical examination; (3) failed to perform an
adequate assessment in consideration of the patient's pain, physical
and psychological function; (4) failed to take an adequate history for
the potential for substance abuse, coexisting diseases and condition;
(5) failed to show the presence of a recognized medical indication for
the use of a dangerous drug or controlled substance; (6) failed to
create a written treatment plan tailored to the individual needs of the
patient; (7) failed to adequately address the need for further testing,
consultation, referrals or other treatment modalities; (8) failed to
discuss the risks and benefits of the use of controlled substances; (9)
failed to do a documented periodic review of his care at reasonable
intervals in view of the individual circumstances; and (10) failed to
keep complete and accurate records of the care provided. Tr. 304-06.
Dr. Kennedy testified that, in his view, there was no medical
justification for issuing prescriptions for controlled substances to
B.C. and, as a result, the prescriptions were issued outside the usual
course of professional practice. Tr. 307-08; GX 22.
Patient M.H.
56. Dr. Kennedy testified that M.H. was being treated for ``chronic
pain syndrome.'' Tr. 309. He testified that Respondent performed a
physical exam; however, the findings were identical to those for other
patients. See GX 15 at 62-63 (sections marked ``PE'' for February 4,
2015, and April 1, 2015); Tr. 310-11. Moreover, Dr. Kennedy testified
that these findings did not support a chronic pain condition and that
the
[[Page 3006]]
treatment was ``outside the scope of acceptable medical practice.'' Tr.
311-12. Dr. Kennedy also testified about an ``extremely'' unusual
situation in which M.H. underwent extensive spinal surgery and was
discharged from the hospital on October 4, 2016. However, the medical
chart entry dated October 5, 2016, shows no mention of the surgery and
no evidence that a physical exam was performed. Tr. 320-22, 323-24; GX
15 at 26 (hospital notes), at 48 (encounter note for October 5, 2016).
Dr. Kennedy described the situation as follows: ``this whole thing is
about scheduled medications to begin with. This is ostensibly a chronic
pain patient. He has been discharged from the hospital the day before
this encounter after having had a major, major spinal surgery. And not
only it is not mentioned in this encounter note, but essentially this
encounter note is normal and identical to all the other encounter
notes.'' Tr. 322-23. Dr. Kennedy also found no justification for the
continued prescribing of alprazolam. As with the other patients, the
factual findings related to insomnia/anxiety were identical to the
findings found in charts of the other patients discussed during the
hearing. GX 15 at 49 (section marked HPI).
57. Dr. Kennedy testified that he also found evidence of abnormal
drug screens, even on M.H.'s initial visit. Tr. 313-14; GX 15 at 63. On
some occasions, M.H. tested positive for illicit substances. See GX 15
at 56 (positive for THC, cocaine, PCP); GX 15 at 53 (positive for
amphetamines); Tr. 314-15. In other cases, he tested negative for drugs
that had been prescribed. GX 15 at 51 (positive for opiates and
oxycodone when patient also prescribed alprazolam and carisoprodol); GX
15 at 49 (same); GX 15 at 47 (same); GX 15 at 40 (UDS negative for all
drugs while patient was prescribed oxycodone oxymorphone, alprazolam,
and carisoprodol); GX 15 at 39 (UDS negative for all drugs); GX 15 at
36 (UDS positive only for oxycodone). In these cases, Dr. Kennedy
testified, there was no evidence that Respondent addressed the
abnormalities other than to order repeat tests. Tr. 313-20.
58. Dr. Kennedy also reviewed the prescriptions for M.H. identified
as GX 19. These included alprazolam, oxymorphone, carisoprodol, and
oxycodone. Tr. 325-27.
59. Dr. Kennedy testified that, in his view, Respondent prescribed
controlled substances to M.H. despite evidence that M.H. may have been
addicted to the habit of using controlled substances. Tr. 327. He
testified that Respondent made no effort to cure M.H.'s habit. Id. Dr.
Kennedy further testified that Respondent: (1) Failed to perform an
adequate assessment in consideration of the patient's pain, physical
and psychological function; (2) failed to evaluate the patient's
history and potential for substance abuse; (3) failed to determine a
recognized medication indication for the use of controlled substances;
(4) failed to create a written treatment plan tailored for the
individual needs of the patient; (5) failed to consider the need for
further testing, consultation, referrals, or use of other treatment
modalities; (6) failed to discuss the risks and benefits of the use of
controlled substances; (7) failed to do a documented periodic review of
the patient's care at reasonable intervals in view of the individual
circumstances of each patient; and (8) failed to keep complete and
accurate records of the care provided to M.H. Tr. 327-29.
60. Dr. Kennedy testified that the controlled substances issued to
M.H. were not issued in the usual course of professional practice. Tr.
329.
Patient M.P.
61. Dr. Kennedy testified that M.P. was being treated for low back,
neck, hip, and shoulder pain. Tr. 331. Dr. Kennedy testified that the
physical exam used to justify prescribing controlled substances for
M.P. was inadequate. Tr. 334. As he explained, M.P. was diagnosed with
degenerative disc disease and right shoulder pain. To determine whether
M.P. had shoulder pain, Dr. Kennedy testified, a physician would have
to test the patient's ``range of motion as far as extension, flexion,
abduction . . . tenderness to palpation specific to the shoulder.'' Tr.
335. With respect to degenerative disc disease, Dr. Kennedy testified
that Respondent should have found, for example, that the ``dorsal
lumber and C-spine range of motion'' was ``decreased in all
directions.'' Id. Dr. Kennedy testified he saw no such findings in
Respondent's medical record. Tr. 334-35. Dr. Kennedy also testified
that M.P.'s pain level was inconsistent with other information in the
record.
62. Dr. Kennedy also testified that, throughout M.P.'s medical
records, Respondent expressed a need to obtain M.P.'s prior medical
records, but Respondent never followed through. GX 7 at 1, 59, 68; Tr.
337-38. This included obtaining M.P.'s x-rays, MRI report, and the
dismissal form from her prior physician. Id.
63. Dr. Kennedy testified that M.P. manifested signs of abuse/
diversion which were not adequately addressed. Initially, M.P. tested
positive for buprenorphine, benzodiazepines, oxycodone, and THC. GX 7
at 68. According to the pharmacy report, which was part M.P.'s medical
chart, buprenorphine had never been prescribed. Tr. 338-39; GX 7 at 19.
Dr. Kennedy also discussed that there was mention of ``termination
paperwork from a previous physician,'' another red flag for abuse and/
or diversion. Tr. 342. Dr. Kennedy pointed out ``highly conflicting''
information in M.P.'s medical chart. Tr. 345. For instance, M.P. listed
her occupational disability as both ``9'' and ``10,'' but stated she
works ``45-60 hours weekly'' as a waitress. GX 7 at 9-10. Dr. Kennedy
also questioned M.P.'s truthfulness when she denied that she had ever
been in a drug treatment program (GX 7, 13). However, following a
heroin overdose, she told Respondent that she refused to go into such a
program because she had tried drug treatment before. GX 7 at 57
(section marked ``HPI''). Dr. Kennedy also pointed out several abnormal
drug screen results. In GX 7, page 58, there is a reference to a
positive test for THC, opioids, and benzodiazepines, none of which had
been prescribed. Tr. 347.
64. M.P. overdosed on heroin in Respondent's waiting room. GX 7 at
25; Tr. 340-41. However, according to Dr. Kennedy, Respondent
incorrectly treated M.P. with Suboxone (buprenorphine).
65. Dr. Kennedy testified that Respondent repeatedly issued
prescriptions for controlled substances to M.P. despite the fact she
was addicted to the habit of using controlled substances. Tr. 348.
Also, up until the point M.P. overdosed on heroin, Respondent made no
effort to cure M.P.'s habit. Tr. 348-49. Dr. Kennedy also testified
that, with respect to M.P., Respondent: (1) Failed to perform a
sufficient physical examination; (2) failed to perform an adequate
assessment in consideration of the patient pain, physical and
psychological function; (3) failed to record an adequate history of
potential substance abuse; (4) failed to determine a recognized medical
indication for the use of controlled substances; (5) failed to create a
written treatment plan tailored for the individual needs of the
patient; (6) failed to take a pertinent medical history and perform a
physical examination as well as perform further testing, consultation,
referrals. And the use of other treatment modalities; (7) failed to
discuss the risk and benefits of the use of controlled substances; (8)
failed to do a documented periodic review of M.P.'s care at reasonable
intervals in view of the individual circumstances; and (9) failed to
keep
[[Page 3007]]
complete an accurate medical records of the care provided to M.P. Tr.
348-50.
66. Dr. Kennedy also testified that the prescriptions issued to
M.P., including those in GX 21, were issued outside the usual course of
professional practice, and that Respondent lacked a medical
justification for issuing the prescriptions. Tr. 352.
67. With respect to patients, B.C, C.F., M.H., M.W., and M.P., Dr.
Kennedy testified that the prescribing of controlled substances to
these patients was dangerous. Tr. 352. As a basis for that opinion, he
cited: (1) Abnormal drug screens that were ``essentially ignored,'' (2)
the lack of documentation about the patients' status; (3) medical
records that were not credible; (4) and maintaining patients on
scheduled medications, sometimes at high dosages ``without having
honest, accurate, complete medical records.'' Tr. 352-53. He testified
that ``[b]ecause medical records will instruct other people who look''
at the patients later, a medical record that ``simply doesn't make
sense or [has] something that is in conflict,'' can ``present a
dangerous situation.'' Tr. 353.
Respondent's Falsification
68. DI testified that Respondent submitted an application to renew
his DEA COR (No. BO4959889) on November 6, 2019. Tr. 529; GX 26. She
testified that Respondent answered ``no'' to the third liability
question on the application. Specifically, the question sought to
determine whether Respondent had ever ``surrendered for cause or had a
state professional license or controlled substance registration
revoked, suspended, denied, restricted, or placed on probation.'' Tr.
530.
69. DI introduced a document outlining an administrative action
against Respondent, titled ``Notice of Charges and Memorandum for
Assessment of Civil Penalties,'' submitted May 1, 2019, by the
Tennessee Department of Health. GX 29; Tr. 531. As the document states,
Respondent was charged with, among other things, prescribing
``narcotics and other medications and controlled substances in amounts
and/or duration that were not medically necessary, advisable, or
justified for a diagnosed condition.'' GX 29 at 5.
70. DI introduced a document from the Chancery Court for the State
of Tennessee, 20th Judicial District, Davidson County, Part III
(``Chancery Court''), staying the proceedings brought by the Tennessee
Department of Health, [omitted] and imposing restrictions on
Respondent's license as conditions of the stay. Those restrictions
included prohibiting Respondent from: (1) Writing prescriptions; (2)
supervising or collaborating with any mid-level practitioners for the
writing of prescriptions; and (3) providing direct patient care
including but not limited to diagnosing, treating, operating on or
prescribing for any person. GX 27 at 2-3; Tr. 533-34. The order is
dated May 17, 2019, approximately three months before Respondent
submitted his renewal application. GX 27 at 4.
71. DI introduced a document, titled Agreed Order, dated August 21,
2018. GX 28. DI testified that the Order provided that Respondent must
surrender his Tennessee Pain Management Clinic Certificate (``Pain
Clinic Certificate''), No. 246, as a result of violations related to
the prescribing of controlled substances. Id. at 5-7.
72. DI testified, as a result of having surrendered his Pain Clinic
Certificate and the restrictions placed upon his medical license by the
Chancery Court, that Respondent did not answer truthfully on his
renewal application. Tr. 536.
Analysis
Findings as to Allegations
The Government alleges that the Respondent's COR should be revoked,
and any applications should be denied, because the Respondent [has
committed such acts as would render his registration inconsistent with
the public interest. 21 U.S.C. 824(a)(4); 21 U.S.C. 823(f) and in
particular the Government relies on Public Interest Factors Two (the
Respondent's experience conducting regulated activity) and Four (the
Respondent's compliance with state and federal laws related to
controlled substances)]. ALJ Ex. 1.\29\ In the adjudication of a
revocation of a DEA COR, the DEA bears the burden of proving that the
requirements for such revocation are satisfied. 21 CFR 1301.44(e).
Where the Government has sustained its burden and established that a
respondent has committed acts that render his registration inconsistent
with the public interest, to rebut the Government's prima facie case, a
respondent must both accept responsibility for his actions and
demonstrate that he will not engage in future misconduct. Patrick W.
Stodola, M.D., 74 FR 20,727, 20,734 (2009).
---------------------------------------------------------------------------
\29\ In its GPHB, the Government argues Factors Two and Four
should be combined for a joint analysis.
---------------------------------------------------------------------------
Acceptance of responsibility and remedial measures are assessed in
the context of the ``egregiousness of the violations and the [DEA's]
interest in deterring similar misconduct by [the] Respondent in the
future as well as on the part of others.'' David A. Ruben, M.D., 78 FR
38,363, 38,364 (2013). Where the Government has sustained its burden
and established that a registrant has committed acts inconsistent with
the public interest, that registrant must present sufficient mitigating
evidence to assure the Administrator that he can be entrusted with the
responsibility commensurate with such a registration. Medicine Shoppe-
Jonesborough, 73 FR 364, 387 (2008).
The Agency's conclusion that ``past performance is the best
predictor of future performance'' has been sustained on review, Alra
Labs., Inc. v. DEA, 54 F.3d 450, 452 (7th Cir. 1995), as has the
Agency's consistent policy of strongly weighing whether a registrant
who has committed acts inconsistent with the public interest has
accepted responsibility and demonstrated that he or she will not engage
in future misconduct. Hoxie v. DEA, 419 F.3d 477, 482-83 (6th Cir.
2005); see also Ronald Lynch, M.D., 75 FR 78,745, 78,754 (2010)
(holding that the Respondent's attempts to minimize misconduct
undermined acceptance of responsibility); George C. Aycock, M.D., 74 FR
17,529, 17,543 (2009) (finding that much of the respondent's testimony
undermined his initial acceptance that he was ``probably at fault'' for
some misconduct); Jayam Krishna-Iyer, M.D., 74 FR 459, 463 (2009)
(noting, on remand, that despite the respondent's having undertaken
measures to reform her practice, revocation had been appropriate
because the respondent had refused to acknowledge her responsibility
under the law); Medicine Shoppe-Jonesborough, 73 FR 364 at 387 (noting
that the respondent did not acknowledge recordkeeping problems, let
alone more serious violations of federal law, and concluding that
revocation was warranted).*\R\
---------------------------------------------------------------------------
*\R\ Remaining text omitted for brevity and clarity.
---------------------------------------------------------------------------
Tennessee Law
As a licensed medical doctor in Tennessee, the Respondent was
subject to TENN. CODE ANN. Sec. 63-6-214(b)(12) through (14),\30\ as
those provisions
[[Page 3008]]
pertain to ``dispensing, prescribing, or otherwise distributing''
controlled substances. Specifically, section 63-6-2 l 4(b)(12)
prohibits a physician from prescribing controlled substances ``not in
the course of professional practice, or not in good faith to relieve
pain and suffering, or not to cure an ailment, physical infirmity or
disease, or in amounts and/or for durations not medically necessary,
advisable or justified for a diagnosed condition.'' Additionally,
section 63-6-214(b)(13) prohibits a physician from prescribing
controlled substances to a person ``addicted to the habit of using
controlled substances'' without ``making a bona fide effort to cure the
[patient's] habit.'' To determine a violation of these provisions, the
Tennessee Board of Medical Examiners uses a nonexhaustive list of
guidelines (``the guidelines'') found in TENN. COMP. R. & REGS. 0880-
02-.14(6)(e).\31\ The guidelines require that a physician: (1) Take a
documented medical history; (2) conduct a physical examination; and (3)
perform an adequate ``assessment and consideration of the [patient's]
pain, physical and psychological function, any history and potential
for substance abuse, coexisting diseases and conditions, and the
presence of a recognized medical indication for the use of a dangerous
drug or controlled substance.'' TENN. COMP. R. & REGS. 0880-
02-.14(6)(e)(3)(i). Additionally, Rule 0880-02-.14 (6)(e) requires
physicians to create a ``written treatment plan tailored for the
individual needs of the patient'' that considers the patient's
``pertinent medical history and physical examination as well as the
need for further testing, consultation, referrals, or use of other
treatment modalities.'' It also requires the physician to ``discuss the
risks and benefits of the use of controlled substances,'' complete a
``documented periodic review of the care . . . at reasonable
intervals,'' and ``keep [c]omplete and accurate records of the care.''
Id. at 0880-02-.14(6)(e)(3)(ii)-(v).
---------------------------------------------------------------------------
\30\ T. C. A. Sec. 63-6-214. License denial, suspension, or
revocation; grounds; examination; investigations; abstract of
record; report; standard of care; disclosure of records; screening
panels; hearings; orders
(a) The board has the power to: (1) Deny an application for a
license to any applicant who applies for the same through
reciprocity or otherwise; (2) Permanently or temporarily withhold
issuance of a license; (3) Suspend, or limit or restrict a
previously issued license for such time and in such manner as the
board may determine; (4) Reprimand or take such action in relation
to disciplining an applicant or licensee, including, but not limited
to, informal settlements, private censures and warnings, as the
board in its discretion may deem proper; or (5) Permanently revoke a
license.
(b) The grounds upon which the board shall exercise such power
include, but are not limited to: . . . (12) Dispensing, prescribing
or otherwise distributing any controlled substance or any other drug
not in the course of professional practice, or not in good faith to
relieve pain and suffering, or not to cure an ailment, physical
infirmity or disease, or in amounts and/or for durations not
medically necessary, advisable or justified for a diagnosed
condition; (13) Dispensing, prescribing or otherwise distributing to
any person a controlled substance or other drug if such person is
addicted to the habit of using controlled substances without making
a bona fide effort to cure the habit of such patient; (14)
Dispensing, prescribing or otherwise distributing any controlled
substance, controlled substance analogue or other drug to any person
in violation of any law of the state or of the United States; . . .
(emphasis added).
\31\ Tenn. Comp. R. & Regs. 0880-02-.14 SPECIALLY REGULATED
AREAS AND ASPECTS OF MEDICAL PRACTICE. [Omitted text of guidelines
for brevity.]
---------------------------------------------------------------------------
Exclusion of the Respondent's Testimony
The Government objected to the Respondent's testimony *\S\ because
prior to the hearing Respondent identified that he may testify
regarding the material falsification allegation, but said he would not
testify regarding the prescribing allegations as he has another matter
pending. However, at the hearing, the Respondent sought to present
testimony regarding the allegations surrounding his prescribing. He did
not offer testimony regarding the material falsification allegation.
[The ALJ permitted all portions of the Respondent's testimony that
could have been reasonably anticipated by the Government and I have
considered Respondent's testimony in reaching my decision. I find it
unnecessary to reach any further conclusions and have omitted the
remainder of the ALJ's analysis for brevity, as the Government did not
take exception to the ALJ's ultimate decision.] 32 33
---------------------------------------------------------------------------
*\S\ Text omitted for brevity.
\32\ [Omitted original text in which footnote appeared.]
\33\ [Omitted original text in which footnote appeared.]
---------------------------------------------------------------------------
Accurate and Complete Medical Records
The Government alleges that the Respondent failed to maintain
accurate and complete medical records for each of the subject patients,
as mandated by the relevant Tennessee regulations and standard of care.
The medical records contain the results of physical examinations and
other tests, which did not occur on the reported dates. The records are
rife, across all of the subject patients, with identical findings,
suggesting the subject examinations either did not take place, or the
results were not reported accurately.
In explaining the identical anxiety and insomnia indications
written in each of his patients' charts to justify benzodiazepines, the
Respondent testified that his patients exhibited the same symptoms
which is common among anxiety patients. However, the fact that UC's
chart reflected that he had the same anxiety indications and other
indications identical to the other five patients, despite the fact that
he testified credibly that he did not complain of any anxiety symptoms,
greatly reduces the credibility of the Respondent's subject
explanations. Tr. 79-80. Indeed, most of the indications within UC's
chart were unreported by him.\34\ UC reviewed Government Exhibit 5 and
noted that he was not asked about any of the reported symptoms. Tr. 81.
As to why individual patients had the same indications within the chart
for long periods of time, the Respondent maintains that the subject
record findings were carried forward from prior tests, as permitted by
the Tennessee standard of care. [However, Dr. Kennedy testified,
``there is no regulation anywhere that allows a physician [to] document
physical exam findings that he did not perform. That's not acceptable
under any regulations.'' Tr. 652.]
---------------------------------------------------------------------------
\34\ UC noted that despite his records stating that ``[UC] . . .
has had a history of insomnia and anxiety for several years,'' he
did not report anxiety symptoms of shortness of breath, of having
palpitations, sweating, dizziness, or shaking. Tr. 79-80; GX 5. The
medical record also reflects that he had a headache that day,
despite the fact that UC did not report having a headache,
dizziness, nausea, or vomiting. Tr. 80; GX 5. No one questioned UC
as to whether he had abdominal pain, diarrhea, and constipation. Tr.
80-81.
---------------------------------------------------------------------------
Similarly, the Respondent justified reporting test results when no
tests occurred, as he claimed was permitted by the Tennessee standard.
Prior test results were simply carried forward within the electronic
medical record. I credit Dr. Kennedy's opinion that reporting test
results purported to have occurred on a particular date, which did not
then occur, is contrary to the Tennessee standard of care. Even a
casual review of the relevant Tennessee regulations reveals the
prominence of the Tennessee physician's obligation to accurately
document. He is required to establish a ``written treatment plan
tailored for the individual needs of the patient'' that considers the
patient's ``pertinent medical history and physical examination as well
as the need for further testing, consultation, referrals, or use of
other treatment modalities.'' It also requires the physician to perform
a ``documented periodic review of the care . . . at reasonable
intervals,'' and ``keep [c]omplete and accurate records of the care.''
Id. at 0880-02-.14(6)(e)(3)(ii)-(v).
Common sense itself would refute the Respondent's position.
Indications and exam results carried forward, perhaps for months or
even years, defeats the whole purpose of medical records, which is to
inform the practitioner and other potential treating practitioners of
the patient's true and present condition, progression of disease or
efficacy of treatment. [Dr. Kennedy testified that
[[Page 3009]]
here the documentation did not ``make sense'' and was ``in conflict,''
which ``present[s] a dangerous situation'' for ``other people who look
at [the records].'' Tr. 353. Based on this testimony, one could
conclude that wrong records are worse than no records at all, as they
would mislead other treating practitioners. And as Dr. Kennedy
testified, here ``you have a medical record which shows consistently
documentation . . . that did not occur, that is outside the scope of
acceptable medical practice, and it does not support legitimate
prescribing of scheduled agents.'' Tr. 652.]
The Respondent has conceded there are factual errors in the subject
records. Although UC's chart contains an entry that his pharmacy
printout was reviewed, the Respondent conceded that no pharmacy
printout was reviewed and that such entry was in ``error.'' Tr. 631-32;
GX 5 at 6. M.H.'s chart contains the inconsistent finding of long-term
insomnia, but with an entry of sleeping well. Tr. 640-41; GX 15 at 47-
48. The Respondent conceded they were inconsistent entries. Tr. 641.
Additionally, while M.W.'s chart reflects he had been dismissed, M.W.
continued to be seen for months afterwards, without any further
explanation documented in the record. Tr. 259-60. And, Respondent
reported a ``history of insomnia for several years'' for M.H.; however,
this note first appears 19 months into treatment. GX 15; Tr. 49.
Additionally, there are conflicts between the Respondent's written
notes and the electronic medical records. Documents UC filled out are
missing from his chart that was seized from the Respondent. The
electronic medical record for a visit by M.W. does not contain the
handwritten information recorded in GX 10 at 8. Tr. 250-51; GX 10 at 9.
Instead, the results of the physical exam mirror those findings made
for UC, rendering M.W.'s chart not credible. Tr. 251-52. The physical
exam notes written for C.F. revealed essentially normal findings,
however the electronic records for this visit failed to include these
findings. Tr. 271; GX 11 at 69. Instead, under physical exam, the same
language that is duplicated so often in the records, appears. Tr. 272.
Dr. Kennedy noted the hand-written exam notes for M.H. did not appear
in the electronic medical records. Tr. 325-36; GX 7 at 68. Instead the
same physical exam notes duplicated throughout the records appear. Tr.
336, 351. So, at times, verbatim records were repeatedly and
inaccurately inputted into the electronic medical records when actual,
accurate indications were available.
Dr. Kennedy noted the actual pain level was left blank at nine
consecutive encounters with B.C., suggesting it was being added later
and that the record was being fabricated. Tr. 294-95; GX 13 at 159; GX
14 at 8.
For these reasons and those discussed below, I find the Government
has sustained its burden in proving the Respondent failed to maintain
accurate and complete medical records as to the subject patients, in
violation of TENN. COMP. R. & REGS. Rule 0880-02-.14 (6)(e).*\T\ [I
further find that each of the relevant prescriptions at issue in this
matter were issued outside the usual course of professional practice
and beneath the standard of care due to Respondent's failure to
maintain complete and accurate records.]
---------------------------------------------------------------------------
*\T\ Omitted for brevity.
---------------------------------------------------------------------------
Undercover
The Government alleges the Respondent failed to perform an adequate
physical exam; take an adequate medical history; assess UC's pain,
physical and psychological function; assess the patient's history and
potential for substance abuse, coexisting diseases and conditions, and
the presence of a recognized medical indication for the use of
oxycodone; and failed to create a legitimate written treatment plan for
UC's individual needs or to discuss the risks and benefits of the use
of oxycodone with UC. At three level one visits, the chart falsely
reflects the results of physical exams, which did not occur. The
Government alleges the Respondent's continued prescribing of controlled
substances to UC was without a legitimate medical purpose and/or
outside the usual course of professional practice.
Dr. Kennedy reviewed the chart and the undercover videos for UC,
the undercover agent. Tr. 216-17, 363; GX 6. Dr. Kennedy acknowledged
that in scheduling the first visit, the Respondent's staff instructed
UC to bring certain medical records to his first visit, the previous
three physician notes, his discharge summary, the record of the
previous three months prescriptions and an MRI, an appropriate protocol
in Dr. Kennedy's opinion. Tr. 364-65; GX 3 at 1.
The Respondent testified that he took a medical history, a
condition-specific physical exam for low back pain, and reviewed the
MRI (GX 6) of UC. Tr. 575-80.\35\ The Respondent agreed that he spent
no more than fifteen minutes with UC in the examination room. Tr. 621.
The Respondent maintains that he performed the required assessments
related to pain, physical and psychological function, and history and
potential for drug abuse. Tr. 582. This involved reviewing the
paperwork UC filled out, authenticating that paperwork, the triage of
UC by staff, UDS, and a final review of the paperwork by the Respondent
with the patient. Tr. 583, 584. UC recalled the Respondent going over
his paperwork with him, but could not remember the extent of the
review. According to UC, the triage by other staff was minimal,
sporadic or non-existent. Tr. 59. UC cited Dr. Morgan, who did not
exist, in his medical history paperwork, yet the staff did not discover
that fact. None of UC's paperwork could be authenticated, as designed.
UC's history was similarly designed to be a ``dead end.'' Tr. 238.
[Accordingly, I find Respondent's testimony that he authenticated UC's
paperwork to lack credibility.] There was no review of UC's
psychological functioning, although he was diagnosed with anxiety.\36\
The Respondent's instant claims are belied by the record.
---------------------------------------------------------------------------
\35\ The Respondent noted that his physical exam of C.R. was not
captured by the video of the encounter. The camera was pointed at
the wall. Tr. 581-82.
\36\ Where practitioner asked his patient whether there was
``any other medication he took for anxiety,'' and where the
practitioner made no effort to determine the extent of the patient's
symptoms before prescribing Xanax to him, the practitioner was not
engaged in the legitimate practice of medicine but instead was
dealing drugs. Henri Wetselaar, M.D., 77 FR 57,126, 57,132 (2012).
---------------------------------------------------------------------------
The Respondent explained that a patient's pain is very subjective.
After reviewing his paperwork, including the MRI, examining UC and
speaking with him, the Respondent claimed that he had no reason not to
treat him as someone who has genuine pain. Tr. 588. UC's statement that
he had used controlled substances for his pain and that ibuprofen was
not working supported the conclusion that his pain was long standing,
and warranted a Schedule II medication. [Omitted for relevance.]
Dr. Kennedy opined that UC's medical chart did not justify the
prescribing of controlled substances.\37\ Tr. 230-31, 240; GX 18 at 1,
3. Although there was an actual MRI report of UC, Dr. Kennedy found the
MRI report internally inconsistent [which Dr. Kennedy testified should
have caused Respondent to question the MRI.] Tr. 387-94. Dr. Kennedy
opined that it
[[Page 3010]]
would be outside the usual course of professional practice to prescribe
controlled substances based on this MRI alone.*\U\ Tr. 483-86.\38\ UC
was being treated for complaints of back pain. However, Dr. Kennedy
opined that the physical exam detailed in the chart was not sufficient
under Tennessee standards, and the exam that was performed revealed,
essentially, a normal back. Tr. 217, 231, 237, 396-97, 440. On
rebuttal, Dr. Kennedy reiterated this assessment after listening to the
Respondent's explanation. Tr. 651-52.
---------------------------------------------------------------------------
\37\ The Respondent cautioned that in reviewing his electronic
medical record, it often referred to other records. For example,
under history of present illness (HPI), he would often reference the
initial encounter paperwork, as included by reference, in the
electronic record. Tr. 592.
*\U\ This sentence has been modified for clarity.
\38\ The Agency has previously found based on credible expert
testimony that relying exclusively on MRI results for prescribing
controlled substances is unprofessional conduct in the applicable
state. Zvi H. Perper, M.D., 77 FR 64,131, 64,140 (2012).
---------------------------------------------------------------------------
The Respondent explained his treatment of UC. After the UC filled
out extensive paperwork, the initial examination by the Respondent
consisted of observing UC, touching his back and causing the patient to
lift his leg. Tr. 217-18, 359-60; GX 6 at 6. Dr. Kennedy noted the
taking of vital signs and a general exam within the chart; however, he
observed that from viewing and listening to the video of this visit,
such exam was not performed as described, or not performed at all. Tr.
218-19, 379-81; GX 6, 4.\39\ The prior medical history reported by UC
was facially suspicious and constituted a red flag. Tr. 238. UC
reportedly came from a clinic, which had been shut down, and provided
medical records from a Nurse Practitioner whose license had been
suspended. Tr. 238. The Respondent conceded UC was a challenge, as the
clinic he reported had been closed, and he could not obtain the
pharmacy information, so the Respondent could not verify that source.
Tr. 583-85. As UC's prior medical records could not be confirmed, the
Respondent claimed that he prescribed a dosage appropriate to a patient
just starting opioid treatment. Tr. 589-90.
---------------------------------------------------------------------------
\39\ The Agency has previously found that falsifying a patient's
medical record to indicate that respondent performed a physical exam
but where video/audio recordings show that a physical was never
conducted demonstrate that respondent knowingly violated the CSA.
Jeri Hassman, M.D., 75 FR 8194, 8236 (2010); Bernard Wilberforce
Shelton, M.D., 83 FR 14,028, 14,042 (2018).
---------------------------------------------------------------------------
The Respondent expected his patients to be honest and truthful with
him consistent with the DEA Physician's Manual, which requires patients
to be honest with their doctors. Tr. 586-87.\40\ In his Post-hearing
Brief, the Respondent continues to complain of the use of an undercover
agent, who operated under ``false colors'' to ensnare the Respondent,
and his disappointment that the Tribunal does not share his sentiment.
The fact of the matter is, there is nothing illegal or improper
regarding the Government's use of undercover agents.\41\ Even if I
shared the Respondent's sentiment, and opined that the use of
undercover agents was somehow unfair, this is not a court of
equity.\42\ We operate strictly by statute and regulation [and here the
evidence clearly establishes that Respondent's prescribing to UC was
outside the usual course of professional practice and beneath the
standard of care in violation of the CSA and its implementing
regulations.]
---------------------------------------------------------------------------
\40\ ``A practitioner who ignores the warning signs that her
patients are either personally abusing or diverting controlled
substances commits `acts inconsistent with the public interest,' 21
U.S.C. 824(a)(4), even if she is merely gullible or na[iuml]ve.''
Krishna-Iyer, M.D., 74 FR 460 n.3.
\41\ [Omitted for relevance.]
\42\ Administrative Law Judges of the DEA ``lack the authority
to exercise equitable powers'' in determining whether a registration
is consistent with the public interest. The Main Pharmacy, 80 FR
29,022, 29,024 (2015).
---------------------------------------------------------------------------
Dr. Kennedy opined that UC's obfuscation, false and misleading
statements to the Respondent and staff, did not relieve the
Respondent's obligation to investigate any suspicious circumstances.
Tr. 375-78, 382. The Respondent misperceives his role. [Omitted for
relevance.] Physicians must be wary of patients seeking controlled
substances for abuse and diversion. Although the Respondent's staff was
suspicious of UC's prior records, as they appeared to have been
altered, their concern appeared to be that the UC was perhaps law
enforcement, ``try[ing] to bring the Respondent down,'' rather than
someone attempting to divert or abuse controlled substances. UC
presented as a patient with no verified history, his paperwork
contained indications of alteration, he complained of pain without
overt indications; yet, the Respondent opined that the record supported
his conclusion that UC was legitimately in pain. Dr. Kennedy disagreed
and opined that it is the practitioner's responsibility to investigate
suspicious circumstances and to resolve them prior to prescribing
controlled substances.
Dr. Kennedy noted that the physical exam included in this first
visit by UC was repeated verbatim in most of the approximately twenty
charts he reviewed. Tr. 220; GX 7 at 65 (M.B.), GX 9 at 69 (M.W.). The
Respondent explained that he performed a physical exam at the initial
visit of each of his patients, as required by the Tennessee pain
management guidelines. Tr. 594. Physical exams thereafter are at the
discretion of the physician. Tr. 594. Although UC had five visits to
the clinic, only two involved encounters with the Respondent. The other
three visits were ``level one'' visits, in which UC met with the
Respondent's staff only. Tr. 622-28, 645-50. Although the medical
records reflect a physical examination took place at the level one
visits, there was no physical exam. Instead, the Respondent explained
he and his staff had carried forward results from prior examinations to
later visit records with new findings added, which Dr. Kennedy opined
was not permissible. Tr. 623-28; supra ``The Analysis, Accurate and
Complete Medical Records.''
Dr. Kennedy noted UC's chart identified him with a ``long-standing
history of insomnia and anxiety,'' however the chart contained no
examination that would support such findings. Tr. 233-34; GX 5 at 4.
Additionally, the reported symptoms of the anxiety finding,
``palpitations, sweating, dizziness, shaking'' was repeated almost
universally throughout the medical records reviewed as to patients
diagnosed with insomnia and anxiety. Tr. 233-34. Similarly, the visit
of October 17, 2017, by UC contains extensive medical findings, but the
video of that visit does not support those findings. Tr. 235-37; GX 5
at 5. The video does reveal the Respondent asking UC, ``how is your
sleep'' to which UC responds, ``not good.'' Tr. 236. The Respondent
then prescribes Elavil, or amitriptyline [which is not a controlled
substance and is not at issue in this case.] Tr. 236. Dr. Kennedy made
a similar observation as to extensive medical findings on subsequent
visits in which UC was not seen by the Respondent. Tr. 235-37; GX 5 at
3-5. Although the medical records state that a physical examination
took place at the level one visits when no physical examination
occurred, the Respondent explained that it was permissible in medical
record-keeping to carry forward results from prior examinations to
later visit records, with new findings added. Tr. 623-28. Dr. Kennedy
disagreed, noting that it is never permissible for charts to reflect
examination results, when no exam occurred. Tr. 652-53. At UC's second
visit, he was called back to the triage room where the nurse asked him
his weight to which he replied, ``210,'' and if his blood pressure was
ok to which he responded, ``yes.'' Tr. 59. He was not weighed, nor was
his blood pressure taken. Dr. Kennedy did not believe UC's chart
reflected the Respondent maintained a truthful and accurate record of
the treatment. Tr. 232; GX 3; 4. I credit Dr. Kennedy's
[[Page 3011]]
opinion regarding the results of non-existent tests.
On the basis of the deficient physical exam, Dr. Kennedy opined
that prescribing controlled substances to UC was not justified.
Although the Respondent prescribed a much lower MME than UC had
purportedly been on before, it was not consistent with the Tennessee
standard, which would require observation, looking for spasms, lumbar
range of motion maneuvers, straight leg raise test, neurologic exam and
motor deficits. Tr. 221-25, 239, 382-83; GX 5 at 6. Other deficiencies
in the records that caused the controlled substance prescriptions for
UC to be unjustified included the deficiency in the prior medical
records provided by UC. Tr. 228. On a positive note, UC's chart
revealed an exploration of alternate treatment by prescribing
Meloxicam, and offering injections. Tr. 228-29.
The Respondent testified he prepared an adequate written treatment
plan with appropriate treatment goals and therapy. Tr. 590-91. However,
Dr. Kennedy opined UC's chart did not include an adequate treatment
plan. Tr. 229. The records reveal a deficient discussion regarding the
risks and benefits of controlled substance medication. Tr. 231. Dr.
Kennedy deemed the diagnosis of degenerative disc disease unjustified
on the basis of the chart and MRI. Tr. 240-42; GX 5 at 2, 6; GX 6 at
12. I find Dr. Kennedy's assessments credible.*\V\
---------------------------------------------------------------------------
*\V\ Omitted. The ALJ found that the diagnosis of C.R. with
insomnia was appropriate. The issue relevant to this case is whether
or not there was a recognized medical indication for the use of
oxycodone. The medication prescribed as a result of the insomnia
diagnosis was not a controlled substance and was not directly at
issue in this case. Accordingly, it is not necessary to determine
whether the records contained sufficient evidence to support the
insomnia diagnosis, because it is not relevant to the case.
---------------------------------------------------------------------------
[In accordance with Dr. Kennedy's credible and unrebutted expert
testimony, and for the reasons above, I find that the three oxycodone
prescriptions Respondent issued to UC were issued outside the usual
course of professional practice and beneath the standard of care. The
basis for Dr. Kennedy's opinion and my finding is that Respondent
failed to: Take an adequate medical history including an assessment of
UC's pain history and potential for substance abuse; perform and
document an adequate physical examination; and create a legitimate
written treatment plan for UC's individual needs or to discuss the
risks and benefits of the use of oxycodone with UC. Additionally, and
in accordance with Dr. Kennedy's testimony, I find that the relevant
prescriptions issued by Respondent were outside the usual course of
professional practice and beneath the standard of care due to
Respondent's failure to maintain complete and accurate records for UC.]
Allegations Common to the Five Remaining Patients
With respect to the Respondent's treatment of M.H., C.F., M.P.,
B.C., and M.W. (``the five patients''), the Government alleges the
prescriptions for controlled substances were not issued in the course
of professional practice inasmuch as the Respondent failed to: (1) Take
an adequate medical history; (2) perform a sufficient physical
examination; and (3) perform an adequate ``assessment and consideration
of the (patients'] pain, physical and psychological function, any
history and potential for substance abuse, coexisting diseases and
conditions, and the presence of a recognized medical indication for the
use of a dangerous drug or controlled substance.'' The Respondent also
failed to create a ``written treatment plan tailored for the individual
needs'' of each of the five patients that considered each of the
patient's ``pertinent medical history and physical examination, as well
as, the need for further testing, consultation, referrals, or use of
other treatment modalities.'' The Respondent also failed to: (1)
``discuss the risks and benefits of the use of controlled substances''
with patients M.H., C.F., M.P., B.C., and M.W.; (2) conduct a
``documented periodic review of the[ir] care . . . at reasonable
intervals in view of the individual circumstances'' of each patient;
and (3) keep ``(c]omplete and accurate records of the care provided.''
As such, the Respondent's conduct violated TENN. CODE ANN. Sec. 63-6-
214(b)(12) and TENN. COMP. R. & REGS. 0880-02 .14(6)(e)(3)(i)-(v).
The Government further alleges the prescriptions the Respondent
issued to M.H., C.F., M.P., B.C., and M.W. failed to comply with
Tennessee state law in that they did not conform to accepted and
prevailing medical standards in Tennessee, and thus, were issued
outside the usual course of professional practice. The Respondent's
conduct, viewed as a whole, ``completely betrayed any semblance of
legitimate medical treatment.'' Jack A. Danton, D.O., 76 FR 60,900,
60,904 (2011).
By issuing these prescriptions for controlled substances, the
Respondent failed to take reasonable steps to guard against diversion
of controlled substances. See David A. Ruben, M.D., 78 FR at 38,382;
Beinvenido Tan, M.D., 76 FR 17,673, 17,689 (2011); Dewey C. Mackay,
M.D., 75 FR 49,956, 49,974 (2010); Physicians Pharmacy, L.L.C., 77 FR
47,096 (2012).
Allegations as to Specific Patients
As to the allegations regarding each of the subject patients, in
his Posthearing Brief (PHB), the Respondent argues the Government's
case suffers weakness by the Government's failure to present the
relevant patients' testimony, testimony of relevant pharmacists, any
evaluation regarding the volume of the Respondent's prescriptions in
relation to other physicians, the absence of any complaints to law
enforcement, and no physician testimony that the subject patients were
seeking detox due to the Respondent's excessive prescribing.*\W\
---------------------------------------------------------------------------
*\W\ It is also noted that Respondent did not offer any of this
testimony in an attempt to rebut the Government's case.
---------------------------------------------------------------------------
In the context of the allegations and evidence, none of the above
constitutes necessary evidence to prove the allegations. Indeed, I
struggle to see any relevance to such evidence in the context of the
allegations made.
Patient M.W.
The Government alleged that the Respondent regularly and improperly
issued prescriptions for large quantities and dosages of oxycodone,
oxymorphone, alprazolam, and carispoprodol to Patient M.W. The
Government further alleged that the initial physical examination and
medical history did not justify the continued prescribing of controlled
substances and the subsequent physical examinations did not
meaningfully evidence any chronic pain condition. The Government
alleged that the Respondent failed to: (1) Order and obtain diagnostic
studies; and (2) adequately address numerous instances in which the
patient had inconsistent drug screens indicating possible diversion,
abuse, and/or use of illegal controlled substances. The Government
further alleged that much of the medical record for M.W. was fabricated
and appeared to be copied from records of other patients, whose records
contained identically worded assessments. Finally, the Government
alleged the Respondent documented that the patient provided ``informed
consent'' when no informed consent document could be located.
Additionally, the Government alleged the Respondent failed to address
substantial evidence that M.W. was engaged in abuse and/or diversion of
controlled substances, a violation of TENN. CODE ANN. 63-6-214(b)(13).
In support, the Government offered the testimony of its expert, Dr.
Kennedy.
[[Page 3012]]
Dr. Kennedy identified his ``chart review'' for M.W. Tr. 243-44; GX 9,
10. M.W. was diagnosed with low back pain, yet Dr. Kennedy credibly
opined that the records did not support such diagnosis. Tr. 245-46; GX
9 at 14; GX 10 at 3. The notes did reference back to M.W.'s initial
encounter. Tr. 441. The Respondent testified M.W. was first seen in
January 2013. Tr. 595. M.W. was a gunshot victim to whom the Respondent
prescribed alprazolam. This, according to Respondent, was based on the
history and physical exam. Tr. 593, 635-36; GX 9 at 69. The Respondent
claimed he obtained a medical history, conducted a physical exam,
performed an adequate pain, physical, and psychological assessment,
history and potential for substance abuse. Tr. 596. The Respondent
claimed that he prepared a written treatment plan. Tr. 601.
Yet, Dr. Kennedy countered there were no findings in the record
that would support a chronic pain condition and justify prescribing
controlled substances. Tr. 246-47. Dr. Kennedy found no credible
physical exam to justify the diagnosis. Tr. 247, 265. Dr. Kennedy
testified that the Respondent did not assess M.W.'s pain level,
physical and psychological functioning, history, potential for drug
abuse, or coexisting diseases. Tr. 265. The Respondent did not follow a
legitimate written treatment plan. The physical exam findings were
generally normal findings, except for limited range of motion at the
lumbar spine. Tr. 247; GX 10 at 7. M.W. reported a pain level, at
worst, at 10 of 10, and at best, 6 of 10. Tr. 248-49; GX 9 at 19; GX 10
at 8. M.W.'s reported pain level was inconsistent with the generally
normal results of the physical exam. Tr. 249-50. The electronic medical
record for this visit does not contain the handwritten information
recorded in GX 10. Tr. 250-51; GX 10 at 9. Instead the results of the
physical exam mirror those findings made for UC, rendering M.W.'s chart
not credible. Tr. 251-52. This finding was bolstered by ``wildly''
inconsistent UDS results. Tr. 252-55; GX 9 at 2-4, 9-11, 84, 96, 102.
After a series of inconsistent UDS, the Respondent noted in M.W.'s
chart that M.W. was dismissed from pain management with one-month
notice. Tr. 258; GX 9 at 84. Yet, at the same visit in which he had
been notified he will be dismissed, the history of present illness
reports the patient is compliant and consistent. Tr. 258. Dr. Kennedy
deemed the chart not credible, accordingly. Tr. 259. However, despite
being dismissed, M.W. continued to be seen for months afterwards
without any further explanation in the medical records. Tr. 259-60.
The Respondent explained that the evaluation of the patient's
potential for drug abuse is an ongoing evaluation with UDS, involving
office screens, confirmatory lab screens, and pill counts. Tr. 596-98,
600. Respondent testified that once a lab-confirmed inconsistent UDS is
discovered, the Respondent initiates a dismissal process. Tr. 598-600.
The Tennessee pain management guidelines leave it to the physician's
discretion on the handling of confirmed inconsistent UDS results. Tr.
598-99.\43\ The Respondent gives the patient a month to come into
compliance. Tr. 600. If he has a consistent UDS within the month, the
patient is permitted to remain in treatment. Tr. 601. The Respondent
claimed was able to bring M.W. back into compliance through counseling,
however, the chart only documents that the patient was counseled as to
the inconsistent UDS without identifying any specific information. Tr.
637-38. Dr. Kennedy later conceded that M.W. was reinstated consistent
with the Respondent's described office protocol. Tr. 459-60. The
Respondent continued to prescribe him alprazalam, amitriptyline,
oxycodone, oxymorphone and Soma. As noted earlier, Respondent's
documentation of these events and his handling of M.W.'s inconsistent
UDS was clearly outside the Tennessee standards.
---------------------------------------------------------------------------
\43\ The Respondent's explanation of the Tennessee standards was
admitted, not as expert testimony, as the Respondent had not been
qualified as an expert to opine on the Tennessee standards, but as
reflecting his understanding of the guidelines to explain why he
took or declined to take certain action.
---------------------------------------------------------------------------
Regarding the alprazolam prescriptions, Dr. Kennedy found it
unjustified based on the information supporting the anxiety diagnosis.
Tr. 260-61, 442-44; GX 9 at 85. Dr. Kennedy noted the indications for
anxiety were not supported by the findings within the chart, and
mirrored those in the charts for UC and other patients. Tr. 261-62. In
his PHB, the Respondent argued that Dr. Kennedy conceded a gunshot
victim would have PTSD; however, I credit Dr. Kennedy's opinion that
the chart did not justify the alprazolam prescription.
Although Dr. Kennedy opined M.W. should have been physically
examined periodically during his treatment, the charts suggest he was
not examined again following his first examination. Tr. 262. Dr.
Kennedy further opined that as M.W. was a 25-year-old diagnosed with
degenerative disc disease, the Tennessee standards would require
diagnostic testing, such as an MRI to confirm the diagnosis. Tr. 262,
447-48. Dr. Kennedy found M.W.'s chart ``not credible and fabricated.''
Tr. 263-64, 266; GX 10 at 5, 23. He noted that of 93 of 98 total visits
shared the identical findings for the physical exams and ROS. Tr. 264.
Similarly, Dr. Kennedy found the diagnosis of insomnia not credible.
Tr. 264. A finding of drug abuse and chemical dependency would have
been supportable, but such indications were not sufficiently addressed
by the Respondent. Tr. 264-65. The credible findings within M.W.'s
chart did not support the prescribing of controlled substances, and the
subject prescriptions were issued outside the usual course of
professional practice. Tr. 267-68. I credit Dr. Kennedy's opinions in
finding the Respondent's subject actions fell below the Tennessee
standards, and the controlled substances were prescribed outside the
Tennessee standards.
[In accordance with Dr. Kennedy's credible and unrebutted expert
testimony, and for the reasons above, I find that the twenty-six
identified prescriptions for alprazolam, carisoprodol, oxycodone, and
oxymorphone that Respondent issued to M.W. were issued outside the
usual course of professional practice and beneath the standard of care.
The basis for Dr. Kennedy's opinion and my finding is that Respondent
failed to: Take an adequate medical history including an assessment of
M.W.'s pain history and potential for substance abuse; perform and
document an adequate physical examination; and create a legitimate
written treatment plan for M.W.'s individual needs. Tr. 265. In
accordance with Dr. Kennedy's testimony, I further find that the
relevant prescriptions issued by Respondent were outside the usual
course of professional practice and beneath the standard of care due to
Respondent's failure to maintain complete and accurate records for M.W.
Tr. 265-66. Finally, in accordance with Dr. Kennedy's testimony, I find
that M.W. exhibited evidence of drug abuse or chemical dependency that
was not adequately addressed by Respondent. Tr. 264-64.]
Patient C.F.
The Government alleged that from August 2014 through August 2018,
the Respondent regularly issued prescriptions for oxycodone and
alprazolam to C.F. The Government further alleged that no credible
physical examination had been performed on C.F. and that the exam
results, as well
[[Page 3013]]
as medical history, did not justify the continued prescribing of
controlled substances. The Government further alleged that no
meaningful follow-up physical exam was repeated, that supported
diagnostic studies were not ordered, and that the Respondent failed to
determine a chronic pain etiology. The Government further alleged that
the Respondent ignored suspicious drug screen results which indicated
illegal drug use. The Government alleged that much of the medical
record for C.F. was fabricated and seemed to be copied from records of
other patients whose records contained identically worded assessments.
Although the Respondent documented that the patient provided ``informed
consent,'' no informed consent document could be located. Additionally,
the Government alleged the Respondent failed to address substantial
evidence that C.F. was engaged in abuse and/or diversion of controlled
substances, a violation of TENN. CODE ANN. 63-6-214(b)(13).
The Respondent explained that Patient C.F. had a stab wound to the
chest, requiring heart surgery, resulting in residual chronic pain. Tr.
601. The Respondent reported he took a medical history, performed a
physical exam, an adequate pain, physical and psychological
assessments, and evaluated her history and potential for substance
abuse. Tr. 601-02. The Respondent noted that he had the benefit of
confirmatory records from Vanderbilt University Medical Center. Tr.
602.
Dr. Kennedy testified that the chart revealed C.F. was being
treated for chronic pain due to trauma, and unspecified inflammatory
polyarthropathy. Tr. 268; GX 12. Dr. Kennedy conceded C.F. had suffered
stab wounds to the chest requiring open heart surgery, which can cause
long-term neuropathic pain. Tr. 451-53. Although in his PHB, the
Respondent characterizes Dr. Kennedy's criticism of the Respondent's
subject treatment as failing to order tests, Dr. Kennedy had more
extensive criticism than that. Dr. Kennedy opined that the history,
physical exams, the pain and physical and psychological functioning,
the potential for substance abuse, written treatment plan, and
alternate treatment considerations were each inadequate, and did not
justify the controlled substance prescriptions.\44\ Tr. 269-70, 285,
455; GX 11 at 106; GX 12, at 7. Dr. Kennedy noted the Respondent did
not discuss the risks and benefits of controlled substance medications.
Tr. 285. The physical exam notes revealed essentially normal findings,
however the electronic records for this visit failed to include these
findings. Tr. 271; GX 11 at 69. Instead, under physical exam, the same
language duplicated so often in the records, is included. Tr. 272.
There were no credible follow up physical exams, supporting studies,
and no reasonable pain etiology. Tr. 272; GX 12 at 5, 6. The ROS
indications were identically repeated in other charts. Tr. 272-73. Dr.
Kennedy noted that the language in the general exam, ``patient is alert
and oriented'' is similarly repeated 102 times throughout the records.
Dr. Kennedy reported inconsistent UDSs for C.F., collected on July 2,
2018, and thereafter. Tr. 273-80, 282; GX 11 at 9, 23, 24, 25, 28, 33,
44, 47, 54, 69, 78, 111, 117; GX 20. Even more concerning, C.F.'s UDS
result was negative for all of the medications she was prescribed. Tr.
275-77. C.F. also tested positive for cocaine and marihuana. Tr. 277,
280. An inconsistent drug screen on July 26, 2017, is not mentioned in
the medical records. Tr. 288-89. Although the records repeatedly noted
that, ``patient counseled at length on unsatisfactory UDS,'' Dr.
Kennedy credibly testified that this was insufficient under Tennessee
standards to address C.F.'s drug abuse and diversion. Tr. 280, 284. I
credit Dr. Kennedy's assessment regarding the Respondent's deficient
handling of C.F.'s ongoing drug abuse and diversion.
---------------------------------------------------------------------------
\44\ The Agency has previously found based on the expert
testimony that where the respondent: (1) ``gave inadequate
examinations or none at all;'' (2) ignored the results of tests; and
(3) ``took no precautions against misuse and diversion'' of
controlled substances, the evidence established that the respondent
exceeded the bounds of professional practice. Carlos Gonzalez, M.D.,
76 FR 63,118, 63,141 (2011) (citing United States v. Moore, 423 U.S.
122, 135, 142-43 (1975)).
---------------------------------------------------------------------------
On May 3, 2017, C.F. tested positive for buprenorphine, a
medication typically used to treat opioid use disorder. Tr. 281-82. The
Respondent had not prescribed it. Although the Respondent explained
that the MED prescribed to C.F. was a relatively low dose, Tr. 603-05;
in light of C.F.'s continued drug abuse and diversion, Dr. Kennedy
opined that the Respondent continued to improperly prescribe controlled
substances without making a bona fide effort to cure C.F.'s addiction.
Tr. 284. I agree.
The Respondent prescribed alprazolam for anxiety and insomnia. Tr.
286; GX 11 at 39. However, the supporting indications are identical to
the other patients who were diagnosed with anxiety and insomnia. Tr.
286-87. The Respondent did not maintain complete and accurate records
for C.F. Tr. 286. Dr. Kennedy concluded that the controlled substance
prescriptions issued to C.F. were outside the usual course of
professional practice. Tr. 287. For the reasons detailed, I concur. I
credit Dr. Kennedy's expert opinions and find that the Respondent's
subject prescribing to C.F. was in violation of Tennessee regulations,
and below the Tennessee standards.
[In accordance with Dr. Kennedy's credible and unrebutted expert
testimony, and for the reasons above, I find that the sixteen
identified prescriptions for alprazolam and oxycodone that Respondent
issued to C.F. were issued outside the usual course of professional
practice and beneath the standard of care. The basis for Dr. Kennedy's
opinion and my finding is that Respondent failed to: Take an adequate
medical history including an assessment of C.F.'s pain history and
potential for substance abuse; perform and document an adequate
physical examination; and create a legitimate written treatment plan
for C.F.'s individual needs and discuss the risks and benefits of using
controlled substances. In accordance with Dr. Kennedy's testimony, I
further find that the relevant prescriptions issued by Respondent were
outside the usual course of professional practice and beneath the
standard of care due to Respondent's failure to maintain complete and
accurate records for C.F. Finally, in accordance with Dr. Kennedy's
testimony, I find that C.F. exhibited evidence of drug abuse or
chemical dependency that was not adequately addressed by Respondent.]
Patient B.C.
The Government alleges that from August 2014 through August 2018,
the Respondent regularly issued prescriptions for large quantities of
oxycodone, oxymorphone, alprazolam, and carisoprodol to B.C. The
Government further alleged that no credible physical examination had
been performed on B.C. and that the exam results, as well as medical
history, did not justify the continued prescribing of controlled
substances. The Government further alleged that no meaningful follow-up
physical exam was repeated, that confirmatory diagnostic studies were
not ordered, and that the Respondent failed to determine a chronic pain
etiology. The Government further alleged that the Respondent ignored
suspicious drug screen results which indicated illegal drug use. The
Government alleged that much of the medical record for B.C. was
fabricated and seemed to be copied from records of other patients whose
records
[[Page 3014]]
contained identically worded assessments. Although the Respondent
documented that the patient provided ``informed consent,'' no informed
consent document could be located.
Dr. Kennedy identified his summary chart for B.C. Tr. 289-90; GX
13; GX 14. B.C. was being treated for chronic pain syndrome. B.C. was
referred from the Clark County Jail, on December 19, 2012,\45\ a
potentially challenging patient. Tr. 458-59. Although not revealed in
the chart, Respondent testified that B.C. had previously been a patient
of the Respondent. The Respondent maintained that he took a medical
history, performed a physical exam, adequate pain, physical and
psychological assessments, and evaluated his history and potential for
substance abuse, and prepared a written treatment plan. Tr. 608.
---------------------------------------------------------------------------
\45\ The Respondent noted the pain management guidelines have
changed since then. Tr. 605. [It appears that Tennessee has been
regulating authority for physicians to prescribe for treatment of
pain since 2014. As the changes seem to have taken place well before
the prescribing of the controlled substances at issue in this case,
this information is not material to my decision.]
---------------------------------------------------------------------------
Dr. Kennedy disagreed, claiming the Respondent did not take an
adequate medical history. Tr. 304. Although a physical exam was
evident, Dr. Kennedy testified that it was insufficient and non-
supportive to justify prescribing the medications prescribed. Tr. 290-
91, 304; GX 13 at 169; GX 14 at 7; GX 22. Dr. Kennedy asserted the
Respondent did not make an adequate assessment of pain, and physical
and psychological function, of history of substance abuse, coexisting
diseases and conditions, written treatment plan or alternate
treatments. Tr. 304-06. He did not conduct any periodic reviews, or
discuss the risks and benefits of the use of controlled substances. Tr.
306. There were no radiologic studies ordered. Tr. 303. There were no
prior medical records ordered or obtained, but the records did include
hospital records. Tr. 303, 459-60. Although the Respondent described
the extensive forms each patient is required to fill out at the initial
visit, some of the described forms, which were referenced in B.C.'s
chart, were missing from the Respondent's records. Tr. 628-29; GX 13 at
5. The Respondent explained that some records were lost in 2014.\46\
Tr. 630. However, the missing records were not recreated despite B.C.
being a long-term patient. Tr. 630.
---------------------------------------------------------------------------
\46\ I ruled the evidence of lost files in 2014 inadmissible as
unnoticed and not reasonably anticipated by the Government,
representing surprise.
---------------------------------------------------------------------------
The Respondent explained why he obtained and kept pharmacy
printouts in his records. They are easier and quicker to obtain than
medical records. Tr. 606. The pharmacy printout informs how long the
patient has been prescribed medications, changes in dosage, and the
prescriber. Tr. 607.
Dr. Kennedy noted indications from the ROS were duplicated
throughout the records. Of 141 encounters, the ROS language was
duplicated 140 times, while the physical exam language was duplicated
134 times. Tr. 291-92. B.C. had serious health issues, including
Hodgkins lymphoma, a cancer of the lymphatic system. Tr. 293. Dr.
Kennedy identified a document in the chart indicating B.C. had been
dismissed from a prior physician, a clear red flag which was not
resolved. Tr. 293-94; GX 13 at 188.
Dr. Kennedy noted the actual pain level was left blank at nine
consecutive encounters, suggesting it is being added later, a further
indication of fabricated records. Tr. 294-95; GX 13 at 159; GX 14 at 8.
Dr. Kennedy opined the Respondent did not maintain accurate and
complete records. Tr. 306. One entry reveals, ``patient lied about his
prescriptions,'' an alarming red flag left unaddressed by the
Respondent. Tr. 296; GX 13 at 169. Despite noting that the ``patient
lied,'' the Respondent issued controlled medications and ``held'' up
UDS for a month. Tr. 297. This is outside the usual course of
professional practice. B.C. continued to have inconsistent UDS results,
which were insufficiently addressed by the Respondent. Tr. 297-98; GX
13 at 33, 79, 150, 155, 156, 158, 164, 165. The Respondent countered
that each of the Respondent's patient records contained the
instruction, ``rule out doctor shopping'', which was a prompt to review
the Tennessee PDMP to determine if the patient was obtaining controlled
substances from multiple physicians. Tr. 608. Although ruling out
doctor shopping is appropriate and necessary action, it does not excuse
the failure to adequately address B.C.'s drug abuse and other red
flags. I credit Dr. Kennedy's findings, and I find that the information
contained in B.C.'s chart did not justify the controlled medications
prescribed by the Respondent, nor support that they were issued in the
usual course of professional practice. Tr. 307-08.
[In accordance with Dr. Kennedy's credible and unrebutted expert
testimony, and for the reasons above, I find that the eighteen
identified prescriptions for alprazolam, oxymorphone, carisoprodol, and
oxycodone that Respondent issued to B.C. were issued outside the usual
course of professional practice and beneath the standard of care. The
basis for Dr. Kennedy's opinion and my finding is that Respondent
failed to: Take an adequate medical history including an assessment of
B.C.'s pain history and potential for substance abuse; perform and
document an adequate physical examination; and create a legitimate
written treatment plan for B.C.'s individual needs and discuss the
risks and benefits of using controlled substances. In accordance with
Dr. Kennedy's testimony, I further find that the relevant prescriptions
issued by Respondent were outside the usual course of professional
practice and beneath the standard of care due to Respondent's failure
to maintain complete and accurate records for B.C. Finally, in
accordance with Dr. Kennedy's testimony, I find that B.C.'s records
included unresolved inconsistent drug screens, a red flag that was not
adequately addressed by Respondent.]
Patient M.H.
The Government alleges that from August 2014 through February 2018,
the Respondent regularly issued prescriptions for large quantities of
alprazolam, carisoprodol, oxycodone, and oxymorphone to M.H. The
Government further alleges the Respondent diagnosed M.H. with ``chronic
pain syndrome'' even though the Respondent made no attempt to diagnose
a specific pain etiology. The Government further alleged that that the
Respondent failed to obtain diagnostic studies and current medical
records from M.H.'s other medical providers and that the results of the
physical examination and medical history did not justify the continued
prescribing of controlled substances. The Government alleged the
Respondent ignored a major surgical intervention that occurred in
September 2016 as well as an abnormal drug screen. As such, the
Government concluded that much of the medical record for M.H. was
fabricated and seemed to be copied from records of other patients whose
records contained identically-worded assessments. The Respondent also
documented that the patient provided ``informed consent'' when no
informed consent document could be located. The Government alleged
that, in some cases, the Respondent failed to repeat certain physical
exams after the initial encounter with M.H., despite the fact the
Respondent provided him with prescriptions for controlled substances
for more than three years.
The Respondent explained Patient M.H. presented with a post gunshot
wound to the abdomen and chronic low
[[Page 3015]]
back pain secondary to degenerative disc disease. Tr. 608. According to
Respondent, he had already been treated for pain management. He had a
history of extensive spinal surgery at Vanderbilt University Medical
Center, including a laminectomy. Tr. 609-11. The Respondent testified
that he prescribed a lower MME than the surgeon prescribed post-
operative at Vanderbilt. Tr. 611.
Dr. Kennedy identified his summary chart for Patient M.H. Tr. 309;
GX 15; GX 16. The chart reveals M.H. was being treated for chronic pain
syndrome. GX 15 at 62, 63. The physical exam indications are identical
to those repeated throughout the medical records and, in Dr. Kennedy's
opinion, do not support any chronic pain diagnosis. Tr. 311. The
records reveal M.H. suffered a gunshot wound in 2008, and although
serious, Dr. Kennedy opined that would not in itself justify pain
medication eight years later. Tr. 323. Dr. Kennedy assessed the
Respondent's treatment as outside the scope of acceptable medical
practice because the Respondent did not make an adequate assessment of
pain, and physical and psychological function, of medical history, of
history of substance abuse, coexisting diseases and conditions,
periodic review of care, written treatment plan or alternate
treatments. Tr. 312, 326-28. The Respondent did not conduct any
periodic reviews, or discuss the risks and benefits of the use of
controlled substances. Tr. 328. M.H. had inconsistent UDSs. Tr. 314-20;
GX 15 at 36, 39, 40, 47, 49, 53, 56, 63. Although several inconsistent
UDS were noted in the chart, there were typically no notes of
discussions. The Respondent failed to adequately address the UDS. Tr.
314-20.
During his treatment with the Respondent, M.H. underwent a serious
and complex spinal surgery, a major surgery. Tr. 320-22, 462-63; GX 15
at 26; GX 16, at 9. M.H. was seen by the Respondent the day after his
release from the hospital. GX 15 at 48. Despite his recent, major
surgery, there is no mention of the surgery in the encounter notes. Tr.
322-23. The encounter notes are identical to all the other encounter
notes for M.H. Tr. 323; GX 15 at 48. The Respondent conceded his
medical findings as to Patient M.H. for the visit just prior to M.H.'s
major back surgery are the same as the Respondent's findings for the
visit the day after the surgery. Tr. 637-38; GX 15 at 48-50. The
Respondent explained that the subject findings were based on
``history.'' Tr. 638. Put another way, Respondent carried forward the
exam indications from the pre-surgery visit to the post-surgery visit.
There is no updated physical exam, as Dr. Kennedy opined would be
required. Tr. 324. The PE and HPI notes are the same as those the four
months prior to the spinal surgery, which is not credible. Tr. 324-25,
491-92; GX 15 at 49, 51. Dr. Kennedy opined that the Respondent did not
maintain accurate and complete records as to M.H. Tr. 328. Dr. Kennedy
reviewed the prescriptions issued. Tr. 325; GX 19 at 1-13. He opined
that the chart, including the number of inconsistent UDS, reveals that
M.H. was addicted to controlled substances, yet the Respondent
continued prescribing them without making a bona fide effort to cure
the addiction. Tr. 325. The Respondent conceded the chart reports that
M.H. has been ``compliant,'' however, on the next page of the chart, it
reports M.H. had an inconsistent UDS. Tr. 638-40; GX 15 at 48-49. The
Respondent explained that the inconsistent UDS related to the point of
care test, not the confirmatory lab test, so the chart was accurate in
that instance. Tr. 640. However, even if the inconsistent UDS result
were at the point of care, as discussed supra, the record discloses
there were eight of them, some of which went completely unaddressed
within the records. I credit Dr. Kennedy's opinion that the
Respondent's failure to resolve the red flag arising from inconsistent
UDS rendered the subsequent prescribing outside the Tennessee standard
of care.
Dr. Kennedy opined the subject prescriptions were issued outside
the usual course of professional practice. Tr. 329-30, 493. I credit
Dr. Kennedy's findings, and find that the Respondent's controlled
substance prescribing were in violation of Tennessee regulations and
the Tennessee standards.
[In accordance with Dr. Kennedy's credible and unrebutted expert
testimony, and for the reasons above, I find that the approximately
fifteen identified prescriptions for alprazolam, oxycodone, and
oxymorphone that Respondent issued to M.H. were issued outside the
usual course of professional practice and beneath the standard of care.
The basis for Dr. Kennedy's opinion and my finding is that Respondent
failed to: Take an adequate medical history including an assessment of
M.H.'s pain history and potential for substance abuse; perform and
document an adequate physical examination; and create a legitimate
written treatment plan for M.H.'s individual needs and discuss the
risks and benefits of using controlled substances. In accordance with
Dr. Kennedy's testimony, I further find that the relevant prescriptions
issued by Respondent were outside the usual course of professional
practice and beneath the standard of care due to Respondent's failure
to maintain complete and accurate records for M.H. Finally, in
accordance with Dr. Kennedy's testimony, I find that M.H. exhibited
evidence of drug abuse or chemical dependency that was not adequately
addressed by Respondent.]
Patient M.P.
The Government alleges that from September 2016 through April 2018,
the Respondent regularly issued prescriptions for large quantities of
oxycodone and oxymorphone to M.P. The Government alleges that the
Respondent failed to request and obtain past medical records, the
Respondent failed to order any radiographic studies, and that the
physical examinations of M.P., including follow-up exams, were
substandard and not credible. The Government alleged that the
Respondent failed to document any evidence to support a pain etiology
and that the Respondent failed to properly address M.P.'s substance
abuse disorder despite the fact that she suffered a heroin overdose in
the Respondent's waiting room. As a result, the Government alleged
there were no objective findings to justify the continued prescribing
of oxycodone and oxymorphone. The Government alleges that much of the
medical record for M.P. was fabricated and seemed to be copied from
records of other patients whose records contained identically worded
assessments. The Respondent also documented that the patient provided
``informed consent'' when no informed consent document could be located
in the medical record. Additionally, the Government alleged the
Respondent failed to address substantial evidence that M.P. was engaged
in abuse and/or diversion of controlled substances, a violation of
TENN. CODE ANN . Sec. 63-6-214(b)(13).
The Respondent explained Patient M.P. was being managed for chronic
pain. In her initial visit, she reported conflicting information
regarding whether she had been in drug rehab treatment. Tr. 641-42; GX
7. The Respondent explained that he could only rely on the information
provided by the patient. Tr. 642. The Respondent claimed that he took a
medical history, performed a physical exam, adequate pain, physical and
psychological assessments, and evaluated her history and potential for
substance abuse, and prepared a written treatment plan. Tr. 615-17.
Dr. Kennedy countered, noting he reviewed the prescriptions issued.
Tr. 348-49; GX 21. He opined that the chart, including the number of
[[Page 3016]]
inconsistent UDS, reveals that M.P. was addicted to controlled
substances, yet the Respondent continued prescribing them without
making a bona fide effort to cure the addiction, until after she
overdosed on heroin. Tr. 348. The subject prescriptions, as well as
those prescribed to the other charged patients, were dangerous and
issued outside the usual course of professional practice. Tr. 352, 488-
89.
Dr. Kennedy reported M.P. was being treated for low back, neck, hip
and shoulder pain. Tr. 331; GX 8. She was later diagnosed with
degenerative disc disease and right shoulder pain. Although a physical
exam was performed, it was inadequate to substantiate the diagnoses.
Tr. 331-34, 339-40, 343; GX 7 at 2. A mechanical shoulder exam and
range of motion back and neck exam should have been performed. Dr.
Kennedy opined that Respondent did not make an adequate assessment of
pain, nor physical and psychological function, of medical history, of
history of substance abuse, coexisting diseases and conditions,
periodic review of care, written treatment plan nor alternate
treatments. Tr. 349-51. He did not conduct any periodic reviews, nor
discuss the risks and benefits of the use of controlled substances. Tr.
349-50. Dr. Kennedy stated that M.P.'s employment as a server, working
45-60 hours per week is inconsistent with her ``occupational
disability'' score of 9 or 10, a significant conflict. Tr. 344-45; GX 7
at 3, 9, 10. Dr. Kennedy noted the hand-written exam notes did not
appear in the electronic medical records. Tr. 325-36; GX 7 at 68.
Instead the PE notes duplicated throughout the records appears. Tr.
336, 351. The pain level is reported as 9, which is inconsistent with
the PE indications. Dr. Kennedy indicated notes generated at the
initial visit appeared to be a reminder to obtain certain prior medical
records from Dr. M. Tr. 337, 468; GX 7 at 1, 68. Those same notes
appear in the record repeatedly thereafter. Tr. 337; GX 7 at 59. Other
than the requested pharmacy report, the prior records were never
obtained. Tr. 338-39. The Respondent explained that in September of
2016, the Respondent requested dismissal records, an X-ray, and an MRI
from Dr. M. Tr. 642-44; GX 7 at 48. Yet, eighteen months later, the
Respondent still had not received the requested records. Tr. 644; GX 7
at 59. There is no documentary proof records were ever requested.
Dr. Kennedy concluded the Respondent did not maintain accurate and
complete records as to M.P. Tr. 350. At M.P.'s initial visit a UDS was
performed revealing inconsistent results, which were never addressed in
the records. Tr. 338; GX 7 at 19, 68. Notes reveal M.B. had been
terminated from a prior physician, a red flag. Tr. 343. The records did
reveal a monitoring of the Tennessee PDMP, and a successful pill count,
both positive steps by the Respondent. Tr. 470. There were emergency
room notes which revealed she was admitted on April 17, 2018 and
released on April 18 for apparent heroin overdose, which occurred in
the Respondent's waiting room. Tr. 340-41; GX 7 at 25.
The Respondent explained those events. He testified that M.P. came
to the clinic overdosing on heroin. Tr. 342, 611-12. She had to be
resuscitated until EMS was able to reverse the effects of heroin with
Narcan. Tr. 612. In the post-overdose notes the Respondent took an
extensive history again regarding her drug use. Following the heroin
overdose, the determination was made that she needed treatment of
Suboxone and no further opioid prescriptions. Tr. 616. He directed she
cannot be on pain management but must be on opioid abuse treatment. So,
the Respondent started her on Suboxone. Tr. 613. The Respondent
explained his understanding of Suboxone induction. The first type of
induction therapy is by observation. He stated that you give the
patient Suboxone and observe them until they reach the point of
withdrawal. The other form of induction is to give the patient Suboxone
and send them home without observation by the physician. Tr. 612-14.
According to Respondent, M.P. was initially receptive to drug
treatment, but later changed clinics. Tr. 615.
Dr. Kennedy viewed Respondent's prescribing of Suboxone as
dangerous and outside the standard of care. Tr. 342, 371-73, 465-66. As
the patient was shown to be on heroin, a UDS would be necessary to
determine if she had heroin in her system before prescribing
buprenorphine (Suboxone), which in conjunction with heroin could result
in permanent withdrawal. Tr. 343. The Respondent argues in his PHB that
a successful UDS was conducted. However, I do not find a successful UDS
in the record prior to the Respondent prescribing Suboxone. There were
inconsistent UDS in the records for M.P. Tr. 346-; GX 7 at 48, 59. I
credit Dr. Kennedy's findings. The Respondent's prescribing to M.B. was
in violation of Tennessee regulations and Tennessee standards. The
Suboxone prescription without determining her heroin level was
dangerous and outside the course of professional practice. The
Respondent's failure to timely address M.P.'s inconsistent UDS results
was outside the Tennessee standards.
[In accordance with Dr. Kennedy's credible and unrebutted
testimony, and for the reasons above, I find that the sixteen
identified prescriptions for oxycodone and oxymorphone and the
prescription for buprenorphine that Respondent issued to M.P. were
issued outside the usual course of professional practice and beneath
the standard of care. The basis for Dr. Kennedy's opinion and my
finding is that Respondent failed to: Take an adequate medical history
including an assessment of M.P.'s pain history and potential for
substance abuse; perform and document an adequate physical examination;
and create a legitimate written treatment plan for M.P.'s individual
needs and discuss the risks and benefits of using controlled
substances. In accordance with Dr. Kennedy's testimony, I further find
that the relevant prescriptions issued by Respondent were outside the
usual course of professional practice and beneath the standard of care
due to Respondent's failure to maintain complete and accurate records
for M.P. Finally, in accordance with Dr. Kennedy's testimony, I find
that M.P. exhibited evidence of drug abuse or chemical dependency that
was not adequately addressed by Respondent until after she overdosed in
his office.]
Material Falsification
In its GSPHS, the Government alleged that, on November 6, 2019, the
Respondent made a material misrepresentation in his renewal application
for his Tennessee-based DEA COR, W18070589C. Specifically, in response
to liability question three, the Respondent answered ``no,'' which he
knew or should have known to be a false response. GX 26. Liability
question three queries whether the applicant has ever surrendered for
cause, or had a state professional license or controlled substance
registration revoked, suspended, denied, restricted, or placed on
probation, or have any such action pending. An affirmative answer to
question 3 would trigger an investigation by a diversion investigator
whether to issue the registration or to deny it. The Respondent
answered ``No'' to question 3.
In support, the Government cites to the State of Tennessee
Department of Health, Notice of Charges and Memorandum for Assessment
of Civil Penalties, dated May 2018. GX 29. [In this document, the state
requested that ``Respondent's certificate to operate a Pain Management
Clinic . . . be suspended, revoked, or otherwise disciplined.'' GX 29,
at 25.] A year later
[[Page 3017]]
in May 2019, the Chancery Court for the State of Tennessee, 20th
Judicial District, Davidson County, Part 3, issued an order Reversing
Denial of Stay, but Accompanying Stay with Conditions. GX 27. The stay
was conditioned upon the Respondent ``not writing any prescriptions
during the pendency of the stay; . . . and/or not providing direct
patient care including but not limited to diagnosing, treating,
operating on or prescribing for any person.'' GX 27, at 2. Therefore,
as of May 2019, the Conditions preclude the Respondent from writing
prescriptions or providing direct patient care during the pendency of
the stay and were reportable restrictions. When asked on his November
6, 2019 application whether Respondent had ever had a state
professional license or controlled substance registration revoked,
suspended, or restricted or had any such action pending, he was
required to, but did not, disclose these events.*X 47
Therefore, I find clear, unequivocal, and convincing evidence that
Respondent submitted a registration application containing a false
answer to the third Liability question.
---------------------------------------------------------------------------
*\X\ Omitted text. The Government also alleged that Respondent's
surrender of his pain clinic's license also warranted an affirmative
response to question 3 on Respondent's personal application. I find
that I do not need to reach a decision on this evidence as the
Government has already presented ample evidence that Respondent
materially falsified his application when he failed to report that
his authority to dispense controlled substances was restricted.
\47\ [Omitted the original text containing this footnote.]
---------------------------------------------------------------------------
[My finding about Respondent's submission of a false answer
involves restrictions on Respondent's state license to dispense
controlled substances. Id. In setting the requirements for obtaining a
practitioner's registration, Congress directed that ``[t]he Attorney
General shall register practitioners . . . if the applicant is
authorized to dispense . . . controlled substances under the laws of
the State in which he practices.'' 21 U.S.C. 823(f). Accordingly, it is
clear that having authorization to dispense controlled substances is a
prerequisite to my ability to grant an applicant's application.
Respondent's false response to the third Liability question directly
implicated my statutorily-mandated analysis and my decision by
depriving me of legally relevant facts when I evaluated Respondent's
registration renewal application. See Frank Joseph Stirlacci, M.D., 85
FR 45,229, 45,235 (2020). Accordingly, I find, based on the CSA and the
analysis underlying multiple Supreme Court decisions explaining
``materiality,'' that the falsity Respondent submitted was material.
Frank Joseph Stirlacci, M.D., 85 FR at 45,235.] *Y
*Z
---------------------------------------------------------------------------
*\Y\ This language replaces the ALJ's original analysis for
clarity.
*\Z\ Omitted ALJ's discussion of the pain clinic's license. See
supra n. *X. I have also consolidated the ALJ's original section
entitled ``Conditions of Stay'' with the preceding paragraph for
brevity.
---------------------------------------------------------------------------
Government's Burden of Proof and Establishment of a Prima Facie Case
Based upon my review of each of the allegations by the Government,
it is necessary to determine if it has met its prima facie burden of
proving the requirements for a sanction pursuant to 21 U.S.C. 824(a)(4)
and 21 U.S.C. 823(f). At the outset, I find that the Government has
demonstrated and met its burden of proof in support of its allegations
relating to the prescribing of controlled substances to patients UC,
M.P., M.W., C.F., B.C., and M.H. The Government has also sustained
their burden as to the material misrepresentation allegation.
Public Interest Determination: The Standard
[Under Section 304 of the CSA, ``[a] registration . . . to . . .
dispense a controlled substance . . . may be suspended or revoked by
the Attorney General upon a finding that the registrant . . . has
committed such acts as would render his registration under section 823
of this title inconsistent with the public interest as determined by
such section.'' 21 U.S.C. 824(a)(4).] \48\ Evaluation of the following
factors have been mandated by Congress in determining whether
maintaining such registration would be inconsistent with the ``the
public interest:''
---------------------------------------------------------------------------
\48\ [This text replaces the ALJ's original text and omits his
original footnote for clarity.]
(1) The recommendation of the appropriate State licensing board
or professional disciplinary authority.
(2) The [registrant's] experience in dispensing, or conducting
research with respect to controlled substances.
(3) The [registrant's] conviction record under Federal or State
laws relating to the manufacture, distribution, or dispensing of
controlled substances.
(4) Compliance with applicable State, Federal, or local laws
relating to controlled substances.
(5) Such other conduct which may threaten the public health and
safety.
21 U.S.C. 823(f). ``These factors are . . . considered in the
disjunctive.'' Robert A. Leslie, M.D., 68 FR 15227, 15230 (2003).
Any one or a combination of factors may be relied upon, and when
exercising authority as an impartial adjudicator, the Agency may
properly give each factor whatever weight it deems appropriate in
determining whether a registrant's registration should be revoked. Id.
(citation omitted); David H. Gillis, M.D., 58 FR 37507, 37508 (1993);
see also Morall v. DEA at 173-74; Henry J. Schwarz, Jr., M.D., 54 FR
16422, 16424 (1989). Moreover, the Agency is ``not required to make
findings as to all of the factors.'' Hoxie v. DEA, 419 F.3d at 482; see
also Morall, 412 F.3d at 173. [Omitted for brevity.] The balancing of
the public interest factors ``is not a contest in which score is kept;
the Agency is not required to mechanically count up the factors and
determine how many favor the Government and how many favor the
registrant. Rather, it is an inquiry which focuses on protecting the
public interest . . . .'' Krishna-Iyer, M.D., 74 FR at 462.
The Government's case invoking the public interest factors of 21
U.S.C. 823(f) seeks the revocation of the Respondent's COR based
primarily on conduct most aptly considered under Public Interest
Factor's [Two and] Four.\49\
---------------------------------------------------------------------------
\49\ [Where the record contains no evidence of a recommendation
by a state licensing board that absence does not weigh for or
against revocation. See Roni Dreszer, M.D., 76 FR 19,434, 19,444
(2011) (``The fact that the record contains no evidence of a
recommendation by a state licensing board does not weigh for or
against a determination as to whether continuation of the
Respondent's DEA certification is consistent with the public
interest.''). Here, to the extent that Tennessee's decision not to
revoke or suspend Respondent's individual authority to handle
controlled substances could weigh in his favor, I find that any such
weight would be significantly reduced by the circumstances of the
loss of his practice's license, and the pending nature of the state
action on his individual license.] Likewise, the record contains no
evidence that the Respondent has been convicted of a crime related
to controlled substances (Factor Three).
---------------------------------------------------------------------------
[Factors Two and Four: The Respondent's Experience in Dispensing
Controlled Substances and Compliance With Applicable Laws Related to
Controlled Substances] *\AA\
---------------------------------------------------------------------------
*\AA\ The ALJ only evaluated the evidence under Factor 4.
However, Respondent's dispensing experience is clearly relevant to
my determination as to whether or not Respondent's continued
registration is consistent with the public interest, and I have made
changes throughout this section accordingly.
---------------------------------------------------------------------------
According to the Controlled Substances Act's (hereinafter, CSA)
implementing regulations, a lawful controlled substance order or
prescription is one that is ``issued for a legitimate medical purpose
by an individual practitioner acting in the usual course of his
professional practice.'' 21 CFR 1306.04(a). The Supreme Court has
stated, in the context of the CSA's requirement that schedule II
controlled substances may be dispensed only by written prescription,
[[Page 3018]]
that ``the prescription requirement . . . ensures patients use
controlled substances under the supervision of a doctor so as to
prevent addiction and recreational abuse . . . [and] also bars doctors
from peddling to patients who crave the drugs for those prohibited
uses.'' Gonzales v. Oregon, 546 U.S. 243, 274 (2006).
I found above that the Government's expert credibly testified as
supported by Tennessee law, that the standard of care requires a
practitioner, before prescribing controlled substances, to take an
adequate medical history including an assessment of the patient's pain
history and potential for substance abuse; perform and document an
adequate physical examination; and create a legitimate written
treatment plan for the patient's individual needs and to discuss the
risks and benefits of the use of controlled substances with the
patient. Additionally, I found that practitioners are required to
maintain complete and accurate records for their patients. I also found
above that Respondent issued approximately ninety-five controlled
substance prescriptions outside the usual course of professional
practice and beneath the standard of care. This is because for each of
the relevant prescriptions, I found that the Respondent failed to take
an adequate medical history including an assessment of each patient's
pain history and potential for substance abuse; perform and document an
adequate physical examination; and/or create a legitimate written
treatment plan for each patient's individual needs and/or discuss the
risks and benefits of using controlled substances with the patient. I
also found that each of the relevant prescriptions were issued outside
the usual course of professional practice and beneath the standard of
care due to Respondent's failure to maintain complete and accurate
records.
Respondent repeatedly issued prescriptions without complying with
the applicable standard of care and state law thus demonstrating that
his conduct was not an isolated occurrence, but occurred with multiple
patients. See Kaniz Khan Jaffery, 85 FR 45,667, 45,685 (2020). For
example, Respondent's medical records for each of the individuals at
issue had verbatim language repeated throughout the relevant time frame
stating, ``Patient has a long standing h/o insomnia and anxiety for
several years. Anxiety symptoms include sob, palpitations, sweating,
dizziness, shaking, insomnia, irritability, pacing, moodiness and
feeling faint. Right now no headache, no dizziness, no nausea, no
vomiting, no abdominal pain, no diarrhoea [sic.], no constipation, no
sob, no chest pain, no palpitations.'' GX 9, at 85; GX 11, at 39; Tr.
286-87. This verbatim language was included in each patient's record
and in UC's records to which UC testified credibly that he did not
report having any of the anxiety symptoms identified in the chart.
Agency decisions highlight the Agency's interpretation that
``[c]onscientious documentation is repeatedly emphasized as not just a
ministerial act, but a key treatment tool and vital indicator to
evaluate whether the physician's prescribing practices are `within the
usual course of professional practice.' '' Cynthia M. Cadet, M.D., 76
FR 19,450, 19,464 (2011). DEA's ability to assess whether controlled
substances registrations are consistent with the public interest is
predicated upon the ability to consider the evidence and rationale of
the practitioner at the time that he prescribed a controlled
substance--adequate documentation is critical to that assessment. See
Kaniz-Khan Jaffery, 85 FR at 45,686. Further, as Dr. Kennedy testified,
``maintaining a patient on scheduled medications . . . sometimes at
high dosages, without having honest, accurate, complete medical records
is dangerous.'' Tr. 352-53. This is because, according to Dr. Kennedy,
``those medical records will instruct other people who look at them as
to what the motivation was for the treatment . . . [a]nd if what is
documented in the medical record simply doesn't made sense or is
something that is in conflict . . . [t]hat can . . . present a
dangerous situation.'' Tr. 353. Therefore, recordkeeping is not only
important for compliance, but also for the safety of the patients.
DEA decisions have found that ``just because misconduct is
unintentional, innocent, or devoid of improper motive, [it] does not
preclude revocation or denial. Careless or negligent handling of
controlled substances creates the opportunity for diversion and [can]
justify the revocation of an existing registration . . .'' Bobby D.
Reynolds, N.P., Tina L. Killebrew, N.P., & David R. Stout, N.P., 80 FR
28,643, 28662 (2015) (quoting Paul J. Caragine, Jr. 63 FR 51,592,
51,601 (1998). ``Diversion occurs whenever controlled substances leave
`the closed system of distribution established by the CSA . . . .' ''
Id. (citing Roy S. Schwartz, 79 FR 34,360, 34,363 (2014)). In this
case, I have found that Respondent issued controlled substance
prescriptions without complying with his obligations under the CSA and
Tennessee law. See George Mathew, M.D., 75 FR 66,138, 66,148 (2010)).
With regard to Tennessee law, I find that in issuing controlled
substances prescriptions that were outside the usual course of
professional practice and beneath the standard of care, Respondent
issued prescriptions that were ``not in the course of professional
practice'' in violation of TENN. CODE ANN. Sec. 63-6-2l4(b)(12). The
Tennessee guidelines require that a physician: (1) Take a documented
medical history; (2) conduct a physical examination; and (3) perform an
adequate ``assessment and consideration of the [patient's] pain,
physical and psychological function, any history and potential for
substance abuse, coexisting diseases and conditions, and the presence
of a recognized medical indication for the use of a dangerous drug or
controlled substance.'' TENN. COMP. R. & REGS. 0880-02-.14(6)(e)(3)(i).
I found above that respondent failed to conduct an adequate assessment
and consideration of the pain and potential for substance abuse and
failed to conduct a physical examination for each of the individuals at
issue including UC. Additionally, Rule 0880-02-.14 (6)(e) requires
physicians to create a ``written treatment plan tailored for the
individual needs of the patient'' that considers the patient's
``pertinent medical history and physical examination as well as the
need for further testing, consultation, referrals, or use of other
treatment modalities.'' I found above that respondent failed to prepare
a tailored written treatment plan for each of the individuals at issue
including UC. Tennessee guidelines also requires the physician to
``discuss the risks and benefits of the use of controlled substances,''
which I found above that Respondent failed to do for UC, C.F., B.C.,
M.H., and M.P., and ``keep [c]omplete and accurate records of the
care,'' which Respondent failed to do for each of the individuals at
issue including UC. Id. at 0880-02-.14(6)(e)(3)(ii)-(v).
Additionally, TENN. CODE ANN. Sec. 63-6-214(b)(13) prohibits a
physician from prescribing controlled substances to a person ``addicted
to the habit of using controlled substances'' without ``making a bona
fide effort to cure the [patient's] habit.'' Crediting Dr. Kennedy's
testimony, I found above that Respondent acted outside the bounds of
this law with regard to patients M.W., C.F., M.H., and M.P.]
The evidence is clear the Respondent violated the Tennessee
regulations alleged, and the Tennessee professional standards. The
Tennessee regulations are related to controlled substances. [Overall, I
find that in issuing ninety-five prescriptions beneath the
[[Page 3019]]
applicable standard of care and outside the usual course of
professional practice in Tennessee, Respondent violated 21 CFR
1306.04(a) in addition to Tennessee law, and these violations of law
weigh against Respondent's continued registration under Public Interest
Factors 2 and 4.] \50\
---------------------------------------------------------------------------
\50\ An expert's opinion that a doctor's treatment of patients
fell below the standard of care is probative of whether the doctor
violated 21 CFR 1306.04(a). Bienvenido Tan, M.D., 76 FR 17,673,
17,681 (2011).
---------------------------------------------------------------------------
Sanctions *BB
---------------------------------------------------------------------------
*\BB\ I am replacing portions of the Sanction section in the RD
with preferred language regarding prior Agency decisions; however,
the substance is primarily the same.
---------------------------------------------------------------------------
[Where, as here, the Government has met its prima facie burden of
showing that Respondent's continued registration is inconsistent with
the public interest, the burden shifts to the Respondent to show why he
can be entrusted with a registration. Garrett Howard Smith, M.D., 83 FR
18,882, 18,910 (2018) (collecting cases). Respondent has made minimal
effort to establish that he can be entrusted with a registration.
The CSA authorizes the Attorney General to ``promulgate and enforce
any rules, regulations, and procedures which he may deem necessary and
appropriate for the efficient execution of his functions under this
subchapter.'' 21 U.S.C. 871(b). This authority specifically relates
``to `registration' and `control,' and `for the efficient execution of
his functions' under the statute.'' Gonzales v. Oregon, 546 U.S. 243,
259 (2006). A clear purpose of this authority is to ``bar[ ] doctors
from using their prescription-writing powers as a means to engage in
illicit drug dealing and trafficking.'' Id. at 270.
In efficiently executing the revocation and suspension authority
delegated to me under the CSA for the aforementioned purposes, I review
the evidence and arguments Respondent submitted to determine whether or
not he has presented ``sufficient mitigating evidence to assure the
Administrator that he can be trusted with the responsibility carried by
such a registration.'' Samuel S. Jackson, D.D.S., 72 FR 23,848, 23,853
(2007) (quoting Leo R. Miller, M.D., 53 FR 21,931, 21,932 (1988)). ``
`Moreover, because ``past performance is the best predictor of future
performance,'' ALRA Labs, Inc. v. DEA, 54 F.3d 450, 452 (7th Cir.
1995), [the Agency] has repeatedly held that where a registrant has
committed acts inconsistent with the public interest, the registrant
must accept responsibility for [the registrant's] actions and
demonstrate that [registrant] will not engage in future misconduct.' ''
Jayam Krishna-Iyer, 74 FR 459, 463 (2009) (quoting Medicine Shoppe, 73
FR 364, 387 (2008)); see also Jackson, 72 FR at 23,853; John H.
Kennedy, M.D., 71 FR 35,705, 35,709 (2006); Prince George Daniels,
D.D.S., 60 FR 62,884, 62,887 (1995).
The issue of trust is necessarily a fact-dependent determination
based on the circumstances presented by the individual respondent;
therefore, the Agency looks at factors, such as the acceptance of
responsibility and the credibility of that acceptance as it relates to
the probability of repeat violations or behavior and the nature of the
misconduct that forms the basis for sanction, while also considering
the Agency's interest in deterring similar acts. See Arvinder Singh,
M.D., 81 FR 8247, 8248 (2016).]
While the Respondent has conceded that his medical charts contained
several errors he never accepted responsibility for [the violations I
have found]. His testimony defending the identical indications among
his patients in support of his anxiety and insomnia diagnoses was not
at all credible. The lack of a credible explanation for the inclusion
of results in UC's chart of tests and examinations which did not take
place weighs heavily against a finding of acceptance of responsibility.
Furthermore, although he testified, he did not address the material
falsification allegation. I therefore find that any acceptance of
responsibility has neither been unequivocal nor complete.
[In all, Respondent failed to explain why, in spite of his
misconduct, he can be entrusted with a registration. ``The degree of
acceptance of responsibility that is required does not hinge on the
respondent uttering ``magic words'' of repentance, but rather on
whether the respondent has credibly and candidly demonstrated that he
will not repeat the same behavior and endanger the public in a manner
that instills confidence in the Administrator.'' Jeffrey Stein, M.D.,
84 FR 46,968, 49,973 (2019). Here, having considered Respondent's case
and statements, I am left with no confidence in Respondent's future
compliance with the CSA.]
Egregiousness and Deterrence
[The Agency also looks to the egregiousness and extent of the
misconduct which are significant factors in determining the appropriate
sanction. Garrett Howard Smith, M.D., 83 FR at 18,910 (collecting
cases).] I find that the proven misconduct is egregious and that
deterrence considerations weigh in favor of revocation. [Respondent
issued approximately 95 prescriptions for controlled substances outside
the usual course of professional practice and beneath the standard of
care.] The proven misconduct involved fabricated medical charts,
failure to meaningfully address serious and ongoing indications of drug
abuse and diversion by several of his patients, as well as other red
flags. The proven misconduct also involved the material falsification
of his application for his CSA registration renewal in Tennessee.*\CC\
---------------------------------------------------------------------------
*\CC\ Remaining analysis of egregiousness omitted for relevance.
---------------------------------------------------------------------------
[In sanction determinations, the Agency has historically considered
its interest in deterring similar acts, both with respect to the
respondent in a particular case and the community of registrants. See
Joseph Gaudio, M.D., 74 FR 10,083, 10,095 (2009); Singh, 81 FR at 8248.
I find that considerations of both specific and general deterrence
weigh in favor of revocation in this case.] Allowing the Respondent to
retain his COR despite the proven misconduct would send the wrong
message to the regulated community. Imposing a sanction less than
revocation would create the impression that registrants can maintain
DEA registration despite ignoring obvious signs of abuse, diversion and
other serious red flags, the wholesale failure to maintain adequate,
complete and accurate medical charts, and after making a material
falsification on a renewal application. Revoking the Respondent's COR
communicates to registrants that the DEA takes all of these failings
under the CSA seriously and that severe violations will result in
severe sanctions.
[Omitted.] *\DD\
---------------------------------------------------------------------------
*\DD\ I agree with the ALJ that Respondent's testimony lacked
credibility and I have given it little-to-no weight in reaching my
decision. However, in light of Respondent's failure to unequivocally
accept responsibility, it is not necessary for me to assess whether
Respondent's testimony also lacked candor and I have therefore
omitted the ALJ's discussion of this topic.
---------------------------------------------------------------------------
Loss of Trust
Where the Government has sustained its burden and established that
a registrant has committed acts inconsistent with the public interest,
that registrant must present sufficient mitigating evidence to assure
the Administrator that he can be entrusted with the responsibility
commensurate with such a registration. Medicine Shoppe-Jonesborough, 73
FR at 387. The Respondent's material misrepresentation compounds the
Respondent's instant burden. Although the Respondent offered some
evidence of mitigation, even if considered, it has not overcome the
loss of trust resulting from the allegations found herein.
[[Page 3020]]
[There is simply no evidence that Respondent's behavior is not likely
to recur in the future such that I can entrust him with a CSA
registration; in other words, the factors weigh in favor of revocation
as a sanction.]
Recommendation
Considering the entire record before me, the conduct of the
hearing, and observation of the testimony of the witnesses presented, I
find that the Government has met its burden of proof and has
established a prima facie case for revocation. In evaluating Factors
[Two and] Four of 21 U.S.C. 823(f), I find that the Respondent's COR is
inconsistent with the public interest. Furthermore, I find that the
Respondent has failed to overcome the Government's prima facie case by
unequivocally accepting responsibility and establishing that he can be
trusted with a registration.
Therefore, I recommend that the Respondent's DEA COR Control No.
BO4959889 should be revoked, and that any pending applications for
modification or renewal of the existing registration, including the
pending application for a new DEA COR Control No. W18070589C, and any
applications for additional registrations, be denied.
Mark M. Dowd,
U.S. Administrative Law Judge.
Order
Pursuant to 28 CFR 0.100(b) and the authority vested in me by 21
U.S.C. 824(a) and 21 U.S.C. 823(f), I hereby revoke DEA Certificate of
Registration No. BO4959889 issued to Samson K. Orusa, M.D. Pursuant to
28 CFR 0.100(b) and the authority vested in me by 21 U.S.C. 824(a) and
21 U.S.C. 823(f), I further hereby deny any other pending applications
for renewal or modification of this registration, the pending
application for new DEA COR Control No. W18070589C, as well as any
other pending application of Samson K. Orusa, M.D., for registration in
Tennessee. This Order is effective February 18, 2022.
Anne Milgram,
Administrator.
[FR Doc. 2022-00952 Filed 1-18-22; 8:45 am]
BILLING CODE 4410-09-P